var title_f7_40_7808="Anomalous pancreaticobiliary union type B-P";
var content_f7_40_7808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choledochal cyst with anomalous pancreaticobiliary union, type B-P",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 496px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHwAWsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxR1G4nv8AqaQMR34p7AbutQPnNAFhSCOtIVPrxUQU4zU0ZzxQAwqSOOlJ5Y9KsrHgH0pSmT0oAqLGM9Kc8eBVhIST04qUwFsZoAzGT2pVhz2rS+zAdetOEOSABgUAZptjQLcd+a1Gh2iovL65oAoCD5hgAU9odp6Vc2e1KYye1AFFYzTihPWrgipRF7UAUWg44AqHyjzkCtGRM9OKjSHmgCmsXzDipmXC4qyItp5FIyZNAGeVLHgYqN460dqA5Y1BMYweKAKRi4pPKx1qwJADkAGkkmJ4CigCNLc5zVhIxjAAzTEn4wy1YgZWBweaAGCNCMMooCBWG0CnSA7uKniXcB60AWrVNyL3JrUso185BtHWq9lbsiA44NbmmWp84SuMKKAIbpRHOQop8IZjjJxU8q+ZIz44zTo0xyFoAdEzI2MZFPuSewwDVq3iEinjmnXFudqjAoAwp0Z+Bn61G8TBcKxzWw9v5ceTjrVN1XPFAFFEfPetExmS1K9ABUBIzV+3cMu1uh4oA5e9Oz5T2rImbvXS6tYbGLDoTxXMXUZVyM0ANjfJ5pWuAp4qqzsMgVCx9aAHz3LHIPQ1SMp3c/yp0rZqs7ZagCYS1IbhxwGYAdgaqA4pSwzQB0BGWPFJtwelTsuWpAhbtQBFtPapEjH4+lTpAcZqdYgKAIY0ZuKtLbcDJ5pyREjAqzGOcN+dAEKQ4Xil8nua0I4ht+Wo3jOTnigCk0eacIAF5qwUx2zSkHHIoAqmInv0qN4sN061bKZIJpXXceT1oAo7ADyKAuT0q0YaaFIoAiMIxkHmomU5xVt/u1XckjgUAROgUc1GCEHrUjqWPNKUwvSgCnNMScKMVXJYjJq4Y+TTfK4IFAFXZ3qGRCcnpV5o8U1ogwzmgDN8s7qkZBjIFWDHg+9HlnpigCqi5PNTKm08cU/ysHpTguDk0ANAz71ct4yV4qNAM8Cr9oqlgKANiwcCNUIyVrT8xioAHFU7O2/iq8kRAJHSgCIAqxI5z1qZN392nshIWgBg3FAF20BCH5cGrqPuUfIDiqFuGZCRzip4MlsE0AQXZJRgVHWsiYFSeOK3blPl6GsmddzHNAGbKCG4FKshTbyRzVvYG7dKYbfKj1oApXkzyRleSM8Vzd3kOeOa6a5iYA46Vg6lHsJJFAGW+SDxVd+eDUjs2eBxUEucGgCCYAdKrEZbpVoKSOahx83NAEYXg01k5NTgelDjDGgDrvJxnd71IsYUcDmr0lr8xamMoAGOtAEEceTk1L5frSqpPSpNnOKAGKuOgqZFGMnk0Rqe1PIOeKAHoTt4WklXdgk/hT4gcUBSB0zQBFGMMcnipGTgE08KSelK2TwRwKAK5QdaTZkZqVlpuT0oAhkGOtQjOSMVa2buTSeWT2oArbSeuKYyc/Srvk4APegx45xQBREfJ4oaLjkVdCc8imshY0AZ5jx2pojPOavGLnGKXygBz1FAGbJFzUGwg4rXeHIBqv8AZyTgUAUWjzjimFNpzWm9qeKb9mHegDNKcjig27MeK0DCdxAAx608RYwR1oAzTEUbBqxbAiSp5Id3Jp0MeGBIoA6HTTuiHrV8LgAYrJ04tuIU1u2iSSZyBQAgjBWoip3dM1rw23HzD8qsJbRgg7fzoAwo9wYqVYA+lWI4pMjaDW15abhiMVYXbx+7HFAGMYpGTBU8VmTwtnkYrtSAY+EFZ13ao/VaAOVEJHIANI0Xc5HvW1LZYHy8Gq0lhI3RjQBg3oXaQDXM6lktzXX31lIoAwcmuX1SFlkwQeKAMRk3GmPGCOtXRFgdKjkiwhIoAz/KyvymqzxkE56VqJGVSoWjJagCiqUhUE5PWtDyhx60z7OuB9KAO9kX8qrSRA9OKvyKAQBzxUBXrxQBVVQvSn4zzUwj9qaU2nigBAtOK+nfrTlpQcUAAAAqRgMAU6Nd5OCKtLDxmgCixAHy9aZlmq89t6DFVmi2tigCLaT14FN256VY2E9ad5eADQBAijoaV12nHXNWAvFG3PagCvtO3mmsvFW2UY5pvl7ugoAqbc0mz61fjtj1NSxw4PSgDNWEt24py2xJya1DECMAYpVh29TQBQFsOMdKiaHBOBWsYwBwahMeDmgDNaEkelRGEkHitRkzxikW3IHGKAMtYTnkUG3wMnpWm0JB6VYFtujBIoAwTH8pCioo0YuQBW0tujOVwfwq9ZaUEbePmJ9aAE0TTiV3yDg101vboPurgfSls7c+QFxyO1aVrbN8ue1AFWSAhfugVXkjbHFdK9oEC55BpPskePuigDm4lYHvV6OL5c4NaZs4933RipkhjGFCigCgkeVwB1pjwFtybTx3raWJMcCpFgU9j+NAHNSWYAAxzRDZqVZm4A610U9uvXFVzbfIwHegDktQt1kJZRXJarYgktjrXoNxbhd2RzWHe2+4dBzQBwbWCE9O1QSaaCOK62S0U8qMGo2syOf0oA4meyYDAHIqqbRky2Oldbc2e1i+OarSWuFPTmgDkjG4bOO9IICR0roTZEk4WkaxYHG2gDfkXGcD/OaqlME+9WXcgAnoRUWR3FACKORStGCxHanED1pB156UAQOuw+tRknpVh1GeDTNgLDFAF6zQBc4FXQvA4qK3TCgCrsSE5yMYoArshxVWdQMe9aLjAzWe5LPjFAEGzNBBxVgRMeAMVNHb+ooApIhY8CpEgY1oRxY6DipPKyOlAFJLZeCx5qcQA4wOKtJEAeBTyuBQBV8j2pfJA7VZAHalxnoKAKgiVTz+VI0YJ45q2y+uBUPnxx5CruNAEfk9+aa8IxliF+tMmuZGztAFVWLP98kmgCeXyEXl+faoftES/dBNQPHmmmPB6UASNchm4GKtxZnXbGSaoJCZH24/GtywtfLXjrQAW9kEXJ+8a1IYNo4ohiY44rStUBO1+PegC1p9uNhY1oQRZbjipYbZ0jAC8dqu2VqR8z8AUAFxCAiDuBUQhB4xzV2X536ZA4pAuB0oApeQcGlEIzxnPpVzaCPk59acsQKkdM0AVoYhvAI7VI8WDjOBVlI9i+9MlHc9KAKpGTileEYyOKmI+bPYUpGSDnAFAHO6lH8nAxXP3UfHTiu3vrZZejDFYV9ZKsROcUAcuEHpVHUJTtwvFa1wNoOOlYl4MHI6UAY9xKzHDEkVnTSMJDknFaEgLSEVSmiLPwMmgBkDSO+1CTmtqK03RqX+9jmn6RYbU3uMGtTyT6UAcwJs4Rqdvz07VTbrViE7lx0oAmj5NTr0qKNcdal6UABAPWliUbgPekHQ5p0P3waANdIcAEcVcEBPC0WsRkjBJxW3aWwCA4zQBjvpjyDGSBTU0tV45zXSiPjmoXjyeKAOels2Q46imKhHGK6F4BnofxqhcwlCSBQBnxp97NLtGBUqjg56mjbzigCMLg8DJ9adsLVKCqpjFQs+w8nigBdu3rioJJwo4X8aa7lycE1EQaAIndnPU00g9qmIoVPSgCuU+b0NBU4xVhk796VBjrQBV8v1qNo8njmrxG4HjirFla+Y2WHANAEdlYtgMRyetbMFvg9KnigwQBVqMc4x9aAGJFzir1palnVhUPOcgVoWYYAZFAGrEpC89AKtIMpz0pLcbkXPWrAj7mgCu6jORTfL/edSRVwxj6UKhoAiWPj0pjRENkGrirgc0Hbjn+VAFXBx7Ck6rzVkYwRUOBk5oAgZScsKrknkdqtt0yTUZAwc0AU5MYHJNZt+hfc3bFbEqDBrLvDhGWgDlb0JjrWJeAY4rV1FDvJrHuT8pyOlAGY8eGJq1ptgZG8xxwKS2jM8nAAGa6K2h2KqgUANhtDI6Rxgn6CuutPDiG2jMkeWxycmr3hnRfuyyD73t0ruFs0CgYoA+SiM09cimZ5zUqgnkUAWYXyOamOSRgVBDCetaFumTjFADYoiRljirUUGD0yKvWlmGwW5rTitFA4AoAh09sKARzW/C6hOOKzEiCsMCtK1QOh3DFAEobI9aQIQxzU8duQu78qV4TjI60AVpDk47VXnj3AnFX1iwDu61C8fB9aAOfnUq+OlMxxkDn1q9qChfmIrMeTJ44FACs3Bx1qF+aXBzxmnbTjkGgCLFJtxzUyxM3SrEdmWxmgCjtJ6LT1icj7ta0dqoHAOasJB8vIoAxVtWI9KetkSeTW5Hb7jwvy1ZjtFPbmgDAjsDkd61bO0IPC8dq0xbBB05qSGIqMCgCBLY+mKmW1wOetXokxHjbk1N5eccUAZYgyBirduhUAHpVgRY6CnCP1FAGhZspAq6ApPFUbRcLV9V4oAXb+NN2c0pBFBcheKAEKkEUoTPUGo/NPc015GGc5A7UAOdCQccVWfg96WWVip+aqMjv2Y0AWWIAxULOSccVXMhbucimsTuxQA+eXgY7Vm3Uo2njmrNw235R+dZGoS7F69aAMPUSS59KxLtdzYWtO/ky/FQWsPmSZYcUAFhbeWgLD5j3rq/DelteTqzL8gNULG182ZY1GSTXqPh3TEt4FXbzigC9p1mIUQDsa2Y4lKAkc02OILgVajX5BQB8aRW+7nHFX4bcDjbSxJwpHSr0SZxQBHHbccjAq9ZQAPUkQA69BU8K/vOKANCCI7eFzVyONsZxiizHHNXQoxxQBTK+1SRZ4wac6AHg06BNx60AaUGW4qWVMLx1p9jEQvWrUkII5oAy2PBzUbhcepqe4Qo3A4qqz7M9yaAMnUULg1lJbsTz0rpXi3qSRxVKO3Bc0AU4bUbelTLbe1aUUBxwKmSEkkbcUAZSwAH7uKlSMZrUFoWHapI9PPXFAGdDDu6Vditgq/MM1bW38rtzUyxjaCOtAFMRjGMYFWIYFAzU6xDHzCpPLBxigCsYTnPalihx9atlQEyeaiLBSKAJ40VRk9alZRgHHPao43U4xmrqhQMHmgCo8ZyDUsUOSM1KAC1SJH3JzQBKFC8dqniww4HNRleOaliABBzQAxx82MVDICAauTHB4quT14oAqMTimZyByatM68gqKYCgGcUAU5M5IzVKQkDHetRmXPzKBVOVQz5UUAVVGFyadGN27J4qSQL0piEDOODQBnXdwobaO1YmpPmtC8+WRicVk30wPBIoAyZwzlcjvVmF0iwGIwKrvOqNtTL5piQmaXnIzQB3Hg6L7TcGTGQDXqFnHtUAdAK5HwNpv2axRmHJGa7mBeBxQBJGvIJqdB8opiinp90UAfItucDGO1XU4AqnjYSe1SpOvegDSiUZzVkEZBFZ0M/J5qws3HBoA3LSQEYzzV9HwOtc/bTZIrXhfegwMmgCWZ8c9altD09KiMLsOVPNXbKF4ycigDVsc44FXD7c/WqULMp9Ktrlx7+1ADJo96npWQ0QMpI7VuDONrAUwWQLbulAGOyHHFEFsCc9/StGeHMm1RxVm1tCoyeKAK0dpvA7Vbjsge1XooAOO9W1i45oAz0slUZA5qQW6+nNaCx8dKQp6CgDOkt8joKrm2OcYwK1nTHNQOMnigDNkjCDDVE0qr061oTwluvNVHtB1oAqNcEjgc1SlkZj1FWpoCDhapyIy9hmgCa3mZWBzmtqObdGDwK5+LO7nitCOTagB6UAaQap4ycgA1ShlHA6g1rWtruwwoAexOQMU6NGMg44q2sHT1qUIFU8c0AUZlO7NQMcNV2QZPHSqtwADQBUnUnJBqoJSMqasTPtPJ4rOuBzuU0ATMxINQ7+OoqN32QnJ5qo8wVMjigCxI4GeKryyqASSQKoT3g528mqZneQkE/hQBVvr3c7qBx61z93OzTHPNdDcWhflfxrIvLJ/M+VTigCjFJlwCBWvp53zovqRWcYPJGXwCegq7orF9RhRe7UAe4aHsWziC9lArciOAMVhaLD5UCgnnFbceBigCwpp6fdFQb8EYpyOdvWgD5FmcliM+v86rktyamZckkn1/nUTEAcUAKk7A9easRXDs2BiqZUlh6VqWVsMZ9aAL9izlgFFdPZK0YBqjpVj8ob+ldDFbgLigB0J8zHGMVcEeelQLHtxircPSgACEck1dgxsBHBqqW7U63dicdBQBfjXdzjNWRHkegplqu3rU5PYUAV/KAkOKsKhwM9Kei1Oq8c0AMjj9Dip1TGKj6Gpw/FAAARSNgLmnbwPrUTnPFAFeXLnikVccVLSOcDpQBFs61HIoxinFueM1FI/OaAInhBXPFU5bdc+tXMnrUbgYJoAzmthznNMKMvQ8Vec45J4qsz5OR+VAEtkcH5hzXRWMmFHpXOwsCR2rVtZdq9aANzd0p0uUX51IyMiqEdyGGMinvcsxG45AGKAFkYbc1Ru5QBTp7gDqRWJquoIiHB5oAWa4BLZqm8oVCwOR6VmG+DAnioDcu3AIwaALt1dcYJ4rMmu93yr0qG4YsTnmmDhRg0AIytnOetINwAOaex9OtMJIIHHSgBXmyucmqrSvnaScDvUz8LgCqs0hQYagDGuZT9pYsc4NaPhuVBqUTM3A5rGuiTMxx3zS6dP5Nyjg9DzQB9EaVcb4lII5ArYSTivPPDOpq0YBfPHFdV9tVY8+3rQBs+bmmPckMQrACuffVUUH5uayJNcG84figDwmY8kZ9f51XbGODUkhJqJQS2AOtAFqzjLkZrorC3LMorKsowqjjkV0Ol483096AOi0yMKgBFa4jGBz1qjZ4A9a0VIKDHWgBuztUYbyzUrNt+tQTAt82elAFhU3nOOKl+UDgYqpbT5O0nmpTJu4oA0IZzt5q3DIGOKzrc/KB3qdSVfI7UAaoXmpMYHBqpbzBh8xwas7uODQASnApiTCmzSDHPJqkHwx4oA0lck+1BbnmqUc5HUcU8ShjjNAE4cZ4NDsCOareYAetOeQEcGgBC2M1WlbGSDUU9wd2Fqu8jEZNAE8c3qaSWQEdaq54zTDknmgB80wz71UaRi/FPdcvio9pDUAHmMOhINWIblgQCxxULLx1pq8cUAaiStjKn9al85goyay43O4YJpLm4dVwpyaALF7c4BOeBXPXkryFsDIomvJC5DVX+1Hk7RQAiAhOgzThnGcYqE33PCLmmSXrhRjaPWgCcxkoWzz71XIKYGDTku3KDlfyqCS5kP8QHtigCZiFXrk96jBJfPeoPNdmye/tSkndyc0ATu2BjvWXelicZq62T0qndjCE9T6UAY0oyx5qADDVOwBY5ODUMg/E0AdL4d1QxMFLHI4FdFeau5tziQjHvXncLtG6lTzWnJeO9u3PbmgDRl1+RQyhyaotrL7jtfArlrm5IduoNVDduCcMcUAX3PT6VYtIyQCRVYruYc1qWsfyqM0AWoF5rb05Qr5rLgjPFaKNsCgUAdFbSDHJrRjlBAArmLd3LDBrUhndFAOKANpXVR81U7y6RFbmqMlzIx6jFZ91L1yc0AW7SYzSttyBmtqIdDWDphBOa20wFJBoAvo46rwanDkj61nJJyAasxNlutAF1CcZpxuGyFAquJR0pwwTzQBcXDDJ60hAz0zUAyOhpzSYxQAGMcknHtVeZ/LOQakMw5zVS6uEKkAc0ANa+2jnpUYvjJwOKzLkFicdKjik2n5jigDXSX5+TSlhnrVGOVSMVKjc5FAFnrTwuTTIlJINSsD279qAIjGck0hCr1qYfnTJMZ4XmgCu7Zx6U0ckgCpCOeaniiIfdj6CgCGKMrksMmmSRjnrk1fZHPIGMU4WvmDJFAHJaghSXGOtULg/KcGuj1WzBbG7kViSWqHOSQKAM1RxSTA7uKueRCDjzGH4UvlQ9TIT+FAGc5ZRgZo3nd8wHFWpPIJIVmqEwo7YyeaAJVKFcggn0pvTr3p622OFPFSGBjjAoAGQhMgdqqTwmSF8dQM1evCUKIvTucVns7LIeR6UAYLDD89ajbJPFXbyLEpwKhVMjAPHegCuq/NjFWo1O3GM+1SLESOBUiRlTjsKAOd1W1dGLgZH8qxGY5Oa7y4hWSPHXisGTTU3tlOc+poAW3TnOK17Zc4xxis2zGa1rQcmgC3BkEVfgiZutRW0WQK0YlGAO1AD7dMduBVoY4qNRjJ7VIOmc0ANb5fpWXPIGc+gq7ey7U96yd2ev3qANTTn2t1/CtuJsjdjmuWikKMCOlb1lcDZ1FAGkrbu1SrKFqmko7YqQYZutAF+FskGp9wJFUY225HHtTw5z14oAvK3ApGf5uKpGcDpUZnJNAE1xJ1wapliR9aGJJJpuD6cUANkGR1rMuyd3HatNkZunSmNZZGSaAM+2nYYB/Oti2KtggVRNrsp8TNC3qKANlSABxTvmY9aow3IcdeauRHdg0ASjnIPHtUUmTnFSE8HINQNxz2oAEXAPrVuBuAMVAhHln1q1agHk9aAHlwTjFJGxEgHYmnkAGnxRhpQewoAztUjCs3HWuZmHzEHPtXY6ggYtg1zN7BhyQaAMaeE8kVTbjjJzW0UAGT0NUp7cliVoAziO1XbeEhQSOKWK32YaTk+lW9w2jHagCGSLb/ABdadGCCMGkbrk8+1SxnJGAQKAGaiCVTd0rKdCScDHua2dQHyKQDxWbIMoTmgDMkj3OfmHpQsK7e2e9GzEh55zUq/K2RQBCFIbpnFTCIlQ2Keke8BsgVMEPAUigCt5YIK4NVnt13HIq+oKyEGnFVPbtQByFkx6d66CwTBB61ztt+7fdiuk09wUHvQBrQDpVxQOB61Vh54q2vQY60ASgEDoOailcqvNLKygcnmqFxMCOvSgCC7dnbrwKhUg496i80nr0NG7A4oAnzyQDgVYtpzG3XiqQOeaerdsUAdFBOrkYAq6mODnk9q521m2kDNbMUobGDQBf3UZ561CrZPWnZoAmTrz0pe/FNHQgHFOQHsM0AKAKnWLd7U6OMbfX+lS4GKAIlQL2pwTNOyPTNSopz7UAV2jDqeBxUEluoXsKuuyp25qpcOSD6UAY11J9mYle1OtNWZhgYBpt4u4nPSseTMZJX9KAOnTUG3DdU/wBoWQ59O1c1a3R4D9a0YpR1FAGwsy9Kv2EinvXPLKC+K17A7VzmgDa8kOeCPrSsvkocYNUYbgq2e1SGTKkk96AIpCTliKxrhCXbHU9q1bhjt5PWqMq59vegDPZTswQKpTKQgPGe9ajpwO9V3jHOQKAM1wGAzwBUB3HOBVqZNwPFRBDgc80ARrkdVNTR9TgMBTgpJHNTEKF4NADnKvHsIOfWqElscFQRz1zVwZCj09ay9SmbOFyCaAM28eOJyqsC1U3utvI+9Ud0uJiTzVVuXFAFh7mRjyaWC5kRvv1EBnGaUryMUAaEd6SRvHNWjOvY8VjINvSonuCGIBoAqYAUH2q9pspRsZ4qiegHtU8DbeaAOnt7nA96sLccVgxXOcY4NWvPx34oA0ZZs9az7uYYC5yaglusg7eaq7mYkmgCyG54qQAnFQIDxU46+9AEq/3cdO9TqCRxVePjFWYz04oAeiHIxWlbsCoHSqSDB4qePgg0AasbADjrU6HI96o27Ej5quRkYoAtQJnk1aTA4xVSIjtVkN7dKAJ16cGmsSelRox705CScUASxLnrU8kmAFApoX5Rt4oJ/OgCFxkHNV5B2PIq0ys4wODQIMDnk0AZEtq0vQYFV30wCt9o/TpUciZ9hQByt1YbTxxSwApwScV0FzACuKzZIMA96AIowzNkHNa9tIfKweKxxGyHIOKmS5bGPSgDaikxyDmrAmBOKw4Lg5wTir0UqkZ3UAWXbOfSq8rfLzTi+OhGKheQE8sAKAE3LjFQynCEjipd0QIJlX8qp380O4ASZ+lAFVn+fGKRhg4xSEw9fMokdTtwwNACD8qQnjAPNRtKBwDmozKu4YPNAFh3O3GOaytSbHJwcDtVqSYZIxWddnKnNAGbMQwJ9aqEYarEhJJWoXJ3DK0AKOlL1pB0qaOHfuAYAgZ5oAjBwDmsWaZvMODWzg7DyM46VgStlzQBfPU/j/OnchRzUZOCTn/OTSE5bHagCxG5P4VKZzjAqoHHQ09SNwweKALCHI61PH71Wi96sxdOaALKHinoec1EhqVaAJUwGBarCdsfdqBT81TxhicUAWozzVqJOMmq8K4GT1q2nTNAFiMc47VMlQI1SbvSgCeOXY5q1HL6Hk1mk45pY5dvJ5NAGsJcjkVNG3es+AmQZIrRiHyYIoAsoTtqREzUcY4qyNu1QvXvQAsaYzTmQH605AetSlcigCoYutRSRZwKuGM4NRlMg+tAGe6HnNUpo9pye9bEsZ71Tnhzz6UAZUkYY1FJCMfLxWjHC80hSNGBHdu9RPHhiD1HWgDNjBDYI4q0jAdanhtyxLBeKq3cZTkcGgB7SDB5qrcS46HFQs/OCaqzyfPgGgB73B6KeKqyuzOSelNdjggGoy6jG7OKAHlvahn2qAeoqIzJ2zUTMc8nrQBbUhuc07aNvB5qtG4RvmOatEqSMdPSgBu0nnNV7mPKknHFXkTcOelRSxFlx2oA56QAMahZiTVy7jMZII4NUnXGOetABk+lPY8DFJF8y4pxUpj1oAfnETsR24rmJh+9bHSulnz9mauamJ81qALjtkYA696UnApmQSOMUM2TigADZNTJ71Co561ZjUYoAnjYY6VZVgcY4qtH3qdAKALKYzUoIxxUEXr3qwgx70ASKenHWr0C+lVol+Y8cdqtxDBGeKALMaE/UVOBgdeKij3KxI6GpVIoAepx3p+7NRk8UzJFAEjvgcmmI5dsDFQSNuY9KtWcXoKANK1JXA7VpwEHGKzo0PGOtXbdDk0AaMYFWY0BPIqrBwPmNX4AMCgCSNB0qQJz04qVEqeOPOOKAKhjJHSmGE56VqLFntT/ACR3FAGN9nJ6iq00GAcCt9ogAcVQul5OKAOfdSrcEg0kVvubJ6VbnQeaanhTYpY8j0oAgaJUAQD6mqF7aIyEg81ps4APHSq8nzQN2oA5WW3AJy3NVJrdN24vxWpco28kfjWfcoQOegoArmCJuj81BJbx7uXqbZkHmq7r0oAY0EIzuYn6Uqxw9g3TuaR1pAORxQA4RRswwDn61bS2BYDdUMSfNxgirsQIb2oAkjtyqE4yKq3DDcucgDrWljFsT3rKn7E0AVby3jnQ4ID9qwpYGXeME7evtWxIxL8HpxVS5ViWOeO9AFCFSoBbpVv7M8pVkGc1JZWpnbbzx3xWneFLOBUXBYUAVV0stanc2G71iPoO5iS/JrWhvJZElG7HBxWI1/KGILMDmgDJeQsAB1pV6cmoc8mnpyKAJVPNW4+gqoo71ZjY8A0AW4+vNSrjA7VEg59qmUAnJHTpQBMnbFWol5FQQoS3PSrka9ulAE6Y6elSq2e1MRSzAKpY+1PZGRirjBHY0ATo3IzUikk89KrIc8GpSwXgdKAJScdTSM4NQyP0pA49KAJ4wGfAHWta1UhRWdZpyT3rXgX5RQBahTpVuIVDCnPerkCHIwBQBYgQ8VoQJwKbbJuI44rUt7cEAngUANji3AVZjjwKnAVQAoFJvwaAE246Clx6jmnF+KRnFADHXIPFUJYGbsauSSelQmYjjNAGRcQKkvzc0S42gLxipL4Zcv2pkaMwoAoyYBJxUYOYmOOKvyQEqQRxVCYeVbsPegDn7w4cgetZ057Gr2of6wEGqEmSRzz7UAVJQ6jOOCarnewwBV/YF3HLEk9zUPzbu2KAKm1+4wfWpI4yxO49PSp5A2MnGKckLnBVWPvQAqqFXPTFSRuSeB+NK8MhTnAFPhSOLlmz7UAWY93kMOCKxrgtuOe1btreQAbSoG7iql5CshbYgA9aAMLblWwDmktoJZiRjAx1rVvfs1jCodhkjms4X6EZhOPrQBeWNbK2JY4PrWJduZXLHBz3q5LJJPGGbkVSYHkAUAQRZjmB7E1HcWKtM7bepzVggNt55B6VaXaVBIycCgDhM81MhAqAEc+tSIc0AWFOeMVOnXAqvE1WEagC3Gfl561ZiHzc1VhG5etXUHANAFpDjBqzHyaqx9vSplznIoAtQTGKQMoyQc0+4neZzI3U1Ufg/KaUscdeO1AFhGGaDJ61UdsLgmgPnGaALYbNPVsEVUDnoBUysDjtQBsWnKg5xWzbrnGOaw7BxtGeRW1bsQwIoA0IgeMcVq2kQJHrVCwiMrcDPtXRWVqAMsMYoAmtIAMM3Aq+DgewqHhcDtSFs8UATM4waZnJ4pqjvTgCDgUAP4I4prZ9eKVBxTZnCqRQBFIQvSqU8uDxT53PXNVJZNzUAWIh5y4NTiAoOlQWLfMM8VqSN+7oAzrgrHGd2CTXO32WUj3rT1VzI21OPWo7e1Dgb6AOVuoGbAArOmQxtjFekGwhCDCiuY1uwSKfeThKAOet7WS4b5AcE96uPpccRHmPye1WYruOPasWOKiurnl2OOB1oAgZYYw20ZwO9Z8l3t+ReM9cVEt2WkYMc5FZ7l/MICls96ANJ58ISTkVA04YDB6UW9sWX5z17VOltDH1P50AJHA9xIGHygd6v3d7DaW2zhmx61n3WpRwIVGDx2rmL3UGkcnOaAK3iG/lkm3Mcis5bxgigkiq+oXXmSbSKpGU4wTxQB0um6q0cmXOU9K25GV1WaLlG7elcFbygkAmuv0SdJrKSMZyvIoAtAAkEDpSbiOAeBTEf5sU5j8xoA4jOM05GwaiPU06MjvQBajNWI2zVRfY1YhBz0xQBp25+XAq6hAXis+A4xV1WA96AJ0PIqUvg1BuCj1pSTtBPQ0AS7896QtyAKg3cUBie9AExJPWngHFRLk8g1NGccEUAWLaNpeFrVg0iZ4yVIyKv+GrGJlDSck12dpYRRMDjINAHF6fpk5OCMAV0Nvp3ygscCui+yxRggJ19qguI8oFHT2oAl0+JIY8R4Y9zVve3vUGnQCMc5NXSgB4FACqcrzSDk0mcnFOxxigB446GpU5PNQR9eanXigBWIAqsxEmSOop8jA8etRuVT7tAFO5wOTWbJLtYelaFwwY4NUpLMTkbWxQBatVYlSOQa07jAjG5sYFR2caW1sOcn1rJ1G5aSTbkAfWgBZfK3lgxzSNKTgKRWLcXJVuDyKqyXj7SQ2KAOoW5VBgklvrWJrge64HOKyort2PLH61ZiuAInd2zx3NAFKHTpd+XIX8aludNHlbTJXPXmuyfaGWPgA9c1mahrlyDkSHNAG7PYRwuCTn8arX8sEIDBh9BXIz6pcSk5lf86o3E7+Su52J+tAHSSas24hBtFVptRkcfMxP41y3msGPzE/jTjK2PvGgDZnuVCtl+frWJdXG0Hacg1DI5OeTVSZiFIB4oAilmOc55NReafwqpI/zGmeYc8GgC6s+Dwea3fDmpiC72vnawwa5Td81SwzmOVWB6GgD0wPGXbZIPxqbfGe4rkvth+RlPUVbjum2DmgDHLc8Uqc9ah3YpUPNAF2I8jFaER4BNZsHXmr8R4oAtxnd0NW4/lHPOaoxA5zmrAbHGaALG+nFvlAB61W8znOKcCCPagCUkjANGcjioGYls5qSLG05OKALMZGADUsDEyKvvVMN8vtViymVJwxGcGgDs9OWaLywFIrt9PZmiAY/NjrXKWOpRsIcICCAM11VthguPwoA01LbMNz70qQg022OJCG6Vc3ADpQA2KMIOaf1ppbdTuiigBmAD3p/QcVGD83NOJ9+KAFBwc0rycdajDc00+9AClhmoJW54pWaoJJNnLUARSEDJY1C8p2jaagursE8Yqk8+Ty2BQBdvNSa2iCjq1c3eXzMdwJPPrUd/ctLITnpVbY0xGOAKANC2Y3OM5rTayiVQSOcd6q6VD5cRJGfpV+bcUyAee1AGNeRKPuYGKzBdfLJA3UVf1F2XPykVzcrOk4cdelAGVeL5V0Tjqay7xzISOcg/nXQ6xAzwiUYBrlb6Rx8sZyaAG/d5NU7q45x2qIiUkndz6VWmjcntj60AODgHp1p5cdqqmNweaniidg2R0oAV2z0qtMCEPqamZJFGFGeOaVomZRxgigDAnJBJxUAfirt3Gwc8VnzHbigAEmWwDU8IZjwMmqcCkyHitOFWWPpyDQBqQxyG2XI6CrSsyqADVS1kfyuv1FTGTmgCpuNPjPY9TUIbHX3qaEhiDQBoxds9auQYxxVCJsmrkLbelAFr7vTml3HHNQrNhSMUzzctQBZ389al8zg1VVgfrTlc96ALMbBjyaGkAbAquDio2lAJzQBZa4xwBU9q2/nvWJ9owevNWYLkLjn5qAPQfDl2gKrIMgV6Lp1yksabe1eN6Deo8yqTjmvUNJcLbqyk57UAdRxvDA1Z81GXA61iC8IIzwDU8UwLcc0AacZYfeqXOUJHaqcchceh71OhCUAN5POaCxA9alEYIyOaaybfegCJSTz0pS2T1prdKZtOc0AJKwWs3UJ8AY71fmXI4rLvY2YDFAGZPJg8VRvZSIfmHJNW7hVgb5/vHtnpWTdOSxJOaAI40LyA9j2q+cRrtAAPrVBHy64qy6yORnjJ60AbenL5candT72R1bOOCOtUJBKioqcjvzVm5l/0VNxyaAOe1educ1zV/Kwwc9s9a6TU3UL61zOpMjY/KgCC6uJH084PQVyM9w7v3Hqa6W+cQ22OxFcvM6KpzmgCN5MLnPNVnmyCKbNOoHQ1X3nPSgC0CTg5PFWoXYDiq0SllBxVtAq4zQBoW2PL3uO3NULu5DEtjFTyOFszgnk1hyEqx5JLUAF0waMtWJP8zcHir945SEj1NZ8eCaAJLZtr/Nwa1rMtI3yjIrMjjjQZZuTWloyvvJQ4FAGs1myxqMEFqge2ZGKknIourqXzRlsgelQNcuWJyaAK3cVbjA25qtGMkGrEfvQBbi4xU4aqwYBeOtOL4X3oAnMgFAfNV1O6pNwU4FAFpGwfanbwoyapGU81G02TnkYoA0vOBFUZp8E5qNZflOTVZ25JY8UATBzKflGKn8l93JqtbsCRtatSBSV+Yg0AJYeZBKrqTkHNeu+FNTS7slyeV6ivJ1ADHpXT+F70WZw5+8aAPRb27bKhcYHatfTDmMP2NYEMZugrpzkVs2IeAbDkr2oA3oQpGV696bIxDcGs+O6ETEHvU8c3mPu4AoA0LaVlzu6VIZATwarllVOec+lN3AjjNAExOf4c0rLtXLDrVYT7G71FcXJkPHSgCaWaGMcnmsW9v13FU4HrTLqcAn+9WVcSbuTQA27U5BPOehqmYFc8mpftBA29frTd6EHa2DQBNBZxA5zzV+8hAgjK4xxmspVYnKy4qy4zEFeYZHvQBYnkWBMyEfMOMVmyymOMFm69BWhpv2eciG4YtzwcdKpeJbJASIJenTNAGRezKV5IrBnAlYsD8ooubabeE8zcaZOwtrbBGDigDC1qfKhPSuanZt5JBNa9y7TOWYYJPSotsanLjJoAxjbvIM8hacsO3BJzitG6O0hiNo7VReQbCQRQBM8mBgcAU1ZzuPfFUzITnPfpSrKVNAGpcSlrLI5HesVpSeo7VfbMsewcA1RkgZZtpycUAZ2os20etVYpMda1dTg2qpYHJrNWMc0ASptdgM8Vr28qxw4Q4z1rF8tl5qaEnGN2KANCWXbjvml3g1ULnJ/iPalTeVBOaANFCAPwqVDxzUJ4PHvQGPQGgCxux1oEmTVd37ZpQ4A680AW1cDtzTDJ8/J5qLd0pJmAXk/jQA95MLjnJqPcduWNQNIcjuKaJtxA6AUAWjJ8vTiomyw5OM0kkq7eOtRj5yM9KALtrGEYZ5rZjZQBxWLbvkj2rRSUgDNAGjEqMdw61p2ABmXjgGsiCT5RxV63m/eAUAenaLfJCF+YbCODW+98gTOQBjNeYw3DQIh3ZB7elP1HWJ5RsXKqByaANzVtfEU7Mr5x2p9j4saUhQorhpJA4+bn6063cxsCDQB61Ya4MHzQTxxinjVXdz8wHpiuBs79SB8xJ781sW04OCG/CgDr47ouOTSvNlfQVgxXJAHNWftQIGaAHXMh3EZrOnbnINWLh8gtWdLLjNACOx55qtJKc5FOZztzmqcr8EZGKAJUvXEgC8gGtB7+NmAZRnFYAcLznmmo5ebPagDr9OmQgtGMEVSv2eZ23E1FpcpVJCvJqeUYTzDjJoAymRIgzO3Nc5rciupwxrZv5wxOOR3rEuypOOKAMEjAOQSDUOwAs3OfStCcouckVnTyrhjuH50ARShprf5hyKzZ1wMY4rQgkHKluo9arTgb8djQBSKjGBUiRgDmpDEd2MUqgL7igCWAZyW6UpuoYyMgEiqt0+Ixt4rPDZPPWgC7q14twQAgGBxWP8AxEjrVpsFiTWezYlIzxmgC2rbsBhmjyTuBBqONvnG2tF422g7ePagB1vBjDMBg0/YB0AqfYHgXqMVILZcDmgCmzjHNRmTGeaZI2ahYknmgCyHFOLVWQ1Ju4oAsBto460xpfXmmo2BVW9mEYwPvUASTTLjAPNQq2eRVON2Y8ircJyuKAHgEtVqFCRioFIB96sxvjpQBfgjXA9atrgYHWqEfyjryatQvigDTtl3Ac4qwijeRnmqdvIdtWo5PmFAFu3d1mCsfard7Pk+WBgAdazoCfMJ/GrEk29cEc5oAiJzxmkRyvU8Uu3nBFG3NAEyuV5U4NadhqBTCyce9ZIIxjFOOVXNAHYwXgZQScfjUxu8cZyK4iO9dDgn5a0Ir5SV+agDrFug6YJ/GoJm/XvWKmoKnHJNTy3hlhGCM96ALU06qMFhWbc3sak4NZ9xOUPzE81i6jeYyFFAGo+oxs3J4FPTUzvAQAg1xv2hncDJ69K3NOQwjfLwT0oA73RboCN9+MkVX1bVYkXAkx7VzCap5L/I3tVHVpi3Ocg80AX7jU85KlfzqrJdpIRmRRXOvORwBUPnc+9AGpqEqYJ8wVjTTJs5c81FcOXPWqNx2APAoAvpNGGBDnNT3EkeV+frWEzbRwaGlZ4cnsaANw3GAeQ1PSRREWJ5Nc0JWB5Y1fspw3DHIoAuXU0bAc1V3KuTnOakm2H+HioZSoABFAEU0vUDjNU8ZcjHNXZIuQw5WnrCg+Y9aAG2kTB1OK6GxjZp1Rj8nesuxtjcSAAknPFb8NqbeRfNJBPagDUfT45IyIxj0qFNL+UbgSa0raJzETHnFI08qsRjpQB5ZPeHJFRx3XPNZskhOeeT1pgl460Ab0VwG6nirSkEVzkM+Op4rQS7G0AGgDQkuAgNZ00vmuWNMmlLDiqu85oA0Ijx1qzG+BzWbHIQOalSQnvQBpK2aliaqcTHHWrKZxxQBejfnGeKnMmMYqkhI+tPLHjNAGxZSHBzV5CS3BFY9hIN34Vpxsc5oA0rdhzn0pQ4yD6VDBk5xTMkMRigC08uWzjrS571HF8wwR0oY8jH4c/5/lQBNkYwO9RyN2zSKxHak4J3HAx60AVpUIycmq0c5hcZJJzVq5uQqYBGaraRc2tvrFrPqFuLmzWQGaE/xpn5gMHg4zg+tAGlHOJl3bsGrFnM6y7WOUJr1PxD8FYLqFb3whqe2ORRIkF1lkYHn5XHI46ZB+teWeINC13wy+zWtOntgTgS43Rueejg49Pf1HOaANe+0iWaxaWM5wM/hXnV5M5mZDkEcV3GleLRHYGzljJLDbvrn10szalIT9zOaAKOm2u7Ej9uRmrd/chE2A81pXcC28GRgAcVzxjeaRnI47CgAt3O4kk81auZBJbDHVaqGJlXpzSxliSjDg0AZs0gzx2qu8xUnBqW4idJGwpxVWVWZehB70ASo+/vUMuAcEEn9KRVkVc4JA7VTuJJCSDkUATssUgI3bW9KqSP1VRkCq7rJnIBo2SMBwaAFJOealhl29Ki2Pj3pYxzyMGgDbglV4lz1qV0D8gCs2DggVpW7YYDFADRFxg9KQx4OO3pWg8Xy7h3qrKSDgjB7UAT2BNtIrc9a32VWi+0ysWz0Fc/aMzKSRnFdHbuH0z98uMdKAH2esmJMLHhc9TV1b2GUbyoyfeueuSBbjap4qmlxIq4ViBQB52z1Hv5pHNRHrQBKZMd6kjn4xmqZPNKCc0AaiSbl60bx0qrCxx1pHY7utAF9WBHWp4yAKzIn9TVlJOnNAGrA3PWr0cgAArGimAJ5q5FKGAAoA093PWnE571TRumTU28cc0AXbZ9ko5raR8gGubV/mBzWvazbo/egDbtbgIc1oW0KTOSB1rAjfHJrW0+faw54FAE9xEbclTXQaH468R6PpsNjp2peTZxbtkfkRtjLFjyVJPJJrm7yXzpDg5NRRkqMY57UAdo3xP8YAnGr8f9e0P/AMRVaX4qeMlzjWP/ACVh/wDiK5cggE9ay7ssGPFAHYv8W/Go/wCY1j/t1g/+IqbSfib491XVrTT7PWd1xcyrEg+yQdScf3OleayM2eelQmV43zG7K2CMqcHB4NAH174k+JvhvwvALe81L+0b+NQrxWoV3ZhwS2MKp7kZHsK8f8XfGbWtbiltdOt4dOsnBRgAJZHB9WYYAx6KD714u0jA8c49a7PwBobaveB51/cA5z60AXPD/hy4visxQiPOR710c9iLfPyjjivRbLSIbO02wLjA4rg/Fl2LKCQNjcSaAOJ1icTTeUjA4Pai3t1VMtgZFUrBfNudx5yc1oXmVBUdBQAgt4mPBBYdBUMqqhYbQrU2KcK6cc55NW7xQWD8YIoAxLyNZE3L171izqd5xXQTKI8tnhuorOvIQBuQZFAGRMzqmMnJqm7Nnk5NXLg5644qo+DnFADGf1pgY4ODn2oPJpynBFACgHGSKem0t8wFG75ck8VNbRGQgoKALEcMbKuB1rSWzVEBX5mNJbwqE56gVJZEvFJjqOlAETSFF2449KhCiRjniraD5CWX5qxp55BcEJ1oA2rOKRRhVyM1rXYmECqU2gc1R0i5CQB3GD6VZOpm6ZkZMHoKAKck5eMoQKi8kelPaFlnK4rRhtA0SlgSaAPHG61Gw4p56mkIz0oAi9aUDinYx16UgFAEsRwKR2+agHAqNjzQBIpqZH4qruqRDQBbV/mq1DLtIrPVuTUyMKANaOTcKnDnislH461bhkBGM0AaMb9Oa0LKXa+09KyVyAKsQsc8mgDoo3Ocdq0bWYDKkViWsgYfNV+J8EEmgDRL4c807eSRioxiTDKM+1SrjGCMGgBSzBSao3MoYdMVe2fu2JNZEqsQ4waAKUz54zVOeUDvU80eOTxWdIBuIOaAJbUefdRx/wB5gK+i/CNhb2WnQqiqvyj86+a7eUxXCOvVTkV6x4b8ZIbVBNIFdeCDQB7N9qRYG5HArwrx9q63erywRH5IzV/xH4/hgs3S1bfM4IwD0ryx755pXldiXbk5oA6fSbjZcL3zWnPmRyD61ymmXYNwgz3rqXYrLkd6AKjpsfrzV24YiBM9cVLFarO6tn5u9O1CMKSFGcCgDIk/eDBquQUYg4K96sMpB+YYqjKSXO2gCG9s4yu6Ik5rGmgaPsa3o2b8PSnPbpccKQD6UAcuiEk5NLsOa1LvT1ibcCevSqjBUTGOaAK20nvVuzJiwc8UxQpGD19at24UYDYxQBdt5t6kZAJq1pkEh38fL7VHY28TzYBAreSM23ygZHqO9AGURHGHEpww6Vy1yx+1sVzjNdNrcJCNMcgMePeudMe5g2eO9AFtJ22AqeaWC/eKUFutV9rjhRxTXXOPWgDoLKSS7lDCuygWNYUDAZA5ridCdrfL9QOQKvSazIXJBwPTAoA8gzSZoIOfalC+nWgCNqdGM04ofSnoMUARPxUTGpJOpqI0AKMGpFIxUI4NOBoAnU1KrYFV1NOB4oAth+KswNyDmqKZ4J6VIJNo4oA2UnUAAmp4p17VhCXNTxSkUAdTZSgt1rWRgfeuUsphuBJ4rctbk/hQBu2jYbOea1YI1m+X+I1gW8qnHrW5YThHVsZxQAy4jaF9pzUFwiPF8mdw6117afDqUSunyvjp61lSaFNDK+7JSgDhb2Fg5HNZEylXI5Nd7e2CqxJHIrktShCyEjoDQBkqmWP+cUjSMhwrY+lTXDqp4qmeSSKAGSMT1NNEhWg8mmOKANCxb98pz3rtLW4imYbpMECuDtiVYt+VatnMd2R1oA9MsYkSLcGBJpbqAyBiOBiuf8P3zB1SRuM9665grx7wRg9qAOSvFKtisiRCHzkV1GpQZbJHHtXP3cZVyMHafagDOldt2AQKktAzzDpgc5zSGMZO4cetTRp5Nu7gZzwKALUyR3UBO3a4PXPWsK6tSpx2q7ZSnEiEHkcUpwQN4yB1oAyDCykYHSpo05PUVsrFDgEY+lQvBmQlBx3oAj03PmgsSK6eO6ENsDMM+may7GGHzPmzhec1Hq95DI3lwPnb2oAsa9drdWIUqBjpiuJW6aJ8cde9aV3MXh+Vju71gzttYZ65oA10u94wcc0qSqXxWOrnPFWYpNuD3oA6PTyZGx0WpprJvNba4xmueW/dCAvTvirC6jKRkE4oA5IxjuKAntTi4zz6U0yDBoAbJ1wKjzigyc01jnpQBG4yaiYc1PUTjmgBmKBQetKBxQBIi0/gCmrwOtIetAD/ADKA2T1qOnqORQBLnipYmJ71CBk1PCoH1oA0LRsfhWjDMcnAxWTE2COa0IOeTQBsW05yK39Mvdsi5Ga5OB8EZP41s6dMqOCeSPWgD0mC5dI4nj4z2q5du5jDbuTyRmsHStSjlQecNuBwa0Yr1ZztGDQBk3G55mLMAPSuU8SQuGATHviuxvVjDlnOOaxtSVJlZkI49qAOEMDdSOtSC32Q5YDdWzdwKsO9WHHb0rDmn5IzzQBTlHzHIqEsM81ZkXK7s5NVZB0NAFiCRcgH86vRgI25TkVjocdasrKVHynmgDorK5G9cnBzXZWl45hGOmO9ea2sz+Yo96662uXWAEgUAdBHIzE7iDmqepwnYGUVHYX4ZgrKv51euLoMuDGCuKAOZeIvNjkj2qaWAhFXmpzuSXKrgZqneXUrSnrgdKAJYI4llVsc9KJoBE7HGQearW0jFjkcdeat3N4zRjCrQBnliXIA4q7p4kefYuDniqiXTLn5F/KrljemEedtUGgDYv8ATvLtMYIb1FcXNCIJ2bcc5rqW1OS6QruxXIa27rKSGyKAGzlH537cVmzhGbAORUMkpPWqs0+08daALDSKhwKcl0FHK5NZZlLNTg5x1oAv/bTyAi1IL1lGAQPwrO5bkUrDmgCk0pNNV6Y/DEY56e/5dv8A61NzgdDigCRmpA9Qlx/kim7+ev6igC0HGeaRxnoetVy3OT/OnLLt7/qKAHYw3NPAGKQENyDz9aXBx3/KgAPHSkJFIR9fypP8/wCeKAHE8U5WqLJ9D+RpRk9j+VAFgNT0c9qrqTnofyqVc+n6UAXIWJNa0BzHmsWHqKuRSsh4zQBrIxHbir8N0FxhRmseKTIyTU8cnPBoA6O3vJJhheK1I5ri3j3gkEc1yllcmGQNmtyfURLEoDDpzQBZGtPKSsq5p8c4O8noBXOzTeW2R0qSK/G1hnk+1AC3kguHbaSuDVC5symGJqWVxywqjJeOSeuB6igCvK5TK1X3YbnkVPKS/PGarY+bHQ0AWXhXaGB49KIow5xk1Eiv06ircCkL/wDWoAv2cKR4Y5JFXmusD2rOVzgdafnI69KALf2llbKnGK2NOvTMdjHoOtcxuJkxWjZsI8EHB+tAHXRxhgRwxPSqstgIVZp2weoFVbbUREmSenuKnk1NZ1yVB/WgCtbNASVOQPWoZYmTccfKehp8zKsRlSMD2xVOLUPOUoUwaAK9xKQCoFMEvmwbeQR0p04w2G53e4qzZ20UmVDZI96AG2U6wxtv/iGKyNQy5OB8ta88OGJPCjqcVl3ZDHAPAoAxZlIGazZ+WORW1OowQRxWTcjPGPxoAqr1qVc0wKQfapUHPvQBIg9KlaPmkiHoMn09as7CQCA7cDkA88fSgD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) showing a choledochal cyst, type IV-A, in a 12-year-old female. Note an anomalous&nbsp;pancreaticobiliary union, type \"BP\" (arrow).",
"    <div class=\"footnotes\">",
"     BP: bileopancreatic.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright &copy; 1997 Taylor and Francis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7808=[""].join("\n");
var outline_f7_40_7808=null;
var title_f7_40_7809="Histology lung 2";
var content_f7_40_7809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology lung 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7809=[""].join("\n");
var outline_f7_40_7809=null;
var title_f7_40_7810="Patient information: Hepatic encephalopathy (The Basics)";
var content_f7_40_7810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16979\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/0/18434\">",
"         Patient information: EEG (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/60/24515\">",
"         Patient information: GI bleed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/42/44706\">",
"         Patient information: Liver cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hepatic encephalopathy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hepatic-encephalopathy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27663767\">",
"      <span class=\"h1\">",
"       What is hepatic encephalopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hepatic encephalopathy is a condition that causes confusion and other thinking problems. It can also cause changes in a person&rsquo;s mood, sleeping patterns, and body movements.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663782\">",
"      <span class=\"h1\">",
"       What causes hepatic encephalopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who get this condition also have a type of liver disease called cirrhosis. In people with cirrhosis, hepatic encephalopathy can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding in the stomach, intestines, or other parts of the digestive tract (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        An infection",
"       </li>",
"       <li>",
"        Changes in diet",
"       </li>",
"       <li>",
"        Constipation",
"       </li>",
"       <li>",
"        Taking certain medicines",
"       </li>",
"       <li>",
"        Worsening of the liver disease &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663797\">",
"      <span class=\"h1\">",
"       What are the symptoms of hepatic encephalopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Being confused",
"       </li>",
"       <li>",
"        Memory problems",
"       </li>",
"       <li>",
"        Mood changes",
"       </li>",
"       <li>",
"        Trouble speaking, drawing, and writing clearly",
"       </li>",
"       <li>",
"        Problems with sleep &ndash; Some people have trouble falling asleep. Others sleep too much.",
"       </li>",
"       <li>",
"        Moving more slowly than normal",
"       </li>",
"       <li>",
"        Flapping hands",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with hepatic encephalopathy usually have symptoms of serious liver disease, too. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A swollen belly and legs",
"       </li>",
"       <li>",
"        Fluid buildup in the lungs, which can cause trouble breathing",
"       </li>",
"       <li>",
"        Yellow skin and a yellow tint to the whites of the eyes. This is called &ldquo;jaundice.&rdquo;",
"       </li>",
"       <li>",
"        Red palms",
"       </li>",
"       <li>",
"        Shrunken muscles",
"       </li>",
"       <li>",
"        Tiny blood vessels that can be seen just under the skin &nbsp;",
"       </li>",
"       <li>",
"        Bad breath",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663812\">",
"      <span class=\"h1\">",
"       Is there a test for hepatic encephalopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do many different tests. Some are used to make sure you do not have problem besides hepatic encephalopathy. The tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Tests for your memory and thinking &ndash; The doctor or nurse will ask some questions to check your memory and thinking. For example, the doctor might have you do simple number and word tests.",
"       </li>",
"       <li>",
"        An EEG &ndash; This test measures electrical activity in your brain and records your brain wave patterns.",
"       </li>",
"       <li>",
"        A CT or MRI scan of your brain &ndash; These are imaging tests that can create pictures of your brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663827\">",
"      <span class=\"h1\">",
"       How is hepatic encephalopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on what is causing the problem. Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taking medicine to treat an infection",
"       </li>",
"       <li>",
"        Taking medicine to have more bowel movements",
"       </li>",
"       <li>",
"        Changing your diet",
"       </li>",
"       <li>",
"        Stopping medicines that might be causing the problem",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663842\">",
"      <span class=\"h1\">",
"       Can hepatic encephalopathy be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting hepatic encephalopathy by asking your doctor or nurse what types of foods you should eat. You should also always check with your doctor or nurse before starting any new medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27663857\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       Patient information: EEG (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"       Patient information: GI bleed (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"       Patient information: Liver cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/40/7810?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16979 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7810=[""].join("\n");
var outline_f7_40_7810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663767\">",
"      What is hepatic encephalopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663782\">",
"      What causes hepatic encephalopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663797\">",
"      What are the symptoms of hepatic encephalopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663812\">",
"      Is there a test for hepatic encephalopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663827\">",
"      How is hepatic encephalopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663842\">",
"      Can hepatic encephalopathy be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27663857\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=related_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7811="Sudden infant death syndrome (SIDS)";
var content_f7_40_7811=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/40/7811/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7811/contributors\" id=\"au116\">",
"       Michael J Corwin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/40/7811/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7811/contributors\" id=\"se4794\">",
"       Teresa K Duryea, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/40/7811/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7811/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/40/7811?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SUDDEN INFANT DEATH SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sudden infant death syndrome (SIDS), also called crib or cot death, is defined as the sudden death of an infant younger than one year of age, which remains unexplained after a thorough investigation [",
"     <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/1\">",
"      1",
"     </a>",
"     ]. The cause of SIDS cannot be identified in most cases.",
"    </p>",
"    <p>",
"     SIDS is the leading cause of death in infants between one month and one year of age in the United States, where approximately 2500 children per year die as a result of SIDS.",
"    </p>",
"    <p>",
"     This topic review will discuss the possible causes of SIDS, how a case of SIDS is investigated, and ways to reduce the risk of SIDS. A more detailed article about SIDS is also available. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"      \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS SIDS?",
"     </span>",
"    </p>",
"    <p>",
"     SIDS is the term used to describe the sudden and unexplained death of an infant who is between one month and one year of age. Most infants are between two and four months and 90 percent are less than 6 months old. Most infants die during sleep, often between midnight and 6 AM, and have no signs that they suffered.",
"    </p>",
"    <p>",
"     Before a child is said to have died of SIDS, all other possible causes of death must be investigated. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Determining the cause of death'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Apparent life-threatening event",
"     </span>",
"     &nbsp;&mdash;&nbsp;An apparent life-threatening event (ALTE) is term to describe an acute, unexpected change in an infant's breathing behavior that was frightening to the infant's caretaker and that included some combination of the following features:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Apnea &mdash; usually no effort to breathe or sometimes attempts to breathe with difficulty (obstructive)",
"      </li>",
"      <li>",
"       Color change &mdash; usually blue-tinged or pale skin, but occasionally reddened",
"      </li>",
"      <li>",
"       Marked change in muscle tone (usually limpness or rarely rigidity)",
"      </li>",
"      <li>",
"       Choking or gagging",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In the past, children who experienced ALTE were believed to be at risk for SIDS. However, the vast majority of infants who die of SIDS do not experience ALTE prior to death. Studies over the past two decades have failed to find any evidence that children who experience ALTE are at increased risk of SIDS. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"      \"Apparent life-threatening event in infants\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SIDS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of factors that can increase the risk of SIDS. The most commonly identified risk factors include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Prone (stomach) sleeping position",
"      </li>",
"      <li>",
"       Sleeping on a soft surface",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       with bedding such as loose blankets and pillows.",
"      </li>",
"      <li>",
"       Infant sleeping in the same bed as an adult or another child (bed-sharing)",
"      </li>",
"      <li>",
"       Maternal smoking during pregnancy",
"      </li>",
"      <li>",
"       Young maternal age (under 20 years)",
"      </li>",
"      <li>",
"       Late or no prenatal care",
"      </li>",
"      <li>",
"       Preterm birth",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       low birth weight",
"      </li>",
"      <li>",
"       Overheating",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Approximately 15 to 20 percent of SIDS cases occur in child care settings.",
"    </p>",
"    <p>",
"     Strategies to reduce the risk of SIDS are discussed below. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Reducing the risk of SIDS'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SIDS CAUSE",
"     </span>",
"    </p>",
"    <p>",
"     By definition, the cause of SIDS is not usually known. However, studies that examined the records of children who died of SIDS have provided a better understanding of how SIDS might occur.",
"    </p>",
"    <p>",
"     The most likely theory is that infants who die of SIDS have an underlying vulnerability (eg, genetic pattern, brainstem abnormality), and are exposed to a trigger (eg, maternal smoking, infection, or stress related to the infant's sleeping position or environment) at a vulnerable stage in the development of the central nervous or immune system. However, it is not yet possible to know in advance if a child has one or more of these vulnerabilities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Vaccines and SIDS",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is NO evidence that childhood vaccinations increase the risk of SIDS. Although there are anecdotal reports of infants dying within a few days or weeks of being vaccinated, this is because most infants in the age range at risk for SIDS are also getting their routine vaccines.",
"    </p>",
"    <p>",
"     Studies of large numbers of children have shown no increased risk of dying as a result of childhood vaccines. Furthermore, the number of cases of SIDS has fallen by more than 50 percent since the mid-1980s, whereas the number of vaccines administered continued to rise. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"      \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Determining the cause of death",
"     </span>",
"     &nbsp;&mdash;&nbsp;Following the unexpected and sudden death of an infant, it is important to try to determine the cause of death. This usually involves reviewing the infant's recent health, behavior, diet, sleeping habits, and general appearance. There will also be a review of the child's sleeping environment, including the type of bed or crib, the amount and position of clothing and bedding, the room temperature, and the type of ventilation and heating. Examining the scene can help to exclude accidental, environmental, and unnatural causes of death.",
"    </p>",
"    <p>",
"     A postmortem examination (autopsy) of the infant is performed in most cases; autopsy is necessary to detect some congenital abnormalities (birth defects), injuries, infections, and metabolic defects.",
"    </p>",
"    <p>",
"     It is difficult for many parents to face this type of investigation while struggling to cope with an infant's death. However, these procedures will enable the parents and physician to understand why the infant died and how other children in the family, including subsequent children, might be affected. This type of examination may also advance our understanding of the cause of SIDS, and help to prevent future deaths of infants in other families.",
"    </p>",
"    <p>",
"     Remaining in contact with the child's healthcare provider can help parents to cope during this time; the physician can discuss the results of the investigation, answer any questions, and provide emotional support. Parents are also encouraged to seek support from their religious group, a SIDS support group, or a grief counseling center. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Coping with the death of an infant'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      COPING WITH THE DEATH OF AN INFANT",
"     </span>",
"    </p>",
"    <p>",
"     The death of a child can be an overwhelming experience, filled with anger, guilt, blame, fear, anxiety, sorrow, grief, and failure. Immediately following a child's death, parents often experience feelings of numbness, shock, and disbelief. Intense feelings of sadness, yearning for the child, anxiety about the future, disorganization, and emptiness commonly develop in the weeks after the death.",
"    </p>",
"    <p>",
"     \"Searching behaviors,\" including visual and auditory hallucinations of the child, are common and may lead the parent to fear that he or she is \"going crazy.\" Despair and sadness are common as the parent comes to accept that the child will not return. Sleeplessness, changes in appetite, agitation, chest tightness, sighing, and exhaustion are common.",
"    </p>",
"    <p>",
"     Grief comes in waves that are often precipitated by reminders of the child; the parent may feel fine one moment, and be overcome with sadness and grief the next moment.",
"    </p>",
"    <p>",
"     Normally, feelings of grief gradually diminish in intensity over a period of months. Anniversaries and important events often trigger waves of sadness, although the severity of the sadness usually diminishes over time. However, the grief may never go away entirely.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Grief versus depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is often difficult to differentiate grief from depression. Signs of depression include feelings of hopelessness, helplessness, worthlessness, and guilt. Parents whose grief is complicated by depression often benefit from an antidepressant medication in addition to individual or group psychotherapy. In contrast, parents suffering only with grief are more likely to benefit from counseling or psychotherapy.",
"    </p>",
"    <p>",
"     Treatment of depression is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Counseling or psychotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Counseling or psychotherapy can be helpful in coping with the loss of a child. Several types of healthcare providers provide counseling, including social workers, psychologists, nurses, and psychiatrists. Some people prefer to meet one-on-one with a counselor while others prefer to meet in a group setting with other people who have had similar experiences.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One-on-one counseling usually includes a discussion of emotional responses to the loss, coping methods, and ways to maintain personal relationships.",
"      </li>",
"      <li>",
"       Group psychotherapy allows people to compare their experiences, overcome their tendency to withdraw or become isolated, and support one another's attempts at coping and recovering. SIDS support groups are available in the United States and elsewhere (",
"       <a class=\"graphic graphic_table graphicRef63630 \" href=\"UTD.htm?25/33/26141\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Relaxation techniques can help to relieve feelings of anxiety, and may include meditation, progressive muscle relaxation, yoga, self-hypnosis, or biofeedback.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      REDUCING THE RISK OF SIDS",
"     </span>",
"    </p>",
"    <p>",
"     It is virtually impossible to prevent the death of an infant related to SIDS. No monitoring system, test, or combination of symptoms has been found to reliably warn parents or physicians that a child is at risk of SIDS.",
"    </p>",
"    <p>",
"     However, there are several strategies that can effectively reduce the risk of SIDS.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Preventive strategies",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       All infants, including infants who were born prematurely, should be placed on their backs for every sleep. Even though the child may be able to roll from the back to the stomach, infants should be placed on their back to sleep. Side sleeping is no longer recommended, and infant &ldquo;sleep positioners&rdquo; should not be used [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/2,3\">",
"        2,3",
"       </a>",
"       ]. Prone positioning (\"tummy time\") is encouraged when the infant is awake and can be monitored by an adult.",
"       <br/>",
"       <br/>",
"       The American Academy of Pediatrics (AAP) began an advertising campaign in 1992 called \"Back to Sleep\", which informed parents of the importance of putting infants to sleep on their back [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/4\">",
"        4",
"       </a>",
"       ]. The rate of SIDS fell by over 50 percent following this campaign.",
"      </li>",
"      <li>",
"       Infants should not share a bed with adults or other children during sleep because this increases the risk of SIDS. For the first six months, the safest place for an infant to sleep is in a crib (cradle, bassinet) in the parents' room [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/3,5\">",
"        3,5",
"       </a>",
"       ]. There is no evidence that &ldquo;co-sleeper&rdquo; devices that are placed within an adult bed reduce the risk of bed-sharing. Infants should not sleep (alone or with an adult) on a sofa, recliner, armchair, or other type of cushioned chair.",
"      </li>",
"      <li>",
"       For parents who want to sleep closely with their infant, a variety of cribs and bassinets are available. These provide a safe sleeping surface for the infant that is separate but connected to the parents' bed.",
"      </li>",
"      <li>",
"       Car seats, strollers, or swings should not be routinely used for sleep because young infants do not breathe as well in the sitting position. Car seats are still strongly recommended for car travel, and infants may sleep in the car seat while travelling. &nbsp;",
"      </li>",
"      <li>",
"       Infants should be placed to sleep on a firm surface. Sleeping surfaces that are soft, such as polystyrene filled cushions, waterbeds, and sheepskin bedding, should be avoided.",
"      </li>",
"      <li>",
"       Soft objects (eg, pillows, quilts, comforters, stuffed animals) and loose blankets should be kept out of the crib, bassinet, or cradle. If bumper pads are used, they should be thin, firm, secured to the crib, and not padded or \"pillow-like\" [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/3\">",
"        3",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       The infant's head should remain uncovered during sleep. If blankets are used, they should be tucked around the mattress to prevent the infant from moving into a position in which the head could be covered by the blanket (",
"       <a class=\"graphic graphic_figure graphicRef83494 \" href=\"UTD.htm?26/42/27299\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Overheating should be avoided; the infant should be lightly clothed for sleep; the bedroom temperature should be comfortable for a lightly clothed adult (approximately 65&ordm;F [18&ordm;C]); if the infant is dressed in a sleeper, no more than a thin blanket is necessary. Infants should not sleep next to a radiator or heater or in direct sunshine. A fan in the infant's room might reduce the chances of overheating and help to circulate the air [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/6\">",
"        6",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       The use of a pacifier during sleep may reduce the risk of SIDS. The AAP suggests that the pacifier should be used when placing the infant to sleep, but not reinserted once the infant is asleep [",
"       <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/3\">",
"        3",
"       </a>",
"       ]. The AAP suggests delaying the introduction of the pacifier until one month of age for breastfed infants to ensure that breastfeeding is firmly established. Breastfeeding is recommended because it might help protect against SIDS, in addition to its other benefits.",
"      </li>",
"      <li>",
"       Smoking during pregnancy and after the child's birth is not recommended. Parents who cannot quit are encouraged to cut down, and to avoid smoking inside the child's home and in enclosed spaces, such as a car.",
"      </li>",
"      <li>",
"       Commercial devices that are advertised to reduce the risk of SIDS, such as baby monitors, sleep positioners, and mattress wraps, have not been sufficiently tested for efficacy and safety and are not recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Home monitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;At one time, experts believed that SIDS was related to apparent life-threatening episodes, when an infant stops breathing (apnea) and has a slowed heart rate (bradycardia). As a result of this theory, home \"apnea monitors\", which monitor a child's heart rate and oxygen level, were commonly recommended to prevent SIDS. However, studies done over the past decade have failed to confirm a relationship between SIDS and apnea (see",
"     <a class=\"local\" href=\"#H3\">",
"      'Apparent life-threatening event'",
"     </a>",
"     above). As a result, home monitors are no longer recommended to reduce the risk of death related to SIDS. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21414?source=see_link\">",
"      \"Use of home cardiorespiratory monitors in infants\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Siblings of SIDS victims",
"     </span>",
"     &nbsp;&mdash;&nbsp;Siblings of SIDS victims have a five- to six-fold increased risk of dying of SIDS. Twin siblings have a two-fold increased risk of SIDS. However, the risk that a second child will die as a result of SIDS remains less than 1 percent for most families.",
"    </p>",
"    <p>",
"     Parents who have lost a child to SIDS are usually counseled to use the measures discussed above. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Reducing the risk of SIDS'",
"     </a>",
"     above.) Other measures, including home apnea monitors or more frequent healthcare provider visits, have not been proven to reduce the risk of SIDS.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child&rsquo;s healthcare provider is the best source of information for questions and concerns related to your child&rsquo;s medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163657\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163664\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/38/38497?source=see_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=see_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163689\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163705\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21414?source=see_link\">",
"      Use of home cardiorespiratory monitors in infants",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/suddeninfantdeathsyndrome.html\">",
"      www.nlm.nih.gov/medlineplus/suddeninfantdeathsyndrome.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www2.aap.org/healthtopics/sleep.cfm\">",
"      www2.aap.org/healthtopics/Sleep.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidshealth.org/parent/general/sleep/sids.html\">",
"      www.kidshealth.org/parent/general/sleep/sids.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       First Candle",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.firstcandle.org/\">",
"      www.firstcandle.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Sudden and Unexpected",
"       <span class=\"nowrap\">",
"        Infant/Child",
"       </span>",
"       Death and Pregnancy Loss Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sidscenter.org/documents/SIDRC/BackToSleep.pdf\">",
"      www.sidscenter.org/documents/SIDRC/BackToSleep.pdf",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/40/7811/abstract/1,3-5\">",
"      1,3-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/40/7811?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7811/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Sudden infant death syndrome--United States, 1983-1994. MMWR Morb Mortal Wkly Rep 1996; 45:859.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration Safety Alert, 9/29/10. Available at:  file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm227575.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7811/abstract/3\">",
"      Task Force on Sudden Infant Death Syndrome, Moon RY. SIDS and other sleep-related infant deaths: expansion of recommendations for a safe infant sleeping environment. Pediatrics 2011; 128:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7811/abstract/4\">",
"      American Academy of Pediatrics AAP Task Force on Infant Positioning and SIDS: Positioning and SIDS. Pediatrics 1992; 89:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7811/abstract/5\">",
"      Vennemann MM, Hense HW, Bajanowski T, et al. Bed sharing and the risk of sudden infant death syndrome: can we resolve the debate? J Pediatr 2012; 160:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7811/abstract/6\">",
"      Coleman-Phox K, Odouli R, Li DK. Use of a fan during sleep and the risk of sudden infant death syndrome. Arch Pediatr Adolesc Med 2008; 162:963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_40_7811=[""].join("\n");
var outline_f7_40_7811=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SUDDEN INFANT DEATH SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS SIDS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SIDS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SIDS CAUSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           COPING WITH THE DEATH OF AN INFANT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           REDUCING THE RISK OF SIDS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/42/27299\" title=\"figure 1\">",
"           Safe bedding for infants PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?25/33/26141\" title=\"table 1\">",
"           SIDS support groups PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7812="Saccharomyces boulardii: Patient drug information";
var content_f7_40_7812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Saccharomyces boulardii: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     see \"Saccharomyces boulardii: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3870517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Florastor&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      Florastor&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a lactose-free diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to yeast, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More thirst.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sprinkle contents of capsule on soft food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with liquid and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may also mix the powder with applesauce or yogurt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10957 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7812=[""].join("\n");
var outline_f7_40_7812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3870517\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022397\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022396\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022401\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022402\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022404\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022399\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022400\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022405\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022406\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=related_link\">",
"      Saccharomyces boulardii: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7813="Hashimotos thyroiditis FNA II";
var content_f7_40_7813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hashimoto's thyroiditis: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of the thyroid in Hashimoto's thyroiditis. Tearing of tissue lymphocytes is seen with scant follicular cells and colloid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7813=[""].join("\n");
var outline_f7_40_7813=null;
var title_f7_40_7814="Homocysteine metabolism";
var content_f7_40_7814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Pathways of homocysteine metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Homocysteine is metabolized by one of two divergent pathways: transsulfuration; and remethylation. The transsulfuration of homocysteine to cysteine is catalyzed by cystathionine-&beta;-synthase (CBS), a process that requires pyridoxal phosphate (vitamin B6) as a cofactor. Remethylation of homocysteine produces methionine. This reaction is catalyzed either by methionine synthase or by betaine-homocysteine methyltranferase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin, which is the cofactor for methionine synthase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7814=[""].join("\n");
var outline_f7_40_7814=null;
var title_f7_40_7815="Chordoma and chondrosarcoma of the skull base";
var content_f7_40_7815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chordoma and chondrosarcoma of the skull base",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Carl Snyderman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Derrick Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7815/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/40/7815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic junction of the neural and facial viscerocranium is termed the skull base (",
"    <a class=\"graphic graphic_figure graphicRef60335 graphicRef65811 \" href=\"UTD.htm?24/61/25561\">",
"     figure 1A-B",
"    </a>",
"    ). This area is critically important because it supports the brain and allows all the neurovascular structures to either enter or exit the skull.",
"   </p>",
"   <p>",
"    Neoplasms may originate within the skull base or involve it by growth from either the dura or extracranial structures. Skull base tumors include a number of different histologic cell types.",
"   </p>",
"   <p>",
"    Chordoma and chondrosarcoma arising in the skull base will be reviewed here. Topics discussed elsewhere include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chordomas arising in the sacrum or elsewhere along the spinal cord (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"       \"Spinal cord tumors\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Chondrosarcomas at sites other than the skull base (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other histologic tumor types involving the skull base (see appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of a skull base tumor depends in part upon the site of origin of the tumor and its direction of growth.",
"   </p>",
"   <p>",
"    Most patients with a skull base tumor complain of headache and intermittent diplopia. Gradually, headache worsens with upper clivus tumors and neck pain develops with lower clivus tumors. Invasion of the cavernous sinus can produce diplopia and facial numbness. Lower clivus tumors initially compress the lower cranial nerves; brainstem compression may follow. The diagnosis of a clival chordoma is often delayed because symptoms are vague.",
"   </p>",
"   <p>",
"    The clinical features of chordoma and chondrosarcoma are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one series of 48 patients with chordoma and 49 with low-grade chondrosarcoma, headache and diplopia from abducens nerve palsy was common in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/1\">",
"     1",
"    </a>",
"    ]. Normal neurologic examinations were more common in patients with chordoma, while visual loss, facial numbness, and multiple cranial neuropathies were more common in patients with chondrosarcoma. These differences probably reflect the tendency of chordomas to originate from the clivus and chondrosarcomas from the petroclival fissure (junction of clivus and temporal bone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the best technique to assess the soft tissue extent of tumor and visualize its dural extension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/3\">",
"     3",
"    </a>",
"    ]. Chordomas and chondrosarcomas are typically heterogeneously bright on T2-weighted images, which can aid with diagnosis. CT scan is more effective for demonstrating bone lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79863 \" href=\"UTD.htm?30/22/31086\">",
"     image 1",
"    </a>",
"    ). Calcification is not uncommon with chondrosarcoma. The characteristic ring-forming calcifications seen on CT scans can be correlated with the histologic pattern of calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/4\">",
"     4",
"    </a>",
"    ]. CT MRI image fusion may provide additional anatomic information regarding the tumor and surrounding tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chondrosarcomas typically originate laterally at the petroclival junction, but there are no pathognomonic imaging findings that distinguish chordoma from chondrosarcoma. Although imaging studies may result in a working diagnosis, biopsy and histologic studies are necessary to confirm the diagnosis. Both chordomas and chondrosarcomas can be staged according to the TNM system for primary malignant tumors of bone (",
"    <a class=\"graphic graphic_table graphicRef62124 \" href=\"UTD.htm?25/43/26301\">",
"     table 1",
"    </a>",
"    ), but this has limited prognostic value in the skull base region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chordomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chordomas are rare, slow growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. These tumors typically occur in the axial skeleton and are most common in the sphenooccipital region of the skull base and in the sacral regions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In adults, 50 percent of chordomas involve the sacrococcygeal region, 35 percent occur at the base of the skull, and 15 percent are found elsewhere in the vertebral column [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/6\">",
"     6",
"    </a>",
"    ]. Craniocervical chordomas most often involve the dorsum sella, clivus, and nasopharynx. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H20#H20\">",
"     \"Spinal cord tumors\", section on 'Chordomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chordomas are divided into three subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional chordomas are the most common. They are characterized by the absence of cartilaginous or other mesenchymal components.",
"     </li>",
"     <li>",
"      Chondroid chordoma is a distinct entity that contains both chordomatous and chondromatous features and has a predilection for the sphenooccipital region of the skull base [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/6,12-14\">",
"       6,12-14",
"      </a>",
"      ]. This variant accounts for 5 to 15 percent of all chordomas and up to 33 percent of cranial chordomas. Chondroid and conventional chordomas appear to have a similar prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dedifferentiation or sarcomatous transformation occurs in 2 to 8 percent of chordomas. This can be present at diagnosis or occur later [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Histologically, the sarcomatous component, which may be a malignant fibrous histiocytoma, fibrosarcoma, osteosarcoma, or chondrosarcoma, is interspersed with areas of conventional chordoma. Most of these aggressive chordomas are aneuploid on DNA analysis (compared to only one-fourth of conventional chordomas) and survival tends to be shorter. In one series of 15 patients with interpretable DNA histograms, 3 of 12 conventional chordomas and all four dedifferentiated chordomas were aneuploid [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/17\">",
"       17",
"      </a>",
"      ]. Four of the seven patients with aneuploid tumors died of disease within two to four years, while only one of eight patients with diploid tumors died of disease at six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On gross examination, chordomas are gelatinous, pink or gray masses with solid and cystic areas. Chondroid chordomas demonstrate both chordomatous and variable degrees of benign or malignant cartilaginous components.",
"   </p>",
"   <p>",
"    Chordomas are composed of lobules that contain epithelioid cells arranged in cords or clusters and separated by fibrous strands in a mucinous matrix. The tumor cells have vesicular nuclei and abundant vacuolated, soap bubble-like cytoplasm (physaliphorous cells) that contains glycogen (PAS positive) or mucin (",
"    <a class=\"graphic graphic_picture graphicRef76084 \" href=\"UTD.htm?24/11/24758\">",
"     picture 1",
"    </a>",
"    ). Nuclear pleomorphism and mitoses are uncommon. Ultrastructurally, chordomas exhibit epithelial features with prominent desmosomes.",
"   </p>",
"   <p>",
"    Tumor cells in almost all chordomas are diffusely and strongly positive for cytokeratin. Staining for epithelial membrane antigen (EMA) is present in more than 80 percent of cases, although it is typically more focal and less strongly positive than other antigen stains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/12-14,18\">",
"     12-14,18",
"    </a>",
"    ]. Other immunostains are variable depending upon the type of chordoma. In one study, all 16 classic chordomas stained for keratin, while only 32 percent of 25 chondroid chordomas did [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/12\">",
"     12",
"    </a>",
"    ]. In the same study, 44 percent of the classic and 85 percent of the chondroid chordomas were positive for S-100 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chondrosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcomas are rare malignant cartilaginous tumors that make up 11 percent of primary malignant bone neoplasms and account for about 6 percent of all skull base tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/4,19,20\">",
"     4,19,20",
"    </a>",
"    ]. Most skull base chondrosarcomas arise in the middle fossa, followed by the posterior or anterior fossae.",
"   </p>",
"   <p>",
"    Grossly, chondrosarcomas are smooth, lobulated, hard tumors, and often are more than 2 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef60109 \" href=\"UTD.htm?0/54/866\">",
"     picture 2",
"    </a>",
"    ). Microscopically, they are lobulated and, depending upon their degree of differentiation, show increased cellularity with hyperchromatic and pleomorphic tumor cells, prominent nucleoli, and binucleated or multinucleated chondrocytes.",
"   </p>",
"   <p>",
"    Microscopic grading has prognostic value in chondrosarcomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated (grade 1) lesions have chondrocytes with small, round nuclei and occasional binucleated cells. Mitoses are absent.",
"     </li>",
"     <li>",
"      Moderately differentiated (grade 2) chondrosarcomas have more cellularity and less matrix than grade I tumors, and mitoses are widely scattered in the tumor. The nuclei of chondrocytes are enlarged, vesicular or hyperchromatic, and often show more than one cell in a lacuna.",
"     </li>",
"     <li>",
"      Poorly differentiated (grade 3) tumors display even more cellularity and nuclear pleomorphism than grade 2 tumors. Cords or clumps of chondrocytes have irregular, vesicular or spindle shaped nuclei, less matrix, and easily found mitoses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of skull base chondrosarcomas are conventional chondrosarcomas that are well differentiated (grade 1), and less commonly, moderately differentiated (grade 2) tumors (",
"    <a class=\"graphic graphic_picture graphicRef70909 \" href=\"UTD.htm?6/28/6595\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/21\">",
"     21",
"    </a>",
"    ]. Osteoid metaplasia may be present within a chondrosarcoma and is distinguished from the chondroblastic variant of osteosarcoma by the absence of osteoid that is lined by cytologically atypical osteoblasts.",
"   </p>",
"   <p>",
"    Other rare types of chondrosarcoma that may present at the skull base include high grade mesenchymal chondrosarcoma, and the so-called extraskeletal myxoid chondrosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H3#H3\">",
"     \"Chondrosarcoma\", section on 'Classification, histology, and clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing chordoma from chondrosarcoma can be difficult histologically but is important because of the significantly better prognosis associated with chondrosarcomas. As an example, in one series of 200 patients with chondrosarcoma, 37 percent initially were referred with a diagnosis of chordoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of chordoma and chondrosarcoma also includes mucinous adenocarcinoma and myxopapillary ependymoma (",
"    <a class=\"graphic graphic_table graphicRef53974 \" href=\"UTD.htm?13/22/13676\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Immunohistochemistry is an important tool in establishing the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chondrosarcomas do not express cytokeratin, while S-100 protein expression is present in both chondrosarcomas and chordomas [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor cells in chondrosarcoma and myxopapillary ependymoma are negative for cytokeratin and EMA, unlike chordomas [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/13,14,18\">",
"       13,14,18",
"      </a>",
"      ]. In addition, they do not have desmosomes on ultrastructural examination.",
"     </li>",
"     <li>",
"      Only myxopapillary ependymoma is positive for glial fibrillary acidic protein (GFAP), while chordomas and chondrosarcomas are negative for this marker. In one series, immunoreactivity was present for vimentin and GFAP in all cases and for S-100 protein in 50 percent of myxopapillary ependymomas [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The differentiation of adenocarcinoma from chordoma may be difficult because both neoplasms are cytokeratin and EMA positive. Although positivity for vimentin and S-100 protein supports the diagnosis of chordoma over adenocarcinoma, this finding should be interpreted with caution, as rare adenocarcinomas may be positive for S-100 protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized clinical trials and no large prospective series that define the optimal treatment for either chordomas or chondrosarcomas.",
"   </p>",
"   <p>",
"    Literature reviews of small retrospective series support a combined modality approach using maximal surgical resection and radiation therapy (RT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is performed both to obtain tissue for diagnosis and to reduce the tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/23\">",
"     23",
"    </a>",
"    ]. Complete resection is desirable for both chordomas and chondrosarcomas of the skull base. However, a complete resection is often not feasible because of anatomic constraints to surgical access and proximity to critical normal structures. Both open (transcranial and transfacial) and endoscopic endonasal surgical approaches are successfully used for these tumors. There is evidence from observational studies that gross total resection of chordomas is better facilitated with a midline endoscopic endonasal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these tumors are slow growing, they are locally invasive tumors and there is a high incidence of local recurrence that can result in death due to uncontrolled local disease. For patients with chondrosarcoma, metastases occur in about 10 percent of cases. For patients with chordoma, dedifferentiation or sarcomatous transformation occurs in 2 to 8 percent of chordomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors involving the skull base are difficult to manage as a result of their proximity to critical neural structures. Maximal surgical resection is the mainstay of therapy, but complete resections are difficult to achieve.",
"   </p>",
"   <p>",
"    Adjuvant RT is commonly employed, although it has been difficult to administer adequately high doses of radiation with older techniques. For patients with chordoma, adjuvant RT is generally advocated because of the poor prognosis in those who recur. For patients with chondrosarcoma, salvage therapy has been successful in some cases, and it is unclear whether immediate adjuvant radiation therapy is better than salvage surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    salvage RT.",
"   </p>",
"   <p>",
"    Conventional two- or three-dimensional conventional RT techniques using photons have a significant risk of damaging the brainstem and cranial nerves, and the lower doses historically used with these techniques have been associated with a high rates of local recurrence and treatment failure. The limitations of photon therapy in the treatment of chordomas are illustrated by a series of 48 patients (20 with skull base lesions), 44 of whom had macroscopic disease following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/25\">",
"     25",
"    </a>",
"    ]. The local control rate with conventional photon radiation was only 27 percent, although 85 percent of patients achieved useful and prolonged palliation of pain. The median survival was 62 months.",
"   </p>",
"   <p>",
"    Higher doses of RT can be delivered by a several newer techniques, including charged particle irradiation (primarily protons), stereotactic radiosurgery, stereotactic radiation therapy, and intensity modulated radiation therapy. The most extensive data comes from proton beam therapy, but there are no randomized trials comparing these different contemporary techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Charged particle RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Charged particle irradiation offers several theoretical advantages over photon RT to minimize incidental irradiation to adjuvant normal structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proton beam RT is the most widely used charged ion technique. This approach appears to be more effective than earlier use of conventional photon RT with lower doses of radiation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chordomas - A systematic review of the literature in patients with chordomas analyzed seven retrospective studies that included a total of 416 patients who were treated either with protons or with a combination of protons plus photons [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/26\">",
"       26",
"      </a>",
"      ]. The radiation doses and schedules varied within and between series, but generally the total radiation dose was 70 Gy equivalents or higher. Clinical outcomes were available for all patients with a minimum follow-up of two years. At a median follow-up of 46 months, the five-year local control and overall survival rates were 69 and 80 percent, respectively.",
"     </li>",
"     <li>",
"      Chondrosarcomas - In patients with chondrosarcoma, the largest series comprised 200 patients treated at a single institution [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/21\">",
"       21",
"      </a>",
"      ]. The median total dose of radiation in that series was 72 Gy equivalents. The 10-year local control and survival rates were 98 and 99 percent, respectively. A subsequent review of the literature included that series plus 54 patients with chondrosarcoma identified in three other studies; the results in those series were similar [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other charged particles, especially carbon ions, have been used in addition to protons in patients with skull base chordoma and chondrosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]. Although these approaches appear to have similar efficacy to proton therapy, there are no comparative studies and these techniques are not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other photon techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other techniques have been used to deliver higher doses of photon radiation to central nervous system targets, while minimizing incidental exposure to normal critical structures. There are no randomized trials that compare SRS, SRT, or IMRT to proton beam or older photon techniques.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stereotactic radiosurgery (SRS) has been used in several retrospective series. A review of the literature identified 109 patients with chordomas treated in five series [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7815/abstract/26\">",
"       26",
"      </a>",
"      ]. The five-year survival rate was 75 percent, at a median follow-up of 56 months. SRS is limited to tumors with a relatively small tumor volume.",
"     </li>",
"     <li>",
"      Stereotactic radiotherapy (SRT) can be used for larger lesions than SRS. In one series of 37 chordoma patients treated with SRT, the five-year survival rate was 82 percent, although the mean follow-up was only 27 months.",
"     </li>",
"     <li>",
"      Experience with intensity modulated radiation therapy (IMRT) for skull base chordomas and chondrosarcomas is extremely limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, chondrosarcomas have been considered resistant to chemotherapy. Although the majority of patients with recurrent or metastatic sarcoma do not respond to the usual chemotherapy regimens for advanced sarcoma, there have been isolated reports of successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Chemotherapy for advanced chondrosarcomas is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H31#H31\">",
"     \"Chondrosarcoma\", section on 'Systemic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chordoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies reporting the use of chemotherapy and molecularly targeted agents in patients with advanced chordoma primarily include patients with tumors arising in the sacral region or spine, as well as the base of skull. Results of these trials are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H20#H20\">",
"     \"Spinal cord tumors\", section on 'Chordomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/48/27394?source=see_link\">",
"       \"Patient information: Chondrosarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both chordomas and chondrosarcomas are rare tumors that can arise in the skull base. Because of their anatomic location and proximity to critical structures, complete resection is difficult and local recurrences are frequent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a primary tumor of the skull base, initial surgical resection can provide a tissue diagnosis. A complete or near complete resection may be associated with a prolonged disease-free period and may enhance the effectiveness of subsequent radiation therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a chordoma, we suggest adjuvant radiation therapy following surgery rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach appears to be associated with a longer disease-free period, and salvage therapy has generally not been successful in patients with chordomas. Many patients with recurrent disease are candidates for additional surgery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a chondrosarcoma, we suggest adjuvant radiation therapy following maximal surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with a low grade tumor who have undergone a gross total resection, deferring radiation therapy is an alternative, and patients who recur should be retreated aggressively with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When radiation therapy is indicated, achieving an adequate tumor dose while minimizing damage to critical neurologic structures is critical. We suggest proton beam radiation therapy when this modality is available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If this is not available, contemporary photon-based techniques, such as stereotactic radiation surgery, stereotactic radiation therapy, are an alternative.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/1\">",
"      Volpe NJ, Liebsch NJ, Munzenrider JE, Lessell S. Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. Am J Ophthalmol 1993; 115:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/2\">",
"      Korten AG, ter Berg HJ, Spincemaille GH, et al. Intracranial chondrosarcoma: review of the literature and report of 15 cases. J Neurol Neurosurg Psychiatry 1998; 65:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/3\">",
"      Meyers SP, Hirsch WL Jr, Curtin HD, et al. Chondrosarcomas of the skull base: MR imaging features. Radiology 1992; 184:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/4\">",
"      Rassekh CH, Nuss DW, Kapadia SB, et al. Chondrosarcoma of the nasal septum: skull base imaging and clinicopathologic correlation. Otolaryngol Head Neck Surg 1996; 115:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/5\">",
"      Leong JL, Batra PS, Citardi MJ. CT-MR image fusion for the management of skull base lesions. Otolaryngol Head Neck Surg 2006; 134:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/6\">",
"      Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 1973; 32:410.",
"     </a>",
"    </li>",
"    <li>",
"     Chordoma. In: Bone Tumors: Diagnosis, Treatment and Prognosis, 2nd, WB Saunders, Philadelphia 1991. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/8\">",
"      Perzin KH, Pushparaj N. Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx. A clinicopathologic study. XIV: Chordomas. Cancer 1986; 57:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/9\">",
"      Harbour JW, Lawton MT, Criscuolo GR, et al. Clivus chordoma: a report of 12 recent cases and review of the literature. Skull Base Surg 1991; 1:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/10\">",
"      Volpe R, Mazabraud A. A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol 1983; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/11\">",
"      Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer 1985; 56:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/12\">",
"      Mitchell A, Scheithauer BW, Unni KK, et al. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 1993; 72:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/13\">",
"      Abenoza P, Sibley RK. Chordoma: an immunohistologic study. Hum Pathol 1986; 17:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/14\">",
"      Coffin CM, Swanson PE, Wick MR, Dehner LP. An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. Mod Pathol 1993; 6:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/15\">",
"      McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/16\">",
"      Meis JM, Raymond AK, Evans HL, et al. \"Dedifferentiated\" chordoma. A clinicopathologic and immunohistochemical study of three cases. Am J Surg Pathol 1987; 11:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/17\">",
"      Hruban RH, Traganos F, Reuter VE, Huvos AG. Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 1990; 137:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/18\">",
"      Meis JM, Giraldo AA. Chordoma. An immunohistochemical study of 20 cases. Arch Pathol Lab Med 1988; 112:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/19\">",
"      Adegbite AB, McQueen JD, Paine KW, Rozdilsky B. Primary intracranial chondrosarcoma: a report of two cases. Neurosurgery 1985; 17:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/20\">",
"      Sen CN, Sekhar LN, Schramm VL, Janecka IP. Chordoma and chondrosarcoma of the cranial base: an 8-year experience. Neurosurgery 1989; 25:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/21\">",
"      Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999; 23:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/22\">",
"      Gherardi G, Marveggio C, Cola C, Redaelli G. Decisive role of immunocytochemistry in aspiration cytology of chordoma of the clivus: a case report with review of the literature. J Laryngol Otol 1994; 108:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/23\">",
"      Crockard HA, Steel T, Plowman N, et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg 2001; 95:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/24\">",
"      Koutourousiou M, Snyderman CH, Fernandez-Miranda J, Gardner PA. Skull base chordomas. Otolaryngol Clin North Am 2011; 44:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/25\">",
"      Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/26\">",
"      Amichetti M, Cianchetti M, Amelio D, et al. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev 2009; 32:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/27\">",
"      Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. Neurosurg Rev 2010; 33:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/28\">",
"      Mizoe JE, Hasegawa A, Takagi R, et al. Carbon ion radiotherapy for skull base chordoma. Skull Base 2009; 19:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7815/abstract/29\">",
"      Schulz-Ertner D, Karger CP, Feuerhake A, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007; 68:449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5179 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7815=[""].join("\n");
var outline_f7_40_7815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chordomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chondrosarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Charged particle RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other photon techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chordoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5179|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/22/31086\" title=\"diagnostic image 1\">",
"      Chondrosarcoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5179|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/30/39397\" title=\"figure 1A\">",
"      Base of skull anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/29/9684\" title=\"figure 1B\">",
"      Skull sagittal section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5179|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/11/24758\" title=\"picture 1\">",
"      Chordoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/54/866\" title=\"picture 2\">",
"      Chondrosarcoma Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/28/6595\" title=\"picture 3\">",
"      Chondrosarcoma Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/43/26301\" title=\"table 1\">",
"      TNM staging bone tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/22/13676\" title=\"table 2\">",
"      Skull base tumors diff dx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/48/27394?source=related_link\">",
"      Patient information: Chondrosarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7816="Treatment of chronic myeloid leukemia in blast crisis";
var content_f7_40_7816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic myeloid leukemia in blast crisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7816/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/40/7816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which results in a constitutively active tyrosine kinase. It is this deregulated tyrosine kinase that is implicated in the development of CML and is the target of current therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate was the first tyrosine kinase inhibitor used in the treatment of CML. Since then, several other tyrosine kinase inhibitors have been developed and tested in patients with CML, most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    (BMS-354825, Sprycel),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    (AMN107,Tasigna), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    (SKI-606, Bosulif). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CML has historically been a triphasic disease. Approximately 85 to 90 percent of patients present in a chronic stable phase. Without treatment, this inevitably progresses to a more aggressive, accelerated phase and then culminates in a very difficult to treat blast crisis. As advances are made in the treatment of chronic phase CML, fewer patients (approximately 6 percent at five years) are progressing to accelerated phase and blast crisis. In addition, 10 to 15 percent of patients will initially present in accelerated phase or blast crisis.",
"   </p>",
"   <p>",
"    The treatment of CML in blast crisis is discussed here. The treatment of CML in chronic or accelerated phase is discussed separately as is the use of hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In approximately 30 percent of cases, blast crisis in CML is of the lymphoid (ie, ALL), rather than the myeloid (ie, AML) variety.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    can be incorporated into a treatment plan for these and other patients with Philadelphia chromosome positive ALL. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link&amp;anchor=H19#H19\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Philadelphia chromosome positive ALL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF BLAST CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blast crisis of CML, occasionally of sudden onset [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], is an ominous clinical event that is difficult to treat. It is usually defined by the presence of one or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ge;20 percent peripheral blood or bone marrow blasts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Large foci or clusters of blasts on the bone marrow biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of extramedullary blastic infiltrates (eg, myeloid sarcoma also known as granulocytic sarcoma or chloroma) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, previous definitions of blast crisis used different cutoffs values for the percent blasts in the bone marrow such that patients with 20 to 30 percent blasts were not included. This is important to keep in mind when making historical comparisons between response rates to treatment. In most patients, blast crisis evolves from a prior accelerated or chronic phase. Some patients, particularly those with Philadelphia chromosome positive ALL, are in the equivalent of blast crisis at their initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major forms of blast crisis in patients with CML: lymphoid and myeloid. Myeloid blast crisis, which occurs in approximately 70 percent of cases, does not respond well to standard AML-induction regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/5\">",
"     5",
"    </a>",
"    ], although responses to tyrosine kinase inhibitors (TKIs), alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] or in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/9\">",
"     9",
"    </a>",
"    ], have been noted. Lymphoid blast crisis with a B lineage immunophenotype accounts for approximately 30 percent of cases and often responds to chemotherapeutic programs used for acute lymphoblastic leukemia alone and in combination with imatinib. The treatment of lymphoid blast crisis with these chemotherapeutic regimens is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link&amp;anchor=H19#H19\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Philadelphia chromosome positive ALL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since myeloid blast crisis is often typically refractory to chemotherapy, the preferred initial treatment is the use of a TKI followed by an allogeneic HCT for eligible patients. Transplantation while the patient remains in blast crisis has poor results with less than 10 percent long term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/10\">",
"     10",
"    </a>",
"    ]. A reasonable plan is an attempt to return the patient to an earlier phase of disease, with suitable candidates subsequently undergoing allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/11\">",
"     11",
"    </a>",
"    ]. TKI treatment prior to transplantation has not been associated with an increase in transplant associated morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H17#H17\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Pretreatment with tyrosine kinase inhibitors or interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for treatment of relapse after allogeneic HCT include donor lymphocyte infusion and TKIs&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Initial studies suggest that there may be a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    maintenance therapy after allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H20#H20\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'MRD and relapse after allo-HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Eligible for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with CML in blast crisis who are candidates for an allogeneic hematopoietic cell transplantation (HCT), we recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    600 mg by mouth daily as initial therapy followed by HCT. At the time blast crisis is diagnosed, a BCR-ABL kinase mutation analysis should be performed and a search for a hematopoietic cell donor should be begun [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    should be used in patients in whom blast crisis developed while they were receiving imatinib or if the CML had been refractory to treatment with imatinib. Eligibility criteria for allogeneic HCT vary by institution. Either related or matched-unrelated donors can be used for CML in the setting of blast crisis since other treatment options are not very effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT has a potential for cure and is an essential component of the initial treatment of CML in blast crisis. The most important prognostic factor for survival following allogeneic HCT for CML is the disease phase at the time of transplantation, with four-year disease-free survival (DFS) rates of &lt;10 percent in blast crisis versus 30 to 40 percent in accelerated phase and up to 80 percent in patients with chronic phase disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/4,5,10,17\">",
"     4,5,10,17",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is given prior to HCT in an attempt to return the patient to an earlier phase of disease. Imatinib treatment for blast crisis can result in objective responses in approximately half of patients with 15 percent attaining a second chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/8\">",
"     8",
"    </a>",
"    ]. The trials of imatinib in patients with blast crisis CML are described in detail in the following section. Because of the truly transient nature of responses in this phase of CML, treatment with imatinib alone should be considered palliative and is not an appropriate longer term treatment alternative for patients who are eligible for HCT.",
"   </p>",
"   <p>",
"    Chemotherapy can be used for patients in blast crisis in an attempt to return the patient to an earlier phase of disease and then proceed with transplantation in eligible patients. This approach is best used in the setting of a clinical trial or in patients who are not responsive to treatment with a tyrosine kinase inhibitor or have a BCR-ABL kinase mutation that is not sensitive to TKIs (ie, T315I).",
"   </p>",
"   <p>",
"    As an example, the Swedish CML group investigated the efficacy of intensive combination chemotherapy in 83 patients with CML in accelerated phase or blast crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/18\">",
"     18",
"    </a>",
"    ]. Chemotherapy regimens included MEC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ), ICE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , cytarabine, etoposide), or other combinations (cytarabine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/5/37973?source=see_link\">",
"     amsacrine",
"    </a>",
"    , with or without etoposide). Younger responding patients were eligible for allogeneic HCT, while older responding patients were considered for autologous HCT. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall response rates for patients in accelerated phase or blast crisis were 46 and 48 percent, respectively. Of the 39 responses, 7 were partial and 32 constituted a return to a second chronic phase.",
"     </li>",
"     <li>",
"      Median survival for the entire group was six months. The median duration of response was six months, with one year survival for responders and non-responders of 50 and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Seventeen patients went on to receive either allogeneic or autologous HCT, with a median survival of 21 months (range: 3 to 66+ months). There were only three long-term survivors (4 percent of the initial cohort).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ineligible for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CML in blast crisis who are not candidates for HCT have a poor prognosis. Treatment options include the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    600 mg by mouth daily or enrollment in a clinical trial. The median survival of patients with blast crisis treated with imatinib therapy in several phase II trials were 3, 6, and 17 months for those with no response, unsustained response, or sustained response, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/7\">",
"     7",
"    </a>",
"    ]. Among patients who show a response to treatment, we recommend continuing imatinib as long as the patient continues to show a response. Even though imatinib is not curative and responses are often short-lived, it is an oral medication that is fairly well tolerated. Detailed information on drug toxicity and management of side effects is discussed separately. The risks of discontinuing treatment in responding patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Aims of initial therapy and duration of treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the development of TKIs, patients with blast crisis were often treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    -based regimens. Although there have been no randomized trials that have directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    with such regimens, a historical comparison shows significantly better response rates (55 versus 29 percent) and median survival (7 versus 4 months) with less toxicity with imatinib compared with treatment with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a summary of trials that have investigated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the treatment of CML in blast crisis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a dose-escalating pilot study, patients with CML in blast crisis (defined in this study as &gt;30 percent blasts in the peripheral blood or bone marrow) were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      at doses ranging from 300 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/6\">",
"       6",
"      </a>",
"      ]. On an intent-to-treat basis, the following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overall response rates were 55 and 70 percent in patients with myeloid and lymphoid blast crises, respectively. Complete hematologic responses were attained in 4 of 38 patients with myeloid blast crisis and 4 of 20 patients in lymphoid blast crisis. Major cytogenetic responses were observed in 7 of the 58 patients; five of the seven responses were complete.",
"     </li>",
"     <li>",
"      Nine of the 21 responders with myeloid blast crisis and 12 of the 14 with lymphoid blast crisis relapsed, at median times of 84 and 58 days, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      was generally well-tolerated, with nausea, vomiting, and edema in 55, 41, and 41 percent, respectively. Grade four neutropenia and thrombocytopenia occurred in 40 and 33 percent, respectively. None of the 16 deaths in the study was felt to be related to treatment with this agent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 260 patients with CML in blast crisis from three large phase II studies evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      600 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/19\">",
"       19",
"      </a>",
"      ]. At 36 months after initiation of imatinib, an estimated 14 percent of patients were alive and only 7 percent were disease free.",
"     </li>",
"     <li>",
"      In subsequent studies, patients in blast crisis were treated with doses ranging from 300 to 1000",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      objective and major cytogenetic responses were noted in 52 and 16 percent, respectively, and were not different between myeloid and lymphoid crises [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Median survivals were 3, 6, and 17 months for those with no response, unsustained response, or sustained response, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      can provide palliative benefit to many patients with blast crisis, the effects are usually transient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of particular note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    has a limited ability to penetrate the intact",
"    <span class=\"nowrap\">",
"     blood/brain",
"    </span>",
"    barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and thus may not be sufficient initial therapy for patients in blast crisis with central nervous system involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT AFTER FAILURE OF INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence to guide the treatment of patients with CML in blast crisis who fail to respond to initial therapy. Options for the treatment of relapse after allogeneic HCT include donor lymphocyte infusion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/13,14,25\">",
"     13,14,25",
"    </a>",
"    ]. The choice is influenced by whether the patient had received a TKI before transplant as well as the results of that treatment. BCR-ABL mutational analysis should be performed for patients who fail to respond to imatinib and may help guide the choice of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H20#H20\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'MRD and relapse after allo-HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At this time, the choice of a second generation TKI for most patients is dependent upon drug side effect profile and patient co-morbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15773374\">",
"    <span class=\"h2\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    is approved in the United States for the treatment of adults in blast crisis with resistance or intolerance to prior therapy. The approved dose in this setting is 140 mg once daily.",
"   </p>",
"   <p>",
"    A phase II, open-label, single-arm clinical trial examined the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    70 mg twice daily in patients with CML in myeloid (74 patients) or lymphoid (42 patients) blast crisis who were resistant to (105 patients) or intolerant of (11 patients)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/27\">",
"     27",
"    </a>",
"    ]. After eight months of follow-up, the following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete hematologic responses were seen in 26 percent.",
"     </li>",
"     <li>",
"      Complete cytogenetic responses were seen in 27 and 43 percent of patients with myeloid and lymphoid blast crisis, respectively.",
"     </li>",
"     <li>",
"      Hematologic responses occurred rapidly with a median time to achieve response of one to two months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      was well tolerated with discontinuation secondary to toxicity seen in only 11 and 2 percent of patients with myeloid and lymphoid blast crisis, respectively. However, dose interruptions were required by 64 percent and 33 percent of these patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extension of this study to include 109 patients with myeloid and 48 patients with lymphoid blast phase CML reported median overall survival times of 11.8 and 5.3 months, respectively with curves suggesting a continual rate of treatment failure with longer follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III randomized trial evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    140 mg once daily versus dasatinib 70 mg twice daily in 210 patients with CML in blast phase who demonstrated resistance to (84 percent) or intolerance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/29\">",
"     29",
"    </a>",
"    ]. The two treatment doses had similar efficacy. Once daily dosing had a trend towards improved tolerability with fewer patients requiring dose",
"    <span class=\"nowrap\">",
"     reductions/interruptions.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 149 patients in myeloid blast phase, complete hematologic responses were seen in 26 patients (17 percent). Rates of major and complete cytogenetic response were 26 and 17 percent, respectively.",
"     </li>",
"     <li>",
"      Of the 61 patients in lymphoid blast phase, rates of complete hematologic, major cytogenetic, and complete cytogenetic response were 18, 43, and 34 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the two dosing schedules appear to have equal efficacy and there may be a decrease in toxicity in addition to the convenience of once daily dosing, the 140 mg once daily dosing schedule may be preferable. Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15773381\">",
"    <span class=\"h2\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is approved in the United States for the treatment of adults in blast crisis with resistance or intolerance to prior therapy. The approved dose is 500 mg once daily.",
"   </p>",
"   <p>",
"    Preliminary results are available for phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    in 546 patients with CML with resistance or intolerance to at least one tyrosine kinase inhibitor that included 60 patients with blast crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/30\">",
"     30",
"    </a>",
"    ]. At a minimum follow-up of 12 months, 28 percent achieved a hematologic response (15 percent complete hematologic response). The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included diarrhea (9 percent), rash (9 percent), and vomiting (3 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    does not have activity against the highly resistant T315I mutation. Bosutinib is also being studied in patients with newly diagnosed CML in chronic phase and in patients with chronic phase or accelerated phase after failure of initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H1349640#H1349640\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Bosutinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H15772961#H15772961\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Bosutinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12150663\">",
"    <span class=\"h2\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    is an orally administered BCR-ABL inhibitor that has demonstrated activity against the native and mutated BCR-ABL proteins, including the T315I mutation. Ponatinib received accelerated approval by the US Food and Drug Administration for the treatment of CML in adults with resistance or intolerance to prior tyrosine kinase inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/31\">",
"     31",
"    </a>",
"    ]. The recommended dose and schedule is 45 mg orally once daily with or without food. Approval was accompanied by a boxed warning alerting patients and clinicians that arterial thrombosis and liver toxicity have occurred in patients treated with ponatinib.",
"   </p>",
"   <p>",
"    Preliminary results of the phase II PACE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    reported major hematologic responses (MHR) in 31 percent of the 62 patients with blast crisis resistant or intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , including patients with T315I mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7816/abstract/32\">",
"     32",
"    </a>",
"    ]. Median time to MHR and median duration of MHR were 29 days and 4.7 months, respectively. The most common toxicities were thrombocytopenia, rash, dry skin, abdominal pain, and headache. Overall, severe adverse events led to the discontinuation of therapy in 11 percent of patients.",
"   </p>",
"   <p>",
"    Data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    in chronic phase or accelerated phase CML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Treatment of disease resistant to initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As advances are made in the treatment of chronic phase chronic myeloid leukemia (CML), fewer patients (approximately 7 percent at five years) are progressing to accelerated phase and blast crisis. However, 10 to 15 percent of patients will initially present in accelerated phase or blast crisis and it is likely that a larger fraction of patients will present in more advanced stages in less medically developed countries. Treatment of these more advanced phases of CML is difficult. In general, an attempt is made to return the patient to a chronic phase with plans to proceed to allogeneic hematopoietic cell transplantation (HCT) after an initial response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CML in lymphoid blast crisis are treated with combination chemotherapy in addition to a BCR-ABL tyrosine kinase inhibitor (TKI). This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link&amp;anchor=H19#H19\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Philadelphia chromosome positive ALL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with newly diagnosed CML in myeloid blast crisis who are eligible for HCT, we recommend initial treatment with a TKI rather than initial HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy, we recommend imatinib 600 mg by mouth daily rather than 400 mg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This regimen is used in an attempt to return the patient to an earlier phase, with suitable candidates undergoing HCT once a maximal response to imatinib is realized. A search for a donor should be begun at the time that blast crisis is diagnosed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Eligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with newly diagnosed CML in myeloid blast crisis who are ineligible for HCT, we recommend initial treatment with a TKI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Among patients who show a response to treatment, we recommend continuing the TKI as long as the patient continues to show a response (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ineligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CML in blast crisis who are intolerant of or resistant to an initial TKI, we recommend the administration of another TKI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This regimen is used in an attempt to return the patient to a second chronic phase, with suitable candidates subsequently undergoing HCT. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment after failure of initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for the treatment of relapse after allogeneic HCT include donor lymphocyte infusion and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      . These options are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H20#H20\">",
"       \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'MRD and relapse after allo-HCT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/1\">",
"      Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006; 107:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/2\">",
"      Alimena G, Breccia M, Latagliata R, et al. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006; 107:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/3\">",
"      Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/4\">",
"      Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/5\">",
"      Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/6\">",
"      Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/7\">",
"      Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/8\">",
"      Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/9\">",
"      Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007; 109:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/10\">",
"      Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/11\">",
"      Lange T, G&uuml;nther C, K&ouml;hler T, et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003; 101:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/12\">",
"      Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/13\">",
"      Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/14\">",
"      DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10:5065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/15\">",
"      Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110:4614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/16\">",
"      Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/17\">",
"      Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011; 118:5697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/18\">",
"      Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol 2002; 118:1048.",
"     </a>",
"    </li>",
"    <li>",
"     Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with imatinib in three large phase II trials (abstract). Blood 2004; 104:abstract 23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/20\">",
"      Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101:5010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/21\">",
"      le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004; 53:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/22\">",
"      Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004; 45:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/23\">",
"      Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004; 45:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/24\">",
"      Rytting ME, Wierda WG. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 2004; 45:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/25\">",
"      Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012; 26:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/26\">",
"      O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/27\">",
"      Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/28\">",
"      Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/29\">",
"      Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010; 116:3852.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf?et_cid=30657199&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203469lbl.pdf (Accessed on December 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7816/abstract/32\">",
"      Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (abstract 915). ASH Annual Meeting Abstracts 2012; 120:915.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4512 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7816=[""].join("\n");
var outline_f7_40_7816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF BLAST CRISIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Eligible for HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ineligible for HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT AFTER FAILURE OF INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15773374\">",
"      Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15773381\">",
"      Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12150663\">",
"      Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7817="Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)";
var content_f7_40_7817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7817/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/40/7817/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/40/7817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypogonadism in women is defined as ovarian failure accompanied by high serum follicle-stimulating hormone (FSH) concentrations. Premature ovarian failure (POF), now referred to as primary ovarian insufficiency (POI), is defined as primary hypogonadism in a woman under the age of 40 years.",
"   </p>",
"   <p>",
"    POI is characterized by loss of oocytes, lack of folliculogenesis and ovarian estrogen production, and infertility. Transient or partial resumption of ovarian activity has been documented in over 50 percent of women based upon hormonal measurements, pelvic ultrasonography, or conception [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several known causes of ovarian failure, including chromosomal defects like Turner syndrome and fragile X syndrome premutation carriers, exposure to radiation and certain drugs, and autoimmune disease. The list of mutations that can cause ovarian failure has increased rapidly, as discoveries from the human genome project increase our understanding of the factors involved in ovarian development. Unfortunately, the etiology remains unknown in approximately 75 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis and causes of primary ovarian insufficiency will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef74029 \" href=\"UTD.htm?43/47/44795\">",
"     table 1",
"    </a>",
"    ); its evaluation and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151094249\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal ovarian development is dependent on a carefully timed cascade of events; as a result, there are multiple potential etiologies for ovarian dysfunction. Pathophysiologically, these defects can be divided into two major categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated follicle depletion",
"     </li>",
"     <li>",
"      Decreased steroid production without oocyte loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other theoretical causes of ovarian failure, including absent germ cell migration or defective ovarian development, have not yet been described, although some genes appear to play a role in normal ovarian development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79730714\">",
"    <span class=\"h1\">",
"     ACCELERATED FOLLICLE DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic, autoimmune, and environmental or toxic causes of primary ovarian insufficiency (POI), formerly referred to as premature ovarian failure, often result in accelerated follicle depletion. Complete follicular depletion indicates that there are no remaining primordial follicles in the ovary. For most women, this process is usually complete by about age 51 (the average age of menopause). However, the rate of follicle depletion may be accelerated by a number of genetic disorders and ovarian toxins, resulting in early menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82311047\">",
"    <span class=\"h2\">",
"     Genetic: X chromosome disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of a second X chromosome (Turner syndrome) is the most common chromosomal defect in humans, occurring in up to 1.5 percent of conceptions, 10 percent of spontaneous abortions, and 1 of 2500 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It is also one of the most common causes of primary ovarian insufficiency.",
"   </p>",
"   <p>",
"    The ovaries in Turner syndrome characteristically consist of small amounts of connective tissue and no follicles or only a few atretic follicles (\"streak gonads\"). The initial reported cases had extreme forms of this phenotype with absent pubertal development, primary amenorrhea, and multiple morphologic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/6\">",
"     6",
"    </a>",
"    ]; however, the degree of ovarian dysfunction and the extent of the defects are variable. While most affected women have no pubertal development and primary amenorrhea, some develop normally and then have secondary amenorrhea, and some have no morphologic defects and normal stature.",
"   </p>",
"   <p>",
"    Early histologic studies of the ovaries of eight XO fetuses are the basis of the understanding of the gonadal failure in Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/7\">",
"     7",
"    </a>",
"    ]. These ovaries contained apparently normal numbers of primordial germ cells up to at least 12 weeks of gestation, but at later gestational ages, the numbers of germ cells were decreased and connective tissue was increased, as compared with age-matched normal fetuses. These results indicate that the ovarian failure is more likely caused by accelerated atresia than by abnormal germ cell formation. The diagnosis of Turner syndrome is established by karyotypic analysis. This topic is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82311058\">",
"    <span class=\"h3\">",
"     Other X chromosome deletions/translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to X monosomy and deletions in the short arm of the X chromosome causing Turner syndrome, X chromosome deletions, inversions, and duplications and balanced X chromosome:autosome translocations are the most common causes of primary ovarian insufficiency (POI). Small deletions and breakpoints in translocated X chromosomes lead to the identification of an X chromosome region critical for ovarian development and function: Xq13 to Xq26 with the exception of Xq22 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/8\">",
"     8",
"    </a>",
"    ]. Unfortunately, mapping the precise location of these breakpoints has not elucidated genes involved in ovarian function because a gene was not interrupted or the interrupted gene had no link to ovarian function. The exception is diaphanous (DIAPH2), which was identified at a breakpoint in an X chromosome:autosome translocation in a woman with secondary amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/9\">",
"     9",
"    </a>",
"    ]. Mutations in the Drosophila melanogaster diaphanous homolog of DIAPH2 disrupt oogenesis and spermatogenesis, supporting a role for DIAPH2 in ovarian function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fragile X syndrome premutation carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of literature demonstrates an association between primary ovarian insufficiency and premutations (defined below) for the fragile X syndrome (the FMR1 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Fragile X syndrome is an X-linked form of intellectual disability that is one of the most common causes of mental retardation worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Premutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetics of the syndrome are complex. Affected subjects have more than 200 CGG repeats in the 5' untranslated region of the FMR1 gene; as a result, a full mutation refers to an allele with more than 200 repeats. Alleles with less than 40 CGG are normal, repeat lengths 40 to 55 are intermediate or \"gray zone,\" and repeat lengths of 55 to 200 are relatively unstable and called \"premutations.\" Premutations can expand to a full mutation when transmitted by females with a rate dependent upon the number of repeats. In males, the premutation may stay the same, expand to less than a full mutation, or even regress when transmitted. Of note, the term premutation is defined based on the ability of the repeat to expand to a full mutation in one generation. Newer studies suggest that the &ldquo;gray zone&rdquo; or intermediate repeat alleles, which may expand to a full mutation over two or more generations, may also be associated with POI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carriers of the FMR1 gene premutation who have repeat lengths of 55 to 200 were originally thought to be unaffected, as they do not have the severe neurodevelopmental problems associated with the full mutation. However, in addition to primary ovarian insufficiency, premutation carriers, particularly males, can present with fragile X-associated tremor-ataxia syndrome (FXTAS) or mild cognitive and behavioral deficits on the spectrum of those seen in fragile X syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link&amp;anchor=H18#H18\">",
"     \"The spinocerebellar ataxias\", section on 'Fragile X-associated tremor/ataxia syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Premutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The percentage of premutation carriers having menopause before the age of 40 years ranges from 12 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/11\">",
"     11",
"    </a>",
"    ]. The number of CGG repeats within the premutation range appears to influence the timing of menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which a premutation causes ovarian failure is not known. Subjects with premutations appear to have increased FMR1 mRNA expression and decreased but not absent FMR1 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In comparison, full mutations in mentally retarded subjects are associated with methylation of the FMR1 gene and lack of transcription and protein production.",
"   </p>",
"   <p>",
"    There is no association between primary ovarian insufficiency and full FMR1 mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\", section on 'Genetics and etiology'",
"    </a>",
"    .) Therefore, since premutation carriers have a normal amount of protein, the increased levels of mRNA are postulated to cause a toxic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although early menopause occurs in less than one-third of patients with premutations, the remainder exhibit hormonal changes of early ovarian aging while still experiencing regular menstrual cycles. This was illustrated in a study of 11 affected women ages 24 to 41 years and 22 age-matched controls who underwent daily blood samples for gonadotropin, sex steroid, and inhibin levels with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular phase length was significantly shorter in the carriers compared with controls (12.9 versus 14.5 days).",
"     </li>",
"     <li>",
"      Serum estradiol concentrations were not different between the groups, but mean follicular phase FSH concentrations were higher in the premutation carriers (21.9 versus 11.2",
"      <span class=\"nowrap\">",
"       IU/L).",
"      </span>",
"     </li>",
"     <li>",
"      Inhibin B concentrations in the follicular phase and inhibin A and progesterone concentrations in the luteal phase were lower in the premutation carriers compared with controls, changes consistent with ovarian aging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is the frequency of fragile X premutations in women with sporadic or familial primary ovarian insufficiency, which has been addressed in several studies. The prevalence of FMR1 premutations ranges from 2 to 5 percent in women with sporadic primary ovarian insufficiency and from 12 to 14 percent in women with primary ovarian insufficiency with at least one family member who also had menopause before age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The frequency of fragile X premutations in normal women is estimated to be approximately 1 in 259 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link&amp;anchor=H15#H15\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Candidates for screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the American College of Obstetricians and Gynecologists now recommends that women with primary ovarian insufficiency or an elevated FSH level before age 40 years without known cause be screened for FMR1 premutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although women with primary ovarian insufficiency have relative infertility, many are still actively trying to conceive when the diagnosis of primary ovarian insufficiency is made. Discovering that she may be a carrier for a mental retardation allele (since premutations are unstable) may help these women resolve their decision to become pregnant with their own oocytes. In addition, identification of carrier status is likely to prompt screening of sisters and cousins who are still fertile, and the discovery of fragile X carrier status may exclude a sister as a potential oocyte donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Somatic chromosomal defects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82311137\">",
"    <span class=\"h3\">",
"     Galactosemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary ovarian insufficiency is common in women with galactosemia. Because the hypogonadism cannot be eliminated by early metabolic control, it is thought to be caused by the toxic effects of galactose metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/29\">",
"     29",
"    </a>",
"    ], rather than abnormalities in the carbohydrate composition of gonadotropins that reduce their bioactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even subtle defects in galactose metabolism may have an impact on ovarian function. In a study of 104 normal postmenopausal women, 15 had decreased galactose-1-phosphate uridyl transferase activity and an abnormal transferase allele by gel electrophoresis; these women had a lower mean age at menopause (45 years versus 49 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a second report of 58 pre- and postmenopausal women who were heterozygous for the classical galactosemia mutation, there were no differences in serum markers of ovarian aging (FSH, inhibin B, antim&uuml;llerian hormone) or antral follicle count on ultrasound in the 42 premenopausal carriers when compared with a cohort of proven fertile women. In addition, the mean age at menopause in the postmenopausal carriers was 49.7 years, no different from that seen in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82311256\">",
"    <span class=\"h3\">",
"     BMP15",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in bone morphogenic protein-15 (BMP15), a regulator of ovulation and folliculogenesis in animal models, and a member of the TGF family of growth factors that includes activin and inhibin, was initially identified in two women with POI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/33\">",
"     33",
"    </a>",
"    ]. In functional assays, the mutant BMP15 was processed abnormally, associated with reduced granulosa cell growth, and antagonized the stimulatory effect of wild-type BMP15 on granulosa cell proliferation. In a follow-up study of 166 patients with primary ovarian insufficiency who underwent genetic screening, seven (4.2 percent) were found to have one of three heterozygous mutations in the BMP15 gene. These mutations were not found in control groups of 95 women who had natural menopause after age 50 and 116 subjects from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82311226\">",
"    <span class=\"h3\">",
"     Other rare defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple kindreds with primary ovarian insufficiency and normal karyotypes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/35-38\">",
"     35-38",
"    </a>",
"    ], suggesting either X chromosome deletions too small to be detected or that the non-sex chromosomes may carry information necessary for normal ovarian development. Rare mutations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the FOXL2 gene, which are associated with",
"      <span class=\"nowrap\">",
"       blepharophimosis/ptosis/epicanthus",
"      </span>",
"      inversus syndrome (BPES) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. BPES type I, but not type II, is associated with primary ovarian insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, mutations in FOXL2 have been described in patients with isolated POI [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations of NR5A1 (also called steroidogenic factor 1) were first described in four families, causing 46,XY disorders of sex development without adrenal insufficiency and 46,XX primary ovarian failure; the mutation was also identified in 2 of 25 women (8 percent) with spontaneous ovarian failure, but in no controls (n = 700) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/42\">",
"       42",
"      </a>",
"      ]. However, in a second study of 358 women with primary ovarian insufficiency, the overall frequency of NR5A1 gene mutation rate was only 1.4 percent, suggesting that this is a rare cause of POI [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FSH receptor mutations (see",
"      <a class=\"local\" href=\"#H3107632\">",
"       'FSH receptor mutations'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107557\">",
"    <span class=\"h2\">",
"     Autoimmune ovarian failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity was first postulated as a cause of primary ovarian insufficiency when it was noted that some women with adrenal insufficiency also had ovarian insufficiency. These women include many with the type I and type II syndromes of polyglandular autoimmune failure, which are associated with autoantibodies to multiple endocrine and other organs (",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"UTD.htm?9/25/9629\">",
"     table 2",
"    </a>",
"    ). A possible association between myasthenia gravis and primary ovarian insufficiency has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is strong histologic evidence that primary ovarian insufficiency, when it occurs in association with adrenal autoimmunity, is a specific entity mediated by an intense lymphocytic infiltration of thecal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/46\">",
"     46",
"    </a>",
"    ]. In this disorder, primordial follicles are spared, although there is likely spillover of the inflammatory infiltrate with time. Theoretically, ovarian function might be restored if a safe and effective immunosuppressive regimen could be developed and used early in the course.",
"   </p>",
"   <p>",
"    In one series, 4 percent of women with 46,XX primary ovarian insufficiency had lymphocytic autoimmune oophoritis and positive antiadrenal antibodies. The frequency of autoimmune oophoritis among women with ovarian failure without coexisting adrenal failure is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23976?source=see_link\">",
"     \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79731003\">",
"    <span class=\"h2\">",
"     Ovarian toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian toxins associated with POI include chemotherapy and radiation therapy. Viral infections have been suspected but not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79731035\">",
"    <span class=\"h3\">",
"     Chemotherapy/radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapeutic drugs and radiation therapy are the most common causes of toxin-induced ovarian failure (",
"    <a class=\"graphic graphic_table graphicRef58142 \" href=\"UTD.htm?5/18/5421\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79731042\">",
"    <span class=\"h3\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses such as mumps have been associated with orchitis and testicular failure in men and have therefore been presumed to cause oophoritis and ovarian failure in women. However, acute oophoritis is much more difficult to diagnose in women than is orchitis in men, and most of the evidence that viral infections can cause primary hypogonadism in women is circumstantial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/47\">",
"     47",
"    </a>",
"    ]. Although viral oophoritis has been experimentally induced in cows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/48\">",
"     48",
"    </a>",
"    ], few cases of viral infection of the ovaries have been documented histologically in women.",
"   </p>",
"   <p>",
"    A report described a woman with widespread cytomegalovirus (CMV) infection who had histologic evidence of CMV oophoritis at autopsy; however, she had had no clinical evidence of hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. While some women with primary hypogonadism can recall a preceding viral illness, a cause and effect relationship has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79731049\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other toxins may have more subtle effects on ovarian function. As an example, cigarette smokers reach menopause approximately two years earlier than nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Endogenous factors that correlate with age at menopause include weight and socioeconomic status, which increase it, and parity, which decreases it [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107584\">",
"    <span class=\"h1\">",
"     PRIMARY HYPOGONADISM WITHOUT FOLLICLE DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some disorders that are not associated with follicular depletion may present clinically as primary hypogonadism. These disorders are genetic disorders of estradiol precursor production or aromatase function, resulting in decreased estradiol and absence of normal FSH negative feedback.",
"   </p>",
"   <p>",
"    There are two major mechanisms of primary hypogonadism without follicle depletion: endogenous mediators of gonadotropin receptor activation and steroidogenic enzyme defects that prevent estradiol production. Secretion of biologically inactive gonadotropins, a cause of secondary hypogonadism, presents in a similar fashion to primary ovarian insufficiency in that serum immunoreactive gonadotropin concentrations are high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107611\">",
"    <span class=\"h2\">",
"     Intraovarian modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many substances that may serve as paracrine regulators of ovarian responsiveness have been identified. Abnormal ovarian production of any of these modulators could cause primary hypogonadism, either directly or by decreasing cellular responses to gonadotropins. However, only polymorphisms in the alpha subunit of inhibin have been implicated in ovarian failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107625\">",
"    <span class=\"h2\">",
"     Steroidogenic enzyme defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the uncommon causes of congenital adrenal hyperplasia are due to genetic defects in the enzymes involved in androstenedione and estradiol biosynthesis in addition to cortisol biosynthesis. These defects result in low estrogen and, therefore, high serum FSH concentrations. Although these disorders are not associated with follicular depletion, patients present with hypergonadotropic hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported enzyme defects include mutations in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroidogenic acute regulatory enzyme (StAR), the enzyme that moves cholesterol from the outer to the inner mitochondrial membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients with congenital lipoid hyperplasia caused by StAR mutations typically have severe adrenal insufficiency very soon after birth, although they occasionally present later in infancy. In patients treated with steroid replacement early, there is absence of pubertal development [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with CYP17 deficiency usually present at about the time of expected puberty because of hypertension, hypokalemia, and hypogonadism. Female (46,XX) patients have primary amenorrhea and absent secondary sexual characteristics.",
"     </li>",
"     <li>",
"      Mutations in the aromatase gene also cause absence of estradiol secretion and primary amenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/57\">",
"       57",
"      </a>",
"      ]. However, the concomitant deficiency of placental aromatase results in androgenization of the mother and fetus due to the failure to aromatize fetal androgens during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"       \"Adrenal hyperandrogenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107632\">",
"    <span class=\"h2\">",
"     FSH receptor mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the ovaries of all women with primary ovarian insufficiency are unresponsive to FSH and luteinizing hormone (LH), specific receptor defects had not been identified until not long ago. Mutations of the gene for the FSH (or LH) receptor that result in production of receptors that either do not bind FSH or cannot transduce the signal normally initiated by the binding of the hormone to the receptor would be expected to cause primary hypogonadism. As noted above, a mutation of the FSH-receptor gene that results in production of receptors that bind FSH poorly was identified in some young women with POI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The mutation resulted in a single amino acid substitution in the extracellular domain of the FSH receptor that prevents FSH binding. Thus, FSH does not stimulate aromatization of precursors to estradiol, and the women are estrogen-deficient. Whether this mutation affects oocyte number and viability remains to be determined. Its effect on male fertility is variable.",
"   </p>",
"   <p>",
"    A mutation in the LH-receptor gene has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/58\">",
"     58",
"    </a>",
"    ]. This defect was identified in males who had hypogonadism, and an affected female in the family had secondary amenorrhea with high serum LH but normal FSH concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3107659\">",
"    <span class=\"h2\">",
"     Gs alpha subunit gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to defects in gonadotropin receptors, defects have been described in the guanine nucleotide regulatory protein of adenylate cyclase (G-protein) that is linked to the receptors and via which activated receptors stimulate adenylate cyclase activity. As expected from the multiplicity of receptors activated by the same G-proteins, including parathyroid hormone, FSH, LH, and thyrotropin receptors, affected subjects may have pseudohypoparathyroidism, abnormal gonadal function, and hypothyroidism, among other problems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/40/7817/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology of hypocalcemia in infants and children\", section on 'End-organ resistance/pseudohypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18246166\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many cases of premature ovarian failure, now known as primary ovarian insufficiency (POI), remain idiopathic, the number of known causes and genetic factors is growing rapidly. However, for 75 to 90 percent of patients, the cause of their ovarian failure remains unexplained. The known causes of primary ovarian insufficiency include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Turner syndrome, the lack of a second X chromosome (45,XO), is one of the most common causes of primary ovarian insufficiency. Although their ovaries have a normal complement of primordial germ cells early in gestation, a process of accelerated follicular depletion follows. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Turner syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fragile X Syndrome &ndash; Women who are carriers of the FMR1 gene premutation are at increased risk for primary ovarian insufficiency. The prevalence of FMR1 premutations is estimated to range from 0 to 3.3 percent in women with sporadic primary ovarian insufficiency and from 12 to 16 percent in women with primary ovarian insufficiency with at least one family member who also had menopause before age 40 years. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fragile X syndrome premutation carriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatic and X chromosome gene defects associated with POI include mutations in FOXL2, NR5A1, BMP15, FSH receptor, Gs alpha, and steroidogenic enzymes. However, the majority of the known genetic factors are extremely rare and do not warrant widespread genetic screening outside a research setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Somatic chromosomal defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune ovarian failure &ndash; Approximately 4 percent of women with 46,XX primary ovarian insufficiency have lymphocytic autoimmune oophoritis and positive antiadrenal antibodies. The frequency of autoimmune oophoritis among women with ovarian failure without coexisting adrenal failure is not known. (See",
"      <a class=\"local\" href=\"#H3107557\">",
"       'Autoimmune ovarian failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxins &ndash; Chemotherapeutic drugs and radiation therapy are the most common causes of toxin-induced ovarian failure (",
"      <a class=\"graphic graphic_table graphicRef58142 \" href=\"UTD.htm?5/18/5421\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H79731003\">",
"       'Ovarian toxins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/1\">",
"      Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994; 79:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/2\">",
"      Taylor AE, Adams JM, Mulder JE, et al. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 1996; 81:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/3\">",
"      Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/4\">",
"      Jacobs PA. The incidence and etiology of sex chromosome abnormalities in man. Birth Defects Orig Artic Ser 1979; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/5\">",
"      Hook EB, Warburton D. The distribution of chromosomal genotypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet 1983; 64:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/6\">",
"      Albright, F, Smith, PH, Fraser, R. A syndrome characterized by primary ovarian insufficiency and decreased stature: Report of 11 cases with a digression on hormonal control of axillary and pubic hair. Am J Med Sci 1942; 204:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/7\">",
"      Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966; 155:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/8\">",
"      Schlessinger D, Herrera L, Crisponi L, et al. Genes and translocations involved in POF. Am J Med Genet 2002; 111:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/9\">",
"      Bione S, Sala C, Manzini C, et al. A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet 1998; 62:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/10\">",
"      Fryns JP. The female and the fragile X. A study of 144 obligate female carriers. Am J Med Genet 1986; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/11\">",
"      Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet 1999; 83:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/12\">",
"      de Vries BB, Halley DJ, Oostra BA, Niermeijer MF. The fragile X syndrome. J Med Genet 1998; 35:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/13\">",
"      Bodega B, Bione S, Dalpr&agrave; L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod 2006; 21:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/14\">",
"      Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 2005; 117:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/15\">",
"      Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/16\">",
"      Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002; 125:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/17\">",
"      Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/18\">",
"      Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005; 20:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/19\">",
"      Kenneson A, Zhang F, Hagedorn CH, Warren ST. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 2001; 10:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/20\">",
"      Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/21\">",
"      Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000; 66:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/22\">",
"      Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004; 89:4569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/23\">",
"      Gersak K, Meden-Vrtovec H, Peterlin B. Fragile X premutation in women with sporadic premature ovarian failure in Slovenia. Hum Reprod 2003; 18:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/24\">",
"      Marozzi A, Vegetti W, Manfredini E, et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod 2000; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/25\">",
"      Uzielli ML, Guarducci S, Lapi E, et al. Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data. Am J Med Genet 1999; 84:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/26\">",
"      Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/27\">",
"      Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995; 57:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/28\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion. No. 338: Screening for fragile X syndrome. Obstet Gynecol 2006; 107:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/29\">",
"      Chen YT, Mattison DR, Feigenbaum L, et al. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science 1981; 214:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/30\">",
"      Kaufman FR, Kogut MD, Donnell GN, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981; 304:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/31\">",
"      Cramer DW, Harlow BL, Barbieri RL, Ng WG. Galactose-1-phosphate uridyl transferase activity associated with age at menopause and reproductive history. Fertil Steril 1989; 51:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/32\">",
"      Knauff EA, Richardus R, Eijkemans MJ, et al. Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age. Reprod Sci 2007; 14:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/33\">",
"      Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004; 75:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/34\">",
"      Di Pasquale E, Rossetti R, Marozzi A, et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab 2006; 91:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/35\">",
"      Piquette GN, LaPolt PS, Oikawa M, Hsueh AJ. Regulation of luteinizing hormone receptor messenger ribonucleic acid levels by gonadotropins, growth factors, and gonadotropin-releasing hormone in cultured rat granulosa cells. Endocrinology 1991; 128:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/36\">",
"      Mattison DR, Evans MI, Schwimmer WB, et al. Familial premature ovarian failure. Am J Hum Genet 1984; 36:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/37\">",
"      Aittom&auml;ki K. The genetics of XX gonadal dysgenesis. Am J Hum Genet 1994; 54:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/38\">",
"      Aittom&auml;ki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/39\">",
"      Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/40\">",
"      Raile K, Stobbe H, Tr&ouml;bs RB, et al. A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. Eur J Endocrinol 2005; 153:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/41\">",
"      Beysen D, De Paepe A, De Baere E. FOXL2 mutations and genomic rearrangements in BPES. Hum Mutat 2009; 30:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/42\">",
"      Louren&ccedil;o D, Brauner R, Lin L, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 2009; 360:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/43\">",
"      Janse F, de With LM, Duran KJ, et al. Limited contribution of NR5A1 (SF-1) mutations in women with primary ovarian insufficiency (POI). Fertil Steril 2012; 97:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/44\">",
"      Li Y, Xiao B, Xiao L, et al. Myasthenia gravis accompanied by premature ovarian failure and aggravation by estrogen. Intern Med 2010; 49:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/45\">",
"      Ryan MM, Jones HR Jr. Myasthenia gravis and premature ovarian failure. Muscle Nerve 2004; 30:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/46\">",
"      Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/47\">",
"      Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. Fertil Steril 1975; 26:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/48\">",
"      Smith PC, Nusbaum KE, Kwapien RP, et al. Necrotic oophoritis in heifers vaccinated intravenously with infectious bovine rhinotracheitis virus vaccine during estrus. Am J Vet Res 1990; 51:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/49\">",
"      Williams DJ, Connor P, Ironside JW. Pre-menopausal cytomegalovirus oophoritis. Histopathology 1990; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/50\">",
"      Subietas A, Deppisch LM, Astarloa J. Cytomegalovirus oophoritis: ovarian cortical necrosis. Hum Pathol 1977; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/51\">",
"      Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/52\">",
"      McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/53\">",
"      Stanford JL, Hartge P, Brinton LA, et al. Factors influencing the age at natural menopause. J Chronic Dis 1987; 40:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/54\">",
"      Shelling AN, Burton KA, Chand AL, et al. Inhibin: a candidate gene for premature ovarian failure. Hum Reprod 2000; 15:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/55\">",
"      Lin D, Sugawara T, Strauss JF 3rd, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/56\">",
"      Mallin SR. Congenital adrenal hyperplasia secondary to 17-hydroxylase deficiency. Two sisters with amenorrhea, hypokalemia, hypertension, and cystic ovaries. Ann Intern Med 1969; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/57\">",
"      Ito Y, Fisher CR, Conte FA, et al. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A 1993; 90:11673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/58\">",
"      Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/59\">",
"      Levine MA, Downs RW Jr, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983; 74:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/60\">",
"      Shapiro MS, Bernheim J, Gutman A, et al. Multiple abnormalities of anterior pituitary hormone secretion in association with pseudohypoparathyroidism. J Clin Endocrinol Metab 1980; 51:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/40/7817/abstract/61\">",
"      Faull CM, Welbury RR, Paul B, Kendall-Taylor P. Pseudohypoparathyroidism: its phenotypic variability and associated disorders in a large family. Q J Med 1991; 78:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7435 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7817=[""].join("\n");
var outline_f7_40_7817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18246166\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H151094249\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79730714\">",
"      ACCELERATED FOLLICLE DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82311047\">",
"      Genetic: X chromosome disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82311058\">",
"      - Other X chromosome deletions/translocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fragile X syndrome premutation carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Somatic chromosomal defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82311137\">",
"      - Galactosemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82311256\">",
"      - BMP15",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82311226\">",
"      - Other rare defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3107557\">",
"      Autoimmune ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79731003\">",
"      Ovarian toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79731035\">",
"      - Chemotherapy/radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79731042\">",
"      - Viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79731049\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3107584\">",
"      PRIMARY HYPOGONADISM WITHOUT FOLLICLE DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3107611\">",
"      Intraovarian modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3107625\">",
"      Steroidogenic enzyme defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3107632\">",
"      FSH receptor mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3107659\">",
"      Gs alpha subunit gene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18246166\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/47/44795\" title=\"table 1\">",
"      Major causes of primary ovarian insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/25/9629\" title=\"table 2\">",
"      Polyglandular autoimmune syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/18/5421\" title=\"table 3\">",
"      Ovarian failure anticancer Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23976?source=related_link\">",
"      Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=related_link\">",
"      Prenatal screening and diagnosis for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_40_7818="Age TBSA survival grid";
var content_f7_40_7818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Age TBSA survival grid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 439px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG3AmEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivMoPi3ZzfFuTwX/Z7Lbh2tk1QzfI90sYcw7NvUAkZ3dRjFAHptFcZa/E/whdapDYQavmaZ544pGtplgkMKlpdsxTyyFUEkhsD8RV3wx468O+KL57PRb9prlYBdCOS2lhLwltolTzFXehPG5cj3oA6aivLpfiJrUfgjXfF9rpOnXujWdzcG1Rrp7aSS1h+XzAdkgZmdXwMINuOTWf4g+L+oaBF4cOqaJots+t2s17E82uNHDHGkaOqs7W/323FQoGMgcnPAB7DRXkF/8a4Lay8KSvpcFk+u2rXW/Vb42tvBhtuwyrG+WJ9QoAwSRU3jn4zW3hOfw4k2kNdrqNut7fPBdK62Fs0iJ5u5QyyDcxAwQDjrzQB6zRWT4j8RaV4b0dtU1q8W2sQyoJArOWZjhQqqCzE9gAazH8feHop7eC5ubu1nuIJ7mOK60+4gcxwjdI214wQAPUc9s0AdTRXAP8YfAqT2MJ1zM19ClxbRrZzlpUckKQAmckqeOvtSar8V/DMOhSX+l6lbXTiwGpoJVnjj+zmURb3ZInKfNkY2lsjp1IAPQKK5FPiL4XNy9q2p4u0votMeEW8277TICyIBsyQQCQwG3AzmqPiD4k6Va6drsWnSTpr1jpdzqEFpqGn3FsJREjHI8xE3rkc7T+NAHeUVyVh4zsrX4caN4p8T3MNlHd2VtcTGNGK+ZKinaiDcx5bAAyaz7v4veCLOylur3WJLWGK6NjJ9osbiJo5wu8oytGGB2+o9utAHe0VwNr8U/DrSXzXN9brbxz20Ft9nS4mnuGnjEka+T5IO4qchU38dcHip/hD4uvfGvhi51PUIYIZI9QuLVFhjeMbEbCkq5JDY69PoKAO3ooooAKKKKACiiigAooooAKKKKACiiigArzrR/CfhzXvFvji61zQNI1K5TVoo1lvLOOZ1QafZkKCyk4ySce5r0WuV8G/8jH47/wCw1H/6brOgA/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+Jq14q1+40ibTLLTdPGoapqUzRW8LzeTGoVS7vJJtYqoA7KxJIAFc94n8fan4Y0eCbVvDgbU5J5R9ktb3zVNtFGZJbhX2AkBRgKVBJIHGQaANf8A4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImqGp/ECOxh8RD7AJrrTjbfYoUnyNQW5AEBU7fl3SbkPDY2E81U8N/EY614rutHceHLU299cWRhfXM3z+UWG9bbyRkHbn7/AEye1AG1/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXP6T8Sb7XNP1i40fQ7UvY/6TEl5qDQi6sT5gS4QrC/LGJhsxgDB3c4re8HeLX1n7Bb6tb2lhqd/YjU7a1t7mS5zbfICzOYkVWDSKNvPqCecADv+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/ia6quL8SeJPEWmeJtO0qx0LSbqLUXkS1nm1aSFvkj3tvQW7behAwzZ46dgC1/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE1h6F8TLSeDV4dXMdvqlnd6jFEn2e4S3kS1eTjztjKzbE3MFy3UhO1dJo/jDStV1FdPtHuZrwBfNaCzuHt4mMYk2tP5YjU7WU4Yg8jjJAoAr/APCuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTU2u+N9A0PUjY6jdzLcoI2kENpNOsIkbahkaNGWPceBuIzVd/HmjSXsVtZXAlb+0G06Z5IZ440lUuroJPLKFwUPykgY+bOCMgDv+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJqn4f8d23iLxomm6OWm0ptNe8FzJaTQ+YwlVAY3cBZEIYncuR05q1N470m0vb21vZJGnhvXso4bG2uLuVykUcrZRIsggSjO3coBHzZJAAHf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E1qatrMWnjSmbYBqF0lsgm8yNssrMMAITu+Xo20dckHg8hqXxd8OR6BLqWkteagVjhnji+w3MPnRPKsfmIWi+ZQXGSoPOAcEigDb/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+Jpy+PPD51G3sWubuO5meKLbLYXCCOSQAxxysyARO2RhHKscjjkVWtPiZ4TuoZpo9TkSGK3a68yazniWSNWCM0ZdAJMMyqQmTkgdaAJ/+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiayNI+JVjPqOurqC3MNtbX8dnYwrpl19rmzbRytug2GUkFn52AbQD3yU8VfE7SrLRUn0C4F/eyrbSxhLSeWJI5ZVQGVlXERI3YDlTkdO1AGx/wrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATWl4i8SaZ4eW3OpyzB7gssMVvbS3Esm0ZYiOJWYgDknGB3rJb4jeFhcQwjU2fzVgcSx2szwqs5xEXlCFEDHgbiOeKAJP+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iazvDXxDsLjQrm78QXMFndWwvbiVY4pNotoLuWAOOu4/IuQCTlhwNwFT/EjxZceHbPRF01SLrVb1bVJZNPnuxEux3ZjFFh2bCYC5B5J6KaALX/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNQp8RvC4iuGl1RlW2ieZ5mtJkjlRGCO8TFcSqGIBKFsZrWvfE+lWPh2bXb2ae30yI4eWW1lVh8+wEIV3kEkYIGCCCMjmgDP8A+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaj034i+GtR1OKwt7q8W6kuPsgWfTrmALNtL+UzPGAjlQSFYgkdAaV/iH4cj+0i4ub62ltxGWgudMuoZmEj+WmyN4w8m5/lGwHnigB/8AwrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATUq+NtGe9s7Nf7UN5dRiVIP7Ju/MjQu0YeVfLzEpZWwX2ggE9OapeMfGieF/FOh2d6jnTb20vJ5nhtJriVWhMG3asQY7cSOWJU9ByOcgFj/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mp4/G3h6WCWaLUlkhiltYWdI3I3XIQwYIXkMJE5HAzzjmqT/EjwwqwMt3eSrPM1vCYdNuZfNlXfuRNsZ3MPLfIGSMDPUZAJv+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJrd0XVLPW9KttS0ucT2Vym+KQKVyPcEAg9iCAR3q7QByv/CuPA/8A0Jvhv/wVwf8AxNQ/Cm2gs/CUtraQxQW0GrarHFFEgVI0GoXACqBwAAAABXYVyvw0/wCRcvP+w1q3/pxuKAOqooooAKKKKACiiigAooooAKKKKACvMofgr4WhtoShvBq0Wp/2r/bH7oXrTby2DJ5fKZP3cY/HmvTaKAPD9G+DV1H4o0sXjW0PhLTP7Q8nTheG5ZhdIUdQfIiKLhiSC0hzwD3rdsPhND4U0HVovBF0keqXFjJY20t5bW0fkhyPmM0UCzMVAyNzMCQM9iPU6KAOaufBmmXHw+Pg7MsGlGxFhugIVwgULkEgjd3yQeaztU+Hdne3nhu8tdX1bTr3QLV7S0ntTAxKMio28SROpOF7AdTXNfFfwtf+JfHOkx2mh6fqcX9jXsPnakHWC1lZ4drhljf94OSo+UkBsMMUwjxxpui6wF1TVpl0y/t7CEx6fG8slp5Vt51yilC0zgmYqBnncCHwFABuQfCvTLPwzBoGm6xrVnpiQtDJEkkMqzBnZ2ZllidQ5ZidyhSMDGMVRi+BvgxYtQjubWa8W5sY9Ph+1FJDZRopUGAlco2TuLHJz6Dis2TW/H1tpi3mnxanqcM11c6bareaesM+HVfs95MgRCiq4dW+VQVIYqOtGoXHijS/EOpQNJqsGmSalDHcatpujJNczKunxYcKsThw0oZS+x9uAo2gcAHZt4X07WvANhoUGry3mlxxRxpdlLW7M6RjA3eZE8bdBztzkdetcwvwg8LafDolhBq+p2VzbpdwW7C4hElwk6nzk2NGVxjJwirt5NcbpF98QtG0rw3p2n297Y2cdhEyebZTOJJjK/mLOsdpMy/Lt43Q/eyCe3S6PJ4g1P4k6FPrQ1sy2l9qKy276b5djaRbJEhaOfyx5m9dpyZG5PReBQB0vgTwB4e8Ja+X0jUbq41C00uHTngmnjcpBvZkdlVQQWIbnodpwODVCz+Cvhez0PxPpVrJqMdtr5HnESoWt0DlxHDlMKgZicEHr1rI8Zv4h034i69eeHxrSXdzZabHZx2+mma1vHWWfek0xiZY1VXyTvQ/NnJxiui8G6r4jv8Axnqekajcl7TQnljuLjyox9taZhJbjgfKY4T8wGMsy9qALcnwy0CT4gW/jBvtf9pwwLD5YkAhdlRkWVlxnzAjFQc8ema5GT4P+CfCkN1qOqa9eWcEtpc6fJdX1xbRfJcght0pjVncbjtLsxHTkDFT/EEaifHD6t4L0OeTXNP0a+inu3094lkdmt/KUSsgExAWUqFLYOeOcHF0628Y+JtX8Mf2rqOrxQW2rSyLcpYFZbdfsMo3SGexhQ/P8qsI8fvSCSwUgA7LXPDWjeJPh5H4V0C8ttTk0M20ERXUUjkt5YNoUySLHIFcAHgxkHpgZyMjwb8JJobg6n4s1F5tWGvHXEFpKrJv2BFV2MS7uMk7UQZPAAqp8PdM8YafZeHtLXUNXt7R9Mury4WeygXZcCeLZDvMI2bg0hO7LEM5HQFaXh7X/iK+javfarcTW9xY2a3slvdWbxjzI5A0kKO9pFHsaMOvEkjA7SHxk0Adpq/wp0bUdbvdY+3apa6ncahBqaXEEkebeaKPy12BkZSCOoYN+FdB4G8J2Xg3R5dO064u7iKW5lunkumUuXkOW+6qjGfas3Rp9W1n4eajf6kJWuNThuLi1tfKAeCB1PkxYAyW27Sc87mI7CuC+Fmk33gSE32paFPmXw9byRw6JpjRea8aFpI548km7ywAZiN/IABBFAHuFFcT8UrWPVPCNvHPDfmJ7qCVo4dPa9GAd2J7dTuki4wyjnpXnhvvEWh+E/s/hvQ9Q0oTahcGGbStNkt4ZFEabXa1kt7mSAMxYBQqjKEll3cgHsup+IdF0q6Ftqmr6dZXBia48q4uUjfylzufDEHaMHJ6DBqxpeqWGrW32nSr61vbfIHm20yyLyAw5UkdGB+hHrXgN3oPizxBpmparqEuvWuoX0Hh8z2sVjEFdvNTzhhoSw8sl3IBwpJ3ArxWlq0njfQHvodETUltbjV7t7i/FqXmkIhgET7UtZ8qx8wkrEFJXG5OhAPeKK5rwdr82pxrYX8UjapZ2ds99cJEY4DNJHuKKH2uGAwxVkBAdc88V4Z4u8G+LbrR/iFBp9ndnSNVvr27nhCt5ryQkmHykxuYSlo+VyMQEfxUAfTFFeB63ocU2p+NVj8NajJ4uuruJtE1KLTZUMLfY4FSQXezYiLIrbgX7EYOa96jDiNBIQz4G4gYBPegB1FFFABRRRQAVyvg3/kY/Hf/AGGo/wD03WddVXK+Df8AkY/Hf/Yaj/8ATdZ0AX/E/hy38QLYu9zd2N7Yzefa3lmyrLC+0qcblZSCpIKspBHasQfDbRrvUVvfEslz4mlWN40XWkhnjjLsCzIgjCoTtUfKAABwBk57aigDiLX4a6Nb3/hq7FxqMkmgw+RbrJMpWZBnyxKNvzeXuOzGMd81JF4D8gavDbeJddgsdTkupprSMWuxXn3bijGAyDBbI+Y4IGcjIPZ0UAcbZfDfw3plys2i2KaUTYy6fMtjHHEtxG4XmXC/M67chuvLZzmtfSfDsWl3GmvbX+omCw08adHavMPJdQUxIyAAGQBMBuOGYY5rbooAKzNR0W3v9Y0nUpnlWfTXkeFVI2sXQod3GTweMEc1p15/rGp6xD8QJLe6uNetdKSOBrKLTdMFxDeMS3mLPN5T+XyFX70eAc57gAuXXw50i5tvJkuL8J9q1C7yHTO+8WVZR93oBM230wM55y6y+H2n2viqy177beSXNnEIYkMdug2iPywGkSJZXXGTtZyueccDHm2meJvH9zDrG9tds4PskE1vJeaVJLNFL5wDxDy7FRuKHGRHOqn5ssM1evPFnjSy0C6mWz8SSXFxoc32ANpf2iX7es0oDP5cCBQUMZUSImVHK7sggG98Q/BGp6vrs11pl7Hp+l3YtX1SSS9Cq4gk3ZMJgYnCgciaMHuCBz0Nv4M0W70u2SK5nubJtTl1tHWRGWV5mkcjIXBjPmtjHOMcnv57q2veNbrxnPp8Nlrh0ab7Xa3EM9nuj2i2kKSRutqoCs4XH79z82CozxV8M2PiPQ4dcktbvWrLUP7KsLq2gnsFFpL5NtHvjeUwkI3yNHguGAYnBIBAB6X4T8C2vhvUYLuLVdVvjbWI022ivHiKQW4ZWCLsjUnG0DLEnHUnis7XfAGha5c6pp0uqzpPeXX9q3NsqWkzqXjSFWUSxO0a4gO1lwd275uBi54Y1XXdU8C6hryRs95fLNeaVZTIqeVFt/0eNsAElgFc5JIMhGcAV5pYJ4gvPEqak0Ou6nJIuhRzzaroiw+Wy3ztOsaGFQFjVt2/BZc7g/AIAPZ9Q8PWl9Bo8UslwF0q4juYCHyWZEZQHJBJGGOe+e9c03wu0Y6PY6cLvUljs9LGlQyCRN4jEscqv9zBcNEnbb1yprjo/EfjOGw1oTf8JNfTK8aw3Vtp/kRxhpSCVjksDJwo+batx8vIOaq23iXx+dH0qa9/t03AubmKS2tdLZJ7hBNiJzI9k0YGzsywZHzZXpQB3J+FmjP4oi8Q3FzPc6p5kM081xZ2UrTyRhQrFmgLRnCrnyinTIweakuPhholxpen2MlxqHlWNlLZQuJEDAPLFLvzt++rwoQenXINedpJ4x8O6bqtto0mvvI3iK7e6Mmn4EVvJLO6SwOlpL5nmEoWKpLtyBtQHI6XSbzxzfRzNfandWa2+gpcpLDpTskt35tyuGV4FkY7FhLRqisTjaFB+YA09S+EWjaqJ5NW1DUb++mvBetd3cVrK28QrDjy2hMRUoi8FDgjIxU0nwr0vyPIt9U1S0tZI7dLm3tUtoorkwPvjZlWHCHPXy9gIHIqb4Z3uu6p4d1JNYl1Vb5JTHFd30Cx7sxqQ0aG2gbaCejx9QQCw5rD8OeIfHupTeGbXU9ImsEuZgLy6FvgosEZ8/zAwwomkAEeAp2kn0wAdlrGi2PitNL1XTtYubWaBXa01HTJIn3RyqAwBdXRlYBTnHYEEVmwfDTRLfSrrToJb5La4SyRv3qlgLVw6EEqeSR8xOc9sV514XHj7wz4B0600tNSuZf+EbWZLa6skT7FcLLEpjUiLdu8tpG2PvYlOB1FbXhO+8d6rf6faXupahb2E01z5t2NOZZo0WOIorNPZwqDuL4YRYIJHJXIAN/UPhtayz+Gbe3bdp2m6hc39w80n76XzZWn8kBVCmMzFGIPaJRzkmuv1rRLbV7rSJ7l5lfTLwXsIjIAZ/Kkjw2QcjErdMHIHPY+d/DPWPHF94sli8UCWK28qYzW0trKqRuJAE8mT7JHGRjIwZ5SQQR0NTeKrzxzG3jW60WW8Isbm2j0y0FqgSWJ4YDM6sY2aQqWlK7c4YEEPgJQBot8KtIe0azm1LV5bFLeS1tLZpY9llHI6uwjxGCfuqMuXIAwMV13iTRbfxBo8um3rzJBK8bloiA2UdXGMgjqo7dK8cn1/wAex+Hrad73VpJFurj91aaVP9rmiCRFFLyaaEUhjIATFGrZX5xsY1dt/E3i+78UXsOkXGqXlxb6tLbNp8+notlHbLb7gXuRGB5gkIGBL3+7jmgDv5/A2mzT3MrT3qtPqw1htsijEwgWHaCFyF2qD6579q5rTPg3oOj2+ofZ9SvlF3arazyS21iwaJXD/ODb7ZGJHLyBmPc5wRgWWseO7qzgitLvxC7TNpyXdzeaKkD2kslwq3CxKYlDxrGWJYhwuAd5zxZ1XUfGMMH9nX914g+wC61C3bULLSUnupwoT7MGVYWQIwaQGRYwDsHK8kgG7Y/DLQrqx8PzWmr3lxY2ISe0kiW1bzAZDMGSZYd6I27G2JkTbgAAE56LxZ4Ri8RahYXo1bU9MubOC4tleyMPzxzeXvVvMjf/AJ5rgjBHPNeT+Dr/AOIGn3HhPSWgubDS7e00uAQyWczRyRfZ4hOJCtpJskDeYvzTRBSoyCMk6uoah45tfCGi6lNqmttqNzva6sbfSgJF25CqpW0m8snIJ8xQGOMFBmgDqm+FejrNALK/1WysY3spGsYHi8mVrTb5JYtGX6IoIDAHGcZ5rY0/wXp1imgLFNdkaLdT3dvudfneZZVYP8vIAmbGMdB15znfEHVtY0/whp82lW+s/bp5Ykke0jV5YAUJLShbefjIwdkTckdBzXLeFtS+IWq6bBJetfW13DpElx5UlikQurtLiZUjdnjG0OixlgApwQRszQB6d4a0W38PaLbaXZPM9vBu2tKQWO5ixyQAOpPatOvNPg/qnizUZr//AISmS4eJYYWRLq1lhkjlO7eAzWlujL04UyEY+8QRXpdABXK/DT/kXLz/ALDWrf8ApxuK6quV+Gn/ACLl5/2GtW/9ONxQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHKeKPEmq6f4k03RdD0mz1C7vLS4uybq+a1VViaJdoKxSZJMo64HHWqNj8SdJktxcakU02OKGVrqOZnaW3ljuRbupCoVKiQ43bs9DtxkjU8S+FBrWr2OqQazqmk31pbzWqSWPkndHKULAiWNx1jXBGCKzZvhpoclvHAkl9FGlv9nO2UEvm4W4Z2LKSXaRck99x47gAvf8ACfeHheQ2r3N3HLI8cZ8zT7hFiaRtsYlYxgRFj90OV3AgjIIJytd+KOjWFjDdWEGo6jC9/BZGWHT7ryj5kwiZo5BEVlK84VCdxG0ckUX3w98NeI/FC+K4JopriR42keO3tLmOZoTtHzyxOyEbdp8tl6diM1Kvw5tU0YaTFrmtR6bDNHcWVuDbkWUkcwlQxsYixwwwBIXGOMdKANG38e+HbjUVskvJ1nYlAZbKeNPMCb2i3sgXzAuSY87xggjINaXhvxDpviXT1vtGllns3VHSZreSJZFZQwKl1G7g84zg5BwQRXMS+BNJ06UX2pa7qP2GO5a8MFzNBHB9qkUxtMSI1O5i5O3ds3Nwo4FbXhXwuPDzQxQ6leXFja6fbabaW0rfLEkKkbyB8rSNkZbaOFAFAGZc+PI9L17XbXX7aGy07TWtUS6hlluJJ3uCRGvkrFkHIxwW5I/CpB4/8P2+taXZ6RYXLx6xPcm4lg024SSO4i2K3mxiLduOQCWwQACeCK0L3wDZ3uu3mp3WqapI11dWd2YMwiNGtZBJEFxHuxkEHLEkE85wQsngKyGpRaha6jqVpdx3txe74jE24zBRJGQ8bDYQi9tw7NQAg+JfhPypZm1N0gjVHEslpOkciNKsQeNigEib3RSyEgbgSQOaZefE7wtZXLwXV1qEU0bRpIraTdgxtIMxq37r5Wb+FTgnsDWPpfwZ8NaXFLDZPPHAzQlFS2tEeMRzxzqPOWESsN0Sg73bIz3wR0uoeCtOv7+8u5prtZLq/s9QcK6gCS1KGMD5funYMjqecEUAQP8AEXwylnDcm9uWWVpl8pLC4aaPyTtlMkQj3xhCQCXUAZHqKnvvE/hfULG9t724t7yyElta3EckDSxObnZ5KkbSGD+YnIyBnnHNZ918OLCS6nurLVdX0+8nkumlntZItzpcMrSRfPGwC5VSCAGGOGqGf4X6S11E9rqGq2dmj2Uj2MEkXkytabfJLFoy/ARQQGAIA4zzQBDr/wAWfDunaBql9pzXF9PZW01xFbm1nhW48pgjhJGj2naxAYrnaOTwM1uXHjnRLX7Gbw6pax3bIkctzpN3FGGd/LVXdogsZLcYcg8g9CCc2++GOiXuj22m3E9+1tBbXtquJFDFbpg0hJ29QR8vp3zVDWvhHpeuanBqOsaxq17ex+STNNHaFyYpN6kN5GY88BhGUDAc5OTQBpf8LL8P21msup3Rjc/aZCLS2ublVigmaJ5GIiBUAr8xIABzgkYY2fiD4yTwnomnajFHYzx3t5FarLeXv2WCMOrESNLsfC/L6d6rw/DjSIbS8t1ub8pdWV7YuS6ZEd1M00hHy/eDOQvYDGQetaXiDwnb6zpGlWP2++sjpk8VzbXFsYzIrxqVUnejKeCc/LQBneC/iBp/iGys2uPJtry7kuo4Y4JjcxTLbsA8iShQChBVgWCkhhgU9viV4UWye8GoyvbJaJfSSR2U7iOB4zIsjYQ7QVU9cc4HUgVTHwxsEdbmHWdah1Q3M91LqMbQCaZpo0jkDDyvLAKxp91FI2ggg1Ja/DLRrbwxqehJc6gbTUNNg0uVzIm9YooyilTsxuIY5JBGewoA6Hw94k0vxD9qGlzTM9q6pNHPbS28iFl3KSkiq2CDkHGD2NYOneL9W1FDqVtoNsvhpbh4mvZ9REcwiRirz+SY9uwFWPMm4gZ210dhotvY63quqRPKbjUfK81WI2r5alV2jGRweck1zjfDuy8q6s49Y1qLRLmWSaTSY5oxbkyEl1B2eYEYsxKB9vJ4oAnX4j+GDavOb26RVaFQkmn3KSP5pIiKRmMM6sVIDKCDjrVKT4naMdd0Wytku57XUY7pnuRaTg2zwPGjJInl5TBdtxbaE2gtgMDUPh/4TaFoaxLayzYiuLe5QraWcDAwsWVWaKBGcEnneWPHUHJNyb4caZJdx3Ed9qUMguL2aQI0REqXbq88LBkPyHYoGMMB0bPNAE8XxI8LPA0zajLDGDBgz2U8O9Zn2RugdBvRm43rlfU11Fhdx31nDdQrMscq7lWeF4XA/wBpHAZT7EA15/ofwh0DRo447SacJHcW1wm21s4nBglWVFMkcCu4JUA72Ykdwea9HoAKKKKACuV8G/8AIx+O/wDsNR/+m6zrqq5Xwb/yMfjv/sNR/wDpus6AOqooooAKKKKACiiigArntX8Z6FpGrDTb+8kS6/dl9ltLJHD5jFY/NkVSke4jA3kZroa5LXfAljrGr3N7JqGp20V4IBe2dvIghu/KbKb9yFx6HYy5Awc0ATS+PfDMVpDcvqiiKVJ5F/dSZxC4jkyu3IIchcEAliAMk1GvxB8OFEP2q7ErzPbi2bT7lbjzFQSFPJMfmA7CGA28gjGapX3wx8PX0viV7lbqRddCieNpAyQkMHJiUghdzgO2cgsOmOKd4b+HOj+HbixubWaTzLKeW4Qra2lsrF4vLIdYIYwQBkgkZz3I4oA1R418PHSm1EanF9nVGkK7W83asvlE+VjfxJ8n3evFc3ovj/RtXj1jS/FJgiaO81G0ZJrOUWstvbySA5kcGNm8pNzLu6ZOAKz7fwx8PdQ1W3uLXX7W4ur7VzqlukOoxN58sbb2hRR96ISEyMgydxyTXQXfw30S9tvs1295Nbm6v7p42kUB2vBIJVOFztAlbbjBGByaAIJvH1hNJpFv4e+bzdRt7K4hurOa3eOGWORlZEdUOD5fytgqcH04SP4t+DZLYXCahfGBoPtQk/sm72mDnMufK/1Yxy/3R3Ipvh74V6JoRtzaSy5gu4btClpZ25LRK6qrGGBC4xIfvZPoRzmxD8NdHi0NdKW51A266HJoAYyJv+zvjLZ2Y38cHGPagDTfxx4ej1c6c+oETCTyTL5En2cSbN+wz7fKD7edu7PtWd4a8cQeJPGM2n6UHfSl02O8SeWzmgaRmkZcoZAoePaAQygg+tUv+FSeHB4gm1YKxedt80T2trIHYpsJ814TMuQM/JIoB6Yya1/CfgmDw5qIvF1bVdRlSyj0+IXrRERQISVUbI1yRk8tknuTQBZvPGei2Ws/2Xey3ltdkSFDNYXCRS7ELsElKbHIUE4VieDVG3+JXhW4tJblNQmCRpDIFksbhJJVlYrGYkZA0oYggbA3Ssq4+EehT+K5dfku9QN3JNPPt2wfKZY3jZfM8rzSmHJClyoOMDHFXr34baVcmydL3U7e5srO0s7aeKSPfELd2aOQZQgt8xByCpB+7QA/w54zfUfCmv65PbP5WnXV2kcQt5YpHjhJ27o2BcOQORtznt2p2hfETRtUsdKd1v4L7ULZLlLM6fctIAdoJA8sFkBYDeBtx82cc1paD4WtdI0S/wBNN1eXqX0s09xNcsnmO8v3z8iqB1PQDFZul+ALOyt1il1XVrzZpb6OjzPEjJbtt4BjjX5l2jDdfXJ5oAkPxF8NLFcvLdXsD28sMMkE+m3UU4aUkRARNGHO4qwBCkZFOX4heHHjtWgub24kuTKEgt9NuZp18pwkm+JIy6bWIB3KOSKw/Dnwg0HQblp7W7v3lae0nYlLaIM1uzMmRFCgJJc7iRuOBznmrWtfC7StWtmtpr+/jge9uL9lWO2dhLM+9ijvCzx45AKMrAd84NAFPw78S4Lq61ebVpJYrWO/msrK0g0a8a4cQsyu5IDeZ9wkhEHl5AY5NdVpnjLQtVv4bPTbx7ueaKOdfJt5XURyIXR2cLtUEKeWI5wOpArmfEXwz8MXlpZ2+pXTRSf2ldXVtJcrbTEzXLtJJGqTxujZPQFSwC9eprpvC3hOw8NzXEtg8haeC3t3UpFGgEKsFKpGiqpO4kgAD0AoAivvHGgWGuPpF1eTJexyxQSH7JM0Uby48tXlCeWpbcAMsMnjrVGz8deDrf8AtF7a7S2RVlvJpfsUsSXARgkkiOUAmIO0EoW7e1U7r4fvqni7WdQ1XU7n+ybu6s7pNOgZBHM0CptM2Y9/DoCArgHAz6VLafDXT7RfLi1TVWght5rWygl8iSOyjlYFxGrRENnaB+934HAoA0v+E70QS28JGri4uAzJb/2NeedtUgF2j8rcqZYDcQF965+f4m21p4ojtb0INKEGomWW0trm5kSS2uY4udsYKrhnLHaVBAw5HJYfg9op022sDqWo/ZoZ2uAFgs1IdiudhEAMIwoGIfL7nqSau3XwxsJLmWe01rWrCSb7cspt3g/eJdzCaVPnibA3AYK4YAdc80AR6p8QhH4hsbPTm0+eze7eCeXfKx8sac12rZ2AKThfu+YNp7McCOy+KVlctqaG0eL7Glo6zvFc/ZpROsZ/1vkfLzIAoIy3Bwozi8vwy0OO7E8El7Cqy+YkSOuxP9B+xBRlc4EXPXO7nOOKZ/wrTThDPbx6pq0dncQWsM1urQlZDbhBG5JjLBsRqDghTzxQBoTfELwxBNeRz6i8S2izNJM9rMsJ8n/WhJSmyQrg5CEkYPHFbWjaxbaxZPdWcd8kSsUIu7Ka1ckAHhJUViOeoGOvoa46x+E+hadrF9qOnSyW010Z24srJ2iabO8rI8DSH7zfKzsuDjBHFbfhTwXYeGdAvdJsri6e3u3d3Y+XDsLKFIjWFESMYGflUc5JySTQBD/wsXwyon+0Xl1ZvA0CyR3un3FtIPOfZGdkkasVLAjcBgY5Iqa28d+H7jUobBLm7S5ldIgJbC4jVJHXcsbuyBUkIIOxiG5HHIrmtC+DPh/RrgT295qDyB7SQnZbRbjbTechby4V3EtwzNlmHfPNakvwy0J/Gz+J0BS+knS5kRrS1lVpFAAYPJC0qfdH3HXkZGCSaAO4rlfhp/yLl5/2GtW/9ONxXVVyvw0/5Fy8/wCw1q3/AKcbigDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKAPLfi9pltfavps13Zz3ghtplSG40CbV7JmYr1jiIZJfl4fpgmucfX/G1jqfhmy0zRda061i/s+K5svJNzbeU5US4f7Mx+QEgl7hSCudpHX3WigDw/wCHek6ppfjHSJ7869ZQTWM0IjSw3Qs4vZ38uVvKYxgqyuCWXOeDjiutuNQGh/FbWbu9sdXe1u9KsYYZrTTLi5RnSW5LKWiRgpAdfvEda9DooA+drnV/HXiC01qzuNM12axltYbiC3v7Qq8c6XkP7vetpEPuFidplGFJDHBrc1/X/iCumaabdNTtrmSa6XUmSxJ+yyDb5UcOy1uDJCQWO/axbHLoflr22igDz3xhDq+pfDPSjeW099cMbOXVrWwV43uIsqZ0RGCvzz8hCsRlTzxXLanpljcXdrB4E8L32k21xJcJcz/2KbVATYXIRo0ljHlHeVUuFXduCksDiva6KAPDtG1LxRpWi+FdJ02+1aR9Xs49Oj/tHT0gl0y5j2GRwjQoXRYjJgsGBaNRk7ia9Pt9RXxX4MvLjTYJ0S7hnht/PCqZR8yK4wSNrYyCccEHArbks7WS9hvJLaF7uFWSOdowXRWxuCt1AOBkDrgVPQB454f05PFN74LsNV8O3jWOj6NLb6lFq2mskPnEW6rGPMXbKd0TNldyjaDnpXTfBvwzZaB4SiePRLbTNQmknE5W0WGV1E8mzfwCQFIxnsRiu9ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV8G/8jH47/7DUf8A6brOuqrlfBv/ACMfjv8A7DUf/pus6AOqooooAKKKKACiiigArzDxO3iVfGmqJoiXNpBcPpEH2630+N28tpLgT/OyHcFXYfmyE3Z43HPp9FAHimo6345shbRvPrtz5F9dWxS10zbPdxLPtikaT7JJCAU9fJBzu3YpniDWfGV/aXuhGDWxcmfWI7iaLSz5bWwimNoElMext37sDaSxPDcnn26igDwO98M+IdPN/Nbz6xf+T4XsYoobjTreWOV/Om3QFBBg7BtbaMN03ZGK2tbv/EV3DrsN22tyail/st9L/sRZrBrZblPLkEpgYO3l/OcycHPyjbx7FRQB4ZL4g+JIv/E2UuopILfUTbWy2Msi7kjc2xgYWmxmJCcNO+7cRtB+USeKLXxZMjW+oah4gurSwv8ASr9LyDTYnmUMX88IiQEOIyEbARmGfmyOK9vooA81+JNpeTX3gTUba712O2s7yRri5sbAT3CB7WRVkaLyXIJYhT8mB5jZAIBWLwXq3iu58WQQ6q2rMrG7/tC2uNNWG0tAsmIPIn2DzMjH8cmRknbjFen0UAeWeK5PG0niPUzpGp6raWMeo6daW8MGnwyRmCXYLiXc8TM2zczZDYXac5HAwfEOs/EaxihtbeTUWgiu76E6h9hJmlCSAW5dIrSYbSpY5WJA2PvL39xooA8Xt9Z+Ilx42trS8eWysne3QmGzma3eJol8x1Y2bbXDl8eZNGAVAZMcnb+EcOpaZ8H4bR31f+1rGzMX2e+svJa3lWIYjiHlr5iA9G+fJJ+Y9B6bRQB4lqGp/EjTdKUW8upajJcabYXc00tgiPaSPIwuEjEcDZKqFO0xysuc4PSqGoeIPiWul6d5ct0qOlyReRafcGQyBx5SzR/2ez4CnqsMQbBww6V75RQB4jqFx4n1XxTpS6t/bKy2mtQypa22ksbBLcW5/f8AnGLcW3sRtMgIzgoMZrc+HniTxBHDdDxJb+ItUc3FrbJP/Z5hizIzKzrG9vBIiLwz7vMCrjDsQ1epUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvw0/5Fy8/wCw1q3/AKcbiuqrlfhp/wAi5ef9hrVv/TjcUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcVFZeKtI8QeIrjStN0S+stTvUvI3udUlt5ExawQlSq28g6wk53dCOBXa0UAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHXVUUAcr9u8cf9C94b/8H0//AMh1a8C6XfaR4fNvqq2y3st7eXkiW0rSxp591LMFDMqlsCQDO0cg8V0FFABRRRQAUUUUAFFFFABRRXP+L/GGjeELX7V4glvLe027muI7CeeKMZA+d40ZU5IA3EZ7UAdBRWfoWsWuuWAvLBbtYC20farOa2Y8A5CyqrEcjnGD61LY6hDezXUUKXStbSeU5mtpIlJ9UZ1Acf7Skj3oAt0UUUAFFFc2/jDT1+ISeDjDdf2m+nf2kJdq+T5fmFMZ3bt2R024x3oA6Siiql9qENlNaxTJdM1zJ5SGG2klUH1dkUhB/tMQPegC3RUN7cx2dpNczLK0cSF2EMTyuQP7qICzH2AJNLazpdWsNxGJFSVBIoljaNwCMjcrAMp9QQCO4oAloorJ8VeItL8KaFc6zr919k0232iWby3k27mCj5VBJ5YDgUAa1FNidZI0kQ5VgGB9Qa53RfGGn6v4x8QeGraG6W+0QQG5kkVRG/mpvXYQxJ465A/GgDpKK53QPFthrfifxHoVpDdJd6E8CXLyqojcyoWXYQxJ4BzkD8a6KgAoormfBfjKz8XtqT6VZXy2Nlcvai9mWNYp5EOG8sBy+B6sqj9aAOmornPAvi+w8aaVc6hpcN1FDb3ctmy3KqrF4yASNrHjnj+VdHQAUUVT1nUbbR9IvtTv3KWlnA9xMwGcIilmOPoDQBcorkNC8fadqmgxaxPYavptlLZtqCPdWhZTbqu7zC8W9FyMkIWDnH3emeg0DWLHxBo1pqukT/aLC7QSQy7GTcvrhgCPxFAF+isfSPEuk6vrOr6Vp1352oaQ8aXsXluvlFwSoyQA2QD90mtigAooooAKKKKACiiigAooooAKKKwY/F2izatremQXMs2oaKiSX1vDayyPGHXcu0Kp3kjsm49utAG9RUVrOl1aw3EYkVJUEiiWNo3AIyNysAyn1BAI7isD4g+MNP8AAvhmbXNXhuprSKRIylqqs5LsFGAzKOp9aAOkooooAKKKyvFWu23hnw3qOt36TSWtjC08qQgFyq9doJAz9SKANWiqGgapBrmhabq1osiW9/bR3USygBwrqGAYAkZwecE1foAKKKKACiiuc0vxpoeraW+o6VPdXtol2bFmt7GeRllBwQVCFgB3bG0etAHR0UUUAFFZHhjxJpPiixmvNCu/tVtDO9s7+W6YkThlwwB4z16Vr0AFFFFABRRRQAUVheN/E1n4N8K3+v6pFcS2dkqtIluqtIQWCjAYgdWHcUa14s0jQvCn/CR6zctZ6SI45GlaNnKCQqFyqBjnLAcZoA3aKbE6yRpIhyrAMD6g1lW/iTSbjxPd+HYbvdrFrAtzNb+W42xscBt2Np69Ac0Aa9FZnifWrfw54d1LWb5JZLWwt3uZVhALlVGSFBIGeO5FY+s+OtM0n4cL41uYLxtLa0hvBFGimbZLt2jBYLn5xn5vXk0AdXRUFhdJfWNtdxBhHPEsqhuoDDIz781PQAUUUUAFFVNT1CHTYUluEunV5FiAt7aSdsnoSsasQPViMDuRVugAooooAKKKKACiiigAooooAK4b436FqXib4Wa/o+h232rUbqONYYd6puIlRjyxAHAPU11msapZ6Nps1/qU3k2kON8m0tjJCjgAnqR2rmf+Fn+EP+gv/wCS03/xFBjUxNGk+WpNJ+bSOM8d/De58XeO/AR1XTGuvDtlYXEGplbrytjNFhF+Vw5BYAfLkevFc5qHgHxbanxPDY+HrO707UfEkdz5cy2lzKbMIVMkKTsYxIOg8zB56da9W/4Wf4Q/6C//AJLTf/EUf8LP8If9Bf8A8lpv/iKDP69hv+fkfvR4HB4U1fwnpfhw+OoLb/hHbPX76Z9H1HUbNBPbvFH5JVWkWFtjCQ+WCMZOFwag8EeBPEWueAPB91FZ3dzoCXl9LdaZCLZZXWRsRzKl0pifGDjcOByuCcj6D/4Wf4Q/6C//AJLTf/EUf8LP8If9Bf8A8lpv/iKA+vYb/n5H70ZujeF9VsPgtc+HdHk1Gw1P7HcwWZ1C6jmnhLF/LDSRgKDgjG3O3IAJxmvJtL+F/i0XryaP4f8A+Eambwh/ZUlwbmDMt95gLuTE7Md4z85GfXGBXtf/AAs/wh/0F/8AyWm/+Io/4Wf4Q/6C/wD5LTf/ABFAfXsN/wA/I/ejxq3+FXiWPwjrNroVlrWkatd6bDBcLcXtjHbXTpIhZI1tlByyhx5smCQ2GzkkdZqfg24u9T8Dz+HPAn/CO22mawl1fRZs48oExv8A3Ujb8dOfm9q7n/hZ/hD/AKC//ktN/wDEUf8ACz/CH/QX/wDJab/4igPr2G/5+R+9HjVp8NfFdtD4ptbDQzNZ6hpl4qXWtRWQ1Jp5QQsa3EMrlgTjJkKjGfal1j4ZeLJbLy7rQ/7Wmk8OWOn6a32qEf2LdRpGJGy7jHzKW3xbicY717J/ws/wh/0F/wDyWm/+Io/4Wf4Q/wCgv/5LTf8AxFAfXsN/z8j96PH/ABZ8KvFOp3XjaW506PVL260fToLG9aaINNdwrGJHXcwKHKvycZyfWvQvi94O1Txf8EpNEgtY7rX1gtpI1mdNwmQpvw7HAYr5i7s87iM4Nb3/AAs/wh/0F/8AyWm/+Io/4Wf4Q/6C/wD5LTf/ABFAfXsN/wA/I/ejx74leAfE3iC2Fto3gm2sLGLSkjsFtodOjuILkS7iskrMSiffYeS3JYZIy2KOv/DLxdqN74uafwy17f6ta6UljqUl3b4tZ4Yo1mlZjJ5ikEMMqpJ57Hn2/wD4Wf4Q/wCgv/5LTf8AxFH/AAs/wh/0F/8AyWm/+IoD69hv+fkfvR5N4m+Gvje8n8fNZAkaldaXKrfaIlOpQwwssyc5C5YqcSAKcc5Ga9J+Dvhd/C9rrESWGsWFrc3CzpBqM1ocMV+cxxWoEcS5xwDzjoK0P+Fn+EP+gv8A+S03/wARR/ws/wAIf9Bf/wAlpv8A4igPr2G/5+R+9HlPhr4beK7XxHojXunBdTtdZnu9T8RtPEw1GzYD9yQGMrbh8uxlCrjg813XwB8GXXg3w3q0Op6Vb6ffXOpTSjy/LLPBn91lkJ4ALYUnjJ4Ga3P+Fn+EP+gv/wCS03/xFH/Cz/CH/QX/APJab/4igPr2G/5+R+9HjfhL4aeKrXVdBB0A6ZeWfiOfU7jWGuLdt1m3/LEbHLtu/ulQBn3NO8K/CvxHYTGbWbHWLjxFG14r6nBeWKWt2kqNy7bftMmTtGyTgdQVHFexf8LP8If9Bf8A8lpv/iKP+Fn+EP8AoL/+S03/AMRQH17Df8/I/ejyLwd8L/FmjXPg2SxsE0i8h0O+stRvI5osxzuJPJL7WJkwxQjG7GB0xVPRPhLrMPhrUoLvQ9WOuzaNd2U8kl1p4s7qUhjE2EAllYybWDzEFSAdxxXtP/Cz/CH/AEF//Jab/wCIo/4Wf4Q/6C//AJLTf/EUB9ew3/PyP3o8mtPhNrG3w9bNoVnDbx+EZ9Pu8tDsW+dTjcATubdg7wDyM5ruPhT4N1PS/h1pGlOdS8IajablvBZJYP8AbZCF/esxSYHgAAna3ByMba6H/hZ/hD/oL/8AktN/8RR/ws/wh/0F/wDyWm/+IoD69hv+fkfvR5dqXwx1+PxB8TW0bSora51yOF9J1iJoEEOFJnjJDCSMyZKkquCTkmtr4b+BddsfEOpXVtbXXgrR5tMtrX7LavaySSXSbd84UCWLkAruYbmznANdv/ws/wAIf9Bf/wAlpv8A4ij/AIWf4Q/6C/8A5LTf/EUB9ew3/PyP3o4rxR8L7nxH8WNDufEEd3rXh220h4Li8nuY4JHm85nRWWHyyQMr0XbwM5PNc94c+GfiCy8YnU9ds9du9Tj1iS7j1SwvLGOKSBj0kZl+0EbePK+7zwV5Nerf8LP8If8AQX/8lpv/AIij/hZ/hD/oL/8AktN/8RQH17Df8/I/ejxjSvhj43tLHxFp2hWqWEN1YOsOqarDaR6m0rSKzRefbySM6sFILOR97GPlFN1j4VeJ9T8NeK7bRdBXQLO70qyt4tIa4gAubuGWN3m/duUBKoy7mILZycV7T/ws/wAIf9Bf/wAlpv8A4ij/AIWf4Q/6C/8A5LTf/EUB9ew3/PyP3o8Z8ZfD3xn4hi+I9zB4dlgk1u00qOzglu7fc7QGLzASJCoxsY5JGe1dVqvwxGkeJvDk1j4bbXfCltbz/atGa4SYreScm4K3MgRyenLZGMgV3n/Cz/CH/QX/APJab/4ij/hZ/hD/AKC//ktN/wDEUB9ew3/PyP3o8l8T/DLWtU8WareXej6xLpk8Nq2kR6XcafbyaZ5aj9wWlDGEKccwEg45DZFd98dfCGp+MNI8K2WnWr3iW2u21ze7Z1hZbdVcO4bcpz8w+783PFbn/Cz/AAh/0F//ACWm/wDiKP8AhZ/hD/oL/wDktN/8RQH17Df8/I/ejx74p/C/xBdTXml+E/DNuuk2VjBHo1xa/ZPPEiuGYTTzt56hfn2+WR1GT1qxd/DPW49a+IFx/wAIzFdz69o0cdjeo9sDDdG2KzhizhlaRycsoIYtknqa9Z/4Wf4Q/wCgv/5LTf8AxFH/AAs/wh/0F/8AyWm/+IoD69hv+fkfvR43rHwy8WS2Xl3Wh/2tNJ4csdP01vtUI/sW6jSMSNl3GPmUtvi3E4x3r0D4yeEfEPiD4LQ6BYr/AGrryC0Ereaqec8ZXzH3OQOcE8muk/4Wf4Q/6C//AJLTf/EUf8LP8If9Bf8A8lpv/iKA+vYb/n5H70eU33gXxakPjW60DwtYWen6zfWbQaHeLaTmNEUiadULNAJC2CASR1z0FZ9j8MPEn/CJ63pN5p+uwWja7/aGm28DafKvl7Wx50BlSApkjMa4GRwMV7N/ws/wh/0F/wDyWm/+Io/4Wf4Q/wCgv/5LTf8AxFAfXsN/z8j96PHLz4a+MdUtfDB8R6Nb/wBlQWtxDdaPoEdjEbeR2YiURzgwbyCAWQ5BGVPXLfEfwz8T3NvcQy+H7zWrdvDn9naWL2+tppdNuA5PzszIu4rj50BI4HTmvZf+Fn+EP+gv/wCS03/xFH/Cz/CH/QX/APJab/4igPr2G/5+R+9GH4i8KeIr79n628M6RL9g8QppNpbMvmhfmRY/Mj3qSOQrLkHBz1wc15f4q+F/inUtC8UR+HvDX9jafepp6W+ifardd0sRUyzfK5jXgEZ3bm6kZr2z/hZ/hD/oL/8AktN/8RR/ws/wh/0F/wDyWm/+IoD69hv+fkfvRi/DPwlqHhr4i/EG4OnpY+HtRmtZdPWJ08t2EbCVginKncRnIGfevHbPwvqXifxd41i8P6V/xNrfxiLhNaLxILCNWJfkt5hJ4+VVIPc8CvfP+Fn+EP8AoL/+S03/AMRR/wALP8If9Bf/AMlpv/iKA+vYb/n5H70eQah4B8aah8SLDWJ/D1vb+V4i82e4sVsYYJtOLDczsCJ5XYbtyvkEdiScVrX4V6/ZeD7jR7XwrFHqKeJor4XsUlsqz2ayEqA28PhRk7WAxnjPNe0f8LP8If8AQX/8lpv/AIij/hZ/hD/oL/8AktN/8RQH17Df8/I/ejy7Svhpr8fj+fU9etdZvbxNdF9aarZXVjHF9nLD5ZS6m42quQYlyh6DH3qzvD/wq8R2Uvhm5k0KKO8g8UXF1ey+dCX+wSYGCd3zIRuygyeTxzXsX/Cz/CH/AEF//Jab/wCIo/4Wf4Q/6C//AJLTf/EUB9ew3/PyP3o5v4C+DrrwZa67Zal4fisbmS/lli1CLyCtxblv3aAqxcBeflZQBnjvXD3fgXxvdfE3TdcbQYbSS28SCeW608WUEUlgWGXZlIuJHI3bg/BHQEk49c/4Wf4Q/wCgv/5LTf8AxFH/AAs/wh/0F/8AyWm/+IoD69hv+fkfvR85aVpUv/Cd+GNIRLO88WxeIrq6vtXtLiC7eSMdGk2O0iBP7sgUA9MnOPQPhL8ONb0HxPpGoeILHWRrNpJcrdalHd2X2S5Rw2Gfav2iUklcCT7p5BAG2vTf+Fn+EP8AoL/+S03/AMRR/wALP8If9Bf/AMlpv/iKA+vYb/n5H70cH8fPCHibxZqog0vQbW/0z+ypUjuYorM3KXZLbVMlx8yRfdOY8NnPI6jkLr4VeLNSstZfVdFW7vpfCtpY2zz3MMjfbY9m7DF+GGD8/Trg817X/wALP8If9Bf/AMlpv/iKP+Fn+EP+gv8A+S03/wARQH17Df8APyP3o8U8ZfDXxlq1nri3+gNrl/e6Lp1vptzJc25OnzRKn2hMyOCCzBzuTOc9eTXpvxd8F6h4q+CMmgWNlDPrUUFs0EUjINssZTdtcnCtt3rnPcjODW9/ws/wh/0F/wDyWm/+Io/4Wf4Q/wCgv/5LTf8AxFAfXsN/z8j96PJ/FXw81q/ub6W28G+dYXOg/YdLsfOtY/7Gu92TLtEmxcnL74yzc4I5NW9P+HXiHRfG11q02g2Gu3s/h2O1j1CUQtGuorFtaSUOwchyMF1BJDc98em/8LP8If8AQX/8lpv/AIij/hZ/hD/oL/8AktN/8RQH17Df8/I/ejwzRfhp43jk8QyHQWsV1PwtNZTW8bWNvC98zfKqRwMF246O+T1y3OB6f4x8Ja3qP7OUXhezsvM10aTZWxtvNQfvI/K3rvLbeNrc5xxxXSf8LP8ACH/QX/8AJab/AOIo/wCFn+EP+gv/AOS03/xFAfXsN/z8j96PF9b+FninVtC8ax6Zoi6PDqGnWMEOnSTwA3dzC8bvKfLdkUkKwBLAknJxk1F44+HPjTxJL45u7fw7NA2rxaWLaGW8t95MKoJASshAxtPfntXtv/Cz/CH/AEF//Jab/wCIo/4Wf4Q/6C//AJLTf/EUB9ew3/PyP3o828TfB8R+NUXQNASXw4vh68tgJ7kS/wClyNIy/wCtcuSWYHd0B7jFdn4f8O6xH8CLXw9rCalHrA002sqWVxEbhW5ACOzhMgY6sBjjNa3/AAs/wh/0F/8AyWm/+Io/4Wf4Q/6C/wD5LTf/ABFAfXsN/wA/I/ejxe3+GnjJfCr6VF4esIreDV9PntnWC0tLyaGLfve48qRkYruAB3FjljjnFdTY+DL66+KGra9ceCTpDqstvpF3ZiyEcbuG3XlwVlEjyEngbW2g9zk13/8Aws/wh/0F/wDyWm/+Io/4Wf4Q/wCgv/5LTf8AxFAfXsN/z8j96PNvg38OdX8N+ItIvtZ07WodUt454r28F5ZfY7kNuILCNfPmJJBHmcqR1wMH3yuM/wCFn+EP+gv/AOS03/xFH/Cz/CH/AEF//Jab/wCIoD69hv8An5H70dnRXGf8LP8ACH/QX/8AJab/AOIo/wCFn+EP+gv/AOS03/xFAfXsN/z8j96OzorjP+Fn+EP+gv8A+S03/wARXQ6Dren6/Ym80m4+0W4cx79jJ8wxkYYA9xQXTxVGq+WnNN+TTNKiiig3KWsaXZ6zps1hqUPnWk2N8e4rnBDDkEHqB3rzFfAvhw+P9W006d/oUGmWVxHH58nyySS3auc7snIij4JwNvHU59bril/5Knr3/YF03/0ffUGNTDUar5qkE35pMof8K58K/wDQK/8AJiX/AOKo/wCFc+Ff+gV/5MS//FV11cRoPxM0HXPH2qeELMXQ1PTw++SRFEUhQgOqEMSSC3IIHQ+lBn9Rw3/PuP3L/Is/8K58K/8AQK/8mJf/AIqj/hXPhX/oFf8AkxL/APFVpx+K/Dsmq/2ZHr+kvqW/yvsi3kZm3/3dmc59sVNZeItEvtTl06y1jTbnUIs+Zaw3SPKmOuUByMfSgPqOG/59x+5f5GN/wrnwr/0Cv/JiX/4qj/hXPhX/AKBX/kxL/wDFVcsPEv27xxqnh+2tN0Wm20Utzd+Z92WQkrEFxz8g3E57gY5zXRUB9Rw3/PuP3L/I8z8OeCPD15rHimC50/fFZaklvbr50g2IbO2kI4bn55HOTk846ACt7/hXPhX/AKBX/kxL/wDFVN4Q/wCRg8b/APYYj/8ATfZ11FAfUcN/z7j9y/yOR/4Vz4V/6BX/AJMS/wDxVH/CufCv/QK/8mJf/iq66igPqOG/59x+5f5HI/8ACufCv/QK/wDJiX/4qj/hXPhX/oFf+TEv/wAVXXUUB9Rw3/PuP3L/ACOR/wCFc+Ff+gV/5MS//FUf8K58K/8AQK/8mJf/AIquuooD6jhv+fcfuX+RyP8Awrnwr/0Cv/JiX/4qj/hXPhX/AKBX/kxL/wDFV11FAfUcN/z7j9y/yOR/4Vz4V/6BX/kxL/8AFUf8K58K/wDQK/8AJiX/AOKrrqKA+o4b/n3H7l/kcj/wrnwr/wBAr/yYl/8AiqP+Fc+Ff+gV/wCTEv8A8VXXUUB9Rw3/AD7j9y/yOR/4Vz4V/wCgV/5MS/8AxVH/AArnwr/0Cv8AyYl/+KrrqKA+o4b/AJ9x+5f5HI/8K58K/wDQK/8AJiX/AOKo/wCFc+Ff+gV/5MS//FV11FAfUcN/z7j9y/yOR/4Vz4V/6BX/AJMS/wDxVH/CufCv/QK/8mJf/iq66igPqOG/59x+5f5HI/8ACufCv/QK/wDJiX/4qj/hXPhX/oFf+TEv/wAVXXUUB9Rw3/PuP3L/ACOR/wCFc+Ff+gV/5MS//FUf8K58K/8AQK/8mJf/AIquurifjRreo+HPhjrmraLcfZtQto4zFLsV9pMqKeGBB4J6igPqOG/59x+5f5Fj/hXPhX/oFf8AkxL/APFUf8K58K/9Ar/yYl/+KrzG3+JuveFZ/Ej+I/tl8tppdtqVnY6j9nhuJVeRY3cSW6mPZubgHLcdBzW94n+M39hrr5/sHz/7KsLK+/4/Nvm/aGRdv+rO3bv685x0FAfUcN/z7j9y/wAjsP8AhXPhX/oFf+TEv/xVH/CufCv/AECv/JiX/wCKrl7n4n65a6tYaZd+D0tb+8tLm9SOfVVIEcQLAkxxuMsB07H866vwr4xj8QfDqDxXBp9wFltZLj7HH+8kJTcCi9NxJUgdM8dKA+o4b/n3H7l/kM/4Vz4V/wCgV/5MS/8AxVH/AArnwr/0Cv8AyYl/+KrzrU/jO954C1bV7aKCyubMwbrW01AG9i3yhCJEmtSi9eSA49CMg12mq+OdSsPHcPh5dGsbqIxtdXFxb6i7PaWy/wDLWWMwgAnsgckn86A+o4b/AJ9x+5f5Gj/wrnwr/wBAr/yYl/8AiqP+Fc+Ff+gV/wCTEv8A8VXO+Bfipc+LdW05LbwtqUej6h53laisczJFszjzSYVjG7aQNkj4PBwat+Jr291H4v8Ahrw7DfXNpYW9lLq9ysEpjNyVcRxxsQclQSSV6HvQH1HDf8+4/cv8jX/4Vz4V/wCgV/5MS/8AxVH/AArnwr/0Cv8AyYl/+Krjz8Ypo7m9kn8PomlWfiA6BLcLf7pd+cCQR+WAR6jdke9WND+Lk2t66lvpvhXU7jSHv3sDfwxzN5ZU48xx5Plqmf8ApqWA5KigPqOG/wCfcfuX+R1H/CufCv8A0Cv/ACYl/wDiqP8AhXPhX/oFf+TEv/xVcLpPxsvbzwhF4iufB8tvY3cyWliw1GNxcXLSMmw/KGRQFJLFfYA8E7/in4i6j4avNL0q/wBBgn13UTK8NtZXM9xGIo1BLFktjJuJyNqxkDGSQOgH1HDf8+4/cv8AI2/+Fc+Ff+gV/wCTEv8A8VR/wrnwr/0Cv/JiX/4quRf4u6gbmytR4RuLa+m0ifVZLbULlrZ4vKZw0ZBiJOQmQ2BnI4FUrH4jeINd8f8AghdGgt4tG1nTJLuSznnAJIzuJcRMQVwcAHDY520B9Rw3/PuP3L/I7v8A4Vz4V/6BX/kxL/8AFUf8K58K/wDQK/8AJiX/AOKrD+Peqa14b8A6h4h8P61dWF1ZCJVhSGCSKTfKiEsJI2bIDHGGArD8b6t4p0fxp4U8P6Xret3y6hbXU0xgh08XMjIoK4MkaxhR34BIz1OKA+o4b/n3H7l/kdx/wrnwr/0Cv/JiX/4qj/hXPhX/AKBX/kxL/wDFV5bp/jrxvf8Ag3wtqCLql/Bm4h1y40KwilvY50bCIIpFK9CNxCkdcY4y3xx8V7tPAvh7/hE/EkI1XVbmfF/fwRQGGKLduWRGBRWztXOADzgc0B9Rw3/PuP3L/I9U/wCFc+Ff+gV/5MS//FUf8K58K/8AQK/8mJf/AIquH1nxZd+IvgJZ+NNL1Ce01bT447x/IlKI8sTBZY5EBwyNhvlI7g169p10L3T7W7VSizxLKFPUBgDj9aA+o4b/AJ9x+5f5HM/8K58K/wDQK/8AJiX/AOKo/wCFc+Ff+gV/5MS//FV11FAfUcN/z7j9y/yOR/4Vz4V/6BX/AJMS/wDxVH/CufCv/QK/8mJf/iq66igPqOG/59x+5f5HI/8ACufCv/QK/wDJiX/4qj/hXPhX/oFf+TEv/wAVXXUUB9Rw3/PuP3L/ACOR/wCFc+Ff+gV/5MS//FUf8K58K/8AQK/8mJf/AIquuooD6jhv+fcfuX+RyP8Awrnwr/0Cv/JiX/4qj/hXPhX/AKBX/kxL/wDFV11FAfUcN/z7j9y/yOR/4Vz4V/6BX/kxL/8AFUf8K58K/wDQK/8AJiX/AOKrrqKA+o4b/n3H7l/kcj/wrnwr/wBAr/yYl/8AiqP+Fc+Ff+gV/wCTEv8A8VXXUUB9Rw3/AD7j9y/yOR/4Vz4V/wCgV/5MS/8AxVH/AArnwr/0Cv8AyYl/+KrrqKA+o4b/AJ9x+5f5HI/8K58K/wDQK/8AJiX/AOKo/wCFc+Ff+gV/5MS//FV11FAfUcN/z7j9y/yOR/4Vz4V/6BX/AJMS/wDxVH/CufCv/QK/8mJf/iq66igPqOG/59x+5f5HI/8ACufCv/QK/wDJiX/4qj/hXPhX/oFf+TEv/wAVXXUUB9Rw3/PuP3L/ACPOm8C+HB4/0nTRp3+hT6Ze3EkfnyfNJHLaKhzuyMCWTgHB3c9Bj0nQdE0/QLE2ek2/2e3LmTZvZ/mOMnLEnsK5xv8Akqeg/wDYF1L/ANH2NdrQXTwtGk+anBJ+SSCiiig3CuKX/kqevf8AYF03/wBH31drXFL/AMlT17/sC6b/AOj76gDXv/tP2G5+wCI3nlt5IlJCb8HbuIBIGcZwDXiPh/4Na5oJ8Karaa3DPr2n30lzfpKQkEiTZE3lusXmFioUDfkdT8vSvW/GfiK28J+G7zW763uri1tArSpaqrOFLAbgCQMDOTz0zXL6n8XPDOnrq8kjXT22mvbxG4RUEc8syb0jjYsMtt5JbaoxyaAPKPDXg7W4tf8ABXh+G0uZLDRL6+nm1ZbS5tiUk6M3nRIu/PA2M+eOmOey8BfDO98H3GlXGp2tnqI0Q3MkOoRajeSTtG6v8sdof3Ss2QDgkHHQk5ro9P8Ai3oWo6Fe6nZwXDpY3QtLmNrqzj8skEh/NecRMpxgFXJ9qqf8Lr8OSaRo2oWljrd4NVmntobe1tVlmEsQBZSofkncMbSw56igDZ+EelXln4Zl1LWYHg1nW7qTUryORcPGXPyRkHkbUCDHY5rt64LSfidpereJToVhp2pPfRiH7QspggNuZBuwySSq7FR97YrY6c13tAHL+EP+Rg8b/wDYYj/9N9nXUV5WsHxDl8Y+M28Enwn/AGd/acQk/tf7R5vm/YbXOPL427dvvnPtV37J8a/X4c/ne0Aej0V5x9k+Nfr8OfzvaPsnxr9fhz+d7QB6PRXnH2T41+vw5/O9o+yfGv1+HP53tAHo9FecfZPjX6/Dn872j7J8a/X4c/ne0Aej0V5R4euvjJr2gaZq9mPh6ltqFrFdxLL9sDqkiBgGAyM4IzgmtD7J8a/X4c/ne0Aej0V5x9k+Nfr8OfzvaPsnxr9fhz+d7QB6PRXnH2T41+vw5/O9rP1y6+MmjWUd1dD4evHJdW9oBH9tJ3zTJCh5xwGkBPtnr0oA9Xorzj7J8a/X4c/ne0fZPjX6/Dn872gD0eivOPsnxr9fhz+d7R9k+Nfr8OfzvaAPR6K84+yfGv1+HP53tZ+p3Xxk0690m1nHw9aTUrprSEoLwhXEMs2Wz0G2FhxnkjtkgA9Xorzj7J8a/X4c/ne0fZPjX6/Dn872gD0es3xFomneI9FutJ1q3+06fcgLLFvZNwDBhypBHIHQ1xX2T41+vw5/O9o+yfGv1+HP53tAGzD8OvC8cOoRvpr3P2+3FpcSXd3NcSNCORGHkdmVQQDhSOQD2qtL8K/B01tfQT6VLNHfQRW1x5t9cO0kcRVo13GTI2lV6HoMdOKz/snxr9fhz+d7WfPdfGSHX7LSGHw9NzdWs92jAXmwJE8KsCeuSZ0xx2PTjIB3V/4T0XUNWtdTu7LzL62tpLOKTzXG2JwQy4DYOQTyRn3qbR/DmmaN4bj0HSoZLTS442iSOK4kDorEk7ZN28HLE5DZHYiuP+yfGv1+HP53tH2T41+vw5/O9oA1Ln4ZeE7u21CG906e7+3iMXMt1fXE0sgjIZF815C4AIBwCBxVy38C6Fba9d6zbR38OoXcy3Fw8Wp3KJM69N8Yk2MB02kYxxjHFc/9k+Nfr8OfzvaPsnxr9fhz+d7QBv6L4D8O6HfR3WlWUtsYpHmjhW7mNvG7ghmWEv5akgkZCjrR4i8KtqfirQfEFjfmyv8ATC8b5i8xbiBwN8bDIwcgEN2PY1gfZPjX6/Dn872s+C6+Mk2v3ukKPh6Lm1tYLt2IvNhSV5lUA9cgwPnjuOvOADQ8N/CbSNN1bU9R1WV9VmudYl1i3RzJHFbSOcj90HKOy84crn6VvQeAfDdvqb31tYywSvc/bHiiu5kgab/noYQ/llu+StYP2T41+vw5/O9o+yfGv1+HP53tAG/b+AfDMHhFfDEelR/2GrF1tmldtrFi24OWLA5JIIOR2pt34C8P3kFrHeQ31xJaTNPb3M2pXL3EDkAHZMZPMUEKPlDAe1YX2T41+vw5/O9o+yfGv1+HP53tAG7H8P8Aw1HcxXI092uI7SWxEsl1M7GGVmaQMS5LFi7Hcctz1pIvh/4agGi/Z7CWB9GQx2MkN3NG8SE5K7lcFlPcMSDzWH9k+Nfr8OfzvaPsnxr9fhz+d7QB2Xifw/pnijRLjSNdtvtWnXG0yReYybtrBhypBHIB4NU9f8HaLr2pWOoajBci/sUeO3uLa9ntnjVvvANE6nmuJ0y6+Mmo3urWsA+HqyabdLaTFxeAM5himyuOo2zKOccg9sE6H2T41+vw5/O9oA3IPh/4btrG2tLGxmsYrdWRGsrye3kwTk7pI3DNk8ncTmpNH8BeGdF1Sz1HS9Kjt7uzt2tYGWR8RxsxZgFLbcksSWxuOetc/wDZPjX6/Dn872j7J8a/X4c/ne0AWda+Gmm3Ph2fQdGlOk6TfX4vdShQPKbgbgzohZ8RBiozgEY7c13iKqIFQBVUYAAwAK86+yfGv1+HP53tH2T41+vw5/O9oA9Horzj7J8a/X4c/ne1n6HdfGTWbKS6tR8PUjjuri0Ik+2g74Znhc8Z4LRkj2x06UAer0V5x9k+Nfr8OfzvaPsnxr9fhz+d7QB6PRXnH2T41+vw5/O9o+yfGv1+HP53tAHo9FecfZPjX6/Dn872j7J8a/X4c/ne0Aej0V5Rod18ZNZspLq1Hw9SOO6uLQiT7aDvhmeFzxngtGSPbHTpWh9k+Nfr8OfzvaAPR6K84+yfGv1+HP53tH2T41+vw5/O9oA9Horzj7J8a/X4c/ne0fZPjX6/Dn872gD0eivOPsnxr9fhz+d7Wfpl18ZNRvdWtYB8PVk026W0mLi8AZzDFNlcdRtmUc45B7YJAPV6K84+yfGv1+HP53tH2T41+vw5/O9oA9Horzj7J8a/X4c/ne0fZPjX6/Dn872gD0eivOPsnxr9fhz+d7R9k+Nfr8OfzvaAOob/AJKnoP8A2BdS/wDR9jXa15N4Rh8bRfFPTP8AhOj4cOdGv/sv9jef/wA97Lf5nm/8Axj3z2r1mgAooooAK4pf+Sp69/2BdN/9H31drXFL/wAlT17/ALAum/8Ao++oA0NeszqOhajZCKGY3NtJCI5mKo+5SMMQCQDnBwDxXnPhD4P6fZfC618L665kvBcfbpruzkKslyD8rxsR/CoCjI7dK9VooA4TV/hxb6wbKbU/EOvXN/Y3SXltdu8G6F1GAFQReVjucpknvVXR/hHoWlS6LLBe6rI+k38+owmWWM75JQoYPhBkfKMYwevJr0WigDh9c+G2l694nstb1e8vLiazuku4IfLt0VHXG0b0iErKMD5WcjgZzgV3FFFAGL4C/wCQ344/7DUf/pvs67CuP8Bf8hvxx/2Go/8A032ddhQBy3xD8XDwhpunyx2Rvr7UtQh02zt/N8pXmlJxufB2qACScH6VleGPifomoWd5/wAJBd6d4fv7PUbjS5be7vkCvNCV3+U7bd6/OnO0HnkCt/xp4VsPFumQWeoSXEDW11He21xbMFlgnjOUddwIyMnqCOelHgzwrYeEtPu7awkuZ5Ly6kvrq5uWDSzzyY3O20BcnA4AA46UAZ1p40km+J9z4Pm0ee1EOmHUkvZZ0ImUSiP5UUnC8nliDx93oa5zwf8AFtfEOs+HoX0VrXTPETXi6Vdi58x5PsxO4yx7B5eQCRhm/CulHgeP/hYH/CXf25q/2/7N9i+z4t/I+z79/lY8rdjdzndu/wBrHFZ/hr4V6F4f1rT7+0uNRlj0xrhtNsp5UMFkZzmXywFDHOSPmZsZ4oA76iiigDlfhP8A8ks8G/8AYFsv/RCVU8I+N5/EOq+K7GTQLuyuNCkjj8h54nlnLx7wMBtik8AfORyMkc4t/Cf/AJJZ4N/7Atl/6ISq/h7wGuha1rmqW/iLWprvWADcmZbUjeq7UkULCMMoGAOVPcGgCDwd8RbDWfDmoaxrqW/hyCz1KbTnF9eRgBozjl+FBPoCRxwT1qt8Q/iLJ4U0JfEFnY6dqnh7y4mF2uqBHnZ3K7IECMJCF+bllBHQ8HGx4D8Fw+DYtQitNW1O+ivbl7uRL3ycLM5y7qY40PzHscgY4A5rM8ZfDHT/ABV4t0/xDd6vrFve2CBbaKJoJIImBJ3iOaJ138jn/ZHpQBi6r8YBY6xfomhSSaNp2oW2m3d29zsmSWYZ+WHYdwUkBsup54BrrfiX/wAi5Z/9hrSf/Tjb1j3/AMJ9Ev8AWJb+6vtVaO5ube9vLQSRrDd3EK4SRwE3A9yEZVJxxWx8S/8AkXLP/sNaT/6cbegDf1ae7ttOuJdOsxe3irmK3MoiEjdgXIO0epwfoelefaT8UJr7SfF866Cbm98NyeXNFp96k0M3yFiUmkEfC4O4bcjsGPFdv4p0WPxH4evtInu72zivI/KeezkEcqqTztYg4z0PHQmuU8P/AAwtNA8G3fhjTNe1mHTLhDHgR2YdAch8MLcbiwOCz7jgDBFAGlo3j7RLjwr4f1nXNQ03RG1i1S5ht7y9RCcqpKqW278bgMgdx61lar8Q7rSfHumeHb3SLMjUbowQeRqayXaxgEi4kt9nyxHa3O8njp2rqPBvh6Pwr4ds9Gtr68vbW0QRQPd+XvSMABUyiKCAB1IJ9Saxr/4fWmp67Zajqms61ew2N/8A2na2M0sRhhn5IKkRiTaMnClyB0xigDA8H/FtfEOs+HoX0VrXTPETXi6Vdi58x5PsxO4yx7B5eQCRhm/Cup8Zf8jH4E/7DUn/AKbrysvw18K9C8P61p9/aXGoyx6Y1w2m2U8qGCyM5zL5YChjnJHzM2M8VqeMv+Rj8Cf9hqT/ANN15QBpeK9Uu9H0h7yxtbO4MbAyte3otIIY+S0jyFWwoA7Kf61wEvxelX4VXfjSHwzcXKW08kLRQ3kfkkI+wyrKwBaMngFUJz2A5r0TxBpUmrWsMUGq6jpcsUolWexZA5IBG1g6srKc8gqegPauOuPhPpMvgvUPDKarrENlqV1JeahMjwmW7kcgsWLRFVGVU4RV6fWgDq5fE+iW99ZWF9q+m2mp3iI8NlNdIs0m7hdqEhmyQQMDkiuFl+MVgvi6/wBOTTZZNFtNNudRGqrKNs4tziQRJj5lyCA+7BKnHHNej6XZNZaZBZz3U995abDNcqgeQf7QRVXpxwori5/hD4Lk8RLq0Wi2dsRZS2LWltbxRQOsmQzlVQHfglQwI4NAEfgH4kS+JdetdJ1LRRplzfaPHrlmUuvPD2zvtAf5F2Pkj5eRz1ra1L/kqfh7/sC6n/6PsKqeC/hxpXhTU01C3vNSv7uGwTS7Z72RG+z2qtuESBEXjOOWyeOtW9S/5Kn4e/7Aup/+j7CgB3xB8XweD9Ea6+zPf6hIH+y2ET7XnKqWY5wdqKoJZsYA9yAeauvilLB4R8Ha6vh2eSHxDPbQMRdII7QzNgAsfnc9wAmDg5K8Z7DxX4S0LxXZtBr2l2V43lPFFNNbxySQBxgmNmU7T0OR3Arl7n4TaS/hbQvD9nqmq6fp2jypcQrai2DSzo25ZZC0Jy2ck4wDnkGgDqNQ8VaRb3l5ptvqNhda7BC8g0pLpPtLkJvC+WCW5GD06HNeb2/xsNv4f1nUvEOhJpd1ptmly+kvcTi9y8ixoGjlt4xtLMMurOBkcV63NaNNpb2cl1c7nhMTXKMElyVxvBUABu+QAAegrh7r4T6Lqa6u3iG/1XW7rUrFNOkub2SMSRwI4dVTy40UYcBskEkjnPNAGj4I8ZT6/rmv6HqmlrpusaKYDcRRXP2iJlmj3oVfYhzgEEFRg+tT6b/yVPxD/wBgXTP/AEff0/wf4MsvDF5ql9HeX+oanqbRG7vb50aSQRrtjX5FVQFGei9+c0zTf+Sp+If+wLpn/o+/oA6LUriS0066uIYGuJYYnkSFOshAJCjAPJ6dDXnvgP4k33iWW8t77w8NP1S2tBdNpH2mUX2C2APLnhhTB/vCQjOB3r0S9t/tdncW5llh86No/Mhba6ZGMqexHUGuT0rwFDp+rX2sNrms3mu3NmtgupXJgaWCEHcFRREI/vcksjZPWgCv4O+JGl6z4HtfEmvSWXh2C4uJbYJe3qBQ6O67d7bQSQhOB79cZrH8S/GDT9L8TTaXZW8FxZ2sVtLd6pNNKtrCJ8GIb4oZR8ykEFtinP3q6v4f+DrfwTo76XY6lqN7ZmRpUW98omNmYs2DHGmcsxPOfbFZXir4XaJ4k1fUL67udRgTU44YtStbaVFivlibMfmZUsMYAyjLwMUAZDfFxR4gMA0Vjog8QDwz9vF1+8+1kdfJ2Y8sHjdvz7V6nXAf8Kp0H/hIf7TE+oLb/wBpjWv7NEiC1+2hcCbG3fnvjdtz2rv6AOV8G/8AIx+O/wDsNR/+m6zq7448S2fg7wnqWv6krvbWMe9kTG5ySFVRnuWIH41S8G/8jH47/wCw1H/6brOtXxXoFh4p8O3+iaxE0tjeR+XIqtgjnIIPYggEe4oA4zSPiXPfeGvEGonQ9+o6OiyT6Xb3DrPEChceaLiKHZwCcrvBAO3d0O1o3j7RLjwr4f1nXNQ03RG1i1S5ht7y9RCcqpKqW278bgMgdx61StfhrZW1hrkaa1rL3+tRxwXupSNA1w8SIUWMZi2AbSRkJnnOc810Hg3w9H4V8O2ejW19eXtraIIoHu/L3pGAAqZRFBAA6kE+pNAHMeIfHOtaL450Pw8dB066/te4dYng1RzNFbpy88kZgAUBecbzkjAPes7wf8W18Q6z4ehfRWtdM8RNeLpV2LnzHk+zE7jLHsHl5AJGGb8K7Cw8I2Np411LxS893dapeQJar57qUtoV52RAKCoJ5OScmsTw18K9C8P61p9/aXGoyx6Y1w2m2U8qGCyM5zL5YChjnJHzM2M8UAd9XK/DT/kXLz/sNat/6cbiuqrlfhp/yLl5/wBhrVv/AE43FAG7q8uoQ2LvpFtaXV2CMR3Vy1vGR3JdY3I4/wBn8q81034sX938PfEHiv8A4RYzWmmTSxQ/Y9QWSO6SIHfMHkSMiMEYyFZj2U4Nei+JdJXXtBv9Kku7uzjvIjC89oyrKqng7SQQCRkZx39eaxdS8C6fdeAY/B9ndXmm6QtuLRvsnleY8W0qykujD5s5JABzzkc0AWrbxlogsNGl1XVNN0y71S3ingtbm8RHbeAQqhiC3JxwOa4DTvjbBdeN59Bk0YxJBdXNtKftWbqFYULGV4SgURnBwRIx9uQK9O8N6T/YWh2emLe3V7HaxiKOa6EfmbBwoOxVXgYHTPHOTzXGWvwg8PQarbXMlxqNxZ2t5PfW+nTSRmCGaX75BCCQg/3Wcj2oAg8CfFN/EutaPZXmif2fFrVjLqGnSrd+czRo5UiVdi7GIwwwXHPXNem1wng/4YaN4W1azv7W81O7awtns7CK7lRks4ncuyptRSck4y5Y4wM13dAHK/DT/kXLz/sNat/6cbirnjvxEPCXhDVNeaymvlsITMYISAzDIB5PQDOSewB61T+Gn/IuXn/Ya1b/ANONxWj4x8N2Hi7w1faHq3nfYrtVEhhfa42sGBB9QVBoA4Twv8W31/w14m1W00A3f9iqjD+z71ZYbkNGXJWSVYiNmMNlcjsGPFdNo3j7RLjwr4f1nXNQ03RG1i1S5ht7y9RCcqpKqW278bgMgdx61RtvhpY28HiEprOsHUdeVI7/AFA/ZxNIiqVChRD5YyrEEhNxznOea6Hwb4ej8K+HbPRra+vL21tEEUD3fl70jAAVMoiggAdSCfUmgDh1+LYPiQ2h0Vl0Ya//AMI2b43Q80Xe3IJg2/6snjdvz3xR4P8Ai2viHWfD0L6K1rpniJrxdKuxc+Y8n2YncZY9g8vIBIwzfhW1cfDLQbvxtF4ovg9xfwz/AGmFDBbxqkgGAxaOJZJMdR5jtg1F4a+FeheH9a0+/tLjUZY9Ma4bTbKeVDBZGc5l8sBQxzkj5mbGeKAO+rlfBv8AyMfjv/sNR/8Apus66quV8G/8jH47/wCw1H/6brOgDqq5Lx94wbwvNoVna2C32pazeiyto5Z/IiVsZLO+1iAB2CkmutrA8a+F7Txdo403UJWjgEolJW2t58kAjG2eORR16gA8cEc5AOI1D4vm2+FsvjGHw5dTtb3DWt1ai6jVbeRZREd0h5ZckYKoxORkDkjpPiN8QNI8D2UL3t1YNeyzQItnNeJDIY3lCNKAckqoLMTjHynkdapap8K9EvPAEXg20utQ03RAd0yWjRb7g7w+XaSNjneA3y49OnFb+t+F4dd8PW+k6tf31wIp4Lg3J8tJZHikWRS21AnJUA4UcenWgDW0vUbLVrGK90q8tr2ylz5dxbSrJG+CQcMpIOCCPqKtUUUAcrqX/JU/D3/YF1P/ANH2FdVXK6l/yVPw9/2BdT/9H2FdVQAUUUUAFeUeLNA8S658U9T/AOEX8W/8I55OjWHn/wDEtivPPzPe7fvkbduG6dd3tXq9crpv/JU/EP8A2BdM/wDR9/QBx/8AwgHxJ/6K1/5bdt/8VR/wgHxJ/wCitf8Alt23/wAVVDxF8Vta0/XtbktbTTjomj6xaaTNDIjm4nMo+aRXDhUwSMAo2eeRXo1x4ka6tdTTQrO5k1G0QsqalZ3VlA5BwcStDhu5+Xdn6HNAHEf8IB8Sf+itf+W3bf8AxVH/AAgHxJ/6K1/5bdt/8VXXfCnxJeeLvh7ouvalHbxXl7EZJEt1Kxgh2HAJJ6D1NeaaL8aNWuddtobmx06YXc2oQDR7cOuoWbW6M8YlyxDeYEI4Rcds8igDd/4QD4k/9Fa/8tu2/wDiqP8AhAPiT/0Vr/y27b/4qofhP8Ur/wAWeJLPS9RfR7j7bpJ1If2cGVrKRZAjW8wZ2ywDKc/L/u8g17BQB4T4Wj8V6HrHiuwufFf227j1NDNdf2dFH5zGztiDsGQuFKrgdduepNdF/afif/oYf/JKL/CsvVrhrXxJ8QbiMKXivkkUN0JGn2p5rij8RJX0/TJlgkiaXSLi/uml0+dVV44UceVvKCRcluAxyMfMM5rxq2IxHtZRg9F5L/I74UqXInJanpP9p+J/+hh/8kov8KP7T8T/APQw/wDklF/hXLQ+M7WS/gtUsb+SJ7pbI3ipGsInKbtuC+/gdSFIzxk1T+HPiybW9L0q21SC7TUptPW8M8qRqlwuQrMoRjjlhwQvXgVi8Vikubm/Iv2NG9rfmdr/AGn4n/6GH/ySi/wo/tPxP/0MP/klF/hRRWX1/Efzfgv8i/q1PsH9p+J/+hh/8kov8KP7T8T/APQw/wDklF/hRRR9fxH834L/ACD6tT7HP/D3UPESeAPDK2+ueVCumWwSP7JG21fKXAyRk4FdB/afif8A6GH/AMkov8K880XxC2h+Fvh7C0TyWt7YxxzeVbyTygLahhsWME9QM8HjPTrT7L4gpiSfUVaO2WS/2olo4kZIJI1TIZgyufMA2leSf4Mc7yxOKu+V6ei8/LyM1So21R6B/afif/oYf/JKL/Cj+0/E/wD0MP8A5JRf4VwWreM7v7Xp0NnpmpW9ymqR2t1ZyCAySo9tLIFUiQqOVU53LjH1rrdB1WDW9Kgv7ZJY45Sy7JQA6MrFWBwSMgqRwSKiWLxUVdy/IpUaTdkvzND+0/E//Qw/+SUX+FYXjK98RT6XZxz67vRtV07A+xxjDfbYdp49Dg474xW7WL4t/wCPCw/7C+m/+lsFKljq8ppOXXsiatCnGEmlsmdh5Xif/oaP/KfFR5Xif/oaP/KfFXH+MPiHP4Y8dnTLu1ik0j+y1uRIobzftLNNsjznGG8kqBjO5l55xWdp/wAX7PT/AA3pk/iyONNWnimmuIrOSKNI0jneLKiWUF/uH5U3McHjpXf7Su1dP8jwPaVbXueg+V4n/wCho/8AKfFR5Xif/oaP/KfFXIa147kn1XR49DhvF086q9ncX7RxGCbZbzO0Sgt5mQyqchQPkI3dje0v4hafPoBvp4rp2gt9PlmZIFjDm7C7CqmRsYLcgscdi3Untq3cXtKvc6HyvE//AENH/lPirnPFMXiIa54P83xHvc6rJ5bfYYxsb7Ddc478bhj3z2pg+JVtJMkdv4e16cSvdJA6JbhZjbuVl25mGACD97Ge2TxVvVNRg1ef4e6lZljbXl/9oiLDB2Pp10wyOxwRR7aqt3+Qe1qLdm35Xif/AKGj/wAp8VHleJ/+ho/8p8VefeI/ibqGj+JfFmk/YrWR7VYo9IOG/fTtFE7pJzyB5wbjHyo/pmr1j8WtHT+xrTVDt1G7t7N7gxSRKkUlwisoCPIJGHzDlVbAPJ60e0r2vf8AIftKu9zs/K8T/wDQ0f8AlPio8rxP/wBDR/5T4q4DXfiROt3b3+nwXlrog0vULxZ57eKVbswtCFdEEofA3Nwxj3Bh16jrZfG2mxbt0N58uqPpJwi/61YzIW+993CnnrntQ6tZdROpVXU0vK8T/wDQ0f8AlPirnL6LxF/wsTRA3iPM39lX+2T7DH8q+dZ7hjocnbz22+9Ux8VrH7CLyTw/r8dr9hTVDI0dvhbVjgSnExOOPu/e7gEc10Gof8lK0L/sEaj/AOjrKj21Vbv8g9rUW7L/AJXif/oaP/KfFR5Xif8A6Gj/AMp8VeVax8XdWsbLxJClhZNq1nqU0VipV/LktI5JEaRxuyWXymBwQMvHwM119z8VfDdt4hudJnmdHt5JYZJvMhKh4kLuPLD+aAArDcU2kjGelN1K66/kNzrdzpvK8T/9DR/5T4qPK8T/APQ0f+U+KuIXx7fSeKSslre6dp00GmCC3u4IpHY3F1JGZPklyoZdo+ZsrtJ2Hode8+JOj2miW2qSW2oG3uLa7ulVUTcFtmCuCN2MnPHP1xSdWt3/ACF7Sr3Og8rxP/0NH/lPirnLGLxF/wALE1sL4jxN/ZVhuk+wx/MvnXm0Y6DB3c993tT4viHb/wBpGyu9B1uzdLqCzmkmSDZDJPt8rdtlJIbcPug4/ixVLxZrFx4f1fxvq9kkT3Nl4esp41lBKFllvSAQCDj8RQq1XZv8gVWp3Ot8rxP/ANDR/wCU+KjyvE//AENH/lPirz2y+Kssms6dFd29vb6fDY3EmsSbWZoLmFC0kSc/w7c8gkh0x1rY0n4q6LqyOunWt7c3nnRQR2kElvK8rSI7rhklMY+WKQncykbeQMjI6tddfyG6lVdTqvK8T/8AQ0f+U+KjyvE//Q0f+U+KuF8OfEOWHSIrjXxcPIftLvEtvH5igaibaNSyuF+UMoIAOcE7ieD0WoeO7S11WXTLbS9Uv75LtrIRWyxZZxAk5ILyKNuxx1I5BGOmR1aydr/kJ1Kvc2PK8T/9DR/5T4qPK8T/APQ0f+U+Ksrwj43s/E9xDFbafqNoLizF9bvdLGFnhLbdy7HYjBI4YA88Zrq6l4iqtG/yE61Rbs4Hw4fEUeveMFi8Q7X/ALUj8xvsUZ3t9itecduNox7Z71v+Z4n/AOhl/wDJCKuS1DVp9FvfFl1apE8j+IrG2IkBI2ywWMbHgjnDHHv61seI/Fltod29u1jf3skNsb24+yqh8iAEje25lzyG4Xc3ynivfoU4SpRlLeyPLr43Fqo1CWnovLy8zV8zxP8A9DL/AOSEVHmeJ/8AoZf/ACQirn5fiDoENteyz3EkbWzTqY2T5n8qPzCVwcfMhBXJBPp1rqoHMsMchR4y6hij43LkdDjvWyo0nsjnlmGMj8UrfJf5FXzPE/8A0Mv/AJIRUeZ4n/6GX/yQiq9RT+r0+xP9qYr+f8F/kUfM8T/9DL/5IRVzvgSTxENEufI8QeUn9qajlfsUbZb7bPuPPqcnHbOK7CuB0jVZ9K0Kz+zrE32vxLe2j7wThHvrjJGCOeKl0KaexpDMcVKLtLW66Lz8jsPM8T/9DL/5IRUeZ4n/AOhl/wDJCKsfXfGNno9/c28lnfXKWcMc95PAqGO1RyQrPuYMfuscKGIAyarzfEHRIbW6eRrhbq3MytZ7B5rNHK0e0c7csynaCwyOexweypdgWOxrV0/wX+R0HmeJ/wDoZf8AyQio8zxP/wBDL/5IRVd7UtV9Xp9jP+1MV/P+C/yKPmeJ/wDoZf8AyQio8zxP/wBDL/5IRVeoo+r0+wf2piv5/wAF/kcf4Ek8RDRLnyPEHlJ/amo5X7FG2W+2z7jz6nJx2ziui8zxP/0Mv/khFXHWOrT6L4Ne5tUieR/EVxbESAkbZdVkjY8Ec4Y49/WtzxH4sttDu3t2sb+9khtje3H2VUPkQAkb23MueQ3C7m+U8VKo07ao2ljsW5NRl1fRdPkavmeJ/wDoZf8AyQio8zxP/wBDL/5IRVz8vxB0CG2vZZ7iSNrZp1MbJ8z+VH5hK4OPmQgrkgn0611UDmWGOQo8ZdQxR8blyOhx3pqjSeyM5ZhjI/FK3yX+RV8zxP8A9DL/AOSEVHmeJ/8AoZf/ACQiq9RT+r0+xP8AamK/n/Bf5FHzPE//AEMv/khFXF6Vq/iKx8ReLY4ta+dtSjaR/skfzt9ithnGOOAo/D3r0KvLNRuXs9W8dXMQUyQ3YkUN0JFjbkZ/KtKOGpOaUlp8z0MtxtavVcakrq3Zd0dR/wAJJ4n/AOg5/wCSkX+FH/CSeJ/+g5/5KRf4V57ovii5OkvqOqeZPAsUcsiwaTPbeSp+826VyJFUcnZzgZwasz+NLaOJJY9M1OaNrZ7wFEjH7hTjzMM4ODkED7xB6V1rC4S1+X8X/me3dnc/8JJ4n/6Dn/kpF/hR/wAJJ4n/AOg5/wCSkX+FcB/wsPQv7VFl5zY3bPO3R4B2b/ubvMxjjdsxnjNJe+LrxU0eaz0K/wDIvrlYh5phDSoYpHGwebwflB+fHGe+KX1bCdFf7wuz0D/hJPE//Qc/8lIv8KP+Ek8T/wDQc/8AJSL/AArg7rx3plrqF9ZzxTia0gmnYJLBIWWJdzDCSFlJHQOFzUF940lEttDZ6Pe/aGuoYpYJfKDmORHZWU+Ztydh6njByBxQ8NhF0/MLs9L8G6lqeofFPTf7Vvvtfl6Nf+X+6WPbmezz90c5wPyr1yvGfh+S3xQ05ipUnRb4lTjI/f2fHFezV5GMpxp1pQgtNPyKWwUUUVzDCuV03/kqfiH/ALAumf8Ao+/rqq4C7g1yb4p63/YOo6bZY0bTvN+22D3W/wDf323btmj245znOcjpjkA1dQ+H/hjUNfOtXmliS/aaO4c+fIsUksYIjd4g3luygnBZSRXQarYQapp81ldGcQTDa5gnkgfGc8PGVYfgR6Vz/wBh8cf9DD4b/wDBDP8A/JlH2Hxx/wBDD4b/APBDP/8AJlAEWn/Djwvp+n6VY21hP9k0u8W/sopL64kFvMoIBXc5wOT8v3cknGa0LPwjo1rrkmsLBcTamyui3F1eTXDQq5yyxeY7CIH0TaO1VPsPjj/oYfDf/ghn/wDkyj7D44/6GHw3/wCCGf8A+TKAL2geFNH0G9ubywt5mvrhVjluru6lupmQdF8yVmbaP7ucVuVyv2Hxx/0MPhv/AMEM/wD8mUfYfHH/AEMPhv8A8EM//wAmUAcPdQx3HjDx1DMu6OTUYkYZxkGwtQaqXPhjR7qytrSez3W9taSWMSea42wugRlyDk5VQMnnjg02z0XxRd+KvGDf27oqzLqcSyt/ZEpV2+xWpBUfaflG0qMEnkE55wNP/hG/FX/Qw6J/4JZf/kqvmsVJRrytK2vn/kd9OvTUEmcrL4HR/FUGqR3SQWcM63ItYllBeQR7MsTKYyfcRhsADPUne0zQNM0x7NrG28prS1+xwfvGbZDkHbyTnlRyeeOtXP8AhG/FX/Qw6J/4JZf/AJKo/wCEb8Vf9DDon/gll/8AkqsHV5tHP8/8i1XpLYsUVX/4RvxV/wBDDon/AIJZf/kqj/hG/FX/AEMOif8Agll/+Sqj3P5l+P8AkP6zAsUVX/4RvxV/0MOif+CWX/5Ko/4RvxV/0MOif+CWX/5Ko9z+Zfj/AJB9Zgc74G0+1uvBvg27ni3XFnp0DwPuI2FoArcA4PBI5zVm/wDCGkXNvdKlnEJplucNKZHQNOVMhKhxkFkU4BGMcFaxPAtt4kbwR4eNtq2jxwHTrcxpJpcrsq+UuAWFwATjvgZ9BW59k8Vf9BnRP/BRL/8AJNbzbU3aX5mkdYq6KXhrwVBpbyT6jcNf3hu1vEkzKBG6xGMY3yO7fKzfeYjngDAro9M0+20yzW1sYvKgVncLuLcsxZuSSeSxNZP2TxV/0GdE/wDBRL/8k0fZPFX/AEGdE/8ABRL/APJNTJufxS/P/IpJR2R0FYvi3/jwsP8AsL6b/wClsFQ/ZPFX/QZ0T/wUS/8AyTWN4th8SxaZayTato8irqVgQF0uVTu+1w7Tn7QeA2CR3AIyM5DpRSnF36rv/kRVu6ckl0Z6nPoOmXGrNqdxZRTXrRRQl5MsNsbmRMKflBV2LBgM578Cs0+CNCEcCQQXdqYBIqPaX9xbvtdzIyl43DMNzE4JIGeMVkfbPGP/AEFvD/8A4J5v/kqj7Z4x/wCgt4f/APBPN/8AJVdft4fzfn/keD/Z+J7fibEngnQZNU/tB7SY3Ama5A+1zCMSshRn8vfs3FWIJxk59agl+H3hqQWytYSqlvDbwIiXcyIUg/1W9Q4DlexYE+9Z32zxj/0FvD//AIJ5v/kqj7Z4x/6C3h//AME83/yVR7eP8/5j+oYnt+J0Vv4Y0e2+zeTZ7fsxuDF+9c7TOxaXqedxJPPTtisrWbG20u88AafYx+VaWmomCGPcW2oun3SqMnJOAB15ql9s8Y/9Bbw//wCCeb/5KrG1mTxXc+IPCcc2q6Hv/tKQxMulSgK32O55YfaTuG3cMAjkg54wahVjJ25vzJlgq8E5SWi8zvX8N6O95fXUlhE9xeuJJpHyxLCLycrk/IfL+X5ccE+pqrB4O0W2uLWa0iu7V7eOKJRbX08SukQAQSKrgSYAx84ORwc1H9j8Y/8AQd8P/wDglm/+S6PsfjH/AKDvh/8A8Es3/wAl1ev835nJ8yBvh54YcTh7CVo5oZrcxteTlEjlIMiIu/CAkA/KB7VZuPBOgXGrNqUtnKboz/aTi6mEfmlNhfyw+zcV4Jxk96b9j8Y/9B3w/wD+CWb/AOS6PsfjH/oO+H//AASzf/JdF3/N+YXfclk8G6C+nGxawzanT10op50n/Hqv3Y87s/8AAvve9Rah/wAlK0L/ALBGo/8Ao6yo+x+Mf+g74f8A/BLN/wDJdc9e2niv/hYGiq2taGbg6XfFHGkShQvm2m4FftOSSSuDkYweDkENavVjWvU6ebwdoE1je2kumxNFePM8xLNvYzOJJMPncoZgCQCBwOOKefCmkf2hcXgiuVa5LtPCt5MtvKWXaxaAP5bEjqSvXnrzVb7H4x/6Dvh//wAEs3/yXR9j8Y/9B3w//wCCWb/5LpXf835i17jLPwF4dtJA8VnO7qbcq017PKV8h/MhA3ucBW5AHHbGOKjk+HfheU3HmafKyzRzRNGbycoqTHMiou/CBjz8oHPSp/sfjH/oO+H/APwSzf8AyXR9j8Y/9B3w/wD+CWb/AOS6Lv8Am/MLvuXrnw3pV1czzz2u6We5gu5G8xxulhKmJuD22rx0OOc1i3Om2ms+NfFGnalF51ldaJYRTR7iu5TNegjIII/A1c+x+Mf+g74f/wDBLN/8l1z1laeK/wDhYGtKutaGLgaXYl3OkSlSvm3e0BftOQQQ2Tk5yOBgktddRrrqdbd+F9Eu5Uln023ZlEykAYD+agSTcBwxZQAS2elUz4I0RrIWki6jJCsqTRmTVLp3hdAQpicybo+GI+QjIODR9j8Y/wDQd8P/APglm/8Akuj7H4x/6Dvh/wD8Es3/AMl0rv8Am/MV33Ej8CeHI9PNkunH7OYZLfabiUnY8vnN8xbOfM+bdnIPQiptJ8HaHpV0l1Z2sv2lZ3ufNmupZnMrxiNmLOxJJQAc59evNRfY/GP/AEHfD/8A4JZv/kuj7H4x/wCg74f/APBLN/8AJdF3/N+YXfcvaR4b0rSGszp1r5Js7T7DB+8dtkOQdvJOeQOTz71r1zX2Pxj/ANB3w/8A+CWb/wCS6PsfjH/oO+H/APwSzf8AyXSavuxNX3Ziw6TZ63qfjWy1KN5Lc6xBJhJXiYMlnZsrBkIYEMAcg9qnufA2hXcYS7hvp8K0bNNqVy7SRsQTG7GTLpkfcYlevHJrN8Oaf4pl1zxaY9a0RJF1OMSltIlYO32K1OVH2kbRtKjBJ5BOecDe/srxd/0H9B/8Es3/AMlV7tHG4eFOMZPVJdDza2Gruo3CVl6sivvBvh++lvpLrTIZHvXgec7mG8w/6voeMYxgYyODkV0FYn9leLv+g/oP/glm/wDkqj+yvF3/AEH9B/8ABLN/8lVt/aOGWz/AweCrS3f4m3RWJ/ZXi7/oP6D/AOCWb/5Ko/srxd/0H9B/8Es3/wAlUf2lh+/4Mn6hV8jbri/DujWWueGJrfUUlaOPWtQmQxTyQujrfT4YOjKwIz61s/2V4u/6D+g/+CWb/wCSq5nwXaeKP7Iuhb6zoqINT1AEPpMrEsLyYMci5HBbJA7AgZOMnSliqVeVoahLDTowvJ21XfzNuXwPoM7o1xb3c7KoRjNf3EhmUMWVZdznzQGJID7gM8YqefwfoM9zNcTabE80t7HqDsWbmeMYR+vYduhycg5NR/Y/F3/Qc0H/AME03/yVR9j8Xf8AQc0H/wAE03/yVXRZdjHml/z8/P8AyOjornPsfi7/AKDmg/8Agmm/+SqPsfi7/oOaD/4Jpv8A5KqrvsZ8i/mX4/5HR0Vzn2Pxd/0HNB/8E03/AMlUfY/F3/Qc0H/wTTf/ACVRd9g5F/Mvx/yM/wAOaRZ634SvLLUo3ktzrF/JiOV4mDJqEzKQyEMCGAOQe1XLnwNoV3GEu4b6fCtGzTalcu0kbEExuxky6ZH3GJXrxyaxPBNr4obRrg2+saKif2lqAIk0mVzu+2TbjkXI4LZIGOAQMnGTv/Y/F3/Qc0H/AME03/yVULVK6N5txm1GdtX3/wAh994N8P30t9JdaZDI968Dzncw3mH/AFfQ8YxjAxkcHIroK5z7H4u/6Dmg/wDgmm/+SqPsfi7/AKDmg/8Agmm/+SqrboZNc28/z/yOjornPsfi7/oOaD/4Jpv/AJKo+x+Lv+g5oP8A4Jpv/kqnd9ieRfzL8f8AI6OvM5IY7nxH4ygnXdFLfIjrnGQbK2BFdT9j8Xf9BzQf/BNN/wDJVclpGh+Ir3X/ABS41rSI5V1FEkP9lSEO32O2IKj7R8owVGCTyCc84GlKooTTkj0MuqU6FRznLS3n3XkRQ+F9MitTbbbyW2Oz9zPfTyphTkDazkY9uh71Qm8EaXLexsfOWxS3eD7Ik8qKd7hiCQ4ynUbMbeeldX/wi3iX/oP6P/4J5f8A5Jo/4RbxL/0H9H/8E8v/AMk11OtRf2fwPY/tLDfz/g/8jIXw9pqXr3McU0bOcvFHcSJC5xt+aINsPAA5Wqy+EtJW0S2WO88mN1kiX7dPmFlBA8s78pwxGFxwa6D/AIRbxL/0H9H/APBPL/8AJNH/AAi3iX/oP6P/AOCeX/5Jp+3o/wAv4IP7Sw38/wCD/wAjnT4O0MtKTaSlZFmQxm5lKKJQRJtTdtXdk52gVZvPDel3byPNbuJH8ol455I2BjyEIZWBUjc3IxnPNbP/AAi3iX/oP6P/AOCeX/5Jo/4RbxL/ANB/R/8AwTy//JNL29H+X8EH9pYb+f8AB/5F34fqE+KGnKM4Gi3w5JJ/19n3PWvZa8b8B6VqWm/FOw/tTULO88zRr7Z9ms2t9mJ7POd0r5zkemMd88eyV4mNmp1pSXl+R20asasFODumFFFFcpqFcrpv/JU/EP8A2BdM/wDR9/XVVyum/wDJU/EP/YF0z/0ff0AZfjXx7e+E9e0u2vNGt5dO1K/h0+3ljv8A/SpWcDLpb+XyisQp+cH25Gde/wDH3hazs9QnXXdOumsOJ7e0uEmmDltoTYpJ3FsKB3JxWLffC2xuviBJ4xTXNbh1YgJGM280UCgAbY1lhcoDznBB+Zuea7PWdI03W7P7JrWnWeo2u4P5N3Asqbh0O1gRnk80Ac38LfGkvjnRL++udKbSp7PUJrCS2acTENHtySQoHVsY56dTXKaX8abe5uLS4u9Fkg0S+e+jtLpLjzJma1Us4kh2jZuCnaAzds4zW/4e+Fei+HFC6DeanpynVf7VlFpKkImPOLd9qDdAMnCHpnrUum/DHQbLxhL4mfzLjVCZTEzQW8SwmTIZgIok3tgkbpN5x35NAFH4f/Ex/FOsWOn3ujrp7ajpf9r2Mkd39oEkPmbCr/IuxxkHA3D3zXo9cT4J+GuheEdYu9WsVefU7iPyWneGCHamQSqpBHGgyQCTtycDJrtqAPNba9h03WviHfXTFbe21FZpCOyrp1oSfyFZlp42vYG0ybxFo0emadqcbvbzR3n2h0KxNLtlQINpMaMflLjIx6Vr6fbxXfiLx9bXKCSCbVEjkQ9GU6daAj8jVCy8BWULWq3up6tqdraRSQ2lteSoyQK6FCQVRWY7GKguWIBNfLYp0/bz5+5Q3xJ8QtJ0e3sJIRNevdtZuscMEpYQXEmxZcKhJ6NhMZJAXgsKu2/jfQbjU1sEublblplt8S2U8arKyB1jZ2QKrlWB2kg9sZ4rHj+GVgsYEms61NNHDawW8zvDut1t5PMi2ARBSQ394Nnvmm6d8PpW1XUbjWtXvLi1k1NdQgto2jVXdYI41lkKxqwk3IThWCcKQM1jy0Lbv+reQFjXviRpOmWFxLDBqE11BJbq9pNYXNvJslmEXmBXiywGW6A5IC5yRV0eONKSa6S4eVTHPHBFBFa3Ely5aBZsNAIt6kK2SAGwMZKnKjC0/wCEOh2EN2kN7qIe4iiiMoW3R18qVZUfKxDe4dAS0m4nvmrmsfDHR9YaWbUrm7ubyW4S5a4mit5TvWBIT+7eIxkMqKSCnXkY4FO2H2u/6t/wQNFfiD4ZaWFE1B3EqwsJFtZmjQSnEe9wm1Nx4+YjnjrU/gzxXD4nj1ExWl1bPZ3k1qRLBKquEkZAwZkUEnbkqMlc4NUYPh7pMOm3dks1ysVyLUP5awxAfZ33ptVI1RcnrhcemK2PD+gR6HPqLWt7dy297cyXf2abyykMkjs7lCFDYLMThmbHbFZy9jyvlvcDyzQPEtp4f8IeA4dReCC2vrCGNrmecRJDttgwyTwckAdR1q5p3j3TrpXnmltILFXvMT+eXDx27IvmLtTaQd4P3geRjdk4XwXpUF74U8D30ryibT9PheIKRtYvbhDu49CemOaNT8CafcQXbI9zJPILx0RphGu+4ZHPzBCVw0a4ODjnIaux+ycmpf1v/wAA9Rc9tBmqeO7OJ9ONgLh0fUEtLtJbC4WVFaCSRdsZUMSdi4wDwTXUaVqNrq2nxXthL5ttLnaxUqeCQQQQCCCCCCMgiuT8OeEL1bt9Q8RXrzXwv0vY/LlWTlIGiAdhFGDw7cBF6Dk856jQ9Lg0bTUsrVpHiV5JAZCC2XdnPQDuxx7VnVVNK0dyocz1Zfrn/HH/ACBbb/sJ6d/6Ww10Fc/44/5Att/2E9O/9LYain8a9SpfCytrfjTTtF1+50zU5rS18uwW9ikuLpYvOYu6+WoPf5OoJ69Kj0vxxYXGm295fbbbzre1lWCISTy754y4QKseWOAcbckgEkLitifQrabWLvUWkmE91ZLYuoI2iMM7AjjO7LnvjpxXOXvgZLTT7b+w5rj7fai1S3lluViKCCNogd3kuCSjsCChBz2rWPsmrPch861Hy+P9Oj1OB/MkOjyWc05mFnOZEeOXy23KFyijDZLKMY612kbrJGrxsGRgGVgcgg964vQPAyW2hfZtUuppbyazurOd4mGNs8rSOQSoywLYBwB/s9q7G1hW2toYEJKRIEBPXAGKmryfYKhzfaJKytR/5Gnwd/2E5f8A0huq1aytR/5Gnwd/2E5f/SG6oofGjHF/wZ+gzWvifb6TrXirTLjTXM+jxRPa4m/4/ndIzsA2/IQ00Q/i4bPbFbGm+PdHubXSmupJLe6voLaVo1hlljgadQUR5VTYpJYAbiueOOafd+BNEvdW1DUryGSe7u5hOHdh+4f7OIMx4H9wfxbueewxlp8K9Bj1KwvYzJ51rFbwnzba1nMogUKhLSQsynaoBKFOmeDzXp/u2j5n3GiHWfiVaW+qRrprRzadHY3t1PcXEFxFEWgaIDy5QhDrln3FFfGB+PUv4p0ZN268xtvW04/un/4+FQuU6f3QTnp71zc3wv0ua1a0l1TV3shZ3NjBbl4tttFOVLhD5eTjYuCxbA9au3PgCwuNWe9Oo6mkLXp1H7Gjx+SJzH5bP9zfyD03Yz0xzSfID5BifE/wm8Syi/uxEYVud7abdKvkscCUkx4EeeN/3Qepq/qH/JStC/7BGo/+jrKqkvw+0qXRm0xri+8htGj0PcHTd5CZw33cb+euMe1W9Q/5KVoX/YI1H/0dZUe7f3fMPdvochqXxht7HTfEMjaQ73+l6k9jFa/aMfaY1d184Nt+UYhlJGDjZjPNdpJ4x0KLVJLCW9ZJo3eNpHgkEIdELsnnFfL3BQSV3ZGDxxWVd/DTw/d22opNHcG4vWuS11vHmxi4l82RU4xjcOMgkDIzycxy/C/w/Lrt9qbR5N60rzwtbWzBmkUq5EpiMy5yTgSAZ9sim/ZsHyMhg+IkF14kktrRV/ssw2Bilure4tnkkuLh4sruQ7lwE2kKFJJy4GSNu48ceHbfTYb+bUNtpNDPcJJ5EhykBAlONuflJHHU9s1m2/w7sluY7i71bV72aP7GEad4flW1lMsS/LGuRuJznkjvnmq1x8LdKuLeW2m1PV2szBdW0Nv5kQS3S4bdIE/d569CxbHSj92HuGpa/EHw5c3yWaXV2lw00dvtm0+5iCSSY8tWLRgLvyNu4jd2zWb4g1r/AIRzxD4y1n7P9p+w6BYz+Tv2b9st6cbsHH1wa277wjYXt7dXUs10JLm9tL5wrLgPblSgHy/dOwZ79cEVlapo9v4g8V+LdIvHlS2vdCsYJGiIDhWlvQSCQRn8DSXL/XyBcpUsfihYXesaRZ/ZfJgutPlvby4kmwti0YYtE3GCwKPnkYwD3FbaePPD728kv2q5UpJHH5L2NwsztIGKbIim99wViCqkHa3oagvPh34euppJDavEs32o3CRtgTtcRiORm752qMYIweaoad8L9K022VNPvbu1ninjuYbq2trOCWJ0V0HKQAOCsjg+YG68YOab9mw9xieGviHbXelxXetPBaq/2huI5lcKt6baPMZQ4z8mcsCGP3QM43NS8a6Fp11JbXN1O1zHcG1aGCzmmfzRGspUKiEn5HVsjj8jWSvw00gaa1m95qUgMEsPnNIm8GS5+0mThMbhJgjjGByDVzR/A9np2rLqb6jqV7fC7kvGluWj+eR4VhOQiKANqjAAGD7cUnybg+Qu+HPGGieI5/J0i6lmcwi4XfbSxCSInG9C6gOueMrnBrfrnfDvhGw0B9MazmunOn6eNNi81lO6PcrZbCj5sqORge1dFUStf3SHa+h5rq3idvCEPjfVUsH1B1122hFukmxmMlpZpwcHnnp39qv2nxL0q48Q6labQulWVlFd/wBohiyymQqAiIFyT86DgkljtxmnWmi2+val4ttrx5kSHxBa3amIgEvFaWTqDkHjKjPt6U68+F/hq4tZrVLZ7ezlthbfZ4ipRQJ/PDgMDlt/POVxxjFae59r+tjT3epcuvHuhx6e00M9y85aWJLYWFwZ/MjUMwaEJ5igBkJJUDDA55FVvCnjm21HTtIbVZLaC9vraxYJCJDma4haTbgrhR8jYO5uByQcZhtfhrp1nb26WGo31lNCZv39nBaW7OkqoHRlSAIQfLQ527hj71SR/DjTILO2htb7UoJbZbNYLhGjMkRto2jjYbkKklWYNlSDngCj93awvcLd98QvDViCZ76YhRMWMdlPJsWGQxys21DtVWUgscDvnHNamgeI9M1/7SNMmld7cr5qTW8kDKGGVO2RVJUjkMOD2NYNr8OdLg068sze6lMLuyu7GWWSRC5W5kMkjZCAbtzHBxj1BrodL0O203Ur2+geZpbuOGJw5BUCIELjA6/Mc/0qXyW0E+Xoaleb6Jq/9kaPF+4877Z4jv7T7+3Zvvrj5uhzjHTj616RXm+k6JHrvh2SJ7u6s5LfXtQuYprbZvV1vrjHDqykc9xXo5Vf2krdjhxtvZrm2uvyZt6v4q0fSL4Wd/dPHPsWR9sEkixKzbVaR1UrGCQQCxGcGhvFehrYT3jajEIoRKXUhvMAicxyYjxvOHG3gdcY6isq88CQXrzNe61q8xuokhveYEF5GjFlVwsQxjcwym0kHBJouvh3olzfXN3IbrzZ7+PUGCyAAMmT5Y4/1bFmLL3LE56Y928zzFGhZXbOwHIpaKKs5gooooA4XR9Y/sPwlJdeR5/meILq1279uPN1OSPdnB6b8474xx1rf13xRpGhTLFqdzJHIYzMRHbyS+XGDgu+xTsTP8TYHvWFo2ixa/4OurKe4uLYDW72dZrcrvR49RlkUjcrL95R1Bqxf+B01AyPea/rMk81u1pcTA26NPATnym2xAAAlsFQrfMfmrNc1tDqkqbm+d9Wa58T6KLa5nbUYFjtjMJNxKn90N0mFPLBRg5AIwQe9asEqzwxyx52SKGXIIOCM9DyPxrj9S+G2g6hLqLyi6j+3PC7LHIAI/LUIQgxwHQbX67hXaVSv1MpqmkuRsKKKKoyCuR0y8/s+48e3uzzPs9+Jtmcbtun2pxnt0rrq5PRrSO/vfHVnMWWO41ARMVOCA1hag49+amXQ1p2tK/b9UaEviWxtdE03UdQMkP29IzFBFE88jOyb9qqilmIAJ4HQE8UWHivQr8gW+pQZKROPMzHkSMyIBuAySyOuOoIwQDWYngnEFijeItaeTTypspiLYPb4QoQuIQGBViDvDdjweajf4c6I4tRI145gtZrXc0oy/mli0jHH+sBeQgjGC7cdMK8jTlo9WzqNL1C11SzF1YyGWAu6B9pXJRirYyBxlTz0PUZFW6o6HpkGjaPZ6baFzBaxLErSHLNgfeY9yep9zV6rXmYStd8uwUUUUElHSv+Sp6P/wBgXUP/AEfZV6PXnGlf8lT0f/sC6h/6Psq9HrzcR/EZ9flf+6w+f5sKKKKxO8K4C71S8034p639j0HUtX8zRtO3fYnt18rE99jd50sfXJxtz0OccZ7+uV03/kqfiH/sC6Z/6Pv6AD/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sqybj4qaTH4/u/B8VjezarayQxOfPtIkYyIHBjEs6vJgHkKpIx05Ge01jUYdJ0y4vrlLmSGBdzLbQPPIf91EBY/gPc8UAYP/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVWZH8UdHm8L+HNZtbPU5z4gm8jT7FI4xcSPkgg5cIoG0kkvitrw34y0nX/Cb+IrZ5bfT4hKbgXCbZLcxEiRXUZwV2npn2zQBB/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlVT8GfEfSvFepxWFvZ6lY3FxZDUrQXsaKLq2LbfMTa7cZxw21sEHFdtQB45pHiDU18TeMnHhDXXaTVI2ZBNZZiP2G1G1s3GM4Ab5SRhhznIGx/wkmqf9CX4g/7/WH/AMk1Lp08Vr4i8fXFw4jhi1SOSRz0VRp1oST+FU9M8c2d3PZLeabqelW99G8lpdX6RpFOFUuejlkOwFsOFOAfSvlsYm687Rvr5/5lE/8Awkmqf9CX4g/7/WH/AMk0f8JJqn/Ql+IP+/1h/wDJNP8AEXjTQfD9pa3GoajbCO4kgRNs8f3Jn2rKcsP3fDMW9FYjOKuWvifQLq+isrXXNLmvJQDHBHdxtI4KhgQoOT8pB+hBrls7X5Pz/wAwKH/CSap/0JfiD/v9Yf8AyTR/wkmqf9CX4g/7/WH/AMk1FqnxC8LWGlTaiutafeW8M0MEv2S7ikKNI4QE/NgAZLHJ+6rHtV0eLdDW3urq41Swt7GCSOMXct5CIpN8ayKVYOcZVhgNgnqAQQS+V78n5/5gV/8AhJNU/wChL8Qf9/rD/wCSaP8AhJNU/wChL8Qf9/rD/wCSavt4n0Fbu2tW1zSxc3IQwRG7j3yhvu7Vzls9sdah8LeLNI8Ti+GkXcUsllcSW80QkRnUq7IHwpOFbaSpOMjmlZ2vyafP/MDzHwLrV/F4I8PRx+GNYmRNOt1WWOW0CuBEvzDdODg9eQD6gVuf29qP/Qp63/39sv8A5IrP8F6rBZeFPA9jKkpm1DT4UiKgbVKW4c7ufQHpnmtSy8T2N3cSRDdCIpLmJ3meNAvkMqu2C24r82cgEAfe25Geua95vl/P/M9WOy1I/wC3tR/6FPW/+/tl/wDJFH9vaj/0Ket/9/bL/wCSKr6j430W2j0+e21HTruzuLwWk1zHeJ5dvmKSTczDI/5Z4wSOtdHaXMF5bR3FnPFPbyDcksTh1ceoI4IqGnFXcfz/AMylrszE/t7Uf+hT1v8A7+2X/wAkVh+Mdav5NIt1fwxrEIGo2DbnltCCRdxELxOTkkYHbJGSBkjvK5/xx/yBbb/sJ6d/6Ww06clzrT8/8xST5XqH9vaj/wBCnrf/AH9sv/kij+3tR/6FPW/+/tl/8kVbn122h1i705o5jPa2S3zsANpjLOoA5zuyh7Y6c1W0/wAV6Xd6YuoTTx2Vm1vBc+ZdzRIFWVdyhvmJU/XAPYmiz35fz/zHfzG/29qP/Qp63/39sv8A5Io/t7Uf+hT1v/v7Zf8AyRUMvjXRo9VtoH1HThYXNs08V8btBG7LIE2KehOc9D2IxXTdeR0pS93eP5/5gtdmc/8A29qP/Qp63/39sv8A5IrK1TxBex+IPCs0vhjWU8rUZGCmS0JkJs7kbVxPjPJPJAwp5zgHta5/xN/yGvCf/YTf/wBIrmqpzSldJde/b1Iq0+eLi3ozc/4TS6/6FDxB/wB/LL/5Jo/4TS6/6FDxB/38sv8A5JrC1HxbYWFv4hmmhumXQ9v2kIqkvujWQbPm54Ydcc5q3N4h0u1ink1G+tLGKKc25e5uYlVnABwDu4OD0OG9ula+2qfyr8f8zi/s2h3Zpf8ACaXX/QoeIP8Av5Zf/JNH/CaXX/QoeIP+/ll/8k1g2vi/S5tdn02S8sovkge1ka6X/S/NBI8sd+g6E5yK6KlKvOO8V+P+YLLKD2bI/wDhNLr/AKFDxB/38sv/AJJrEm8T3tz8QNHli8Ka5vj0u+XyTJZ7mDS2h3D/AEjbgbQDkg/MMA8436oWP/JStJ/7BF//AOjrOro13Kdml179vUxxOApUaTnG90a3/CR6p/0JfiD/AL/WH/yTR/wkeqf9CX4g/wC/1h/8k1j3vxV8P2ela3fTJff8SnUG02aARr5skgYruQbsFPlc5JHCNxxXWDXdJOrNpY1SwOpqu5rT7QnnAYzkpndjHPSulprdHkNNdDL/AOEj1T/oS/EH/f6w/wDkmj/hI9U/6EvxB/3+sP8A5Jqpb+P9Ju/EVxp2nT2l/bwx2pN1a3sTKJJpni8s5YDK7QcBix3ABScA70mvaPHbJcSarp6W7pJIsrXKBWWM4dgc4IU9T270NNdAat0Mz/hI9U/6EvxB/wB/rD/5JrnrLX9SHxA1qUeEdcZ20uxUwiWy3IBLdkMf9I24OSBgk/KcgcZ6q08X+Gr25ht7PxDo9xcTOY4oor2J2dh1VQGyT7CsTVNYt/D/AIr8W6veJK9tZaFYzyLEAXKrLekgAkDP4imuqsNdVY0v+Ej1T/oS/EH/AH+sP/kmj/hI9U/6EvxB/wB/rD/5JqCy8f6Le6vounW5uGm1SxN/GxUBYYwCcSZOVbhhjB5U5xitOLxV4el0+e/i17SXsYGCTXC3kZjjY9AzZwD7Gk010E010Kf/AAkeqf8AQl+IP+/1h/8AJNH/AAkeqf8AQl+IP+/1h/8AJNQeGfHOna1p0V5K9vaQSmcrK13EYysdy0CkEkMd5CkELt+YDJOM6+o+JND0wSHUtZ020EcnlP591HHtfaG2nJGDtZTjrgg96GmnawW6WM//AISPVP8AoS/EH/f6w/8Akmj/AISPVP8AoS/EH/f6w/8AkmtPStf0fWJpotJ1bT76WEAyJbXKSsgPQkKTjPvWlSbtuhX8jznwxr+pJrfi5l8I65IZNURmVZbLMZ+xWo2tm4AzgBuMjDDnOQOh/wCEj1T/AKEvxB/3+sP/AJJrCuPE9l4QPjjVtTjuZLVNbt42W3QO+Xs7NQQCRnk/X0zW5B430WbxHqOjico9haJeT3TlVt1RsEDeT1wyk8YwRzVtN62KavrYX/hI9U/6EvxB/wB/rD/5Jo/4SPVP+hL8Qf8Af6w/+SasXfi/w/b6L/ap1zSmsWLLHP8AbIxHI4H3A+cE8dBzUHhnxbZ61punXE/k2U15bWs6xSXMbZeeMyLGvO4kAN1Vc4JGcHE2dr2F52E/4SPVP+hL8Qf9/rD/AOSaP+Ej1T/oS/EH/f6w/wDkmrl54q8PWWz7br2k2/mMyJ5t5Gm5lYqwGTyQwII7EEVb0nWNM1iOWTSNRsr+OJtkjWs6yhG9CVJwfal52/MXyMj/AISPVP8AoS/EH/f6w/8AkmuW8Faxqi6RdeV4S1uZTqmotuSayABN7MSvzXAOVJKntkHBIwT6dXnen+KtP8IeEDfass5tpvEGoWu6JQ3llr64O9skYUAEkjJx2row+InRblTWpFSlGtHlkuv+Zqf23q//AEJmvf8Af+x/+SaP7b1f/oTNe/7/ANj/APJNWrbxvos2ta/p0lx9mGiLE13dXDLHAPMzjDluxBBzjnjmna7400LSfDj6wdW0yWBoZJLU/bI1W6ZATsjbJDHIxxnrXT/aWI2svuOf6hS25Sn/AG3q/wD0Jmvf9/7H/wCSaP7b1f8A6EzXv+/9j/8AJNauj+JLLUXSF5Ibe6coqQvcRlpGaFZiqqG3ZCtnDBTgE424JW48WeHLWSCO51/SIXnAaJZLyNTICxUFQW55Vhx3BHaj+08R2X3C+oUuxk/23q//AEJmvf8Af+x/+SaP7b1f/oTNe/7/ANj/APJNdHpOradrNqbnSL+0v7YMUMtrMsqBhjIypIzyOPertL+1K66IPqNHseYeCNX1SPRrlY/CetTA6nqDbkmsgATeTEr81wDkElT2yDgkYJ3/AO29X/6EzXv+/wDY/wDyTWbY+J7Lwh4DvtW1OO5ktU1vUI2W3QO+X1GZQcEjPJ+v1rcg8b6LN4j1HRxOUewtEvJ7pyq26o2CBvJ64ZSeMYI5qv7RrrZKxcsDSk27FX+29X/6EzXv+/8AY/8AyTR/ber/APQma9/3/sf/AJJrTu/F/h+30X+1TrmlNYsWWOf7ZGI5HA+4HzgnjoOag8M+LbPWtN064n8mymvLa1nWKS5jbLzxmRY153EgBuqrnBIzg4X9p4i17L7ifqFLexT/ALb1f/oTNe/7/wBj/wDJNH9t6v8A9CZr3/f+x/8Akmte88VeHrLZ9t17SbfzGZE828jTcysVYDJ5IYEEdiCKt6TrGmaxHLJpGo2V/HE2yRrWdZQjehKk4PtR/adfey+4X1Gl2Od/tvV/+hM17/v/AGP/AMk1znh3W9Si1rxXjwprUjPqSMyLLZ5jP2O2G1s3AGcANxkYYc5yB6nXD6fdx2Gp+PLyYM0dvqCysFHJC6fak49+K6cFjamIqcs9rXMa+Hp0qbcVr8+5J/wkOp/9Cdr3/f6x/wDkmj/hIdT/AOhO17/v9Y//ACTWg+u6bBotvqt9dwWFjPGkiyXcqxAbwCASTjPPrVmz1GyvmK2V5bXDBEkIilV8I2drcHocHB74Net8zzr215Pz/wAzG/4SHU/+hO17/v8AWP8A8k0f8JDqf/Qna9/3+sf/AJJrdtbmC7i821miniDMm+Nww3KSrDI7gggjsQRU1FvMXOl9lfj/AJnOf8JDqf8A0J2vf9/rH/5Jo/4SHU/+hO17/v8AWP8A8k10dFOz7i51/Kvx/wAzn/COo3N/8U9M+1aPf6Zs0a/2/a3gbzMz2WdvlSP0x3x1GM849ZrzjSv+Sp6P/wBgXUP/AEfZV6PXnV/4jPrMsd8NF+v5sKKKKxO4K5XTf+Sp+If+wLpn/o+/rqq4C7n1yH4p63/YOnabe50bTvN+2372uz9/fbdu2GTdnnOcYwOueAB3jHwNqPiy9t4dV12A6Fb6jDqMdqlhi4UxjiMTeZjbnJz5e7nG6tyXwrp9lb6lJ4Z0/RtI1W9UrJeLp6nfk5JcIUZ+/wDEOTnmq327xx/0L3hv/wAH0/8A8h0fbvHH/QveG/8AwfT/APyHQBydn8KLmD4e6P4an1bTrmfSLjzbHUDYTxSQjDdPKukYPubO4OBgYKnrWz4d+H83h3StI0nS9ac6TCbp9Vt7q1WY6o8wPLMTmMKxJwvUcH1rT+3eOP8AoXvDf/g+n/8AkOj7d44/6F7w3/4Pp/8A5DoAwvh58LoPCWvNq81/9quI7T7DaW8KzJb2sJYMwRZZpWGSBwGCjsoya9Hrlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q6AOet7KHUtZ+IljdAtb3WorBIB3VtOtAf0NZUXga/uo9Pttf11L+x06KSO1SKyEEhLRNDvlfewYhHYDaqDJzio9Hu/Fo8TeMjHomhNK2qRmZW1iYBG+w2uAp+yncNu05IHJIxxk7P23xj/ANAHw/8A+Dub/wCRK+XxbnGvPla38ijmU+GuossD3PiG2kubS3sYLR104qifZZvNQuvmkvk8HBX2x0pNP8E63eazqkuq31ta2Z1mPU4/s9r+9ndLeJA6uZWCJvVvkKlvlPzENXT/AG3xj/0AfD//AIO5v/kSj7b4x/6APh//AMHc3/yJWPtavdfgByMPwrvyb2a+8Tvd3s0FvEk8sE0mGhuFnV2Ek7Zyy4KpsXk4C1d1f4bXWp6hNqb64ItUku0u98MM0MYItUgcYjnWTB2bhiQYzg7u/Q/bfGP/AEAfD/8A4O5v/kSj7b4x/wCgD4f/APB3N/8AIlHta173X4AYFr8MobfSL2xjvYYxcrYqDHbuVj+zS+ZxvkZiGPqxx6mum8K6Fc6FJqkb30NzZXV5Newxi3KSRNLI0jqz7yHGW4wq4A5zUH23xj/0AfD/AP4O5v8A5Eo+2+Mf+gD4f/8AB3N/8iVEpVJq0mvvQHnOgeGrTxB4Q8BzaikE9tY2EMjW08AlSbdbBRkHgYJB6HpVe/8AhxCunXMVrPiFUvzFa21si48943VFDMFwvlBcHAOf4RVnwLc+JF8EeHhbaTo8kA063EbyapKjMvlLglRbkA47ZOPU1ufa/FX/AEBtE/8ABvL/API1dkp1Iydn+KPUUYtao53w/wCGtX1DUm1TX9lrNHqcV5HF5KKXWO3aIDassgTl853t93oM8dd4Z0n+w9HjsBN5+ySWTfs2/fkZ8Yyem7H4VT+1+Kv+gNon/g3l/wDkaj7X4q/6A2if+DeX/wCRqzm5z3t96KioxOgrn/HH/IFtv+wnp3/pbDR9r8Vf9AbRP/BvL/8AI1YnjG58SHSLcT6To6J/aNgQU1SVju+1xbRg244JwCewJODjBVOD51/mglJcrNLW/Bena1r9zqepw2l15lgtlFHcWqy+Swd28xSe/wA/QAdOtYN14Ju9JsLGfTZ5L2+sRZCFEtkYEwQvEWZXmQEESE/fBUgYJrp/tfir/oDaJ/4N5f8A5Go+1+Kv+gNon/g3l/8AkarjOotLq3qhOMX0/M5vQPA93JoDLq86Q31zYXtpIgiDeWbid5N3DYyAwBUEj/arvrKD7LZwW+7d5UapuxjOBjOKxftfir/oDaJ/4N5f/kaj7X4q/wCgNon/AIN5f/kapm5z3a+9Djyx2Ogrn/E3/Ia8J/8AYTf/ANIrmj7X4q/6A2if+DeX/wCRqxPENz4lOr+GDLpOjq41FzGF1SVgzfZLjgn7ONoxuORnkAY5yFCDv9/VdglJWHeIfhzp2tv4lmuhaNeats8m5ks1kktNsSx/KxOT93PBXr+NVPEfhjU7K8fU9D827vpZ7pwggiZUSZIwQd80eCDEMMCepBUiuk+1+Kv+gNon/g3l/wDkaj7X4q/6A2if+DeX/wCRqtVKitqvvQnGL6GFpvgJ08PCzubxEuZLTToXKxbgjWu0nByMhiPbHvXe1z/2vxV/0BtE/wDBvL/8jUfa/FX/AEBtE/8ABvL/API1RPnnu196HHljsdBVCx/5KVpP/YIv/wD0dZ1nfa/FX/QG0T/wby//ACNVKyuvE/8AwsDS2XR9FNwNLvQqHVZQpXzbTcS32bIIO3Awc5PIwM3h4NVF8+q7HNjnehJF3UPhHp97Dq0kl/IL+9ku3SYR/JGJ5mkGU3fMyB5FDZHEjcc8SXXwujudbv7mXU3exu557nyGNz5kMk0bIxQicRDG44JiJwcZ710f2zxj/wBALw//AODqb/5Eo+2eMf8AoBeH/wDwdTf/ACJXoc8+/wCR87zT7nPw/Du9e7t7jUNbtpWt106OJbfTzCojtJzKoI8xuWyRkYA6gdqp3nwsurvTm06TX4hYRWt9a2qCwO+NblgxLt5nzlcY4C5H511n2zxj/wBALw//AODqb/5Eo+2eMf8AoBeH/wDwdTf/ACJRzT7/AJBzS7/kUtQ8DxXWpXt2l0kJudQsL/aLcfILUphM7ud2zGe2ehqp4g0X/hI/EPjLRvtH2b7doFjB52zfs3S3oztyM/TIrY+2eMf+gF4f/wDB1N/8iVz1ld+K/wDhYGtMui6Gbg6XYh0OryhQvm3e0hvs2SSS2RgYwOTkgC5u/wDWgK467+FWlyTzNbXVxBHcrercLjcT9pjCEIc/IqncwXBGWNV9P+Gd1ZCG4i1i2bU7e5guIbmW3uZ1IiSVAsiS3L5GJmxsKYPPpjp/tnjH/oBeH/8AwdTf/IlH2zxj/wBALw//AODqb/5Eo5p9/wAg5pdzmh8MHbSmtZtaDzmCZBMLTA8x737WH27+gYBdueR3FaOk+BrmDxAusapqsF7dG/lvnWOy8pCXtlgCgF2IACZySfT3rU+2eMf+gF4f/wDB1N/8iUfbPGP/AEAvD/8A4Opv/kSlzT7/AJBzS/qxV8H+Cl8OSaOy3on/ALP0kaWcQbPM+dX8z7xx0PHPXrXX1zX2zxj/ANALw/8A+Dqb/wCRKPtnjH/oBeH/APwdTf8AyJUtOTuyWm9WYjaAviO88WWbziFYvEVndEmPeGEVrZSbcZHXbjPbPQ1SuPhFpws7i0sNQube3ktEt13ZaQOlwJ1cuGUkDCpgYIVRhgQDU/hi78VjW/Fxh0XQ3c6ohlDavKoRvsVrwp+zHcNu05IHJIxxk9D9s8Y/9ALw/wD+Dqb/AORK0bktEy7yWzOctPhxeWTQ3VnrFrFqSvc+bNJaz3CyrOkSMSJbl3EgEK4bfjHG3rl1t8NZrO0sBaaxGt5Yrp/kSy2hZN1rE8WWQSAkOHbgMMccmuh+2eMf+gF4f/8AB1N/8iUfbPGP/QC8P/8Ag6m/+RKXNPv+QuaXf8jnbf4ZuNM1G3utXSe4vdPv7JphZ7drXUzSmQLvP3S2NuecdRXVaF4eXSdX1G+ScOLuG2h8sR7dnkqy5znnOfwx3qv9s8Y/9ALw/wD+Dqb/AORKPtnjH/oBeH//AAdTf/IlJuT3f5Cbk9zpa880zw3D4m8MQ29zIFgtvEWo3MiMm4TKL26UoeRjIbrz9K3vtnjH/oBeH/8AwdTf/Ilc94Fu/Fa6Jci20XQ5E/tTUSTJq8qEN9tm3DAtjwGyAc8gA4GcASaV0CTS0K0vwjtI7a4hsNVuYQUtPKeTcZBLBJLIZJHR0Zi5lOdpQg8g09fhldQW8osdYtILq6tbm0u5Hs5pxIszBmdfNuGdXyOSXYHPSun+2eMf+gF4f/8AB1N/8iUfbPGP/QC8P/8Ag6m/+RKfPPv+RXNPuYf/AAr24t9Sj1LTtYji1CG7juYWmszJGoWyW1ZWUSKTkDcDkYJxz3gh+F4XSbyzm1VZWudMj04yG0HG24lmL43d/Nxt/wBnOew6P7Z4x/6AXh//AMHU3/yJR9s8Y/8AQC8P/wDg6m/+RKOaff8AIXNLv+Rd0TQ10vV9dvUmDjVLiOfyxHt8rZDHFjOec+XnOB1x71sVzX2zxj/0AvD/AP4Opv8A5Eo+2eMf+gF4f/8AB1N/8iVDTZLTZiaZoC+I/Bz2bziFYvEV3dkmPeGEWpyybcZHXbjPbPQ1SuPhFpws7i0sNQube3ktEt13ZaQOlwJ1cuGUkDCpgYIVRhgQDTvBGpeKYtHult9E0SRP7U1Ekvq8qHcb2YsMC2PAbIBzyADgZwN/+1fF3/QA0H/wdTf/ACLXYsLid4rTfoRLEwhJrmW5h2nw4vLJobqz1i1i1JXufNmktZ7hZVnSJGJEty7iQCFcNvxjjb1y62+Gs1naWAtNYjW8sV0/yJZbQsm61ieLLIJASHDtwGGOOTW1/avi7/oAaD/4Opv/AJFo/tXxd/0ANB/8HU3/AMi0/qmK/l/In63D+ZGJb/DNxpmo291q6T3F7p9/ZNMLPbta6maUyBd5+6WxtzzjqK6rQvDy6Tq+o3yThxdw20PliPbs8lWXOc85z+GO9UP7V8Xf9ADQf/B1N/8AItH9q+Lv+gBoP/g6m/8AkWk8HinvH8hPFU3vJHWVwlpZ/wBoX3j+z3+X9pvxDvxnbu0+1Gcd+tX/AO1fF3/QA0H/AMHU3/yLXNeH73xQ2ueLGi0bRS7amhlVtWlARvsdsMKfsx3DaFOSBySMcZPVgMNVo1eapGysc2JqRnTag1f18ywPCettb6OJdb01p9HZWs3XS3CcRNEfMUzndlW4KlSCO/SqQ+GMOLPGqzI0NrJE5SILvmLvJHKADhfLeWRlXkcrz8tdF9s8Xf8AQD0H/wAHM3/yLR9s8Xf9APQf/BzN/wDItexyx/q5we0rLZr8DQ8NaUuh6DY6aspnNvGFeYrtMj9WfHbLEnHvWnXOfbPF3/QD0H/wczf/ACLR9s8Xf9APQf8Awczf/ItUmkYuEpO7a+9HR0Vzn2zxd/0A9B/8HM3/AMi0fbPF3/QD0H/wczf/ACLT5kL2T8vvX+Zq6V/yVPR/+wLqH/o+yr0evJvCM2ry/FPTP7ZsbC0xo1/5f2S8e43fv7LO7dFHtxxjGc5PTHPrNedX1qM+syxWw0V6/mwooorE7grldN/5Kn4h/wCwLpn/AKPv66quV03/AJKn4h/7Aumf+j7+gCHxN49tPDerW1rq2latFZXF5FYJqQjjNuZpFyqgeZ5hHYsEIByM8GqUHxT0ObxFHpa2+oCCTUn0ePUTGn2Z7xFyYgd+/PYHZtJ71m698NtX1f4kW/imfxJbXNvZMG0/TL7TnlhszgZdNk6AuSCdzA44/uioofhDEmuwSPq4fQINak16PTja/OLh1xtMu/BjByduzPOCTQB6Fr2py6VaxSW+lahqkssoiWCyEe8cE7iZHRVUY6lhyQO9cTD8YNBu9K0i70yy1bULjU1uHhsbeKPz0EH+tLbnCDbjsxz2zU3jX4axan4Xl0TwZeWng+G5lDXradp6D7VHtIMbBChAORkg9AR0NZ138KXn8NaHplve6TY3OkCWO1vLKxuYHhjdcEIVuwwY/MWLs6sTyvXIB1b+O9CX4f8A/CZm5f8AsP7P9p8zyzvxnG3b/e3fLj1/Ojwf40svE95qNjHZ3+nalp4ia4s75EWRUlXdGw2MykEZ6HIxggVjQ/DlrTQE8OWuqRS+Fo9IOnjS72yEqvPv3faXkVkc+mxSo7gg4qz8N/h/F4NuNTvZdQl1DUdQ8pJJGMmyOKMERxoJJJHwMn7zsfoABQBR06eK18RePri4cRwxapHJI56Ko060JJ/CqemeObO7nslvNN1PSre+jeS0ur9I0inCqXPRyyHYC2HCnAPpU9vZQ6lrPxEsboFre61FYJAO6tp1oD+hrKi8DX91Hp9tr+upf2OnRSR2qRWQgkJaJod8r72DEI7AbVQZOcV8tilT9vPn7lGx4i8aaD4ftLW41DUbYR3EkCJtnj+5M+1ZTlh+74Zi3orEZxVy18T6BdX0Vla65pc15KAY4I7uNpHBUMCFByflIP0INcUnw11Flge58Q20lzaW9jBaOunFUT7LN5qF180l8ng4K+2OlJp/gnW7zWdUl1W+trWzOsx6nH9ntf3s7pbxIHVzKwRN6t8hUt8p+Yhqx9nRt8X9aeQHRap8QvC1hpU2orrWn3lvDNDBL9ku4pCjSOEBPzYAGSxyfuqx7VdHi3Q1t7q6uNUsLexgkjjF3LeQiKTfGsilWDnGVYYDYJ6gEEE8TD8K78m9mvvE73d7NBbxJPLBNJhobhZ1dhJO2csuCqbF5OAtXdX+G11qeoTam+uCLVJLtLvfDDNDGCLVIHGI51kwdm4YkGM4O7u+Shtzf1p5eoHYN4n0Fbu2tW1zSxc3IQwRG7j3yhvu7Vzls9sdah8LeLNI8Ti+GkXcUsllcSW80QkRnUq7IHwpOFbaSpOMjmuXtfhlDb6Re2Md7DGLlbFQY7dysf2aXzON8jMQx9WOPU103hXQrnQpNUje+hubK6vJr2GMW5SSJpZGkdWfeQ4y3GFXAHOazlGkovld2B5/4L1WCy8KeB7GVJTNqGnwpEVA2qUtw53c+gPTPNall4nsbu4kiG6ERSXMTvM8aBfIZVdsFtxX5s5AIA+9tyM89oHhq08QeEPAc2opBPbWNhDI1tPAJUm3WwUZB4GCQeh6VXv/AIcQrp1zFaz4hVL8xWttbIuPPeN1RQzBcL5QXBwDn+EV2ONJyfM9f+H/AOAeonNLRG7qPjfRbaPT57bUdOu7O4vBaTXMd4nl2+YpJNzMMj/lnjBI610dpcwXltHcWc8U9vINySxOHVx6gjgiuC8P+GtX1DUm1TX9lrNHqcV5HF5KKXWO3aIDassgTl853t93oM8dd4Z0n+w9HjsBN5+ySWTfs2/fkZ8Yyem7H4VnVjCKtF6lRcnualc/44/5Att/2E9O/wDS2Gugrn/HH/IFtv8AsJ6d/wClsNRT+NepUvhZbn122h1i705o5jPa2S3zsANpjLOoA5zuyh7Y6c1W0/xXpd3pi6hNPHZWbW8Fz5l3NEgVZV3KG+YlT9cA9iaqa34L07WtfudT1OG0uvMsFsoo7i1WXyWDu3mKT3+foAOnWsG68E3ek2FjPps8l7fWIshCiWyMCYIXiLMrzICCJCfvgqQME1rGNJrfUhua6HQy+NdGj1W2gfUdOFhc2zTxXxu0EbssgTYp6E5z0PYjFdN15HSvO9A8D3cmgMurzpDfXNhe2kiCIN5ZuJ3k3cNjIDAFQSP9qu+soPstnBb7t3lRqm7GM4GM4qKqgtIMqDk9yauf8Tf8hrwn/wBhN/8A0iua6Cuf8Tf8hrwn/wBhN/8A0iuamnv8n+Q5bCaj4tsLC38QzTQ3TLoe37SEVSX3RrINnzc8MOuOc1bm8Q6XaxTyajfWljFFObcvc3MSqzgA4B3cHB6HDe3Suc8Q/DnTtbfxLNdC0a81bZ5NzJZrJJabYlj+Vicn7ueCvX8aqeI/DGp2V4+p6H5t3fSz3ThBBEyokyRgg75o8EGIYYE9SCpFbKNKVlf+rL9bkNzXQ6K18X6XNrs+myXllF8kD2sjXS/6X5oJHljv0HQnORXRVwWm+AnTw8LO5vES5ktNOhcrFuCNa7ScHIyGI9se9d7WdRQT9xlRcvtBVCx/5KVpP/YIv/8A0dZ1fqhY/wDJStJ/7BF//wCjrOqw/wDEXz/I5sd/u8v66jb34q+H7PStbvpkvv8AiU6g2mzQCNfNkkDFdyDdgp8rnJI4RuOK6wa7pJ1ZtLGqWB1NV3NafaE84DGclM7sY56VwmofCPT72HVpJL+QX97Jdukwj+SMTzNIMpu+ZkDyKGyOJG454kuvhdHc63f3Mupu9jdzz3PkMbnzIZJo2RihE4iGNxwTETg4z3r0mqfRnzrUO5sW/j/SbvxFcadp09pf28MdqTdWt7EyiSaZ4vLOWAyu0HAYsdwAUnAO9Jr2jx2yXEmq6elu6SSLK1ygVljOHYHOCFPU9u9cZD8O717u3uNQ1u2la3XTo4lt9PMKiO0nMqgjzG5bJGRgDqB2qnefCy6u9ObTpNfiFhFa31raoLA741uWDEu3mfOVxjgLkfnRaHcVodztbTxf4avbmG3s/EOj3FxM5jiiivYnZ2HVVAbJPsKxNU1i38P+K/Fur3iSvbWWhWM8ixAFyqy3pIAJAz+IqXUPA8V1qV7dpdJCbnULC/2i3HyC1KYTO7ndsxntnoaqeINF/wCEj8Q+MtG+0fZvt2gWMHnbN+zdLejO3Iz9MiklH+vkC5TRsvH+i3ur6Lp1ubhptUsTfxsVAWGMAnEmTlW4YYweVOcYrTi8VeHpdPnv4te0l7GBgk1wt5GY42PQM2cA+xrlLv4VaXJPM1tdXEEdyt6twuNxP2mMIQhz8iqdzBcEZY1X0/4Z3VkIbiLWLZtTt7mC4huZbe5nUiJJUCyJLcvkYmbGwpg8+mHan3C0O50Hhnxzp2tadFeSvb2kEpnKytdxGMrHctApBJDHeQpBC7fmAyTjOvqPiTQ9MEh1LWdNtBHJ5T+fdRx7X2htpyRg7WU464IPeuKHwwdtKa1m1oPOYJkEwtMDzHvftYfbv6BgF255HcVo6T4GuYPEC6xqmqwXt0b+W+dY7LykJe2WAKAXYgAJnJJ9Pek1DuDUO50+la/o+sTTRaTq2n30sIBkS2uUlZAehIUnGfetKuQ8H+Cl8OSaOy3on/s/SRpZxBs8z51fzPvHHQ8c9etdfUSST0Idr6Hntx4nsvCB8catqcdzJaprdvGy26B3y9nZqCASM8n6+ma3IPG+izeI9R0cTlHsLRLye6cqtuqNggbyeuGUnjGCOaxW0BfEd54ss3nEKxeIrO6JMe8MIrWyk24yOu3Ge2ehqlcfCLThZ3FpYahc29vJaJbruy0gdLgTq5cMpIGFTAwQqjDAgGtLQ+1v/wAMae71Owu/F/h+30X+1TrmlNYsWWOf7ZGI5HA+4HzgnjoOag8M+LbPWtN064n8mymvLa1nWKS5jbLzxmRY153EgBuqrnBIzg45u0+HF5ZNDdWesWsWpK9z5s0lrPcLKs6RIxIluXcSAQrht+McbeuXW3w1ms7SwFprEa3liun+RLLaFk3WsTxZZBICQ4duAwxxyaLQtuK0O51t54q8PWWz7br2k2/mMyJ5t5Gm5lYqwGTyQwII7EEVb0nWNM1iOWTSNRsr+OJtkjWs6yhG9CVJwfauGt/hm40zUbe61dJ7i90+/smmFnt2tdTNKZAu8/dLY255x1FdVoXh5dJ1fUb5Jw4u4baHyxHt2eSrLnOec5/DHepajbRiaj0Zu153p/irT/CHhA32rLObabxBqFruiUN5Za+uDvbJGFABJIycdq9ErzzTPDcPibwxDb3MgWC28RajcyIybhMovbpSh5GMhuvP0oja2oRtbU3bbxvos2ta/p0lx9mGiLE13dXDLHAPMzjDluxBBzjnjmna7400LSfDj6wdW0yWBoZJLU/bI1W6ZATsjbJDHIxxnrXKS/CO0jtriGw1W5hBS08p5NxkEsEkshkkdHRmLmU52lCDyDT1+GV1Bbyix1i0gurq1ubS7kezmnEizMGZ1824Z1fI5Jdgc9Kq1PuVaHc7HR/EllqLpC8kNvdOUVIXuIy0jNCsxVVDbshWzhgpwCcbcErceLPDlrJBHc6/pELzgNEsl5GpkBYqCoLc8qw47gjtXMf8K9uLfUo9S07WI4tQhu47mFprMyRqFsltWVlEik5A3A5GCcc94IfheF0m8s5tVWVrnTI9OMhtBxtuJZi+N3fzcbf9nOewVodxWj3O70nVtO1m1NzpF/aX9sGKGW1mWVAwxkZUkZ5HHvV2sfRNDXS9X129SYONUuI5/LEe3ytkMcWM55z5ec4HXHvWxWbtfQh26Hnmh6tBovhq4urpJXjfXr22AjAJ3S6lLGp5I4ywz7etdFqes6XpUkCapqVlZPOdsS3E6xmQ+i7iMnkdK5S00aXXvB13Z290lpOmv3lzHLJEZVDRanLIAVDKSCVx1HWjWfBur6u9zNda3p63N3ZNp1y0emNsMBbPyK0x2vy3zEsDx8vFfW0nJU42XRHiVY03VlzO2rOyS+tHgnnS6gaG3ZlmkEgKxlfvBj0BHfPSpopEliSSJ1eNwGVlOQwPQg157qvwxhvX1PytXuYI7p0MSBNwgUxiO4Xr83moMHpg4Ir0RQFUKoAUDAA7Vqm+qOecYJLldxaKKKoyCuT0a7jsL3x1eTBmjt9QErBRkkLYWpOPfiusrkdMs/7QuPHtlv8AL+0X4h34zt3afajOO/Wpl0NadrSv2/VG2+u6bBotvqt9dwWFjPGkiyXcqxAbwCASTjPPrVmz1GyvmK2V5bXDBEkIilV8I2drcHocHB74NciPCettb6OJdb01p9HZWs3XS3CcRNEfMUzndlW4KlSCO/SqQ+GMOLPGqzI0NrJE5SILvmLvJHKADhfLeWRlXkcrz8tK8uxpyUv5jv7W5gu4vNtZop4gzJvjcMNykqwyO4III7EEVNWZ4a0pdD0Gx01ZTObeMK8xXaZH6s+O2WJOPetOqXmYSsm7bBRRRTJKOlf8lT0f/sC6h/6Psq9HrzjSv+Sp6P8A9gXUP/R9lXo9ebiP4jPr8r/3WHz/ADYUUUVid4VwF3ql5pvxT1v7HoOpav5mjadu+xPbr5WJ77G7zpY+uTjbnoc44z39crpv/JU/EP8A2BdM/wDR9/QAf8JRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lU/UPHfh7TtZXS769lhuWuUsxI1pN5AndQyxmfZ5Ycgg4LZ5pI/H3hqXxF/YaamDqBuGtAPIkERnVdzRCbb5ZkA6pu3e1ADf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8AkqtbX9esNBhgk1Frj9/J5UUdtay3MkjYLYCRKzHhSenGKwpviX4Sj0fT9TGrebaX4kNt5FtNLJIIxmT90iFxs/iyo298UAT/APCUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVah8R6OPDX/AAkB1G2/sXyPtP2zf+78vGc5/p1zx1qDwv4s0bxQt1/Yt28r2pQTxSwSQSR713IWSRVYBhyDjBHSgDznSPEGpr4m8ZOPCGuu0mqRsyCayzEfsNqNrZuMZwA3ykjDDnOQNj/hJNU/6EvxB/3+sP8A5Jqxo7rH4p8dO7BUXVoyWJwAP7Ps+TTNF8Z6FrV5DbafdyvJOjSQGS1liS4Vepid1CyAdflJ456V8rjNa87RvZ+f+ZSIv+Ek1T/oS/EH/f6w/wDkmj/hJNU/6EvxB/3+sP8A5Jra1TUrTS4YZb6Xyo5p4rZDtLZkkcIi8A9WYDPQd6uVycy35V+P+YHM/wDCSap/0JfiD/v9Yf8AyTR/wkmqf9CX4g/7/WH/AMk1tatqVppFl9r1CXybfzI4t+0t80jrGgwATyzKPx54qaG4SaaeJFlDQMFYvEyqSVDfKxADDBHKkgHI6gijmVr8v5/5gc//AMJJqn/Ql+IP+/1h/wDJNH/CSap/0JfiD/v9Yf8AyTXTVT0vUrTVIZpbGXzY4Z5bZztK4kjco68gdGUjPQ9qOZb8q/H/ADA8g8C61fxeCPD0cfhjWJkTTrdVljltArgRL8w3Tg4PXkA+oFbn9vaj/wBCnrf/AH9sv/kiqvgbULW18G+DbSeXbcXmnQJAm0neVgDNyBgcAnnFbdjrFlfTPFaPJKySywswhfarxkK6lsYByeMnnnGcGuyp8TfL+f8AmetHZamd/b2o/wDQp63/AN/bL/5Io/t7Uf8AoU9b/wC/tl/8kVo6pqkGmz6dFOsjNf3P2WIoAQG2O+WyemIz0zzir9Q2l9n8/wDMq3mc/wD29qP/AEKet/8Af2y/+SKw/GOtX8mkW6v4Y1iEDUbBtzy2hBIu4iF4nJySMDtkjJAyR3lc/wCOP+QLbf8AYT07/wBLYaqnJc60/P8AzJknyvUP7e1H/oU9b/7+2X/yRR/b2o/9Cnrf/f2y/wDkitKXVrKLUJ7J5sXUFsLuRNjfLESwDZxg8o3A54pdL1O11S3juLFpJIJYo545GidFdHXcpBYDPHUdR3xS8+X8/wDMfzMz+3tR/wChT1v/AL+2X/yRR/b2o/8AQp63/wB/bL/5IrSOpwjXF0rbJ9oa2N0GwNm0MFxnOc5I7VepNpfZX4/5jt5nP/29qP8A0Ket/wDf2y/+SKxtc1bUrjW/C6r4X1hXXUXZUaW0zIfslwNq4nxnBJ5IGFPOcA9zWVqP/I0+Dv8AsJy/+kN1V0mnK1vz/wAzGvJwpyknsH23W/8AoTtb/wC/9j/8kUfbdb/6E7W/+/8AY/8AyRXR3PjDQba412C41FI5tEiSbUFZGzCjJvU9PmyP7ueoHXitbTr231HT7a+spPMtbmJZon2kbkYAqcHkZBHWul0IreP5njf2nXXRfccN9t1v/oTtb/7/ANj/APJFH23W/wDoTtb/AO/9j/8AJFdVq3iC00vVbSwuY7p5bm3nuUMEJlwsJj3DauWLHzVwFU5wfx16PYw7B/adfyPPvtut/wDQna3/AN/7H/5IrMi1TVbb4gaVLL4T1rf/AGXeqsImsyzAy2mWH+kbcDAByQfmGAeceqVzWof8lK0L/sEaj/6OsqqnThGV0iJ4+rVi4StZh/wkeqf9CX4g/wC/1h/8k0f8JHqn/Ql+IP8Av9Yf/JNNuPHvhm30zVNQm1RFtdMvDYXbeW+Y5wwUpt25PJ6gEdeeDXT1o9N1+ZxPTdHNf8JHqn/Ql+IP+/1h/wDJNH/CR6p/0JfiD/v9Yf8AyTV6bxBaReIJdHeO6NzHBBcFo4TIu2WR41+7kjBjJJICgck9ca9DdugX8jmv+Ej1T/oS/EH/AH+sP/kmuestf1IfEDWpR4R1xnbS7FTCJbLcgEt2Qx/0jbg5IGCT8pyBxn0auOudStNG8a+KNR1KXybK10Swlmk2ltqia9JOACT+Apxd76DT30Ln/CR6p/0JfiD/AL/WH/yTR/wkeqf9CX4g/wC/1h/8k1bg8VaLcahpVjBfpJdapbG8s0VWPmwgA784wBg98ZrapN23Qtt0c1/wkeqf9CX4g/7/AFh/8k0f8JHqn/Ql+IP+/wBYf/JNXvD/AIgtNdtxLaR3SAvOg82EgZimaJvmGV5ZSQM5I5x1xr0N20aBu3Q5r/hI9U/6EvxB/wB/rD/5Jo/4SPVP+hL8Qf8Af6w/+Sa6Wilddguux5z4Y1/Uk1vxcy+EdckMmqIzKstlmM/YrUbWzcAZwA3GRhhznIHQ/wDCR6p/0JfiD/v9Yf8AyTWZba9pnhu68b6lrd0tpYprMKNKyswBays1GdoJ6kc9u9dLBr2mT+ILjRIbpX1S3gW5lgCt8kbHAO7G3n0zmrl3sU/Qzf8AhI9U/wChL8Qf9/rD/wCSaP8AhI9U/wChL8Qf9/rD/wCSa6K4lWCCSZwSsalyB1wBms/w9rdtr2mWl9Zx3KRXNtDdKJoSuElTco3fdJA6hScHr2qb9bE38jN/4SPVP+hL8Qf9/rD/AOSaP+Ej1T/oS/EH/f6w/wDkmulopXXYLrsc1/wkeqf9CX4g/wC/1h/8k1z3gXX9Si0S5WPwlrk4Oqai26OWyABN7MSvzXAOVJKntkHBIwT6NXD+HNe0zw/4ZafWLpbaG417ULWN2ViDI9/cbQcA46dTgDuapO60Q07rY0/+Ej1T/oS/EH/f6w/+SaP+Ej1T/oS/EH/f6w/+Sa0rHXtMv9b1LSLS6WXUdOEZuoQrfuvMBKc4wcgdATjvVnVb6PTNLvL+dXaG1hedwgBYqqliBnHOBS8rC+Rif8JHqn/Ql+IP+/1h/wDJNH/CR6p/0JfiD/v9Yf8AyTWzpeow6lD5sCTqu1G/exMg+ZA4wSMNwwyVJAORnIIq5Re3QL+RzX/CR6p/0JfiD/v9Yf8AyTR/wkeqf9CX4g/7/WH/AMk10tFK67Bddjy7wZruoxaVdqnhTW5gdU1FtyS2YAJvJiV5uAcgkqe2QcEjBO7/AMJDqf8A0J2vf9/rH/5Jqt4Z1G10vw9dT30vlRPrl/ArbS2Xk1GZEHAPVmA9Oea6yvraK/dx16I8HESSqy93q+/f1Oc/4SHU/wDoTte/7/WP/wAk0f8ACQ6n/wBCdr3/AH+sf/kmujorWz7mHOv5V+P+Zzn/AAkOp/8AQna9/wB/rH/5Jo/4SHU/+hO17/v9Y/8AyTXR0UWfcOdfyr8f8znP+Eh1P/oTte/7/WP/AMk1geGtd1FNZ8VsvhTWpDJqSMyrLZ5jP2O2G1s3AGcAHjIww5zkD0KuW0G4itNS8b3Nw2yGHUlkdsE4UWFqScDnpUtbamkJJqXurbz7rzJv+Eh1P/oTte/7/WP/AMk0f8JDqf8A0J2vf9/rH/5JrdtLiK7tYbm3bfDMiyRtgjKkZBweelTU7eZHOl9lfj/mc5/wkOp/9Cdr3/f6x/8Akmj/AISHU/8AoTte/wC/1j/8k10dFOz7i51/Kvx/zOc/4SHU/wDoTte/7/WP/wAk0f8ACQ6n/wBCdr3/AH+sf/kmujoos+4c6/lX4/5nP+EdRub/AOKemfatHv8ATNmjX+37W8DeZmeyzt8qR+mO+OoxnnHrNecaV/yVPR/+wLqH/o+yr0evOr/xGfWZY74aL9fzYUUUVidwVyum/wDJU/EP/YF0z/0ff11VcBd69Z6J8U9b+2w6lL52jadt+xabcXeMT32d3ko23qMbsZ5xnBoAz/Hfg/xN4p8RaVKH0y1tNN1OG8guxe3DMIk52tZlTC0mSR5hbIHTHSsW2+E+rprtrbyXlh/wj9t4ll8RrOssgu2LLxCU2gDBJ+ffnHYV3/8Awnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8JzUf/jFAEGq+HL6w0s2nhoS3cVw/+lR6nr18km3HBiuMyPGc4yAOR6VwFp8Jte03wr4bhsbyzHiLShdpHdxXPkxwRTk5j2tbyeeOTksEYnncCa9G/wCE80j/AJ8/En/hOaj/APGKP+E80j/nz8Sf+E5qP/xigDlYvh3qdv4FTwNIdN1DwumjGBmklkt7qS98zeCGCuqRdx8rMDjgjrofC7wRqnh3Vtb1nxFqIvNS1JIIAquJPKhhUqgaQRx72OeTsXoOpya2v+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGKAObFguqan8R9Pkdo0u78QM69VDabaLkfnWE3hPxDq9tpFjrr6Tb2ulQyok1lLI73DtbvApKMiiNQshJAZ8nHOKsaP4w01PE3jKQ22ulZtUjdQuhXpIAsbVfmAhypyp4bBxg9CCdj/hNdL/AOfXxB/4IL//AOM18vinUjXnyrr2KOCvPhvr2qQWn9rW3h+ZrG0062ht2mkkjn+zTF33lovlDqzLwrYDEHI6po3grVLjxPf3cGjaVpBtdYiuI74F/NWNLWFfIhXylDQFsru3KCAw2ggV33/Ca6X/AM+viD/wQX//AMZo/wCE10v/AJ9fEH/ggv8A/wCM1n7atZrl/BgeZW/wl1t7fUxexeHibiK2It4wiQSTRXCyklY7ZAisu9ORIwDYLMK1Nc+Gmrag1xJbrpVrbyXsNyNLjdTb7Fs44NuZLd0+VkJXMR4P8J6dz/wmul/8+viD/wAEF/8A/GaP+E10v/n18Qf+CC//APjNHt6978v4f12A4m3+FtzHZysws21KNNPWyuJpzNLbeRJukAlESYyvygqoyOCAK6z4f+Fm8MXOuKdP0qGO7vZbmK6tOJZY3kd1SRdgxsDbRhmHXpVr/hNdL/59fEH/AIIL/wD+M0f8Jrpf/Pr4g/8ABBf/APxmonOtNOLT/EDzPRfDza54W+HszSvHa2VjHJN5VxJBKQ1qFGxoyD1IzyOM9elUL/wHqFvYXZgvESJE1NlIkmmlKzvE6KcAuxKxsGwS3PG41reBfFFhb+CPD0MlvrBePTrdGMekXbqSIlHDLEQw9wSD2rc/4S3Tv+fbW/8AwSXv/wAarrc6sZOy0/4f/M9NKDWrOE8O+E21qeSWbQrDTtKTVobk2TQPHFJGlq8bbUkiRjlnB+ZFBw3XHPoPg7SZtD8PW+nXDRM0Ly7fKJKqhkZkUZA6KVGO2MdKh/4S3Tv+fbW//BJe/wDxqj/hLdO/59tb/wDBJe//ABqoqSqVNGtCoqEdbnQVz/jj/kC23/YT07/0tho/4S3Tv+fbW/8AwSXv/wAarD8Y+J7CfSLdEt9YBGo2D/PpF2gwt3Ex5MQGcDgdScAZJAqKdOfOtBylHlepc13wg+r+J73UpZ5Ugk0tLOJYLyaBvMDyMS/lkBlw69Se/Hry974QvtK0aza7S1v4rePT45bIRzzR3PkwvGysscTtt3MrD5SPlGQK7j/hLdO/59tb/wDBJe//ABqj/hLdO/59tb/8El7/APGq0jOqtLOxLjB9Tg9D8BT6n4ZiN/p9lbyHT76G2t5kI+zSy3DyRMFK/KFUjsGHoK9WsY5IbK3imbfKkaq7ZzkgcnJrF/4S3Tv+fbW//BJe/wDxqj/hLdO/59tb/wDBJe//ABqpqOpU3Q4qEdmdBWVqP/I0+Dv+wnL/AOkN1VT/AIS3Tv8An21v/wAEl7/8arNv/FOnt4k8KSC31nbFqMjsDo92CR9juV+UeVljlhwMnGT0BIKFOSmtDLFSToySfQv678MpdY8Ua7q017HDHezIyQpkieNbeJRHLxwBNCj8buAR/EazI/hfq66xot1NdW86WdvYR70uEiktmgVVcRM1tI5VipbAePdkg9c13v8Awmul/wDPr4g/8EF//wDGaP8AhNdL/wCfXxB/4IL/AP8AjNeip1FpY+b5pnnVz8LNYmtLqFItCiuH02/sn1BZX8++knZCkk/7rIxtOfmbGeOOBvXvgvXZNWkSFtM/sttafVxK88gm+aAx+XsCbeCxOd3I7Dv0/wDwmul/8+viD/wQX/8A8Zo/4TXS/wDn18Qf+CC//wDjNPnm+gc0+x5+3wdRNBNvb2mjR6gNAhslmCkYv0yTcZ2Zzzw/3scYAr0DUP8AkpWhf9gjUf8A0dZUf8Jrpf8Az6+IP/BBf/8AxmuevfF2mt8QNFnFtrmxNLvkIOiXoYlpbQjC+VuI+U5IGBxnGRlXnJ6+YXlJ6mFqvwhu76312UX8C3N9c3dxHb5byWaSaRoZHOMhkSaVSADyw5+UVaufhtq8vjHUtUW/VPtMtxJDfRzok8IkiZFQr9mLuq5AA88DgHAIxXaf8Jrpf/Pr4g/8EF//APGaP+E10v8A59fEH/ggv/8A4zT56nYOaZw2l/DbU7e8imSy0DTERtL3x2MrkTG1uTLJKxMS5dlIAzk5ABPeotQ+HHiO70UaT5mkJbWtlqNpbzefIXlNy4ZWdfLwmAMEAt6+1d9/wmul/wDPr4g/8EF//wDGaP8AhNdL/wCfXxB/4IL/AP8AjNHPPsHNPsctL8MLa31u4v8ASLLSrMjU7C7tTGpRoYoinnqML8pcK2QOGz8xq34s0e48Qav430iyeJLm98PWUEbSkhAzS3oBJAJx+Bre/wCE10v/AJ9fEH/ggv8A/wCM1z1l4u01fiBrU5ttc2PpdigA0S9LArLdk5XytwHzDBIwecZwcCc3q/62C8nqzPl+FdzBfGfTdW8tnhvYElbIe0jmjIijix1VHeRskg/Nx0qhpfww1Wx05o2t9LnH2u3nmsJrpfsl4saSqQ6xWkYU5kVslZNxRc9M16B/wmul/wDPr4g/8EF//wDGaP8AhNdL/wCfXxB/4IL/AP8AjNHPU7BzTOFg+GWrx6AtmsmlQSx20yRxQu4iVzqAuo1HyDCbQFJxkdga0Ifh/e6rr7X/AIqtdGntZtTkvZbJZGnTabSOFB88ahiGTPIA6Ec8V1X/AAmul/8APr4g/wDBBf8A/wAZo/4TXS/+fXxB/wCCC/8A/jNLmn2Dmn2ML4deA5fCl1ps5WxSRNJFnfNbZzcXAcMJCSo3cbhuPPOMYr0Kua/4TXS/+fXxB/4IL/8A+M0f8Jrpf/Pr4g/8EF//APGamSlJ3aJlzSd2jmtU8PSeJ28W6fH5G0eJLKeVZiQrRx21k7rwDyVBA/pWVP8ACfUYbbUIbHWRLLdWEds93PxLM6Tq4VxtYbPKRIs/N05UjIOz4Y8XabFrfi12ttcIm1RHXbol6xA+xWq/MBFlTlTwcHGD0IJ6H/hNdL/59fEH/ggv/wD4zV8046Iq81ojgrf4Z6nBp9rC1lo97Ck1076dfXQe2UypEqyoI7WNAyGNsJ5ePnY7gTVux+H2t6fa6VJDLps15py6WyRPM6RytbQSRSAv5ZKg+ZlTtPTkCuy/4TXS/wDn18Qf+CC//wDjNH/Ca6X/AM+viD/wQX//AMZo559g5p9jhJPhbfahpt6usR6PNeyWWopbnc7pBdXFw8scikpkbQ33gMjtmu18F+FF8M6nqr2kVpb2F3HbbILYbQJEQrI5GAMt8vPU45qb/hNdL/59fEH/AIIL/wD+M0f8Jrpf/Pr4g/8ABBf/APxmk5Tas0Jub0OlrzD/AIRc+LfCENi5i+zR+JNRmuVkJG6IXl0rBcA/N83Ga6r/AITXS/8An18Qf+CC/wD/AIzXO+BvGOl22i3McsGtljqmov8AJot64w17Mw5WIjOCMjqDkHBBFEITt7qdxaxVzEufhTqq2uqxQavFcyXkdm000+Fa8kjllklEoKOqq3mLgFXA2gFcCo5/hfqh0iO0Nro96n2a6hS11C63xWcsrAiaHZbIoI5+URpjs1d//wAJzpH/AD769/4Ib7/4zR/wnOkf8++vf+CG+/8AjNaWr/yv7g9s+5y8fgbXLHW4NYsX02e5tr2O4jgmneNHQaetq4LCNiCGBYcHI647ZbfCe8utMlTUV0ia/XS4rS2lJY+ROtzNKzqSmVG2RQCOeCOnXvP+E50j/n317/wQ33/xmj/hOdI/599e/wDBDff/ABmjlrfyv7mL2r7i+DvDK+Gr3Xls4rW20u8u0ntLW2G1YVEEaP8ALgBSXRjxnOc9a6auY/4TnSP+ffXv/BDff/GaP+E50j/n317/AMEN9/8AGah0ar1cX9zJck92coNKvNY8FXVvpv2c3UfiG6uUW4kaNG8rVZJCpYKxGQpGcGq3izwnrviWdrm8sNCMzWb2kUct5LKtk5bIuYm8kEyc4xhT8q4bk1Z8GeLNOh0m7V7fWiW1TUXBTRbxxhryZhyIiM4IyOoOQcEEVvf8Jlpn/Prr3/givv8A4zX01JRdOKb6I8ipKrCrLlj1fc5XU/AniB49ag03XEhtLuTdFGzMNwmjCXRkwME9XTrhupGTXpMESQQxwwoEijUIqjoABgCsD/hMtM/59de/8EV9/wDGaP8AhMtM/wCfXXv/AARX3/xmtVyrZmE/a1ElKO3kdHRXOf8ACZaZ/wA+uvf+CK+/+M0f8Jlpn/Prr3/givv/AIzVcy7mXsqn8r+46OuOsbSS/f4gWcJVZLi98pSx4BbT7YDPtzV7/hMtM/59de/8EV9/8ZrA8N+LNOi1nxW7W+tES6kjrt0W8YgfY7ZfmAiypyp4ODjB6EEy5J21NKdOolJ8r27eaGXvhvxBqWj6LZalpugzwaW0ZazkvpJIL0CJk/eZgG3BKuOHGR24NVbLwFr1j9kaw1eK0k+xGO48l3AMyPI9uo4yYl80qQcEqijGCa6z/hMtM/59de/8EV9/8Zo/4TLTP+fXXv8AwRX3/wAZqbR7mntKyVlHT0LXhDSpNE8OWVjcvG90il7h487Xmdi8hGecFmbrzWzXOf8ACZaZ/wA+uvf+CK+/+M0f8Jlpn/Prr3/givv/AIzVpxWlzCVOpJtuL+46Oiuc/wCEy0z/AJ9de/8ABFff/GaP+Ey0z/n117/wRX3/AMZp8y7i9lU/lf3GrpX/ACVPR/8AsC6h/wCj7KvR68m8I6za6v8AFPTPssV/H5WjX+77XYT22cz2WNvmou7pzjOOM9RXrNedX1qM+syxOOGin5/mwooorE7grldN/wCSp+If+wLpn/o+/rqq5XTf+Sp+If8AsC6Z/wCj7+gC3r3jDQdA1nSdJ1bUUg1HVZBFZwbGdpGJAH3QdoycZbA9+KrR+PvDUviL+w01MHUDcNaAeRIIjOq7miE23yzIB1Tdu9q4nxv8JLvV/F2na9pOv3iXA1iC/uxdNEfKjjVgog/ck5XPCsSnLE8nNVLb4T6umu2tvJeWH/CP23iWXxGs6yyC7YsvEJTaAMEn59+cdhQB69q+pWejaXdajqlwltZW0Zlllfoqj+f0HJ7VzMnxL8JpoemauNUeSy1NZXtDFaTySTLHnzGESoXwuCSSuAOaq+IfhrY6rp9vbQax4gthbz/akD6g14HlAwm4XQl4B5AGBnnqARwuk/CPxBpHgzwtbWl/bt4l0dLqJbxbwRwwxzZyiqbV/NTnJDBWBJw4GMAHr58R6OPDX/CQHUbb+xfI+0/bN/7vy8Zzn+nXPHWoPC/izRvFC3X9i3byvalBPFLBJBJHvXchZJFVgGHIOMEdK4iL4d6nb+BU8DSHTdQ8LpoxgZpJZLe6kvfM3ghgrqkXcfKzA44I66Hwu8Eap4d1bW9Z8RaiLzUtSSCAKriTyoYVKoGkEce9jnk7F6DqcmgBdHdY/FPjp3YKi6tGSxOAB/Z9nyaZovjPQtavIbbT7uV5J0aSAyWssSXCr1MTuoWQDr8pPHPSq4sF1TU/iPp8jtGl3fiBnXqobTbRcj86wm8J+IdXttIsddfSbe10qGVEmspZHe4drd4FJRkURqFkJIDPk45xXy2KjB158z6/16lHdapqVppcMMt9L5Uc08Vsh2lsySOEReAerMBnoO9XK8cvPhvr2qQWn9rW3h+ZrG0062ht2mkkjn+zTF33lovlDqzLwrYDEHI6po3grVLjxPf3cGjaVpBtdYiuI74F/NWNLWFfIhXylDQFsru3KCAw2ggVj7Cnb4tv67gesatqVppFl9r1CXybfzI4t+0t80jrGgwATyzKPx54qaG4SaaeJFlDQMFYvEyqSVDfKxADDBHKkgHI6givErf4S629vqYvYvDxNxFbEW8YRIJJorhZSSsdsgRWXenIkYBsFmFamufDTVtQa4kt10q1t5L2G5Glxupt9i2ccG3Mlu6fKyErmI8H+E9H7Cltz/1p/wAED1+qel6laapDNLYy+bHDPLbOdpXEkblHXkDoykZ6HtXl9v8AC25js5WYWbalGmnrZXE05mltvIk3SASiJMZX5QVUZHBAFdZ8P/CzeGLnXFOn6VDHd3stzFdWnEssbyO6pIuwY2BtowzDr0rOVOnGLaldgct4G1C1tfBvg20nl23F5p0CQJtJ3lYAzcgYHAJ5xW3Y6xZX0zxWjySskssLMIX2q8ZCupbGAcnjJ55xnBri9F8PNrnhb4ezNK8drZWMck3lXEkEpDWoUbGjIPUjPI4z16VQv/AeoW9hdmC8RIkTU2UiSaaUrO8TopwC7ErGwbBLc8bjXY4U5Sd3Z/8AD/8AAPUUpJaI9D1TVINNn06KdZGa/ufssRQAgNsd8tk9MRnpnnFX68k8O+E21qeSWbQrDTtKTVobk2TQPHFJGlq8bbUkiRjlnB+ZFBw3XHPoPg7SZtD8PW+nXDRM0Ly7fKJKqhkZkUZA6KVGO2MdKzq04wWj1KhJy6G1XP8Ajj/kC23/AGE9O/8AS2Gugrn/ABx/yBbb/sJ6d/6Ww1FP416lS+FmlLq1lFqE9k82LqC2F3ImxvliJYBs4weUbgc8Uul6na6pbx3Fi0kkEsUc8cjROiujruUgsBnjqOo74rnNd8IPq/ie91KWeVIJNLSziWC8mgbzA8jEv5ZAZcOvUnvx68ve+EL7StGs2u0tb+K3j0+OWyEc80dz5MLxsrLHE7bdzKw+Uj5RkCtY06clo9SHKS6HpR1OEa4ulbZPtDWxug2Bs2hguM5znJHar1eR6H4Cn1PwzEb/AE+yt5Dp99DbW8yEfZpZbh5ImClflCqR2DD0FerWMckNlbxTNvlSNVds5yQOTk1NWEY6RdyoSb3RNWVqP/I0+Dv+wnL/AOkN1WrWVqP/ACNPg7/sJy/+kN1RQ+NGOL/gz9Do7nxhoNtca7Bcaikc2iRJNqCsjZhRk3qenzZH93PUDrxWtp17b6jp9tfWUnmWtzEs0T7SNyMAVODyMgjrXnGu/DKXWPFGu6tNexwx3syMkKZInjW3iURy8cATQo/G7gEfxGsyP4X6uusaLdTXVvOlnb2Ee9LhIpLZoFVXETNbSOVYqWwHj3ZIPXNenywa3PmeWL6npereILTS9VtLC5junlubee5QwQmXCwmPcNq5YsfNXAVTnB/HXrxW5+FmsTWl1CkWhRXD6bf2T6gsr+ffSTshSSf91kY2nPzNjPHHA3r3wXrsmrSJC2mf2W2tPq4leeQTfNAY/L2BNvBYnO7kdh3ThHowcY9GemVzWof8lK0L/sEaj/6Osq8/b4Oomgm3t7TRo9QGgQ2SzBSMX6ZJuM7M554f72OMAV6BqH/JStC/7BGo/wDo6yosk9HfcVknoxtx498M2+mapqE2qItrpl4bC7by3zHOGClNu3J5PUAjrzwa6evHNV+EN3fW+uyi/gW5vrm7uI7fLeSzSTSNDI5xkMiTSqQAeWHPyirVz8NtXl8Y6lqi36p9pluJIb6OdEnhEkTIqFfsxd1XIAHngcA4BGKbhDoxuMejPQpvEFpF4gl0d47o3McEFwWjhMi7ZZHjX7uSMGMkkgKByT1xr15Dpfw21O3vIpkstA0xEbS98djK5ExtbkyySsTEuXZSAM5OQAT3qLUPhx4ju9FGk+ZpCW1rZajaW83nyF5TcuGVnXy8JgDBALevtQ4R7hyx7nsdcdc6laaN418UajqUvk2VrolhLNJtLbVE16ScAEn8BWFL8MLa31u4v9IstKsyNTsLu1MalGhiiKeeowvylwrZA4bPzGrfizR7jxBq/jfSLJ4kub3w9ZQRtKSEDNLegEkAnH4GklHv/WgJLudTB4q0W41DSrGC/SS61S2N5ZoqsfNhAB35xgDB74zW1XlMvwruYL4z6bq3ls8N7AkrZD2kc0ZEUcWOqo7yNkkH5uOlUNL+GGq2OnNG1vpc4+12881hNdL9kvFjSVSHWK0jCnMitkrJuKLnpmnyQezDlj0Z6d4f8QWmu24ltI7pAXnQebCQMxTNE3zDK8spIGckc464168gg+GWrx6AtmsmlQSx20yRxQu4iVzqAuo1HyDCbQFJxkdga0Ifh/e6rr7X/iq10ae1m1OS9lslkadNptI4UHzxqGIZM8gDoRzxScI9GDjHuen0V578OvAcvhS602crYpImkizvmts5uLgOGEhJUbuNw3HnnGMV6FUSST0ZEkk9Dh7bXtM8N3XjfUtbultLFNZhRpWVmALWVmoztBPUjnt3rpYNe0yfxBcaJDdK+qW8C3MsAVvkjY4B3Y28+mc1xGqeHpPE7eLdPj8jaPEllPKsxIVo47ayd14B5Kggf0rKn+E+ow22oQ2OsiWW6sI7Z7ufiWZ0nVwrjaw2eUiRZ+bpypGQdOWL3ev/AAxpaL3Z65cSrBBJM4JWNS5A64AzWf4e1u217TLS+s47lIrm2hulE0JXCSpuUbvukgdQpOD17V5hb/DPU4NPtYWstHvYUmunfTr66D2ymVIlWVBHaxoGQxthPLx87HcCat2Pw+1vT7XSpIZdNmvNOXS2SJ5nSOVraCSKQF/LJUHzMqdp6cgUuSNtxcse56vRXj8nwtvtQ029XWI9HmvZLLUUtzud0guri4eWORSUyNob7wGR2zXa+C/Ci+GdT1V7SK0t7C7jttkFsNoEiIVkcjAGW+Xnqcc0nGKWjE4pdTq64LwrqFrp+jyfbJfL+067qNvF8pO6Rr64wOBx0PJ4rva8sh0y/wBS8OxNpS2r3Nn4lvrvy7mVokcJfXGRuVGIPPoa9HKtKkrdv1OHGpOmk+6/JnoVFeZ+I/B+ua/qM17dWuipcTwRQxStdSSvpjJIxMlufKXczBhn7nKjJYUl54C1uUX9pBq0SaRc3xxZln2fY5XaSdSuMeYWYheoCjGRuNe7zPseYqMLazPTaKQcDApas5gooooA5DwpqNrpfhqee+l8qJ9avoFbaWy8mozIg4B6swHtmuvrzyHSrzWPA09vpv2c3UfiC5uVW4kaNG8rVJJCpYKxGQpGcGoPFnhPXfEs7XN5YaEZms3tIo5byWVbJy2RcxN5IJk5xjCn5Vw3JrNSaWx1ypxlN3lbVnpVFeZan4E8QPHrUGm64kNpdyboo2ZhuE0YS6MmBgnq6dcN1Iya9JgiSCGOGFAkUahFUdAAMAVSbe6MZwjFJxlckoooqjIK5bQbiK01Lxvc3DbIYdSWR2wThRYWpJwOeldTXHWNpJfv8QLOEqslxe+UpY8Atp9sBn25qZdDWna0r9v1R1dpcRXdrDc27b4ZkWSNsEZUjIODz0qavOr3w34g1LR9FstS03QZ4NLaMtZyX0kkF6BEyfvMwDbglXHDjI7cGqtl4C16x+yNYavFaSfYjHceS7gGZHke3UcZMS+aVIOCVRRjBNLmfY09jDrI9PorG8IaVJonhyysbl43ukUvcPHna8zsXkIzzgszdea2atGEkk2kFFFFBJR0r/kqej/9gXUP/R9lXo9ecaV/yVPR/wDsC6h/6Psq9HrzcR/EZ9flf+6w+f5sKKKKxO8K4C716z0T4p639th1KXztG07b9i024u8Ynvs7vJRtvUY3YzzjODXf1yum/wDJU/EP/YF0z/0ff0AH/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMU6Tx3oK+JLzQI5b+41WzaJLmK2025nWAyKGTe6RlFBBzknHX0NEfj7w1L4i/sNNTB1A3DWgHkSCIzqu5ohNt8syAdU3bvagBv/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMVf8V+KtH8J2tpca7cyQR3lytnbiK3lneWZgSqKsasxJ2nHFUNS8f+HtLsrS61G4vbYXfmeRBLptytw4jGXbyfL8zao5LbcY5zQAf8J5pH/Pn4k/8ACc1H/wCMUf8ACeaR/wA+fiT/AMJzUf8A4xWofEejjw1/wkB1G2/sXyPtP2zf+78vGc5/p1zx1qDwv4s0bxQt1/Yt28r2pQTxSwSQSR713IWSRVYBhyDjBHSgDznR/GGmp4m8ZSG210rNqkbqF0K9JAFjar8wEOVOVPDYOMHoQTsf8Jrpf/Pr4g/8EF//APGasaO6x+KfHTuwVF1aMlicAD+z7Pk0zRfGeha1eQ22n3cryTo0kBktZYkuFXqYndQsgHX5SeOelfK4yKdeb5W9f66FEX/Ca6X/AM+viD/wQX//AMZo/wCE10v/AJ9fEH/ggv8A/wCM1tapqVppcMMt9L5Uc08Vsh2lsySOEReAerMBnoO9XK5Pc3s/v/4AHM/8Jrpf/Pr4g/8ABBf/APxmj/hNdL/59fEH/ggv/wD4zW1q2pWmkWX2vUJfJt/Mji37S3zSOsaDABPLMo/HnipobhJpp4kWUNAwVi8TKpJUN8rEAMMEcqSAcjqCKPdtez+//gAc/wD8Jrpf/Pr4g/8ABBf/APxmj/hNdL/59fEH/ggv/wD4zXTVT0vUrTVIZpbGXzY4Z5bZztK4kjco68gdGUjPQ9qPc3s/v/4AHkHgXxRYW/gjw9DJb6wXj063RjHpF26kiJRwyxEMPcEg9q3P+Et07/n21v8A8El7/wDGqq+BtQtbXwb4NtJ5dtxeadAkCbSd5WAM3IGBwCecVt2OsWV9M8Vo8krJLLCzCF9qvGQrqWxgHJ4yeecZwa7KiXM3Z/18j1ot2Wpnf8Jbp3/Ptrf/AIJL3/41R/wlunf8+2t/+CS9/wDjVaOqapBps+nRTrIzX9z9liKAEBtjvlsnpiM9M84q/UPlXR/f/wAArXuc/wD8Jbp3/Ptrf/gkvf8A41WH4x8T2E+kW6Jb6wCNRsH+fSLtBhbuJjyYgM4HA6k4AySBXeVz/jj/AJAtt/2E9O/9LYaqm4c60/H/AIBMublYf8Jbp3/Ptrf/AIJL3/41R/wlunf8+2t/+CS9/wDjVaUurWUWoT2TzYuoLYXcibG+WIlgGzjB5RuBzxS6XqdrqlvHcWLSSQSxRzxyNE6K6Ou5SCwGeOo6jviptHez/r5Du+5mf8Jbp3/Ptrf/AIJL3/41R/wlunf8+2t/+CS9/wDjVaR1OEa4ulbZPtDWxug2Bs2hguM5znJHar1D5V0f3/8AAHr3Of8A+Et07/n21v8A8El7/wDGqzb/AMU6e3iTwpILfWdsWoyOwOj3YJH2O5X5R5WWOWHAycZPQEjsqytR/wCRp8Hf9hOX/wBIbqtKDjzrT8f+Ac+Kv7GV+xuf8Jrpf/Pr4g/8EF//APGaP+E10v8A59fEH/ggv/8A4zU9z4w0G2uNdguNRSObRIkm1BWRswoyb1PT5sj+7nqB14rW069t9R0+2vrKTzLW5iWaJ9pG5GAKnB5GQR1ruaS3R8xZLoYX/Ca6X/z6+IP/AAQX/wD8Zo/4TXS/+fXxB/4IL/8A+M1e1bxBaaXqtpYXMd08tzbz3KGCEy4WEx7htXLFj5q4Cqc4P469GnYNOxzX/Ca6X/z6+IP/AAQX/wD8Zrnr3xdprfEDRZxba5sTS75CDol6GJaW0IwvlbiPlOSBgcZxkZ9GrmtQ/wCSlaF/2CNR/wDR1lTjy3HG1w/4TXS/+fXxB/4IL/8A+M0f8Jrpf/Pr4g/8EF//APGabcePfDNvpmqahNqiLa6ZeGwu28t8xzhgpTbtyeT1AI688GunpNJboTSW6Oa/4TXS/wDn18Qf+CC//wDjNH/Ca6X/AM+viD/wQX//AMZq9N4gtIvEEujvHdG5jgguC0cJkXbLI8a/dyRgxkkkBQOSeuNeh2XQNOxzX/Ca6X/z6+IP/BBf/wDxmuesvF2mr8QNanNtrmx9LsUAGiXpYFZbsnK+VuA+YYJGDzjODj0auOudStNG8a+KNR1KXybK10Swlmk2ltqia9JOACT+Apxs76DVtS5/wmul/wDPr4g/8EF//wDGaP8AhNdL/wCfXxB/4IL/AP8AjNW4PFWi3GoaVYwX6SXWqWxvLNFVj5sIAO/OMAYPfGa2qTst0LRbo5r/AITXS/8An18Qf+CC/wD/AIzR/wAJrpf/AD6+IP8AwQX/AP8AGaveH/EFprtuJbSO6QF50HmwkDMUzRN8wyvLKSBnJHOOuNeh2WjQOy6HNf8ACa6X/wA+viD/AMEF/wD/ABmj/hNdL/59fEH/AIIL/wD+M10tFK8ewaHnHhrxhpcGt+LXkg1vE2ppIoXRL1iB9itV+YCLKnKng4OMHoQT0H/Cc6R/z769/wCCG+/+M1l2Oo2ul614wnvpfKifWreANtLZeSzs0QcA9WYDPvzXVV7VLLadWEZtvVI8+vjXTm48pk/8JzpH/Pvr3/ghvv8A4zR/wnOkf8++vf8Aghvv/jNa1Faf2TS/mZj/AGi/5fxMn/hOdI/599e/8EN9/wDGaP8AhOdI/wCffXv/AAQ33/xmtaij+yaX8zD+0X/L+Jk/8JzpH/Pvr3/ghvv/AIzXKeDPFmnQ6Tdq9vrRLapqLgpot44w15Mw5ERGcEZHUHIOCCK9BrkfCGoWun6Eftkvl/adb1C3i+UndI19PgcDjoeTxW+HwccNK8Xv3Jq4n29Ozj1XX18i3/wmWmf8+uvf+CK+/wDjNH/CZaZ/z669/wCCK+/+M10dFdupxXp9n9//AADnP+Ey0z/n117/AMEV9/8AGaP+Ey0z/n117/wRX3/xmujoo1C9Ps/v/wCAc5/wmWmf8+uvf+CK+/8AjNH/AAmWmf8APrr3/givv/jNdHRRqF6fZ/f/AMA838GeNdHtNJuYp11YSf2lqD4XSLtsBryZhkiI4OCMjqDkHBBFbv8Awn2hemsf+CW9/wDjVcfZala6TpWpXV87pCNYvkykbSMWa+lVQFUEkkkDgVradfQ6hAZoEuUQNtxcW8kDZ/3XUHHPXGK6qeGUor3tbH0H9lUanvtvXXp/kbX/AAn2hemsf+CW9/8AjVH/AAn2hemsf+CW9/8AjVZ9FafU/wC8H9j0O7/D/I0P+E+0L01j/wAEt7/8ao/4T7QvTWP/AAS3v/xqsc3tuNQFiZP9KMRmCbT9wEAnPTqRVij6on9oP7Hod3+H+Rof8J9oXprH/glvf/jVYPhzxto0OseKZHGq7Z9SSRNukXbHH2O2XkCLKnKng4OMHoQTM19brqMdg0mLuSJp1TaeUUqpOenV1/OsfR5o7a/8WTzNtiivld2wTgCztyTxUSwquve/qxSymik1d6+n+R2H/CfaF6ax/wCCW9/+NUf8J9oXprH/AIJb3/41XPaRrNpqylrJbzZtDhprOaFWB6FS6gN+Ga0apYRNXUif7Hod3+H+Rof8J9oXprH/AIJb3/41R/wn2hemsf8Aglvf/jVZ9V7y+t7OS1juZNj3UvkQjaTufazY46cKxyfSm8IlvIP7Hod3+H+Rsf8ACfaF6ax/4Jb3/wCNUf8ACfaF6ax/4Jb3/wCNVn1XvL23szbi5k2G4lEEfyk7nIJA46dDzQ8IlvIP7Hod3+H+R0Hg3X7HXPinp32AXn7nRr/f9osprfrPZ4x5iLu6HpnHfqK9crxvwF/yVOw/7At9/wCj7OvZK8PGQ5K0o/1seph6MaFNU47IKKKK5jYK5XTf+Sp+If8AsC6Z/wCj7+uqrgLvXrPRPinrf22HUpfO0bTtv2LTbi7xie+zu8lG29RjdjPOM4NAGT41+H2peI/E9teQaf4c054NTgvf7cti6ai0MagGJgI+SeV3GTG3Hy8Vl23wn1dNdtbeS8sP+EftvEsviNZ1lkF2xZeISm0AYJPz7847Cu//AOE80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGKAKOveDYxpsNrp+k6f4gg+0ebNa+Jr+4ulGEYBo3lE2xgT2XBBPSuHtvhJrmmeGPDsenX0B8RaZ9rVLsXpjht4p8/uVR4JfMjAOMEIeOCM8ejf8J5pH/Pn4k/8ACc1H/wCMUf8ACeaR/wA+fiT/AMJzUf8A4xQBysXw71O38Cp4GkOm6h4XTRjAzSSyW91Je+ZvBDBXVIu4+VmBxwR10Phd4I1Tw7q2t6z4i1EXmpakkEAVXEnlQwqVQNII497HPJ2L0HU5NbX/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFAHNiwXVNT+I+nyO0aXd+IGdeqhtNtFyPzrCbwn4h1e20ix119Jt7XSoZUSaylkd7h2t3gUlGRRGoWQkgM+TjnFSaX420iDxR4xeWLWlE+pxyIP7EvdwH2G1X5l8rKnKnhsHGD0IJ1v8AhP8AQ/8Annrf/givv/jNfMYr2sa8+WPXsWotrY4i8+G+vapBaf2tbeH5msbTTraG3aaSSOf7NMXfeWi+UOrMvCtgMQcjqmjeCtUuPE9/dwaNpWkG11iK4jvgX81Y0tYV8iFfKUNAWyu7coIDDaCBXcf8J/of/PPW/wDwRX3/AMZo/wCE/wBD/wCeet/+CK+/+M1n7WvZrl/BhyvsecW/wl1t7fUxexeHibiK2It4wiQSTRXCyklY7ZAisu9ORIwDYLMK1Nc+Gmrag1xJbrpVrbyXsNyNLjdTb7Fs44NuZLd0+VkJXMR4P8J6dn/wn+h/889b/wDBFff/ABmj/hP9D/5563/4Ir7/AOM0e2xF78v4f12DkfY4+3+FtzHZysws21KNNPWyuJpzNLbeRJukAlESYyvygqoyOCAK6z4f+Fm8MXOuKdP0qGO7vZbmK6tOJZY3kd1SRdgxsDbRhmHXpUn/AAn+h/8APPW//BFff/GaP+E/0P8A5563/wCCK+/+M1E5V5pxaf3MOV9jznRfDza54W+HszSvHa2VjHJN5VxJBKQ1qFGxoyD1IzyOM9elUL/wHqFvYXZgvESJE1NlIkmmlKzvE6KcAuxKxsGwS3PG41reBfFFhb+CPD0MlvrBePTrdGMekXbqSIlHDLEQw9wSD2rc/wCEt07/AJ9tb/8ABJe//Gq6nOrGTstP+H/zPSSg1qzhPDvhNtanklm0Kw07Sk1aG5Nk0DxxSRpavG21JIkY5ZwfmRQcN1xz6D4O0mbQ/D1vp1w0TNC8u3yiSqoZGZFGQOilRjtjHSof+Et07/n21v8A8El7/wDGqP8AhLdO/wCfbW//AASXv/xqoqSqVNGtCoqEdbnQVz/jj/kC23/YT07/ANLYaP8AhLdO/wCfbW//AASXv/xqsTxh4msbjSreOK21nd/aNg3zaPdqCFu4SRkxDJwOB1JwBkkCop05860e45SjyvUt674QfV/E97qUs8qQSaWlnEsF5NA3mB5GJfyyAy4depPfj15e98IX2laNZtdpa38VvHp8ctkI55o7nyYXjZWWOJ227mVh8pHyjIFd9/wklr/z4eIP/BFe/wDxmj/hJLX/AJ8PEH/givf/AIzWsXWWnK7ehk5UX9pfeee6H4Cn1PwzEb/T7K3kOn30NtbzIR9mlluHkiYKV+UKpHYMPQV6tYxyQ2VvFM2+VI1V2znJA5OTWX/wklr/AM+HiD/wRXv/AMZo/wCEktf+fDxB/wCCK9/+M1NT21TeL+4calKO0l96NqsrUf8AkafB3/YTl/8ASG6qL/hJLX/nw8Qf+CK9/wDjNZepeJLRfEfhSV7PXESLUZGbdot4pObO5XCgxZY5I4GTjJ6AkFGlNTTcX9xniasJUZJSV7dy3rvwyl1jxRrurTXscMd7MjJCmSJ41t4lEcvHAE0KPxu4BH8RrMj+F+rrrGi3U11bzpZ29hHvS4SKS2aBVVxEzW0jlWKlsB492SD1zXe/8Jrpf/Pr4g/8EF//APGaP+E10v8A59fEH/ggv/8A4zXoKdRaWPneaZ51c/CzWJrS6hSLQorh9Nv7J9QWV/PvpJ2QpJP+6yMbTn5mxnjjgb174L12TVpEhbTP7LbWn1cSvPIJvmgMfl7Am3gsTndyOw79P/wmul/8+viD/wAEF/8A/GaP+E10v/n18Qf+CC//APjNPnm+gc0+x5+3wdRNBNvb2mjR6gNAhslmCkYv0yTcZ2Zzzw/3scYAr0DUP+SlaF/2CNR/9HWVH/Ca6X/z6+IP/BBf/wDxmuevfF2mt8QNFnFtrmxNLvkIOiXoYlpbQjC+VuI+U5IGBxnGRlXnJ6+YXlJ6mFqvwhu76312UX8C3N9c3dxHb5byWaSaRoZHOMhkSaVSADyw5+UVaufhtq8vjHUtUW/VPtMtxJDfRzok8IkiZFQr9mLuq5AA88DgHAIxXaf8Jrpf/Pr4g/8ABBf/APxmj/hNdL/59fEH/ggv/wD4zT56nYOaZw2l/DbU7e8imSy0DTERtL3x2MrkTG1uTLJKxMS5dlIAzk5ABPeotQ+HHiO70UaT5mkJbWtlqNpbzefIXlNy4ZWdfLwmAMEAt6+1d9/wmul/8+viD/wQX/8A8Zo/4TXS/wDn18Qf+CC//wDjNHPPsHNPsctL8MLa31u4v9IstKsyNTsLu1MalGhiiKeeowvylwrZA4bPzGrfizR7jxBq/jfSLJ4kub3w9ZQRtKSEDNLegEkAnH4Gt7/hNdL/AOfXxB/4IL//AOM1ztn4w0yP4gazO1vrYSTS7FFH9iXu7Ky3ZOV8rcB8wwSMHnGcHBH2kul3/wAMK8t2UJfhXcwXxn03VvLZ4b2BJWyHtI5oyIo4sdVR3kbJIPzcdKoaX8MNVsdOaNrfS5x9rt55rCa6X7JeLGkqkOsVpGFOZFbJWTcUXPTNd9/wnOkf8++vf+CG+/8AjNH/AAnOkf8APvr3/ghvv/jNXy1/5X9wvbPucPB8MtXj0BbNZNKgljtpkjihdxErnUBdRqPkGE2gKTjI7A1oQ/D+91XX2v8AxVa6NPazanJey2SyNOm02kcKD541DEMmeQB0I54rqP8AhOdI/wCffXv/AAQ33/xmj/hOdI/599e/8EN9/wDGaOWt/K/uYvavuYnw68By+FLrTZytikiaSLO+a2zm4uA4YSElRu43DceecYxXoVcx/wAJzpH/AD769/4Ib7/4zR/wnOkf8++vf+CG+/8AjNRKlVk7uL+4mU+Z3bOW1fSrzWJvGNvpv2c3UfiCyuVW4kaNG8q3sZCpYKxGQpGcHrVTxZ4T13xLO1zeWGhGZrN7SKOW8llWyctkXMTeSCZOcYwp+VcNyat6D4t01Ne8WSG31orNqcbrt0W8YgfY7ZfmAiypyp4ODjB6EE7n/CZaZ/z669/4Ir7/AOM19Hh4r2MVLsjyq0qsarcY/n2Ryup+BPEDx61BpuuJDaXcm6KNmYbhNGEujJgYJ6unXDdSMmvSYIkghjhhQJFGoRVHQADAFYH/AAmWmf8APrr3/givv/jNH/CZaZ/z669/4Ir7/wCM10LlWzOaftaiSlHbyOjornP+Ey0z/n117/wRX3/xmj/hMtM/59de/wDBFff/ABmq5l3MvZVP5X9x0ded2mmX+peGLdtKW1e5s/Ed7d+XcytEjhL64yNyoxB59DXQ/wDCZaZ/z669/wCCK+/+M1geCfFmnQaNcI9vrRJ1LUH+TRbxxhryZhysRGcEZHUHIOCCKhuLe5rCFSMW1F7rp6lXxH4P1zX9Rmvbq10VLieCKGKVrqSV9MZJGJktz5S7mYMM/c5UZLCkvPAWtyi/tINWiTSLm+OLMs+z7HK7STqVxjzCzEL1AUYyNxrqv+Ey0z/n117/AMEV9/8AGaP+Ey0z/n117/wRX3/xmlyw7miqV0rKP4HRDgYFLXOf8Jlpn/Prr3/givv/AIzR/wAJlpn/AD669/4Ir7/4zWnMu5zeyqfyv7jo6K5z/hMtM/59de/8EV9/8Zo/4TLTP+fXXv8AwRX3/wAZo5l3D2VT+V/cebajpVxrPhrUrSzMfnf25dSgPK0QITUZHI3qCykhTggZBqrqnhXUtR0yCCMQWNxHJI/ntqNxdvtKY8sO4Vgj9GGcADIBJyL2g+JLGOC+DQasd2pX7jbpV03DXcrDOI+Dg8jqDkHBBFaP/CUWH/PvrH/gou//AI1XfCNKUIuT6I+zpXUEcla+F7y58U3kw02xskgvbSZLsFt6JHBFujh+QAoSCpOR3BHFQad8PtTtba8je4gkmkhWMymYBbrEqORKqwq3zBSpYu5AYjnNdp/wlFh/z76x/wCCi7/+NUf8JRYf8++sf+Ci7/8AjVHsqPV9+vcvUwH8JTjUre+tdE8O2siWsluI1O5IHLbkkX9yNx65GF6nnms3SfAGoRNOt8umi1nntJZLeIr5Z8pnL/KkMa8hhgYPTBJrsf8AhKLD/n31j/wUXf8A8ao/4Siw/wCffWP/AAUXf/xqm6VFu7f5Bqc/pvguTT9fs70WelXEEEtwscbkg28bzLJG0fyH5kAYBeANxwa1rS3e8bxnbRFRJNd+WpboCbK3Az+dWv8AhKLD/n31j/wUXf8A8arH0LxHZR6p4iZoNVIkv0Zdul3TED7LAOQI8qcg8HBxg9CDTtThZJ9f0AgtvC2onQX06aC3jlKRIlw2rXN15bKf9aiOoCMvVQpHPGcVkXvhDUJbiCwbTNNuXGnTxG7mZ9gkaQYnzsJ84/eIyOc4au2/4Siw/wCffWP/AAUXf/xqj/hKLD/n31j/AMFF3/8AGqTpUWrX/INTll8DakviJr17/wA3L7kvBKqToPL2Yx5JZh1481QfQGj/AIQiZtN06J9C8OfaLKeOWQ7yVvQI3RvMJhyDlg3O/n866n/hKLD/AJ99Y/8ABRd//GqP+EosP+ffWP8AwUXf/wAao9lR7/ig1OPu/A2s3Opanc79Li+1W15BuhCx+Z5qkJuCwhuDjJZ37kY6VavfAX75mtLHSJLZZbWZbSYbY3ZFdZd3yNgtuU5wc7ea6b/hKLD/AJ99Y/8ABRd//GqP+EosP+ffWP8AwUXf/wAao9lR7/iF2dT8PF2fE7TV2KmNEvRtTov76z4HA4r2evDfhfqlvqXxTtPs8d4nl6Ne5+0WctvnM9p08xVz07Zx+Ir3KvEx7Trya8vyRa2CiiiuMYVyum/8lT8Q/wDYF0z/ANH39dVXK6b/AMlT8Q/9gXTP/R9/QBcuvFuj2/iAaJ59xPqY2eZDa2c1x5G8/KZWjRliB65cqMc9Oaqx+PvDUviL+w01MHUDcNaAeRIIjOq7miE23yzIB1Tdu9q868TfCDU9R8a6lqdhNpUcV/qVrqKalKX+3WPlAB44gEwytgdXUAdQeKktvhPq6a7a28l5Yf8ACP23iWXxGs6yyC7YsvEJTaAMEn59+cdhQB6t4h17TfDtgLzWLoW8DSLCmEZ3kkb7qIigs7Hsqgk1k6p498P6VY2V1qVxeWwvfMMEEmnXIuHEfLt5Hl+YAoGSSoGOehzXNeO/hgmq2ejnSGN6+n6il69nruoXF3BdJtKtGzSmUrkHspHqDXN2nwj1zTPD+i/2beWqeILCW8MU0d4Y4LOK46wIrwS+bGPQiM+hHYA9cPiPRx4a/wCEgOo239i+R9p+2b/3fl4znP8ATrnjrUHhfxZo3ihbr+xbt5XtSgnilgkgkj3ruQskiqwDDkHGCOlcRF8O9Tt/AqeBpDpuoeF00YwM0kslvdSXvmbwQwV1SLuPlZgccEddD4XeCNU8O6tres+ItRF5qWpJBAFVxJ5UMKlUDSCOPexzydi9B1OTQBg3U0dv4w8dTTNtjj1GJ2OM4AsLUmoD4h03yrGRZ3cX1s93bLHDI7SxqoYkKFJzhl+XGTnABNLq1u114k+INvGVDy3yRqW6AnT7Uc1w1z8OboaPYW9pdZuI9GudPn+0Xs8sfmyQqimNW3BU3A52heMcHGB87iIwlWlzO2v6HqU3JU1ZHpincoYZwRnkYP5VR0DVINb0Wy1O0SRILuJZkWUAMARkZwSM/jXmh0O6h8eWUf8AZsd3OmpR3T6mbebfFCIMeV5jR+XsB6bZOuBtznHQeBPBUnhm50uVUsozHpf2S8NvkGefehDn5RuAAYZPIzjFYypQjG99S1OTex3VFFFc5oFFFFAHK+BtQtbXwb4NtJ5dtxeadAkCbSd5WAM3IGBwCecVt2OsWV9M8Vo8krJLLCzCF9qvGQrqWxgHJ4yeecZwa4vRfDza54W+HszSvHa2VjHJN5VxJBKQ1qFGxoyD1IzyOM9elUL/AMB6hb2F2YLxEiRNTZSJJppSs7xOinALsSsbBsEtzxuNdThTlJ3dn/w//AMlKSWiPQ9U1SDTZ9OinWRmv7n7LEUAIDbHfLZPTEZ6Z5xV+vJPDvhNtanklm0Kw07Sk1aG5Nk0DxxSRpavG21JIkY5ZwfmRQcN1xz6D4O0mbQ/D1vp1w0TNC8u3yiSqoZGZFGQOilRjtjHSs6tOMFo9SoScuhtVi+Lf+PCw/7C+m/+lsFbVYvi3/jwsP8AsL6b/wClsFTR/iR9UKt/Dl6M7GbxFpMHiE6HNeJHqgtDfeSykfuAxUvuxt6g8ZzxnGKk8Pa1p/iLR7fVdGuPtNhcBjFLsZN2GKnhgCOQeorjfGPw8k8T+MH1SW+FpbfYYLUNFkykCSbzkI6BXimK5zkHnHArl9S+E+r3Gn6bb+fZzR28VxEbcTpEsRkuHlWSJ3tpirbXUEqqEFRhjXqqEGtz5VRi1uesa1rVvpE2mR3KTOdQuvskXlru2v5byZPOcYjbpk5I4q/azrc20M8YkVJUDqJI2jYAjIyrAMp9iAR3ry2T4eam3iOK9aLSJmTUpL06pNKxvXiaB4xAf3eNqll6NghQcA9YIvh74itNITTbaTSZIp7TSYbmWSeRWjez27tiiM7g20YJK47j0XJHuHLHueu1zXiz/kPeC/8AsLyf+kF3XHW3wntTNZy6hYaPcSiTUnu2ZCxn8+UtBnK/NsBHX7p5XPWtz7Bc6VafDLT7+VZry0ult5pFYsHdNNulYgkAkEgnJGaOVLZhZLZm5c+MNBtrjXYLjUUjm0SJJtQVkbMKMm9T0+bI/u56gdeK1tOvbfUdPtr6yk8y1uYlmifaRuRgCpweRkEda84134ZS6x4o13Vpr2OGO9mRkhTJE8a28SiOXjgCaFH43cAj+I1mR/C/V11jRbqa6t50s7ewj3pcJFJbNAqq4iZraRyrFS2A8e7JB65p8sGtw5Yvqel6t4gtNL1W0sLmO6eW5t57lDBCZcLCY9w2rlix81cBVOcH8devFbn4WaxNaXUKRaFFcPpt/ZPqCyv599JOyFJJ/wB1kY2nPzNjPHHA3r3wXrsmrSJC2mf2W2tPq4leeQTfNAY/L2BNvBYnO7kdh3ThHowcY9GemVzWof8AJStC/wCwRqP/AKOsq8/b4Oomgm3t7TRo9QGgQ2SzBSMX6ZJuM7M554f72OMAV6BqH/JStC/7BGo/+jrKiyT0d9xWSejG3Hj3wzb6ZqmoTaoi2umXhsLtvLfMc4YKU27cnk9QCOvPBrp68c1X4Q3d9b67KL+Bbm+ubu4jt8t5LNJNI0MjnGQyJNKpAB5Yc/KKtXPw21eXxjqWqLfqn2mW4khvo50SeESRMioV+zF3VcgAeeBwDgEYpuEOjG4x6M9Cm8QWkXiCXR3jujcxwQXBaOEyLtlkeNfu5IwYySSAoHJPXGvXkOl/DbU7e8imSy0DTERtL3x2MrkTG1uTLJKxMS5dlIAzk5ABPeotQ+HHiO70UaT5mkJbWtlqNpbzefIXlNy4ZWdfLwmAMEAt6+1DhHuHLHuex1w+o39tpXjfxLqF/L5Vpa6JYzTSbS21FlvSTgAk8DtWTL8MLa31u4v9IstKsyNTsLu1MalGhiiKeeowvylwrZA4bPzGp/GGlz63rnjTS7R40uL3w7aW8bSkhQzSXwBJAJxz6GuvL0lXXK76P8jmxUY+yab00/NHaqwZQy8gjIpa8/1/QNe18ac2p6RoE8VkXB0+e+klguNybQ7EwDDIRwNrfePIODVG18DeI9NUNpmuRJKLCDcWZx5t7DlV39SYShCkHJ4BxxX0PM+x4qowtrKzPTqKzPDGljRPDum6YGDm1t0iZx/GwHzN+JyfxrTq0YNJOyCiiigRyGk6ja6Xqni6e+l8qJ9at4A20tl5LSzRBwD1ZgM+9dfXnl/pV5rH/CX2+mfZzdR+ILK5VbiRo0byoLKQqWCsRkKRnB61B4s8J674lna5vLDQjM1m9pFHLeSyrZOWyLmJvJBMnOMYU/KuG5NZ8zXQ6nTjJq7tt+SPSqK8y1PwJ4gePWoNN1xIbS7k3RRszDcJowl0ZMDBPV064bqRk16TBEkEMcMKBIo1CKo6AAYAqk290ZThGKTjK5JRRRVGQVyPhDULXT9CP2yXy/tOt6hbxfKTuka+nwOBx0PJ4rrq87tNMv8AUvDFu2lLavc2fiO9u/LuZWiRwl9cZG5UYg8+hqZOzNqaTi0+6/U9EorzPxH4P1zX9Rmvbq10VLieCKGKVrqSV9MZJGJktz5S7mYMM/c5UZLCkvPAWtyi/tINWiTSLm+OLMs+z7HK7STqVxjzCzEL1AUYyNxpcz7FqjC2sz02ikHAwKWrOYKKKKAPJLLUrXSdK1K6vndIRrF8mUjaRizX0qqAqgkkkgcCtbTr6HUIDNAlyiBtuLi3kgbP+66g4564xXMajpVxrPhrUrSzMfnf25dSgPK0QITUZHI3qCykhTggZBqrqnhXUtR0yCCMQWNxHJI/ntqNxdvtKY8sO4Vgj9GGcADIBJyO+nOcYRsrqyPtqXwL0O7orza18L3lz4pvJhptjZJBe2kyXYLb0SOCLdHD8gBQkFScjuCOKg074fana215G9xBJNJCsZlMwC3WJUciVVhVvmClSxdyAxHOav20+kO/9bGh6Qb23GoCxMn+lGIzBNp+4CATnp1IqxXCP4SnGpW99a6J4dtZEtZLcRqdyQOW3JIv7kbj1yML1PPNZuk+ANQiadb5dNFrPPaSyW8RXyz5TOX+VIY15DDAwemCTR7Wpe3KB6K19brqMdg0mLuSJp1TaeUUqpOenV1/OsfR5o7a/wDFk8zbYor5XdsE4As7ck8Vh6b4Lk0/X7O9FnpVxBBLcLHG5INvG8yyRtH8h+ZAGAXgDccGta0t3vG8Z20RUSTXflqW6AmytwM/nRzSdm1bX9ANXSNZtNWUtZLebNocNNZzQqwPQqXUBvwzWjXCW3hbUToL6dNBbxylIkS4bVrm68tlP+tRHUBGXqoUjnjOKyL3whqEtxBYNpmm3LjTp4jdzM+wSNIMT52E+cfvEZHOcNS9rUS1j+f+QHqVV7y+t7OS1juZNj3UvkQjaTufazY46cKxyfSuCXwNqS+ImvXv/Ny+5LwSqk6Dy9mMeSWYdePNUH0Bo/4QiZtN06J9C8OfaLKeOWQ7yVvQI3RvMJhyDlg3O/n86ftan8oHotV7y9t7M24uZNhuJRBH8pO5yCQOOnQ8153d+BtZudS1O536XF9qtryDdCFj8zzVITcFhDcHGSzv3Ix0q1e+Av3zNaWOkSWyy2sy2kw2xuyK6y7vkbBbcpzg5280e1qPaIWPUvAX/JU7D/sC33/o+zr2SvGPh4uz4naauxUxol6NqdF/fWfA4HFez14OYf7xL5fki1sFFFFcYwrgLvXrPRPinrf22HUpfO0bTtv2LTbi7xie+zu8lG29RjdjPOM4Nd/XK6b/AMlT8Q/9gXTP/R9/QAf8J5pH/Pn4k/8ACc1H/wCMUf8ACeaR/wA+fiT/AMJzUf8A4xVu88aeFrLUm0698S6Jb6gjiNraW/iSUMcYBQtnJyOMd6uJ4g0Z9aOjpq+nNq4G42IuUM4GM58vO7pz0oAyP+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGK6JL20e/ksUuoGvY41le3EgMiIxIDFeoBIIB74NWKAOV/4TzSP+fPxJ/wCE5qP/AMYo/wCE80j/AJ8/En/hOaj/APGK6qigDwJvFenf8Jh4vl+z61sm1GJ1H9jXm4AWVsvzL5WVOVPBAOMHoQTZ/wCEt07/AJ9tb/8ABJe//Gq1JnWPxn44eRgiLqUTMzHAA+wWnJol1XTooYppb+0SKWJriN2mUK8SgMzg55UAgk9ADXzeL5XWlo9/66Hq0b+zWpl/8Jbp3/Ptrf8A4JL3/wCNUf8ACW6d/wA+2t/+CS9/+NVvqwZQykFSMgg5BqtpWoW2q6dbX9hL5tpcxiSJ9pXcp5BwQCPxrn93ez+//gGuvcyf+Et07/n21v8A8El7/wDGqP8AhLdO/wCfbW//AASXv/xqugopXh2f3/8AAD3u5z//AAlunf8APtrf/gkvf/jVH/CW6d/z7a3/AOCS9/8AjVdBRReHZ/f/AMAPe7nEeA9ftofA/h2JrLXGZNOt1LR6LeSIcRKMqyxEMPQgkHtW7/wklr/z4eIP/BFe/wDxmtj4d39nafDzwVDdXVvBNc6XaRwJJIFaVvIU7VB+8cc4FdNa39pdzXMVpdW88ts/lzpFIGaJsZ2sAflOOxrunh4OTev9fI8P+1KkdOVHA/8ACSWv/Ph4g/8ABFe//GaP+Ektf+fDxB/4Ir3/AOM13eraja6Rp09/qEvk2sA3SPtLbRnHQAnvU1tcwXQkNtPFMI3aJzG4ba68FTjoR3FT9Xh5/wBfIP7Vq/yr8Tz7/hJLX/nw8Qf+CK9/+M1jeKvEVq1hZf6FriBdU09yZNFvEGFvISeTEOcDgdScAZJAr1+ua+IX/IBtf+wvpf8A6XwVVOhBSTV/6+QnmdSa5WlqH/Ca6X/z6+IP/BBf/wDxmj/hNdL/AOfXxB/4IL//AOM1uG/s/wC0TYfa7f7cIvtBtvMHmCPO3ftznbnjPTNLp99aalZx3enXUF3ayZ2TQSCRGwcHDDIPII/CtdOx5unYwv8AhNdL/wCfXxB/4IL/AP8AjNH/AAmul/8APr4g/wDBBf8A/wAZrY1LVLLTHs0vpxCbyb7PDlSQz7GfGQOPlRjk4HH0qza3EN3bRXFrLHPbzIJI5Y2DK6kZDKRwQRzkUadg07HPf8Jrpf8Az6+IP/BBf/8Axmue8UeL9Mk1rwlILfXFWHVHdt+iXqkj7FdL8oMQLHLDgZOMnoCR6NXLeNf+Qx4N/wCwu/8A6Q3da0IxnUUO+hMpKEXK2yf5Dv8AhOdI/wCffXv/AAQ33/xmj/hOdI/599e/8EN9/wDGa0IrmCaaeGKaKSaAhZUVwWjJGQGHbIIPPY1NXsf2TS/mZ5f9ov8AlMn/AITnSP8An317/wAEN9/8Zo/4TnSP+ffXv/BDff8Axmtaij+yaX8zD+0X/L+Jk/8ACc6R/wA++vf+CG+/+M1z174y0tviBo1wINa8uPTL6Mg6LehstLaEYXytxHynJAwOM4yM9vXOX/8AyUXQ/wDsFah/6Os6P7Kpx15mVDMG38Pf8i7/AMJzpH/Pvr3/AIIb7/4zR/wnOkf8++vf+CG+/wDjNaFtcwXSu1tPFMsbtE5jcNtdThlOOhB4I7VNR/ZNL+Zk/wBotfZMn/hOdI/599e/8EN9/wDGaP8AhOdI/wCffXv/AAQ33/xmtaij+yaX8zD+0X/L+Jk/8JzpH/Pvr3/ghvv/AIzXKHxppEfxA1a4kj1dY5NMskUHR7wNlZbsnK+VuA+YYJGDzjODj0GvOvEM8Vt4+1ee4lSKGPSLNnkkYKqqJbvJJPAFdGEy2FOqmpP+kb4essZJ0ZKyZtf8J9oXprH/AIJb3/41R/wn2hemsf8Aglvf/jVYWmavpuqiQ6XqFneiPG/7PMsm3PTO0nHQ/lV2vaWETV1I6v7Hod3+H+Rof8J9oXprH/glvf8A41R/wn2hemsf+CW9/wDjVZ9RyTxRyxRSSxrLKSI0ZgC+Bk4HfA5o+p/3g/seh3f4f5Gp/wAJ9oXprH/glvf/AI1R/wAJ9oXprH/glvf/AI1WfUcs8MUsMcssaSTMVjVmALkAkhR3OATx2Bo+p/3g/seh3f4f5FXw5420aHWPFMjjVds+pJIm3SLtjj7HbLyBFlTlTwcHGD0IJ3v+E+0L01j/AMEt7/8AGq4zTLy1sL3xTc39zDbW6ajHulmcIq5tbYDJPHWtnTtRstTgM+m3ltdwhihkt5VkUN6ZBIzyKiGFT05u/wCZUspoyd7v8P8AI2v+E+0L01j/AMEt7/8AGqP+E+0L01j/AMEt7/8AGqz6Kv6n/eJ/seh3f4f5Gh/wn2hemsf+CW9/+NUf8J9oXprH/glvf/jVZfnxfaBb+bH55TzBHuG7bnG7HXGTjNSUfU/7wf2PQ7v8P8jQ/wCE+0L01j/wS3v/AMarB8FeNtGttHuI5Rqu46lqEg2aRduMNeTMORERnBGR1ByDggirRnhFytuZYxOyGRY9w3FQQCwHXAJHPuK57w9f2em6BcT6hd29pB/aV8vmTyLGuTdzcZJxUPCpS+L+tCllNG1rv8P8jtf+E+0L01j/AMEt7/8AGqP+E+0L01j/AMEt7/8AGqx7C+tNRthcafdQXUBJAkgkDqSOoyOKsVawieqkT/Y9Du/w/wAjQ/4T7QvTWP8AwS3v/wAao/4T7QvTWP8AwS3v/wAarPqMTwm5a3EsZnVBI0e4bgpJAYjrgkHn2NH1P+8H9j0O7/D/ACNT/hPtC9NY/wDBLe//ABqj/hPtC9NY/wDBLe//ABqs+o/Pi+0G382PzwnmGPcN23ON2OuMjGaPqf8AeD+x6Hd/h/kcr4f8S2C216fJ1Vg+pX0gKaVdMMNdSsORH1wRkdQcg4IIrS/4Siw/599Y/wDBRd//ABqoPDd5a2Hh+6ub65htrdNRvt0szhFGbyUDJPHWtnTtRstTgM+m3ltdwhihkt5VkUN6ZBIzyK2pcyjGN1t/XU9WMVFWRm/8JRYf8++sf+Ci7/8AjVH/AAlFh/z76x/4KLv/AONVuUVpafdfd/wRmH/wlFh/z76x/wCCi7/+NUf8JRYf8++sf+Ci7/8AjVbHnxfaBb+bH55TzBHuG7bnG7HXGTjNSUWn3X3f8EDD/wCEosP+ffWP/BRd/wDxqsfQvEdlHqniJmg1UiS/Rl26XdMQPssA5AjypyDwcHGD0INdgZ4RcrbmWMTshkWPcNxUEAsB1wCRz7isXQpEi1LxTJK6pGl+rMzHAAFpb5JNRLmutVv28n5gO/4Siw/599Y/8FF3/wDGqP8AhKLD/n31j/wUXf8A8aq7pmtaXqjummalZXjIMuLedJCo9TtJxV+qXM9U193/AAQMP/hKLD/n31j/AMFF3/8AGqP+EosP+ffWP/BRd/8Axqtyo5p4YWiWaWONpX8uMOwBdsE7R6nAJx7Gnafdfd/wQMf/AISiw/599Y/8FF3/APGqP+EosP8An31j/wAFF3/8arcqOaeGAxiaWOMyOETewG5j0UZ6ng8UWn3X3f8ABAm+F+qW+pfFO0+zx3ieXo17n7RZy2+cz2nTzFXPTtnH4ivcq8b8Bf8AJU7D/sC33/o+zr2SvnMff6xK/l+SLWwUUUVxjCuV03/kqfiH/sC6Z/6Pv66O8u7extnuL24it7dMbpZXCKuTgZJ4HJArh7DxFoi/EnXbptY04W0mk6fGkpuk2M6zXpZQc4JAdCR23D1FBEqkIO0mkQeKPDmq+LPiXoy6naeV4P0MfbkLSIwvr3ogKAkhYwSckDJz1FcTY/D3xNF4osbaSw/0a28XT+IX1gzx7Zbdl4j27vM8w/dI27eBya9j/wCEr8O/9B7Sf/AyP/Gj/hK/Dv8A0HtJ/wDAyP8AxoJ9vS/mX3nGaR4M161+K2oaxPr+sSac9jbRrO62WbhklkZoHVYQQgDDkBW+Y/MccemVjf8ACV+Hf+g9pP8A4GR/40f8JX4d/wCg9pP/AIGR/wCNAe3pfzL7zZorG/4Svw7/ANB7Sf8AwMj/AMaP+Er8O/8AQe0n/wADI/8AGgPb0v5l955drUMlx4h+IcMK7pJL1UUZxknTrUAV5/N4S8SW2k6Oba7v7i8ttDurYI8kEf2S4aBFRY2RVP3lxuLNjaDkdT3zavpv/CYeL5v7Qs/Jn1GJ4pPPXbIosrZSVOeRuVhkd1I7VZ/tnS/+glZf9/1/xr5+vKpCtLlXXselTrUHBXmvvR5ob6+h8eWWn3N5ey6kdSjJWHUw0aWvkZ2PbrJkHPJZkweu7kCtv4deHtW0D+x4rn7WlsNJ8u7iluzKiXIZNoVSxC/LvHyAD15xXYf2zpf/AEErL/v+v+NH9s6X/wBBKy/7/r/jWMpza5VE0VWgnfnX3ov0VQ/tnS/+glZf9/1/xo/tnS/+glZf9/1/xrD2c+zNPrNH+dfei/RVD+2dL/6CVl/3/X/Gj+2dL/6CVl/3/X/Gj2c+zD6zR/nX3o5j/hGNR8SeBPhidMCo9jp8VwLhmAEEosx5LEZyR5gTIGeM1SbwT4w0mPVl0t5nF1qcF1dPbzbJLzNqolZcTwso8/cdpkQ49Rwe6+Het6VafD/wzb3Wp2MFxDpdrHJFJOiujCJQVIJyCDwQa6H/AISLRP8AoMab/wCBSf417DlNNpI+UeJinbmR5PrXhnxffaKbO/h1rVGewijtit8lssMolcv9ojFwRIdnlgEtKDjnBJNb15ZeMrPU5LyCDUb6BpdTiW2jvkXaJGQ20nzyAbVCsOPmXPA5Nd1/wkWif9BjTf8AwKT/ABo/4SLRP+gxpv8A4FJ/jS5p9hfWYd0eax+FPFlzbQSXt5raXavpUREWrugEQSNbw4WTBb/WEk5JIyvJydi8sdQ03wg1rqUlzIqeJbP7K1zcGd/s51KAx5ckseD/ABHPrXZf8JFon/QY03/wKT/Gue8da3pVzolsltqdjM41TTpCsdwjEKt7CzNgHoFBJPYAmhOTaTQfWINrVGL438E6zrvxAfVdLnWxjGmQ2X2tmHzI0k4nQAfNuCSK6nGNyrzwa5s+EPGmnaHpOn6WL60sreG5RYbCVd8EjXMjo5H2qBWHlsmAxcDBBXmvX/8AhItE/wCgxpv/AIFJ/jR/wkWif9BjTf8AwKT/ABoU5pWsCxMVpdHnF54e8T3XiazuLu11K5mttVkuRe/b1W1W2NvKkapB5vyuGZQTsz1+Ygmmw6d47tdISzaHU7m6ubTSQbgahHi2ki2/agxaQMWbByVBDZOT6+k/8JFon/QY03/wKT/Gj/hItE/6DGm/+BSf40c0+wfWYd0ee2vg/wAQTzWct9fa8plk1JrxU1qVVAMpNoFCyfKNuD8uPRuOK17mPUItO+GketFjqqXSLdlmDHzhptzvyRwTuzyOK6v/AISLRP8AoMab/wCBSf41zXi7WtLn1Xwm8GpWUiQ6o8krJOhEa/Y7ldzYPA3Moye7Ad62wzk60LrqZVq8JU5K62f5MypYddsPEHiz+z9Iu3OqtEbO/jkt/KiYW6R73VpA+FYZOFJwOAax7XSvF8On3c9hDq0M0CWcsVpf6oJ2u7iOQmYBvMYJG6fLgkDPO0Y59C/t/R/+gtp//gSn+NH9v6P/ANBbT/8AwJT/ABr6O0e54ixVui6fh8zE8KWXiWPXr2XxHc+dbwW0cFtJG4VLhmJeRzGOFK/KgJGcKT3NddWZ/b+j/wDQW0//AMCU/wAaP7f0f/oLaf8A+BKf41aaXUynUU3fQ065y/8A+Si6H/2CtQ/9HWdaH9v6P/0FtP8A/AlP8awL3V9Nbx5o9wuoWZgj02+jeUTrtVmltCqk5wCQrEDvtPoaUpK246clffo/yZjC18S2ujeIdKsNH1CG5u9RurmC+juLdYzG8pfAPm71ZkyoO3hmBOACRGml+L4oRcaQNQtVXUcQWeo34uJI7d4djvIxdw22Q+YqlmPy474Hef2/o/8A0FtP/wDAlP8AGj+39H/6C2n/APgSn+NTaPc0+t+S/r5mX4Ltddil1afxJIWmedYbdRJuRoY0CiUKOFZ23MQAOw7V09Zn9v6P/wBBbT//AAJT/Gj+39H/AOgtp/8A4Ep/jVppaXMZ1FJ3NOvJviVZz6jrXiqzs08y5uPD9vFGmQNzF7wAZPA59a9G/t/R/wDoLaf/AOBKf41w+rajYv481C4S8tmgbTbONZRKpUsst0WUHOMgMpI/2h61pScXNJvv+TO/K6kY17t9GcvJa+IZ9IaK1OtxaiJYjBLfS2iJFjO4kQffTHBVgScjGOSMO8g12fUDp9uutLqKaVA6n+0hsgnM0waWTDgOpx0CtwANo4A9J/tKx/5/bb/v6v8AjR/aVj/z+23/AH9X/Gu2VOm/t/ij6X29P+ZfecI+leLzrmoypd3KbzdfZ5AwaAqyN5IIM/y7Ts5EOcjkkEmpH0W6muNEujpWvj7JM/2hJdW3SHdHjerefjbuAyMjgn5eSK7f+0rH/n9tv+/q/wCNH9pWP/P7bf8Af1f8afs6X834oPrFP+ZfeecrpnjKS41JhFeWqT2kiqi3xZVm8xCpRmncj5d/IWP0x0q7qXhzUhrUMvlare6baX3mwompMJvLe2KsVdpFPEnYsOM44JB7n+0rH/n9tv8Av6v+NH9pWP8Az+23/f1f8aXsqX834oPrFP8AmX3nHa1Y3eoWvieHTo5ZLldatJQIWQPhIrRiV3/LkAEjPFLqlp4kutMg/s1tZjvlkkLSXtxbRny9nKbYcoST91iMqckkDg7GhXtrFqniJ5LmBFlv0eMtIAHX7LAuR6jKkfUGtj+0rH/n9tv+/q/40JQlduVvn5sPb0/5l95wNrFq134pvI7Iaun2S9tMvNf7oYYfIiaSN08w72OW52nk53dah07SPGUdtefari/a5aFVcCYBJiJULGNzO2xigcDEcY+bnGBXon9pWP8Az+23/f1f8aP7Ssf+f22/7+r/AI0vZU+s+/XuH1in/MvvOLfR7xNattRtNJ1nC2UsCR3Gqksku8MpkPnnKHnoW7ccCqOk6R4qkaeK8/tG3tJZ7Rtv21t6KGfzgrGeRsY2/wAQz2ANehf2lY/8/tt/39X/ABo/tKx/5/bb/v6v+NP2dK9+b8g+sU/5l95xOnaBqlv4osby9g1K6t4GureN1vzujjM6NEz5kBdNobIO4nAyDgYdPZXt74Yh/s2O4eaDXbqc/ZmiEiqt3Pkr5vyZ5712n9pWP/P7bf8Af1f8ax/Cl7awaXOk1zBG5v71wHkAJVrqVlPPYggj1BFHLTT5VLf/AIAe3p/zL7zH1az8RXNpaNYf2ysyB/tP2m6t4nliyMxqIjsEh/hcYwActzVGzi1u+1q8OmNqUT2+oyIbi4vN1ukQhGIzFvOW3EHO3/gVd9/aVj/z+23/AH9X/Gj+0rH/AJ/bb/v6v+NNwpt35/xD29P+Zfeed6dpPi2OxlFzJqbE+R58IuArTAPmQxSm4cqxB7CMYHY1ck0bUIdYn1Cw0nVmMumeTElxqrZjlVpTiVhMSQQy7SC2Cc/Kckdx/aVj/wA/tt/39X/Gj+0rH/n9tv8Av6v+NJUqS+1+KD6xT/mX3nA6To3iaVkg1BtRisjqMcjAXrI4g8iQONwnkfG/ZxvPXIA7W/D+h6pa+ILC81S31Gci3e3MwvsiPbNIUMg8wbwYyvZueozzXZ/2lY/8/tt/39X/ABo/tKx/5/bb/v6v+NEadJW97bzQfWKf8y+8465sbvUPBFxDp0cslwutTygQsgcBNRdiV3/LkAEjPFLqlp4kutMg/s1tZjvlkkLSXtxbRny9nKbYcoST91iMqckkDg7HhS9tYNLnSa5gjc3964DyAEq11KynnsQQR6gitj+0rH/n9tv+/q/40JU5RTcraLqHt6f8y+84G1i1a78U3kdkNXT7Je2mXmv90MMPkRNJG6eYd7HLc7Tyc7utQ6dpHjKO2vPtVxftctCquBMAkxEqFjG5nbYxQOBiOMfNzjAr0T+0rH/n9tv+/q/40f2lY/8AP7bf9/V/xpeyp9Z9+vcPrFP+ZfecW+j3ia1bajaaTrOFspYEjuNVJZJd4ZTIfPOUPPQt244FUdJ0jxVI08V5/aNvaSz2jbftrb0UM/nBWM8jYxt/iGewBr0L+0rH/n9tv+/q/wCNH9pWP/P7bf8Af1f8afs6V7835B9Yp/zL7zidO0DVLfxRY3l7BqV1bwNdW8brfndHGZ0aJnzIC6bQ2QdxOBkHAxswQSXK+NoIV3Sy3JRFyBkmygAFbv8AaVj/AM/tt/39X/GsfQr21i1TxE8lzAiy36PGWkADr9lgXI9RlSPqDTtTjZJ7v9A9vT/mX3mLY2Wvf8I79j267HexxwpA1xNaJHE4x8wMJ3MgxyrZyOME1lXsOuNcQae8etSakdPnciDUgi/aPMAExPmKPL54XBwDjbxXo/8AaVj/AM/tt/39X/Gj+0rH/n9tv+/q/wCNJ06bVuf8UHt6f8y+84VdK8XjxE0st5cEB8pPHgwbfLxtZDOABuyeIWOecmoptC1C40/SXn0zX3u7S6jlug+rZab91IrNCfPwvzMD/BwcDuK7/wDtKx/5/bb/AL+r/jR/aVj/AM/tt/39X/Gj2dL+b8UH1in/ADL7zz2707xfLqWpyW0N3bxy215GirelkLsp8lkLTtg5APCR7c9xzU+p+G9UM6/Jql7ZQXFrcJGNSbzWOyRZtjNICDkocbgOuO9d3/aVj/z+23/f1f8AGj+0rH/n9tv+/q/40eypfzfig+sU/wCZfebHw8GPidpowy40S94c5I/fWfU5OT+Nez14d4K1bTrb4k2V1cX9pFbLpN5GZXmVUDtNaFVJJxkhWIHfafQ17RYX9pqMHnafdQXUIJXzIJA659Mg9a8THtOvJry/JGkKsJaRaZZooorjNSC8tLe+tnt723iuLd8bopUDq2DkZB4PIBrN/wCEU8O/9AHSf/AOP/CtmuN+JmqeINC0V9V0K70qOKFoo3gvLGSZnZ5VTIdZkwBuzjac46igiVOE3eSTNn/hFPDv/QB0n/wDj/wo/wCEU8O/9AHSf/AOP/CuG1PxnrfhXxdfW2vpNrVja6KmoTnSLJIEgAllDylZZixwiKMB2JxkL1rR1H4i6VpF9qPmSanek3lvawwYt4ow0lsJgI3dowFKAsTK+d2QvYUE+wpfyr7jqP8AhFPDv/QB0n/wDj/wo/4RTw7/ANAHSf8AwDj/AMKx/GXi260r4ZX/AIn03TpvtUVsJ47S7QKykkD5xvA4yScNyBxnjNLxV8TtP8J2tpP4j0u/08ToZHSa6sRJEA5XlBcbn4G792H4PrkAD2FL+VfcdL/winh3/oA6T/4Bx/4Uf8Ip4d/6AOk/+Acf+Fcho/jy4ttf1201u01CWxj10abb6gkcQt7fekQjjfDBzl3I3bWA3jJHbL0/4uafonhywfxPcNc6pcPeSFVltrciGO6kjU/vZI1bhQAq5Y4JweTQHsKX8q+49D/4RTw7/wBAHSf/AADj/wAKP+EU8O/9AHSf/AOP/CqWu+IrNPC+m6xDd3sdnez2YhltI4y7ieWNUBEgICneN38QBOOcVB4V8dWXibVrmy06w1ARQGVTdv5RiLRyeWwIWQuhJBwJFXIUkZxQHsKX8q+41P8AhFPDv/QB0n/wDj/wo/4RTw7/ANAHSf8AwDj/AMK5DVfHdxoHjTxPFqNnqN5oen2lncNLaxRFLJX83zJHyyuw+VThQ5AUnArTl+I+jweNIfDNzHLHeTu0cUguLaUOQhf/AFaStMoIU4LRgZwO4yB7Cl/KvuNz/hFPDv8A0AdJ/wDAOP8Awo/4RTw7/wBAHSf/AADj/wAK5K3+Lugy+H59altb+201BF5M8rW+ycyNtVQwlKxt0JWUoVBycc4k0n4raRrUMC6JYajqV/NPNbixtXtpHBiRHdvME3klQJI+RIeWA65FAewpfyr7jqf+EU8O/wDQB0n/AMA4/wDCj/hFPDv/AEAdJ/8AAOP/AArD8G+KT/wqqz8TeJbk/u7N7q7mKAEBSxPyqMZwOgqvd/E2yslkj1DQtetdQV7ZY7CSKEzzLO5SN02ylSNwIILBgeoHFAewpfyr7jpP+EU8O/8AQB0n/wAA4/8ACj/hFPDv/QB0n/wDj/wpPCviGHxFaXcsVpd2U9ncvZ3NtdBPMikUAkEozKeGUghiMGsHQ/iNY6vqFrbJpOr20V5Jcw2t1cJEsU8kG7zFXEhYcIxBYAHB5zxQHsKX8q+43/8AhFPDv/QB0n/wDj/wo/4RTw7/ANAHSf8AwDj/AMK8/wBV+MVtJpGqtoOnSy6tp72u+2ee1nXZLcLEfmhuGUMORtLAglSRtya3n8cwWV/fJdWeuvqDT2trFpLJbFlmljZwkbK+37qMzF5Co28ECgPYUv5V9x0X/CKeHf8AoA6T/wCAcf8AhR/winh3/oA6T/4Bx/4Vzx+JFo72FvaaHrd3qV3JcwmwijhEsEluV8xZC0qoOHUghiCOh5GamtfF3w/pGjaVq1zFc/2bqNsl0kpmto2RWOCDFJMsjMOchFbpxmgPYUv5V9x1n/CKeHf+gDpP/gHH/hR/winh3/oA6T/4Bx/4VQ8Eare6neeKo76bzUstYktbcbVXZEIYWC8AZ5djk5PNc83j6fUvFHh1NKsdRi0O5kvA11MsCxXyxROR5eX3qNy5BYICO+KA9hS/lX3HYf8ACKeHf+gDpP8A4Bx/4Uf8Ip4d/wCgDpP/AIBx/wCFcDqXxgtrjQdXn8PafJNqmmy2iy2zz2s67JpxHndDOyZ4YYLgglSRt5rc1j4l6domr6bp2tafeWFxfNFGqy3VmzxtIwUAxrOZDgkZKKwGc5wCQB7Cl/KvuOi/4RTw7/0AdJ/8A4/8KP8AhFPDv/QB0n/wDj/wpnibxFDoJsIvsV7qF9fzGG2tLNUMkhClmOXZUUBVJJZh+ZArnJvihp5W2Fjo2t388ttcXUkFvFCHtxBJ5cqyb5FAZWyMAnOOM5GQPYUv5V9x03/CKeHf+gDpP/gHH/hR/wAIp4d/6AOk/wDgHH/hUGq+LdN03wYvid/Ol0x4Yp4/LUB3WUqE4YgDO9eWIA6kgCqmieN7TVbzS7U6fqNpPqIuTCJxEy4g2bjvjkZWB8wYKlgcHOMUB7Cl/KvuNL/hFPDv/QB0n/wDj/wo/wCEU8O/9AHSf/AOP/Cuf074kWWq/Y10jRtavprqwj1FYoo4QVhd3TLFpAoIKHIzk5GM8gQap8RdIn0WOezm1SNJ9Oj1Mz2kUJkt43lRFVhJkB2YsMEHhH5BAoD2FL+VfcdP/wAIp4d/6AOk/wDgHH/hR/winh3/AKAOk/8AgHH/AIVmp4501547ZLe8N6+py6X9m2p5iyRo0jOfmwI9gD7s9GXjJxXI6v8AFa31PRdWi0Ay2Wr2EtkXDy2tyAkl2kTDMMkqA43AqxDDIIHegPYUv5V9x6B/winh3/oA6T/4Bx/4Uf8ACKeHf+gDpP8A4Bx/4Uni7xFb+F9IOo3kLSwhwjBbi3gxnPJaeSNMcf3s+1crD8WNLvLHT7nSdI1nUxeWc98EtFgJjjhk8uTczShSQwIG0kHsTkZA9hS/lX3HV/8ACKeHf+gDpP8A4Bx/4Uf8Ip4d/wCgDpP/AIBx/wCFcT43+JBXwzqE3hS11G4mjsre7N/FHF5NqJsNHvEjAklTnCq2ARnFdT441S80z/hH/sM3lfatXt7Wb5Q26Nt25eQcZwORzQHsKX8q+4u/8Ip4d/6AOk/+Acf+FH/CKeHf+gDpP/gHH/hXEW/xu8KXIvmt2nmitrO4vUaGW3kM8cI3PtRZS6EjkCVUzWv/AMLJsI471bvSNatL+3+zeXYyxRGa5+0Myw+XtkK/MVYfMy7cHdigPYUv5V9x0H/CKeHf+gDpP/gHH/hR/wAIp4d/6AOk/wDgHH/hXF3XxNvJNc0qy03wxqju+o3GnX1pKbYTo8dqs42N54j5DqcliMKw4O3MnhLx7O+rXWna3aaiyTa9eaZaah5UQtwUaQxw8MHzsQjcUxngtmgPYUv5V9x2H/CKeHf+gDpP/gHH/hR/winh3/oA6T/4Bx/4VV8S+K4tE1C30+HS9T1W/lgkujb2CRlo4UIDOxkdB1YAAEsT0BrmfDviu+8UfEeRNMk1EeGrfT7S6ieBLbyJ/PSRw0pcmYDhQoQDDK27gjIHsKX8q+47D/hFPDv/AEAdJ/8AAOP/AAo/4RTw7/0AdJ/8A4/8KyLvx5Zw+L5vDtvpupXl7CyJK8Hk7UZ03r8rSByMEZYKVGeSMHHP6L8U5E+H+l+IfEeiz2pulGWF3ZQROcZ3J51yPl7YJ3Z7Y5oD2FL+Vfcdv/winh3/AKAOk/8AgHH/AIUf8Ip4d/6AOk/+Acf+Fc+nxO0N9LlvkivmjFjbahAnlqHuo7htkaxgty+/CEEjBI7EGu4ByASCCex7UB7Cl/KvuMf/AIRTw7/0AdJ/8A4/8KP+EU8O/wDQB0n/AMA4/wDCtmigPYUv5V9xjf8ACKeHf+gDpP8A4Bx/4Uf8Ip4d/wCgDpP/AIBx/wCFbNFAewpfyr7jG/4RTw7/ANAHSf8AwDj/AMKP+EU8O/8AQB0n/wAA4/8ACtmigPYUv5V9xjf8Ip4d/wCgDpP/AIBx/wCFH/CKeHf+gDpP/gHH/hWzRQHsKX8q+4xv+EU8O/8AQB0n/wAA4/8ACj/hFPDv/QB0n/wDj/wrZooD2FL+VfcY3/CKeHf+gDpP/gHH/hR/winh3/oA6T/4Bx/4Vs0UB7Cl/KvuMb/hFPDv/QB0n/wDj/wo/wCEU8O/9AHSf/AOP/CtmigPYUv5V9xjf8Ip4d/6AOk/+Acf+FH/AAinh3/oA6T/AOAcf+FbNFAewpfyr7jG/wCEU8O/9AHSf/AOP/Cj/hFPDv8A0AdJ/wDAOP8AwrZooD2FL+VfcY3/AAinh3/oA6T/AOAcf+FH/CKeHf8AoA6T/wCAcf8AhWzRQHsKX8q+4xv+EU8O/wDQB0n/AMA4/wDCj/hFPDv/AEAdJ/8AAOP/AArZooD2FL+VfcY3/CKeHf8AoA6T/wCAcf8AhR/winh3/oA6T/4Bx/4Vs0UB7Cl/KvuMb/hFPDv/AEAdJ/8AAOP/AAo/4RTw7/0AdJ/8A4/8K2aKA9hS/lX3GN/winh3/oA6T/4Bx/4VoWFhaadB5On2sFrCSW8uCMIufXAHWrNFBUaUIu8YpBRRRQWFZniTRbfxBo8um3rzJBK8bloiA2UdXGMgjqo7dK06KAOd1rwjYaveatc3Mt0smp6WdImEbKAsJMh3LlTh/wB43JyOBxWXdfDuxlN2bfVdVtGunheXyzC6P5cKwqrRyRsjDagPzKfm5GK7aigDml8F6UvgI+ER9o/so2ptN28eYFP8QOMA5OemPbHFYWt/C601pLz7f4i15pr+yGn30y/ZVe6iDOyhiIPlxvI+QKCANwY5J9CooA43/hX9kdauL2TU9UktJ9RXVZNOZofs5uVChXyI/MwDGhC78ZUHFQx/DiytEtm0jWNZ0y6hSeI3NrJEZJY5pmmZGDxsuA7sVIUMPWu4ooAxdX8O22raLZ6Zd3F20VtNbTiXzAZHaCRJFLMQc5ZBu7nJ6daytC8B2WleJf7cfUdSv75YZIIzdmIlEcqWBdI1eT7igeYz4A4xXX0UAcbr3gCz1rVtSvJ9U1SG31OGG3v7GFohDcxx7tqsTGXAO9gdrrkHFV0+GmnR6sl5HqusJAmozarHZpJEsS3EqOrvkR+YeJGxlzjjGBxXdUUAeep8KdJLXU1zqmr3N/MIdl87QpPC0UnmI4aOJQ77uS0gcnoSea0JfAvnPa3MniXX21W2kmePUS8BlCSqivEF8rywh8tDgIMEZBySa7KigDnbLwhplt4H/wCEUl8+60o2z2j+e4Mjo2c5ZQOeTyAKyovh1Ytdreajq2sanfpPaypc3ckRdVt33xxjZGo27iS3G5s8t0rt6KAMvRNEttGm1WW1eZ21G8a9l8wghXKIhC4AwMIOuT15rCPw80dtN06xkmvXt7F7x0BkUF/tQlEgYhRwBM2MYIwOT37GigDz6P4W6d9juLe51jWbnzLOGxjeQwKbeOGQSR+WEiVcqwB5BzjnNXrn4fWdzJLcz6tqzao89vdLqAaFZY5oUZFdQIwnKuwIKlSCeK7OigDlNF8DadpN/p99HdX9xe2jXUjTzyKzXElwUMjyYUDP7tQAu0AcYrn7n4O6NJpj6fBq2tWttNpqaVcCF4C1xApZlDM0RKnLn7hUHjINel0UAZeiaJbaNNqstq8ztqN417L5hBCuURCFwBgYQdcnrzXJN8K9KkCQXGq61NpkUV1Db6e0sQhgS4RkkVSsYcjDnG5iRxjjIPoNFAHAJ8L9PNtfxXes6zdvd2ltZCWVoFaCO3kMkXlqkSqCrHPKkHHIPOS7+GNnd3tzc3Ova47Xc9rdXi5t1F1LblDGz4hBH+rUbVKr3wDzXf0UAYfibw7DrxsJftt7p99YTGa2u7NkEkZKlWGHVkYFWIIZT+YBrM0rwBpWmOj28160gsbiyd5JFZpfPlEssrnbzIXGc9OTx0x19FAGBJ4Yg/4Q618OW99f2ttbW8NtHcQuom2xhQMkqVOQuCCpUgkEYOKwbb4Y6dZQWv8AZ+ratZXtvPPP9tt/ISRzMqrIpXyvLUEIn3EUgrkEHOe9ooA5bwl4I03wvNbS2E95K1vp0emL57q2Y0d3DHCj5sucnpjHFUrb4a6Hbad4gsoHvEi1q5FzOfMUmLD7xHH8uFQMXIGDy7c88dtRQByd74B0W98T6lrtwLlrrULFrCaMSYjCsArOoAyJCqopbPRQKy4PhbpqwPFc6vrF2pt7a0TzWgXyooJhNGqhIlA+ZQCSCSPfmvQKKAMDxZ4Yt/Ef9mvJeXdjdadc/arW5tfLLRvsZPuyI6Hhj1UkdsVl6F8PNL0ZIxBd6jOyWd3Z755EZmW5n8+RiQo+bceD0x1BPNdnRQB57d/CvTJtPNhb6xrdnYyWltZ3MEEkOLpYFCxs5aMkNgAHYVBwMiuv1zRbfWf7P+1PMn2K8jvY/LIGXTOAcg8c9sH3rTooA4RPhrZJoV1oY1vXP7DmtZrOKw86IR28coIIQ+XubaCdu9nA7CpfFvgePUTfahp7THWJIrNIC10IFia2ld43V/Kkw37x85RwcAYHJrtqKAPM/Dnw4vY7N7nWtbvINfbVpdVW8spIpXjZ4FgKEvAEcFF5/dKBngDFdJH4J02P7PtnvP3GsS62uXXmeTzMqfl+5+8bA68DmuoooA5vxL4Ti1vUIL+HVNT0q/igktTcWDxq0kLkFkYOjjqoIIAYHoRUnhnwlpnhq6nl0pZY0ltbazEJYFEjgVlTbxnOHOSSc8V0FFAHI6l4EstS8Uwa1eajqMpgnjuYrRjEYo5EA27WMfmquRkqrhSc5HJzm2/wwtLVdLFpr+uwNpYmjsXQ2xa3hlwHiUmE8HaPmOXGOG616BRQB55H8N7WDVvBCwlX0rwxbSRxvNITcTPhBGrBVClQV35/vKuAOa7PQ9M/smze3+2317vmkm8y8l8x13uW2A4HyrnCjsABWhRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Outpatient, survival and good outcome expected without requiring initial admission; high benefit/resource, survival and good outcome expected (survival &gt;=90 percent) with limited/short-term initial admission and resource allocation (length of stay, &lt;=14 days, one to two surgical procedures); medium benefit-resource, survival and good outcome likely (survival, &gt;50 percent) with aggressive care and comprehensive resource allocation, including initial admission (&gt;=14 days), resuscitation, multiple surgeries; low benefit-resource, survival and good outcome &lt;50 percent, even with long-term, aggressive treatment and resource allocation; expectant, survival &lt;10 percent even with unlimited, aggressive treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ABA Board of Trutees Committee on Organization and Delivery of Burn Care. Disaster management and the ABA plan. J Burn Care Rehabil 2005; 26:102. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7818=[""].join("\n");
var outline_f7_40_7818=null;
var title_f7_40_7819="Proportion of preterm birth by etiology";
var content_f7_40_7819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proportion of preterm birth by etiology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous preterm labor",
"       </td>",
"       <td>",
"        30 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PPROM",
"       </td>",
"       <td>",
"        5 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple gestation",
"       </td>",
"       <td>",
"        10 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia/eclampsia",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antepartum bleeding",
"       </td>",
"       <td>",
"        6 to 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal growth restriction",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        8 to 9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPROM: preterm premature rupture of membranes.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Slattery MM, Morrison JJ. Lancet 2002; 360:1489.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7819=[""].join("\n");
var outline_f7_40_7819=null;
var title_f7_40_7820="Collecting family history";
var content_f7_40_7820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for collecting family history information",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Resource",
"      </td>",
"      <td class=\"subtitle1\">",
"       URL",
"      </td>",
"      <td class=\"subtitle1\">",
"       Content",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       US Surgeon General: My Family Health Portrait",
"      </td>",
"      <td>",
"       <p>",
"        https://familyhistory.hhs.gov/",
"       </p>",
"       <p>",
"        https://familyhistory.hhs.gov/fhh-web/home.action?request_locale=es",
"       </p>",
"      </td>",
"      <td>",
"       Tool for patients to create their own family tree (Available in English and Spanish).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       National Society of Genetic Counselors: Your Family History - Your Future",
"      </td>",
"      <td>",
"       file://www.nsgc.org/consumer/familytree/index.cfm",
"      </td>",
"      <td>",
"       Guidelines on how to gather and record family history information.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       American Medical Association: Family History Tools",
"      </td>",
"      <td>",
"       file://www.ama-assn.org/go/familyhistory",
"      </td>",
"      <td>",
"       Tools for collecting family history in prenatal, pediatric, and adult settings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       American Academy of Family Physicians: Family History Program",
"      </td>",
"      <td>",
"       file://www.aafp.org",
"      </td>",
"      <td>",
"       Guidance on efficient approaches for collecting and evaluating family history information.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Utah Department of Health",
"      </td>",
"      <td>",
"       file://health.utah.gov/genomics/familyhistory/toolkit.html",
"      </td>",
"      <td>",
"       Resource to help patients collect their own family histories.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       American Heart Association",
"      </td>",
"      <td>",
"       file://www.americanheart.org/presenter.jhtml?identifier=3044889",
"      </td>",
"      <td>",
"       Resource for patients to collect family history information pertinent to heart disease and diabetes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ohio State University Comprehensive Cancer Center - James Cancer Hospital",
"      </td>",
"      <td>",
"       file://www.jamesline.com/patientsandvisitors/prevention/",
"      </td>",
"      <td>",
"       Online resource which provides cancer risk assessment based on family history.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       March of Dimes",
"      </td>",
"      <td>",
"       file://www.marchofdimes.com/pnhec/4439_1109.asp",
"      </td>",
"      <td>",
"       Printable preconception/prenatal family and medical history questionnaire.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7820=[""].join("\n");
var outline_f7_40_7820=null;
var title_f7_40_7821="Cancer risks BRCA1 and BRCA2";
var content_f7_40_7821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated cancer risks associated with",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cancer type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk in",
"        <em>",
"         BRCA1/2",
"        </em>",
"        carriers to age 70 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        General population risk to age 70 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast",
"       </td>",
"       <td>",
"        40 to 75 percent",
"       </td>",
"       <td>",
"        7 percent",
"       </td>",
"       <td>",
"        <p>",
"         The range of risk reported in the literature is wide. In most studies, risk in",
"         <em>",
"          BRCA1",
"         </em>",
"         carriers is higher than that observed in",
"         <em>",
"          BRCA2",
"         </em>",
"         carriers",
"        </p>",
"        The incidence of breast cancer diagnosed younger than 50 years of age is higher in",
"        <em>",
"         BRCA1",
"        </em>",
"        carriers compared to",
"        <em>",
"         BRCA2",
"        </em>",
"        carriers, but both groups have an increased risk of premenopausal breast cancer, as well as increased lifetime risks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contralateral (opposite) breast",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          BRCA1",
"         </em>",
"         : up to 65 percent",
"        </p>",
"        <em>",
"         BRCA2",
"        </em>",
"        : up to 50 percent",
"       </td>",
"       <td>",
"        0.5 to 1 percent per year after diagnosis",
"       </td>",
"       <td>",
"        <p>",
"         Risk is affected by other factors such as tamoxifen use and oophorectomy (ovary removal)",
"        </p>",
"        For",
"        <em>",
"         BRCA1/2",
"        </em>",
"        carriers who have had lumpectomy: Risk of developing a second breast cancer in the affected breast appears to be elevated over long follow-up periods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          BRCA1",
"         </em>",
"         : Approximately 40 percent",
"        </p>",
"        <em>",
"         BRCA2",
"        </em>",
"        : Approximately 15 percent",
"       </td>",
"       <td>",
"        &lt;1 percent",
"       </td>",
"       <td>",
"        <p>",
"         The risk estimates provided here are representative of findings from multiple studies",
"        </p>",
"        The incidence of ovarian cancer diagnosed younger than 50 years of age is higher in",
"        <em>",
"         BRCA1",
"        </em>",
"        carriers, and overall rare in all carriers younger than 40 years old; risk of fallopian tube cancer is also substantially elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"       <td>",
"        2 percent",
"       </td>",
"       <td>",
"        If elevated, risk is small; studies have not been consistent about whether risk is elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate",
"       </td>",
"       <td>",
"        Elevated; absolute risk not well defined",
"       </td>",
"       <td>",
"        <p>",
"         8 percent Whites",
"        </p>",
"        12 percent African Americans",
"       </td>",
"       <td>",
"        Risk appears to be higher in",
"        <em>",
"         BRCA2",
"        </em>",
"        carriers and possibly in men younger than 65 years old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male breast",
"       </td>",
"       <td>",
"        Elevated but &lt;10 percent",
"       </td>",
"       <td>",
"        &lt;1 percent",
"       </td>",
"       <td>",
"        Risk appears to be higher in",
"        <em>",
"         BRCA2",
"        </em>",
"        carriers; rarely occurs in men younger than age 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic",
"       </td>",
"       <td>",
"        Elevated but &lt;10 percent",
"       </td>",
"       <td>",
"        &lt;1 percent",
"       </td>",
"       <td>",
"        Risk appears to be higher in",
"        <em>",
"         BRCA2",
"        </em>",
"        carriers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other sites",
"       </td>",
"       <td>",
"        To be determined",
"       </td>",
"       <td>",
"        Varied",
"       </td>",
"       <td>",
"        These sites may include cancer of the stomach and skin (melanoma)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These risks are estimates based upon review of the literature. Specific studies have reported risks that are lower or higher than the ranges or estimates quoted; however, the estimates reported here are representative of findings from high quality studies. Risks will also vary based on an individual's current age and other risk factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7821=[""].join("\n");
var outline_f7_40_7821=null;
var title_f7_40_7822="Prevalence food allergy";
var content_f7_40_7822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Percentage of children under age 18 years who had a reported food or digestive allergy in the past 12 months, by age group: United States, 1997-2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Statistically significant trend.",
"    </div>",
"    <div class=\"reference\">",
"     Source: CDC, NCHS, National Health Interview Study. From: Branum, AM, Lukacs, SL. Food allergy among US children: Trends in prevalence and hospitalizations. National Center of Health Statistics Data Brief, number 10. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7822=[""].join("\n");
var outline_f7_40_7822=null;
var title_f7_40_7823="TCBS agar stool with answer";
var content_f7_40_7823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vibrio species on TCBS agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5eooopCClpKWgArTs8CBAeoNZlXrRiYuvTigaLIUndxQRgBe9M98mgA0DuFKFJIAGSa1vDmgah4gvlttOhLY5klbiOJf7zN0ArtPtuheCEaLSUh1jW8Ya/lUGK3Yf88lPU5/iP/1qynVUXyxV2aQp31exm6T4Gkito7/xVcjRtNcZTzBmaX2VOo+pq8fF2neHVki8G6dHBnj7fdgSzt7jPCj2ArktQv8AUNbvWuby4luJW6yytkD/AD6VEiQxuFQG7mPf+EVk4c38R38un9epsnb4SW9v9R1a4ae6mluJGP35XJ/nVby4skTTliP4Yhn9a1LfSrm7INw2yM/wLwAP8/WuhsdFtoQu1AWHqOamdeMFYqNJyOVtbeZebayC56NLyanTSrqVx5rhWY9O9d3FZgAbQB9BUi6WHdGxkg1zPGGyoI42Pw4jKBJvJHvVqPwxEecEegBrt49O74x9e1WobJCuBg1zzx0u5oqEexwI8Lw4wSc0xvC0ZBxgn8q9BksMAnFU5bcIcFgCe2aUcbJ7MHRiuhwT+GpE+40g/wB16il0i4RCfN5HRZEyD+I/wrvWjI61XkhXbyorVYuXUl0YnnEkMsDZmtiv+1C2P0oWZZGHlSK7DnDfIw/Gu6urCOUEFRk1z2o6ETlkAbv05rqhiYy3MZUmtjW0bx9rGmW/2K6aLULJutrqK+YMezf5HtU7aD4W8URk6LcNousOflsbpi0Ln0V8cf54riJI7i2O0jzEH/LOQZ/KkilSRsISjf8APKQ/yNaezXxQdn5GfM1pId4k8P6p4fuxb6tZvbuc7SeVcDuCODWTn3r0HRfGM0FsdP1+2GraYwCmC55eIdMox6f56VW17wdBcae2r+Erhr6x6yWhGZ7cH+8B1A9f59auNZxfLU08+n/AJlTvrE4XrmsucBZWAPGa1iMHB4rPvYij7/4WroMJIgSRkbKnBqZryVv7o/Cq9FIm4ruzsSxyT1pKKKBAKKKKAClpKXmgYUlLz60dqACkNLRQAUY5oooAkWMlQePzooVgFHJoq1YdyGlooqSQooooAKvWoxEPfmqSjcwHrWkq4AA6Y4oGh4Xiun8IeEZtdWe8uplsdHtRm4vJQcD/AGV/vN7VP4E8KDXHmv8AVJfsmgWWGu7k8H2RfVj+mfpV3xV4gm8QzW+laNB9n0e0+W0tV4AUfxue7HqSfWuepUbfJD5vt/wTop0/tMTxF4oh+xNovhe3ew0Y/ej6yXDf3nbr2HGa5aW3aLa1yBk4IU56Vryi30eLauJbxgMkjp/n0rNjZ3mM8py33iSMgCphZL3dvzNGtddxrq9xG7tlYI/4QMA/Sqdpqj20nyKoX0xWjb6rEd8bKdgU4rDIQykjJ9BWkVe6kjKcrWcWa2o63NcoohJRV6gd6dHr99D5SiRuKg0NIVumluUJhTllzjPtWhql7YTBJ7S0CN93GSQPSoainy8t0NOTXM5Fq68Y3RjZYsIwwMgVf0TxvOLiGO6VZFyAxwMmuJJaRztRdzdhXU+FPCF3qsiTINsSsN5Y4xWValQhBuasiqdSrOXunYfEXVZLXSLY2TMq3A3Fhxx6VwvhnxDeWmpRt5zFCw3j1Fexa34bttS0WGwdiphACP8Ah3riZPh9JZ2l1KkgklCnYo7152ExGH9k6ctzrq0qjmpLYZqnxBeeKZLSIROPuv1OK4O71m8urjzZZ3Z/XNXLHQb2XUBCIWyTg8VuQfD7UXkIcIi56lhXdBYbDaKyOeSrVToPA97LqeluLkl3iIGT3GP/AK1bU8PPAxUmg6PDo1gIIzuc8ux7mrMozXlTqKVRuGx2xTUUmZDx+1QOnHStR4+cGq7x88fSrjMlow7yyinBDoD71y+p6My7io3J+orvWiweaje1SRfl4b0NdFOu4GcoKR5l5rwgR3AMkK8A/wAS/StTRtUvNGu01DSroxuON4HUejLW9q2grKrPDxJ6djXHywzWFwWRcMPvIehFehCrGqrHPKDgd3daTpvjqCS50eOOw8RRqZLi1Jwl0epaP0Oe3v8AjXml5bvE8lvcxNHIpwyOCCD9K2bWdkZLqydo3iIf5ThoiO49q7WVLb4j2GQIoPFsCZBHypeIO3oGA/zjoKTo7/D+X/A/IUoqotNzxjGCRS44q5qtrJa3ciSxtG6sVdWGCrDgg1SrqOTbQKlMI8jzFfODgjFRUdqAEpcUUUAGKKKKAHFGCByp2nv2plTecfs5hxxnOaioAKOlFBoAKWkpaAEooNFMBtLSUtIkKWkpaBk1om6TJ6LzXW+C/Ds3iTWUs1kWC3VTJcXD/dhjHVj/AC/GsHSrOS4khhgQvPOwVFHck4Ar0vxO8XhLw6vha12nUJNsuqTKc/N1EQPoOP8AOayqzatGO7/q5tShfV7FXxnr8eom18P+HovJ0azPlwop5uG6GV/Unr7Vn3EsOgWZgiCSXbj55ccn0/D0H40WITRdMa7m/wCPudf3akZ2j/JB/IVzFxNJdXDSSEs7HOTWEKal7q+FfizplLl9SSPfcTbnJLE5yTmtC5MdpZtvGWdSAKzVvEtZFAAb1NUrh3klJdiVJznNbuLb8jB1FFabkQUsxZQce1b3hbRX1TUUjO5EPO7bkAVlWtu88uy2yX7e9eteC4ZbLSNt0m1y5IyOSMCscXXdKHu7lYelzyu9jgNftHttTlsoYCkO8jgcn3roLDTdD03Sw2pXCyvL90IQdpqp4/1t5btrNUCqhxuHU1i2Gh3upWAeAFwrcc1nZzpRc3ymjaU2oq51Ok+DLW8mjurO/jkgzz8pyD6Yr0yySKzt0igUAAAcDGcDrXlY1C48JaSIFA+1THdzztFWPC/jG8vLxLe7KsrkDOMEVw4ihWrpyveK2N6dSFN8trNnp0lyecsAarveD1z9DWbLN3zVWS4/+tXDGijoczX89FYsiKG9cc01rnPP51jG4PYgCjzmHTmtFQJ5zWacE9aiZsn2qispNSeaM85z9Kfs7C5iyxyCajcDoOlN3nGcdelLnJOP50WFchZM/wCNQMMH3qy+KgkzjgCrQhFOT8x49Ky9d0mO8gLoAJRyDirjfKeOtSRS5IzzWibg+aIr30Z5hd28tlcM6ZVgcMvrTILmW2mS8spGikRgw2HBQ+oruvEWmrPGZI1+cA9O9cHPG1tMXUcdCK9WjVVWJy1IcjujutetYPiBoUmq2caR6/aoBc28YBNwo/5aAdcjP6Y9K8jdSjlWGCDgiut0TU7jQ9Tg1CwbBQ5Genup9qvfE7T7KYWXiLSSBb6iW8+If8sphyw/HOfwp037KXJ0e3+X+RnUXMubqcFRS0V0nOJRRS0AJRRS0AJRRRQAUGig0AFLSdqWgByxFhmirdu6iFQRz/8AXoplWKBoopaRmFSQxmSQKvU1HW/4S0e41nWLOxtAPtFzII0J6DPUn2A5/Ck3ZXZUVd2PQvh/aW2g6Dd+KdQiBlhHkaYjj78xHLj2X/GuZ05X1LU5r3UJGkijJlmkkOd7e5/Wuh+JepRm/tfD+mf8eOkL9kiA/wCWknAd/wASMfhWJqzjTdMi02L/AF7YeZgOM9QP8+g9a402/e6y/Bf1+J3LT5GPrF69/du7E7AcKvYD0qrGAqOxz060jDHGMAdTVO4nLPhDhR0FdMY6WRzylrdkR+8STmtbRdKa9nUP/q26n0rOtIWuJ1RByegrc8P213FqSAqwAPPHbvRUlaLsyKcbvVHSafa6ZoZRriRDKDlSRzXT2t9HcRboZA6HuK8z8Yq66huLEggY/KotE1S+i/dWrEkn7uM1xTw3tI899TrjX5JcltDvtX0K01OYSyApJ3I71qaXaw6fbLDCoAHf1qpYyyNbRtKMSFQSK5vxV4gnsbgW1odjKAScetcqhOr+7TN5TjD3ze8S6GmsorK4SVRgEjg1n+HfC39nXKz3EiuynhRVbwh4hnvLtbe5O8t0JruPLLY6flSnKpRXsm9BRUKnvpFZt1QsCeCcVfMS5PBOO570xYQTt2rnuTWKkkaWKJTB7k0u08DHNXxbgH5cA+uKDbgHHr2p+0QrFJAR1qRCMZJqWSEjsM+1QlTnkc073EPDZHzdKdvHSmsj+SX4Cr3/AKVAZMY5qbXC5ZL+tQuQePSo/M3Dr+lN356dKfLYLjX4J/lTA3zcGiRqjZ+ev4GtEiS5gSRkGuQ8R6cEfeq8HrgV1duwxz07YqLVLYTwsMDPvTpT9nMbXMjzEL5UjQyD92/T2NbOgSpcQ3eg3rIIL3AjkfpDKPuOP5H2NVNVtCpYEciqJcvEsgz5kfDe4/z/AFr1dJxORrlZlavpt1pOoTWV9EYriI4ZT/MeoqnXo3iOKPxH4XtdVPzX9qRBcN/EV/hY/wCfWvPJY2ikKN1FXTm5LXcxqQ5XpsMpDS0hrQzCl7UUCgApKWkoAWkPWlpKAF7UUmaWgBQxAoptFMBKKDSikIlt4/MfHYda9X+GcTaLoet+LSQslnH9ks8/89pBjP4A5/OvMbFMDd616p46RtA8KaD4dRireT9vuh0zLJ0B/wB0fzrCu72p9/y6m9FW97sc34fhFzqE99csTFagysTzk8n/ABNZ17O91cy3MgCljwAcge34dPwrYkzp3hiGJABNenex744/+t+Zrn78+TbhVPNZw96Tl8jol7sSlcy4QgYJbrVIAZ46mlyWbLGrNjEkkmZSFUetdWxxfEzX8OWG6UTOCNp4967GFQB15rI09o47YFCAignNUE8Rn7XtEY2Zxyea4pqVVux2RcaaSZ0N/p8F6gE6ZI6EHBplho9taTb4UO/1Y5xWhanz4Y3HCOMgn0q35OxsdT7Vyuo0uW5uoJ6joE4xj8awvEXhltSm8+3YCQgAqT1roowcD5QMdzVqLOec/hWKqypvmiW4KSsznvCfhVtNnFzcsDKPuqtdiqdMAe+ajjYen51MH446VhVqTqS5pFRhGCsgKk5HTPWnLEMYPbtSbhjIp6sPSs9ShVjH93BpxjGMgZFCtn61IuM9eOntU3YFWSHPaqc0XJNa/XrUMkXHTmmp2Bq5jt935jx61TcfMTitma3xzVCaFh1Ga6ITRm0UGOG54pN+PapHTB6HFQSBsHGPxrZakCMxB/rUTMc/zpzA9+aZjBq0IsW5wR3q8QHj68VnxdQK0oDlOue9Y1NNS4nK+IrMEeYoPoa48jybog/cfg5r07UrcSwuMdRXnerwbWbI5UkV3YSpzKzMa0bao0fB91HbapJZXJP2a6Qwtn36H/PrXLeIrR7PUHgkGGjJQ++D1q+XO2GcH5h8pxWn49Rb2Gy1SPnz48Pjs68H/PtXUtJ+v5mMlzQt2OJpKcRzSVucolGOKWigBKKWigAxTacaSgAFFLRQMaaKKKCQpwpppycmgDrfAmktrHiTStPC5E0y7/8AdBy36A1v+N79vEXjm9k3ZSS48mPHTy1+Vf0FWvg0i2+uahqbkBdO06acH/aAAFY3hdfO15ZWPyxhnJ9P85rkqS9+Uv5V+f8ASOylHRLux3iecNqggXCxWqbcepA5P64/CuSvbqSaQhjmtDVLtnnuJgf9Y5P58/1rGJ3NmtqNPlijOtPmdhyjJx3rQtrF54cpw2ehqtaW7zt8vQdfauiz9jsi7DOBt/GnUnbREU4J6vYqWeoJb4tmBcHIY1ch8PLJMsqSjyzhvcCudhKNchmPGa3LzVt1j5NqSCvBPqKicZJ+71LhJNe90O70yKKKJEQ4VQACDk1fALE5Jz715r4Z1S5trl33HYEO7ntSnxVe/a9wfAz93tXFLCTcnZnTHExUVc9LC4OOKepIPWqOj3q6hYxz8AsMMB61bLA+wriaadmdKd1dFlH9+KlVxj8aoh8D71OV/rzU8orl1JPXn2qRZM+1U0fg1MpGKloZaVzjGeakR/mGD+FV1+lO5wfQ1nYZbV+makDdjzVDfjgVIsvqalxHcsOmckcVVmhPPrVhZMgfypGOc96SbQbmTLDliT1qpLB14BrZlQHp68VWli4OB17VtGoS4mNJH1yM4NQbeBnpWpKmOo/GqciYrojO5DiQpw1XrcHgflVRRg9KtWxGeDg+/SiewRLE65U/lXCeJLUx3MnHDZNegupK/SuU8VQ/cfpyQfxows7TsFRXRwsKblmiPUDcv4df6VvWu2+8G3kLcvbyLKPYHg/1rFH7rUBnoeK2fCShr25s3+7NG8Z/L/61etN6X7anLBa2+Rw0yFJGB6g1HWxfwKRKWXEiZ/Ssiug5GrCUdqKKBBRRRQAGko70UAFKaKDQMbRS0UEgakhx5qZ6ZGajNS22DMmfUUAj1HwcotvAfi68TIMi29qp+r5I/IVjaJ+5sdSnUkN5JUc9M5rfsWS3+DdwVxuuNWVSO5Cx5rImiFpo1yoGCYoWP/Agrf1rhbvzeb/yO+Ksl6HNS2r3MX7oEkEnAqi1pKkm0o2fTFbuktjHPUCrV2w54/Gt/aOL5SHRUlzFKxhEC4H3jjNXnjWeBonPynnj1qmsgB6ipopkHG4Cokm9S4pWsUZtGkR90Z3oBnIrPgV1uAApPPTFdPFeIuPn/KnLJYiTeVXdnPCmmqkluiHQu9DS07SbdrFsrseZMH/ZNc6fDF59p2hMrn7w6V0Ueqw8AFj+FWP7UjXtJ+C1zKdSDdupvKipWujS0m2FhYR24OSOpHc1ZL9T3rF/tiH0l5/2aUaxAO0n/fNc7pybuzVJpWsbAfr6mnq+QMVjDV7fuXH/AAA1Mmq2p/5aEfVTQ6cuwWZtRtnHAPFWo26fhWNDqVocYmUfWr9veWzciePPf5qxnB9hpM1E5GaVunANQRzxMMLIh+jCpTID/ED9DXO00XYa9ND4Pf8AOlY89aYDxTESK+PbHSpQ5A68mq5p2aloZOW3fWoWxye3vSbx+NB6ZpbDIZVyPb0qlKhrQcA9vqRVd0yTWkZWJaM9l5qxD2Bzj1oaPnmpYUUnpjNW5aCUS4o+TjpWB4lhBtSfQ5rpoYzt9aydeizaS+lZUZ2qIqUfdPLNUTZcq3oc/rmtLRm8nxJB2DMP1GP61U11MOD7/wBKdG5XU7WQf3VI/A1761ivQ4rWl9xW8QRiK+1CMDhXf+ZrmK6vxz+51e9UfxOP1Ga5St4O8Uzmq6SaEpaKKozA0lFFAgopKXvQAUppKDQMSijNFBIVNajMyZ9ahNT2gzMn1oBHq6xqfgxanAB/tc8/9sz/APWrG1yZJ7C6MR+UR264HqI0H9K2rZg/wTkUdYdaUkexjrmXO/S7seqRN/L/AAriitW/P9UdzelvIzdMbGPoKu3JyvNZuntyPpWjLyvNayXvBB3gVAq56U9AvpTGPTtSqeaoi+pai2joKtRlOhVaoIfSrEbe9ZyRqpGlCyg8AD6VbVhjnGazYm4q0jBhhsHJrGSHcvIRz8oqdfpVONueanRvlH1rJopMsKFOAQPxp6xRseY1P4VEp78ZqeM8j61DKTJo7WBuDEtWo7C1IP7leahjbnjFXInwOTWE2+5rFgmlWeOYV59zUp0uzOP3K9OxqWOQYqYODWDnNdTRMpHTLUciMj8TQthCn3dwH+8av4BppHYml7SXcepWFsoHDP8A99GgREDh2z9asFeefzppBJ5P0qeYWpFtYdGJ+tPVWyMnj6VIiZI4qeOHOalzsUo3K4Vu/Q0NE3UrWglv7CpVtjjj9axdZItUzF8o9ShqWKLB+6a1xaE/wmpY7Q5AwaiWJRSolWCL5fSsvxBGBaP05FdbBacdKyfEdv8A6K+ARxWVHEJ1UipUvdPF/EagFfUn+lQY/wBJtP8Ac/qa0vFcSrIoA6Z/lUXkZ1Ozi/2AP1NfWU5e4vmeXKHvMzfiAwbWpipGCQeD/siuUrpPH0ofxHdRp0jIH44Fc5XVS+BHFW+NiGig0VZkHakNLSUAFBooNABQaKDQMSilopiENWLQ/vk+tV6mtSRKmPWkJHp3hiR5/h14rtV5MMlvcgeg3FSfyxXPWTmWC6hGSfs5wPcE10vwiAu9R1vSW/5f9MmjUf7Yww/ka5XRX8vVYt3Q5Uj/AD9K5WrOa+f4f8A607pGfaNh/bNaZOU4rOkTyL2WPptcj+n9K0YiDHWk+46W1iu3U00HFPkGDTAKES1qTJ1FTIRwagXpU6ZpMuJZjx6mrUZ44PNU46sRn0NYtFl2NvmqdW4696oo/NTLJyazaGmXkbpn8anVxheaoRvz71YSTNZuJSZeR/yqZJeRg1QV6cJMHrWbgWpGtHNVqGTP0rFikPc/rV+3fIGTWE4FxkaynIyP51IuCKrQsMCrUeSeelcktDZDSnTinpFz0OKnRc1Yhh54rCVSxoo3IIrc56ZrRgtMYzxT0e2t3jW4mjjd/uqxwTSG1tPEluhsrpl+zy8lcj8DXFUrPd6R72OqnSuWls8Y4JqdbPocVpvGIonc4AVSeTjp71lWUt5qmkO8YS0uC+Eb7wKg9a85V5TXNey/zOqNFDr20nGnTmyVTdbP3e48ZpNMhni02GTVTHHOF/eHIAHP/wCqprp5PtcRS5VIbRd1zx14GP0zUGpWrayjwLdR/ZXKTLgchR1B/nSVRtJSdk9W7O68vu1NfZI2YYE4AI3YzjPasTxRbKIMdM1ka+1z/axuNMuCgeNY1ZTjA6VDNr11cammmTxq/loUeTPLOByf0rXD4WqpRqxd9LtdUKcFazPNPGEBa9RAPvYH5nH9adbW2/xNEoHEaoD/ADrS1uz/ALQ8QeQAQm7BI9h/jisvUbkafa6leqcOCYojnnONoP5HP4V9nRnzRjFb2/M8StBRbbPPteujeavd3B/5aSsw+meP0rPPSnOcsTTTXsJWVjwpO7bEooopiEopaSgQUGlpKACg0uO/akPWgYUUtFMQ2pLc/vU+oqM0qnHNIR23gTU20fxjpV62PLWYJJ/uN8rfoTUvjLTJPD/i7ULVhtEFwWTH9wncv/jprm45N4VgeozXo3xMkOuaf4e8SxLn7XaC2uD6TRcHP17ewrCfu1E+j0/y/U6Y6xdjjNej8vUFmXGyZQ4/z9QfzotXyv4VNcA3ehoyDMlqdrfQ4wf5VStJM4oWsbdik7S9S1IO/eoh1xUzj5c1EeG7UJlSWo9amUjFQoanB9aTHElU1IrHBzUIPbPFOz+VQyrE4bmpFfnmq26nqx/GpaAuo4/CpkfnrVJDU6t71DQ0y2H7U/d0NV1NTKScdxUNFXLUJ/OtC2wfzrNjHzdq0bbtXPUNImpC2PSr0B6Gs+HPH9a0IP8APFcFTQ6Yl2IEnoM1o2y5Iqlbrz1rVtRyK8yvKyOmnEdLotlqFxbzXUReSE5Q5x+dXtO0eOxv/Os38m3KndAo4Zv7xrKa/wBTTxFBZwWG+xZctN6fj0rq4uBXk4mpVglFy0a2vf8A4Y9CmkYum2E2byG4vfMiMxKqj5IBzlW/PpVqz0i3tJLd4zIWhQouW4IJycikj0hLX7S9hK8Ms7h3Y/N35A/OpZro/aUtsSRSE5VyuVYDk81jOpKbfJLR/Lp/w5uOjt4Le2l8pDIHySC24v7c1k3aR3MDiwWW3eRsSnGAFHqPwxV+9SOKHyUjQIoyqgZ+YngD9fzqleTqtu1vI24R/NLnseoUVVG7fMtXf+v0KSMDVWggJSFXVR8xVxkriq2i2yxW1xqEgG987GI5CjrUjQvfXPlZCySncT/dWp/FF2ttp3kqRjGwfQda9mLdo0Y7vf0IqOyuzktPJN7e38n3YYyQfUnn+i1wPjl2it7O3z/AZm9yx4/ka9CngePR7e3IxNdPuYE8gdf8Pyryvxpfi+1aRk4jX5F9wOM/1r6XALmqOS2/y0/zPAzCXLTt3OdNJRRXsngiUUUUAHakpT0ooEFJS0UDEpe9FAoAKKDRVCGmig0VIi7ZyjbtJORXpvgab+3PBuu+Fype7A/tGy7kugG9QPUr/WvJlYqwIOCK6Xwhr8uha9YarajMlrIGK/3l6MPxBI/Gs6sHOOm/Q0pzs9S1pEgW5kt5QRHONh9jVGaN7S8khcYKnt0/Cut+Imkx2GupqFiR/ZuqKL21Ydlbkr9QT0+lY2rx/a7GG/TmUfJMB69j/n2rNTTtJbP8zdrS3YrodyfSomOKW2bcKSQfMaa3KequOQ8+1TKarKamXkUNBEnB/KnZ6nmo19DTgeKk0H54pQTzTM+lHbrSsIsxtzVhG45qmh5A5qeM8VDQWLiZqxH7VUQ+narUfQVlIpFyH61ftyeKoQ84zWhbjp0rlqM2gjRt8nHXrWpbr3qlaKSPete2g4GOK8yvNI7Kcblm2TkDn1rVtV9u9VbaEnGa1beEelePiKqO2nAs24IFXU6VDEuKi1e5ez06WaIKZRgKCOpJrx5XqSUV1OyKJb25NsqN5TyKWwxX+EepqFGlghdp28+UksiqMHb6VB/aLywy7YZlkjITKrkbiOTj0FMjujNZwmdxvBy+BtO3p+pxVqlJLVGiQ2MKxN0FcMThY5DkZ9QfSsG8nMr7GYO6nMjjq7dh+HStC7umWyVtuGfKx442r3rEYfZipUfvDhgPftXpYanq2/kWXIJJLa6S1gAkmYh5JBzt/wBmsPVSb3VYrdTujQ4Y9sA8n8Tx+NbU4Gk6e7sw+0ydW9D3/KufJa0sXm63FyQsfsO38yfxrvwqvJzj6Lzfc5a76GX4jvliivrzdiOGPyIT/tHuPxNeK3cvmzM3avRviTcx2el2enIxMrHzXHtggfzP6V5ma+sy+koUr9/yPl8xq89Tl7CUlLRXeeeJRRSigBpoopaACiijAzz0oADSrTTTxTAaaKDRQA2ig0UiQp8L+W4PbvTKKAPWfBksfinwrc+HLiXN9aA3Ol5PLcEvH9D1A+vpXM6fKLeaWC4DCJwUdT2/wIP+eKxPDmpT6dfw3NrIY7iBxJGwPQivSvF1pDrenR+LdJjVI7htl7bKMi3m6En/AGW/rXNJckrPaX4P/g/mdcHzLzRxM0LWdyUJyhOVPqKJBnkVoQqt5b/Zpflc/wCpcnqe6/y/Q1nYeJ2imVgy8EMOaaeuu412GYxToWLKCw61GXG0sAeO1CuETJ9OauxN7Mtqflp2arxSh8jkH0NSg9aho1TJAc0ufTio80qnsaVh3J165qwn0qvGePerMVZsZZiGQPWrkK9KrQLz61pW0ZODWE3YuKJYEJIrXs4TlcYqC2gJOMVuWNryDjJrzq9VJHVTgWbG3yQMVYsZ7ptcksms2FuqhhPzzxTdTu5dItYpYbN7hnbBA/hrrdNQz2kMroULruKHtXh4rEOEedq6ei9T06VLoQP5VpbtNcOEiTlmNWIry1Gnm9STfbBd24DPH0q3PYw3Vu8FwgeN+GU96dHYW8VibSJAkBUrtX0NeJKvCS1ve/yt/mdkYpFFtTG62kjiLWcqlmmJwE+tTpfK1i9zcwtEiNwGGSR2Iphgt9K0hoxG80MY+6fmJyadNO0iiMQoInQEM54B9CO1JqEvhWl9/L/M0WpHdSO21plOwlTEigqS3YE/zrOnmWMMCoWLcSTnk+2P5U+6ZldrbzWaGMck5PPUDNZdwXuZkgiyWPr1/GuuhSvvsaJBEHu5ZrhgBFCu8gcDjtTtMiMjPfTsNzk7AegHc1tJFDaWYhAUjGG4++a57Vbnc/2aINgH5/Lx09PT610Upus3GKsv0M5ySRQvpP7RvCzgfZk9emOoH49T/wDXrLe4WeWa8mIWztkYgn+6Mkn8auXMJliNnHLgLkyy9DyScfXGB9MVxHxL1ldP0xNGs5F86cBrjb1jQdEPuev0+te/gqHtJKEf+GXf5nlYyv7KDkzz/wAT6s+s6xcXjjAkPyr6KOAKyaCcmkr6qMVFWR8vJuTbYUUUUyQopKU9KYCUUgpaQBRRRQAnenimDrTxTAaetFB60UwGGig0dqkkKWkpaAHwuY5VcdjXe+A/EcOjag6XsZuNJvU8q7gH8adiPcHmvP6s2kxjYL2PT2pTiprlZcJuLueleMfD7aLNHPbP5um3I86znU53L1GfcA4rFjYatFtbC36c5JwJAP61seDPFVvbWkmh6/EZ9GuztLE5a1bp5ifnkj/9Rp+LfDNxoV4rJJ9osJgHtb2IfJKD6EcZ9RmuVXT5J79H3Opu+qMCRCx9GHUetRucocflWrHLFqKiKfEN6OFcnCyfX396z7mB4pCsyFXHFaxetmQ+6GKRhXHYZp9pI7LiU5bGR9KrsuImUGrMB3vvJAC5AGKp7BHcnzxmlU1XjYB3VTuQHIx29qWV2WNinUVFjS5fi6Yq5CvArNs5t8YJBB7j0rSt2DAYrGeha1NC2XkVtWcQ7jrWRakCtywPTv71xV27G9NGxYW42jArpdOtwCvA/CsPTsDFa18IpNOaB7xbRpOFkLYNeBiZOTselRidHBEViYoo344z61D4YfVZFn/teNUIbEeB2rK0LXbZL1NHDvPJCuDMW4Y11SSjjFeFilOleEo77Prby9T0oWa0LQFZsEE6alcXLXgktnGFjzwtSX1xGsISRHkWU7CEGSM1gzpNpsk0KSIlnKflDjIGeo//AF1zYek5Jq9m/L+tTSMTavJ52uY4bfagIDmQ8ggHkVT1R0E7IwHmuuAw549CKomeQWoAHnKHAUpxkjjGKW5R7a2Z3YmeQDLE8oK6YUVFpGqikVppQoIXkgY4GNxqxbBbCAzSBmmkAJA6/QVXsVXPmn+HiMevvRNI80hSAgyY5cHhR9f6/wBa7HHm9zp1JnOxUu7m6mvMF1HZY1PK/U+v8qz7yQWy+XCFad+pznv/ACH6mrV5dJa/ubUB5j95vb/D+dZOrXkHh+wbUNSOZWOI4j9+Vvb0A9eg9zxXp4ag52UV8u5wVqygryZW1vUo/DWkm4kYG6l/1MTHl2/vEegrwzVLyW+vp7mdy8krlmY9yTWp4l1e51S5kubuTdLIcKvZF9AOwrAr6zC4ZUI+b3PmMXiHWl5BSUUV1nIJRS0UAJQelLSGmDEFLQKKACg0tIaAEFOpBS0AIaKQ9aKAuIaBQaB0pEhRSUpoAKXtSUUAattKZIR6jg13XgvxdDZWjaL4kha/8PS5PlLjfA/99D19eM9680ileI5Q1oW12kmFk+Vu3pUTgpq0jSE7M7/xb4Ok0mGK/s501DRbj5oLyHoP9l/7rVkxuJrUJe5kRRtWZBzH6bx6VL4R8X3/AIbkkW32XFjPxPZzjdHKPcdj711R0TTvEcZvvBMrLeIvmT6ZK2HTjnYSMMvb/OK55OUNJ7d/8+35HSmpbHCXmnvAAwAkibo68g/j/SqPlFYmC8qevt9a6iKOa0nmKp9lulJWW2mX923qCv8ACf0+lMubK0mkCHdYXxG5Y5G+Rv8Adb0/OqU2txOJzqvlRkYpd2Sa0NR025tnX7TAQG6Og+9+XB/CsqZW5VTg98iri1LVEu6H2zHMiZ4xip1uXhNswPyAYYVAiNAp3jaev4U5FeSNVyuwgZyeRQ0mVFvY6LTb1J2IjJ3D1GM1vWU67yu4ZB5FchpsQglLlizYwOwAzmtO0SKK6kuELb5OSCa4a1NNux1U5Nbnc2dyODu4Hal1nTU1hYcTmN4z+BFc5Be7e4q/BqeOpxXmyoTjLmhudkKq2Z2emQWdm8cqRL9oVAhk7nAxW3Ff9Durz6DU+fvDFXU1ZEHLD6Zry6+BlN3lqzup10dJc2dzLqUt1bXxi3pgL6HFaMMBltFi1KX7QysGBHFclHrRxwQB6mhddEu3a+8t90Adfwrnng60kl28tfvOmOIidcxgicGLOEOVUfdU1gahfG8uBjcQRyMHj8KZafbtQVjDGViH8ZPGfr0/n9KnkezsTh5DdXAOdg5Gff8Az+FTToqlL+aRp7W6uWolkmjyT5UAG0se49B/9b8+1U7q8Dk2+nJgE4L4zn/H6UJFf63IxKny06qpwqj3NZGteLLDw7G9vozR3eqD5HlxmOId9o7n/PtXbhsFKpK1rv8ABepx18VGmtSzrN/p/hK0FxqQ86/lG6G3U8k+renavF/Emr3etai95fyb5DwAOFRewA9KZqt7PfXstzcymWaVizMxzk1iX1yGOxDkdzX1eFwkaCvuz57E4mVV6kFzL5j57DgVDSE5NLmuw4b3Cik7UUAFFFLTAKSlPSkoBhRRRQAtIetLSHrQADrS03vS0AJRQTRQIQ9KUYKkU2gUCClpKWgBKO1FB6UAApRSCikI07GcyRlG5Zeh9q07K6uLG5jubSaSCeM5SSNirKfYisfTVYOZCPkxitEkFc+tFrmsWelaf4807WbaKz8aWHmyL8o1S1AWcehYdGA/yDWldeEpmsjceHbu28RaaD8whUF0/wB6PqD9MGvIm4FXdI1a+0m9S70y7ltbleFkjbB+nuPauaWHtrTdvLp/wDdVP5juYY/KZ4YZXtJOjWt0C8R9sH5k/HNU3sIri4I1G1l06Ig4uIVM0Gfw6A/Wr9j8S49Q2w+NNIt9WQAKtzEPJnQd+RgH6cVraZ/wi2p3m7w14km0m4fJNtqY2qf+B5x+GTXO1OHxL9f6+aNFKL6nPS+C/tIVNH1O01NjgeWrCOQE5+XY5BJHtkc9aw9Y0G/0a6FvqFrLbzbPMCSIVYr6gdxweRXs1h8NpNQEtxqltbXG1Sy3OnlWZj9AVY/hmuT1jw+La6kUS3UbRHYi3cW4MB/syDOPbJrOGJvK17mns9Lo84g81lLIkhH0qwsrIcZPY5ANdYGv7UNCs2ntGTklrfy/w+UkAe1Umuoo1XztMsCOxXK5H/fNaObfQaVlqzKtJGmkCK3znpk4/U05rgoejtj0WtNL+yDcaZb56H5j/hSrqlsh+TSbEH1YZ/8AZazblf4fyLVu5nRXcrnbHFIx9K07Oy1e6A8q0lX6qf64H61Yh8S3qfLapbQcYxHFn8Ov9K07NPEusYitYb+Td3SPYv54H86xqOouiXqzWNu4620BocPquoxRDP3ck4+vT9Ca0bK40fTIxHaQtfSjq7D5fy6fzp58BXdmfO1zUNOsBjJM1xub9Ov51GuueDtGBWNbrWbheOB5UWf54/CuSVCVbS7l6aL+vmbRrxh/VzTt21nXZFjt0kWPH+rgHA+p6Cr14mheGoTNrF1Hc3Q/5c7ZgWJ/2m7VxGsfELWr+1NvZSJp1kPuw2wC/L6Z61y80yQ2e+5LZJOB3LVrSy7pLRdkRUxsnsdL4v8AG93f2pitxHp1ntO22gONw/2j3rzuR2mkUkkluveo7q4kunLyHJ/+tSR7Qjf3gvXtXtUaMaUbRR586jm9SC4b5mA6Af0rBY10UiAEnA5rPudPMhBthljzs/wrY5pxbMylodGQ4dSPqKSmZBmikpaACl70lFACkknkkn3oFAopgHrigUUoHFA0FIetLikoGFBopTQA09aKDRQSf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vibrio species can be selectively recovered from stool by culture on thiosulfate-citrate-bile salts-sucrose (TCBS) agar. On this medium, V. parahaemolyticus usually produces a green colony and V. cholerae a yellow colony (indicative of the fermentation of sucrose).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_40_7823=[""].join("\n");
var outline_f7_40_7823=null;
